#uniprot	wtpos	mutpos	Neutral	effect	?
P00547	139	139		H->L: 35-fold decrease in kinase activity. {ECO:0000269|PubMed:8973190}.	
P00547	203	203		H->L: 2-fold decrease in kinase activity but nearly no change in substrates affinity. {ECO:0000269|PubMed:8973190}.	
P00547	206	206		H->Q: 3500-fold decrease in kinase activity. {ECO:0000269|PubMed:8973190}.	
P00547	235	235		R->H: 250-fold decrease in kinase activity but no change in substrates affinity. {ECO:0000269|PubMed:8973190}.	
P00547	235	235		R->L: 26200-fold decrease in catalytic efficiency. {ECO:0000269|PubMed:8973190}.	
P0AF03	49	49		D->A: Loss of activity. {ECO:0000269|PubMed:10636880}.	
P0AF03	82	82		D->A: Loss of activity. {ECO:0000269|PubMed:10636880}.	
P0AC98	131	131	1	L->V: Acquires ability to transport lactic acid. {ECO:0000269|PubMed:23844911}.	
P0AC98	164	164	1	A->G: Acquires ability to transport lactic acid. {ECO:0000269|PubMed:23844911}.	
P0A6Y8	32	32		G->D: In SEG-1 and dnaK756(TS); confers temperature sensitivity. {ECO:0000269|PubMed:1592823, ECO:0000269|PubMed:2674651}.	
P0A6Y8	436	436		V->I: In SEG-2; confers temperature sensitivity. {ECO:0000269|PubMed:2674651}.	
P0A6Y8	455	455		G->D: In dnaK756(TS); confers temperature sensitivity. {ECO:0000269|PubMed:1592823}.	
P0A6Y8	468	468		G->D: In dnaK756(TS); confers temperature sensitivity. {ECO:0000269|PubMed:1592823}.	
P08622	19	20	1	RE->AA: No effect.	
P08622	25	25		Y->A: Loss of activity.	
P08622	26	26		K->A: Loss of activity.	
P08622	27	27	1	R->A: No effect.	
P08622	28	28	1	L->A: No effect.	
P08622	29	29	1	A->G: No effect.	
P08622	30	31	1	MK->AA: No effect.	
P08622	32	32	1	Y->A: No effect.	
P08622	33	33		H->Q: Loss of ability to stimulate DnaK ATPase activity. {ECO:0000269|PubMed:8106526}.	
P08622	34	34		P->F: Loss of function.	
P08622	35	35		D->N: Loss of ability to bind DnaK. {ECO:0000269|PubMed:9860950}.	
P08622	36	36		R->A: Decrease in chaperone function.	
P08622	37	37		N->A: Decrease in chaperone function.	
P08622	38	38	1	Q->A: No effect.	
P08622	41	42	1	KE->AA: No effect.	
P08622	44	44	1	E->A: No effect. {ECO:0000269|PubMed:12454054}.	
P08622	46	46	1	K->A: No effect.	
P08622	47	47		F->A: Loss of function.	
P08622	48	49	1	KE->AA: No effect.	
P08622	51	52	1	KE->AA: No effect.	
P08622	54	54	1	Y->A: No effect. {ECO:0000269|PubMed:12454054}.	
P08622	55	55	1	E->A: No effect. {ECO:0000269|PubMed:12454054}.	
P08622	58	59	1	TD->AA: No effect.	
P08622	60	61	1	SQ->AA: No effect.	
P08622	62	63	1	KR->AA: No effect.	
P08622	67	68	1	DQ->AA: No effect.	
P08622	144	144		C->S: Loss of DnaK-independent chaperone activity; when associated with S-147; S- 197 and S-200. {ECO:0000269|PubMed:12941935}.	
P08622	147	147		C->S: Loss of DnaK-independent chaperone activity; when associated with S-144; S- 197 and S-200. {ECO:0000269|PubMed:12941935}.	
P08622	161	161	1	C->H: No effect on chaperone function; when associated with H-183. {ECO:0000269|PubMed:12941935, ECO:0000269|PubMed:15683252}.	
P08622	161	161		C->S: Loss of function; when associated with S-164; S-183 and S-186. {ECO:0000269|PubMed:12941935, ECO:0000269|PubMed:15683252}.	
P08622	164	164	1	C->H: No effect on chaperone function; when associated with H-183. {ECO:0000269|PubMed:12941935, ECO:0000269|PubMed:15683252}.	
P08622	164	164		C->S: Loss of function; when associated with S-161; S-183 and S-186. {ECO:0000269|PubMed:12941935, ECO:0000269|PubMed:15683252}.	
P08622	183	183	1	C->H: No effect on chaperone function. Same effect; when associated with H-161 or H-164. {ECO:0000269|PubMed:12941935, ECO:0000269|PubMed:15683252}.	
P08622	183	183		C->S: Loss of function; when associated with S-161; S-164 and S-186. {ECO:0000269|PubMed:12941935, ECO:0000269|PubMed:15683252}.	
P08622	186	186	1	C->H: No effect on chaperone function. {ECO:0000269|PubMed:12941935, ECO:0000269|PubMed:15683252}.	
P08622	186	186		C->S: Loss of function; when associated with S-161; S-164 and S-184. {ECO:0000269|PubMed:12941935, ECO:0000269|PubMed:15683252}.	
P08622	197	197		C->S: Loss of DnaK-independent chaperone activity; when associated with S-144; S- 147 and S-200. {ECO:0000269|PubMed:12941935}.	
P08622	200	200		C->S: Loss of DnaK-independent chaperone activity; when associated with S-144; S- 147 and S-197. {ECO:0000269|PubMed:12941935}.	
P0ACG4	15	15	1	C->S: No action on toxicity. {ECO:0000269|PubMed:1943700}.	
P0ACG4	25	25	1	T->K: Non-toxic. {ECO:0000269|PubMed:1943700}.	
P0ACG4	29	29	1	L->P: Non-toxic. {ECO:0000269|PubMed:1943700}.	
P0ACG4	30	30		C->S: Prevents the formation of dimer. {ECO:0000269|PubMed:1943700}.	
P0ACG4	41	41	1	V->A: Non-toxic. {ECO:0000269|PubMed:1943700}.	
P0ACG4	49	49	1	S->E: Non-toxic. {ECO:0000269|PubMed:1943700}.	
P13738	133	133		D->N: Loss of antiport activity. Abolishes ability to grow on high salt medium. {ECO:0000269|PubMed:7737413}.	
P13738	163	163		D->C: Loss of antiport activity. {ECO:0000269|PubMed:11258962, ECO:0000269|PubMed:7737413}.	
P13738	163	163		D->N: Loss of antiport activity. Abolishes ability to grow on high salt medium. {ECO:0000269|PubMed:11258962, ECO:0000269|PubMed:7737413}.	
P13738	164	164		D->N: Loss of antiport activity. Abolishes ability to grow on high salt medium. {ECO:0000269|PubMed:7737413}.	
P13738	225	225		H->A: Loss of antiport activity. Abolishes ability to grow at alkaline pH. {ECO:0000269|PubMed:11258962, ECO:0000269|PubMed:7592922}.	
P13738	225	225		H->C,S: Slightly reduced antiport activity. No effect on pH sensitivity. {ECO:0000269|PubMed:11258962, ECO:0000269|PubMed:7592922}.	
P13738	225	225		H->D,R: Shifts threshold for pH-sensitive inactivation. {ECO:0000269|PubMed:11258962, ECO:0000269|PubMed:7592922}.	
P13738	338	338		G->S: Loss of pH-sensitivity. {ECO:0000269|PubMed:11258962}.	
P0A9G2	134	134		E->A: In nhaR1; increases the transcription of NhaA.	
P00956	94	94	1	G->R: 6000-fold increase in Km for isoleucine and 4-fold increase in Km for ATP, with no effect on activity. {ECO:0000269|PubMed:3282306}.	
P00956	97	97	1	C->S: No effect on activity. {ECO:0000269|PubMed:3282306}.	
P00956	102	102	1	I->N: No significant effect on activity. {ECO:0000269|PubMed:3282306}.	
P00956	183	183		K->A: Abolishes translocation from the aminoacylation site to the editing site, without effect on aminoacylation activity and posttransfer editing; when associated with A-421. {ECO:0000269|PubMed:12515858}.	
P00956	241	241	1	T->A: Nearly the same editing activity as the wild-type. {ECO:0000269|PubMed:9554847}.	
P00956	242	242		T->A: Abolishes editing activity against valine, with little change in aminoacylation activity; when associated with A-250. {ECO:0000269|PubMed:10889024}.	
P00956	242	242		T->P: Abolishes editing activity against valine, with little change in aminoacylation activity. {ECO:0000269|PubMed:10889024}.	
P00956	243	243		T->A: Abolishes editing activity against valine, with little change in aminoacylation activity. {ECO:0000269|PubMed:11864608, ECO:0000269|PubMed:9554847}.	
P00956	243	243		T->R: Abolishes pretransfer editing. {ECO:0000269|PubMed:11864608, ECO:0000269|PubMed:9554847}.	
P00956	246	246	1	T->A: Nearly the same editing activity as the wild-type. {ECO:0000269|PubMed:9554847}.	
P00956	250	250		N->A: Abolishes editing activity against valine, with little change in aminoacylation activity. {ECO:0000269|PubMed:10889024, ECO:0000269|PubMed:9554847}.	
P00956	333	333		H->A: Alters the specificity for hydrolysis of the aminoacyl tRNA ester, with no effect on pretransfer editing. {ECO:0000269|PubMed:11864608}.	
P00956	342	342		D->A,N: Strong decrease in total editing and deacylation activities. Severely deficient in translocation from the aminoacylation site to the editing site. {ECO:0000269|PubMed:11782529}.	
P00956	342	342		D->E: Reduces 2- to 3-fold the total editing activity and 2-fold the deacylation activity. Moderately reduces translocation from the aminoacylation site to the editing site. {ECO:0000269|PubMed:11782529}.	
P00956	421	421		W->A: Abolishes translocation from the aminoacylation site to the editing site, without effect on aminoacylation activity and posttransfer editing; when associated with A-183. {ECO:0000269|PubMed:12515858}.	
P62623	12	12		C->S: Loss of activity. {ECO:0000269|PubMed:15469281, ECO:0000269|PubMed:20080550}.	
P62623	41	41	1	H->N: No effect on the activity. {ECO:0000269|PubMed:19569147}.	
P62623	74	74		H->N: Reduces activity 2-fold. {ECO:0000269|PubMed:19569147}.	
P62623	96	96		C->S: Loss of activity. {ECO:0000269|PubMed:15469281, ECO:0000269|PubMed:20080550}.	
P62623	99	99	1	V->A: No effect on the activity. {ECO:0000269|PubMed:19569147}.	
P62623	124	124		H->N: Reduces activity 100-fold. {ECO:0000269|PubMed:19569147}.	
P62623	126	126		E->D,Q: Reduces activity 100-fold. {ECO:0000269|PubMed:19569147, ECO:0000269|PubMed:22137895}.	
P62623	167	167		T->C: Reduces activity 3-fold. {ECO:0000269|PubMed:19569147, ECO:0000269|PubMed:22137895}.	
P62623	167	167	1	T->S: No effect on the activity. {ECO:0000269|PubMed:19569147, ECO:0000269|PubMed:22137895}.	
P62623	197	197		C->S: Loss of activity. {ECO:0000269|PubMed:15469281, ECO:0000269|PubMed:20080550}.	
P62623	225	225		S->C: Reduces activity 100-fold. {ECO:0000269|PubMed:19569147}.	
P62623	227	227		N->Q: Reduces activity 20-fold. {ECO:0000269|PubMed:19569147}.	
P04036	159	159		H->A,Q: 135 to 200-fold reduction in catalytic activity. {ECO:0000269|PubMed:9398235}.	
P04036	163	163		K->A,C,Q: 625 to 830-fold reduction in catalytic activity. {ECO:0000269|PubMed:9398235}.	
P0A754	41	41		D->K: Strongly reduced potassium efflux. {ECO:0000269|PubMed:19523906}.	
P0A754	107	107		G->S: Does not bind FMN. Lacks oxidoreductase activity, but is still able to activate potassium efflux. {ECO:0000269|PubMed:21742892}.	
P0A754	112	112		H->W: Lacks oxidoreductase activity, but is still able to activate potassium efflux. {ECO:0000269|PubMed:21742892}.	
P0A754	149	149		F->W: Lacks oxidoreductase activity, but is still able to activate potassium efflux. {ECO:0000269|PubMed:21742892}.	
P03819	262	262		E->K: Increases potassium efflux in the absence of glutathione, but not in the presence of glutathione. Increases constitutive potassium efflux; when associated with D-551.	
P03819	264	264	1	D->A: Increases constitutive potassium efflux. {ECO:0000269|PubMed:19523906}.	
P03819	412	412		Q->A: Increases constitutive potassium efflux and reduces glutathione-mediated inhibition of potassium efflux. {ECO:0000269|PubMed:21041667}.	
P03819	412	412		Q->K: Increases constitutive potassium efflux and abolishes regulation of potassium efflux by glutathione and glutathione adducts. {ECO:0000269|PubMed:21041667}.	
P03819	416	416		R->A: Increases constitutive potassium efflux and abolishes regulation of potassium efflux by glutathione and glutathione adducts; when associated with A-516 and A-551. {ECO:0000269|PubMed:19523906, ECO:0000269|PubMed:21041667}.	
P03819	416	416	1	R->S: Increased constitutive potassium efflux. {ECO:0000269|PubMed:19523906, ECO:0000269|PubMed:21041667}.	
P03819	441	441		F->D,L: Reduced activation of potassium efflux by glutathione adducts. {ECO:0000269|PubMed:21041667}.	
P03819	441	441	1	F->W,Y: No effect on activation of potassium efflux by glutathione adducts. {ECO:0000269|PubMed:21041667}.	
P03819	499	499		D->A: Strongly reduced activation of potassium efflux by glutathione adducts. {ECO:0000269|PubMed:21041667}.	
P03819	499	499		D->G: Mildly reduced activation of potassium efflux by glutathione adducts. {ECO:0000269|PubMed:21041667}.	
P03819	499	499	1	D->S: No effect on potassium efflux. {ECO:0000269|PubMed:21041667}.	
P03819	516	516		R->A: Increases constitutive potassium efflux and abolishes regulation of potassium efflux by glutathione and glutathione adducts; when associated with A-416 and A-551. {ECO:0000269|PubMed:21041667}.	
P03819	520	520		E->G: Strongly reduced potassium efflux. {ECO:0000269|PubMed:19523906}.	
P03819	522	522		A->V: Strongly reduced potassium efflux. {ECO:0000269|PubMed:19523906}.	
P03819	526	526		G->V: Strongly reduced potassium efflux. {ECO:0000269|PubMed:19523906}.	
P03819	551	551		N->A: Increases constitutive potassium efflux and abolishes regulation of potassium efflux by glutathione and glutathione adducts; when associated with A-416 and A-516. {ECO:0000269|PubMed:19523906, ECO:0000269|PubMed:21041667}.	
P03819	551	551		N->D: Increases constitutive potassium efflux; when associated with K-262. {ECO:0000269|PubMed:19523906, ECO:0000269|PubMed:21041667}.	
P0ABQ4	16	16	1	M->F,S: Increases catalytic rate about 2- fold. {ECO:0000269|PubMed:16510443}.	
P0ABQ4	16	16	1	M->N: Increases catalytic rate about 2- fold. Increases catalytic rate about 7- fold; when associated with L-20; Y-42; F- 92; A-85 and S-152. {ECO:0000269|PubMed:16510443}.	
P0ABQ4	20	20	1	M->I,V: Increases catalytic rate 2-fold. {ECO:0000269|PubMed:16510443}.	
P0ABQ4	20	20	1	M->L: Increases catalytic rate 2.5-fold. Increases catalytic rate about 7-fold; when associated with N-16; Y-42; F-92; A- 85 and S-152. {ECO:0000269|PubMed:16510443}.	
P0ABQ4	42	42	1	M->V: Increases catalytic rate almost 2- fold. {ECO:0000269|PubMed:16510443}.	
P0ABQ4	42	42	1	M->Y: Increases catalytic rate almost 2- fold. Increases catalytic rate about 7- fold; when associated with N-16; L-20; A- 85; F-92 and S-152. {ECO:0000269|PubMed:16510443}.	
P0ABQ4	85	85		C->A: Decreases catalytic rate by one third. Increases catalytic rate about 7- fold; when associated with N-16; L-20; Y- 42; F-92 and S-152. {ECO:0000269|PubMed:16510443}.	
P0ABQ4	92	92	1	M->F: No effect. Increases catalytic rate about 7-fold; when associated with N-16; L-20; Y-42; A-85 and S-152. {ECO:0000269|PubMed:16510443}.	
P0ABQ4	92	92	1	M->L: No effect. {ECO:0000269|PubMed:16510443}.	
P0ABQ4	152	152	1	C->S: Increases catalytic rate 1.5-fold. Increases catalytic rate about 7-fold; when associated with N-16; L-20; Y-42; A- 85 and F-92. {ECO:0000269|PubMed:16510443}.	
P06992	66	66		E->A: Loss of activity. Overexpression of the mutant has a negative effect on cell growth, probably because it sequesters the small subunits in the free form and limits their participation in the translation cycle. {ECO:0000269|PubMed:18990185}.	
P31554	529	538		Missing: Impairs assembly of the LptD/LptE complex. Does not form native disulfide bonds. Severely compromises outer membrane integrity. {ECO:0000269|PubMed:21257904}.	
P31680	15	15		L->R: Loss of activation of rcs. {ECO:0000269|PubMed:9364918}.	
P31680	16	16		M->R: Only partial activation of rcs. {ECO:0000269|PubMed:9364918}.	
P31680	233	233		H->Q: Loss of activity. {ECO:0000269|PubMed:9364917}.	
P0AA37	28	28		K->M,R: Forms inclusion bodies, indicating precipitation even within the cell. {ECO:0000269|PubMed:10924141}.	
P0AA37	29	29		P->G,L: Reduced structural stability and decrease in activity. {ECO:0000269|PubMed:10924141}.	
P0AA37	64	64		D->N,T: Loss of activity. {ECO:0000269|PubMed:10383384}.	
P0AA37	117	117	1	C->A: No change in activity. {ECO:0000269|PubMed:10529181}.	
P0AA37	128	128	1	C->A: No change in activity. {ECO:0000269|PubMed:10529181}.	
P60240	183	183		K->A: Loss of function. Still interacts with RNAP. {ECO:0000269|PubMed:11751638}.	
P60240	280	281		DE->AA: Loss of function. Still interacts with RNAP. {ECO:0000269|PubMed:11751638}.	
P22186	15	15		R->A: Abolishes DNA binding. {ECO:0000269|PubMed:24659771}.	
P0AEN4	70	70		L->H: Impairs both localization and function, and reduces the efficiency of dimerization. {ECO:0000269|PubMed:10613870}.	
P0AEN4	84	84		L->D: Impairs both localization and function, and reduces the efficiency of dimerization. {ECO:0000269|PubMed:10613870}.	
P0AD68	307	307		S->A,T: Unable to bind penicillin. {ECO:0000269|PubMed:3911028}.	
P0AD68	307	307	1	S->C: Still able to bind penicillin. {ECO:0000269|PubMed:3911028}.	
P0AD68	361	361		N->S: In PBPBR1; obtained after selection for increased resistance to cephalexin, causes a change in the shape of the cell: The polar caps are pointed. {ECO:0000269|PubMed:3049550}.	
P0ABG4	145	145		R->A: Loss of flippase activity. Does not affect localization at the division site. {ECO:0000269|PubMed:24711460}.	
P0ABG4	150	152	1	ELT->AAA: Does not affect flippase activity. {ECO:0000269|PubMed:24711460}.	
P0ABG4	153	153		K->N: Loss of flippase activity. Does not affect localization at the division site. {ECO:0000269|PubMed:24711460}.	
P0ABG4	154	156	1	LSL->AAA: Does not affect flippase activity. {ECO:0000269|PubMed:24711460}.	
P0ABG4	170	170		E->K: In ftsW201; TS; blocks division at the initiation stage.	
P0ABG4	172	172		R->S: Does not affect localization, but affects its thermosensitivity. {ECO:0000269|PubMed:15576787}.	
P0ABG4	181	181		P->L: In ftsW1640; TS; blocks division at a late stage.	
P0ABG4	243	243		R->Q: Lack of activity. {ECO:0000269|PubMed:15576787}.	
P0ABG4	253	253		P->L: In ftsW263; TS; blocks division at the initiation stage.	
P0ABG4	311	311		G->D: Thermosensitive. Fails to localize to the division site at 42 degrees Celsius. {ECO:0000269|PubMed:15576787}.	
P0ABG4	368	368		P->A: Can not recruit FtsI at the division site; when associated with A- 375. {ECO:0000269|PubMed:15576787}.	
P0ABG4	375	375		P->A: Can not recruit FtsI at the division site; when associated with A- 368. {ECO:0000269|PubMed:15576787}.	
P0ABG4	402	402		R->Q: Does not affect localization and activity. {ECO:0000269|PubMed:15576787}.	
P17952	344	344		G->D: In murC3.	
P06136	29	29		L->R: No change in activity. Correctly assembled, interacts with FtsB and FtsL, but fails to localize efficiently to the cell division site; when associated with R-32. Does not insert into the membrane and lack of activity; when associated with R-32 and P-38. {ECO:0000269|PubMed:17693520}.	
P06136	32	32		L->R: No change in activity. Correctly assembled, interacts with FtsB and FtsL, but fails to localize efficiently to the cell division site; when associated with R-29. Does not insert into the membrane and lack of activity; when associated with R-29 and P-38. {ECO:0000269|PubMed:17693520}.	
P06136	38	38	1	V->P: No change in activity. Does not insert into the membrane and lack of activity; when associated with R-29 and R-32. {ECO:0000269|PubMed:17693520}.	
P06136	91	91	1	D->K,Q: Does not affect localization. {ECO:0000269|PubMed:18312270}.	
P06136	113	113		K->D: Impairs localization. {ECO:0000269|PubMed:18312270}.	
P06136	125	125		E->K: Impairs localization. {ECO:0000269|PubMed:18312270}.	
P06136	237	237		D->N: Localizes to mid-cell, but is unable to form a functional complex with FtsL/FtsB. {ECO:0000269|PubMed:18312270}.	
P0A9A6	1	32		Missing: No interaction with MreB or YeeV.	
P0A9A6	33	49		Missing: No interaction with CtpA.	
P0A9A6	105	105		G->F: In FtsZ-84; loss of GTPase-activity and conversion to an ATPase.	
P0A9A6	108	108		T->A: In FtsZ-Z3; lethal; greatly reduced GTP binding.	
P0A9A6	317	383		Missing: No interaction with MreB or CbtA (YeeV).	
P62395	1	1		M->V: Protein is not produced, (and therefore neither is SecA) indicating this is the start codon. {ECO:0000269|PubMed:10986266}.	
P62395	24	24	1	M->C: Protein is produced; this is not the start codon. {ECO:0000269|PubMed:11948148}.	
P62395	29	33		Missing: Loss of the ability to repress SecA-LacZ fusion proteins, translational pausing is very long, with almost no secretion. {ECO:0000269|PubMed:9748461}.	
P62395	31	34		Missing: Loss of the ability to repress SecA-LacZ fusion proteins. {ECO:0000269|PubMed:9748461}.	
P62395	163	163		R->A: Abolishes translation arrest. {ECO:0000269|PubMed:10986266}.	
P62395	166	170		Missing: Abolishes translation arrest. {ECO:0000269|PubMed:10986266}.	
P62395	166	166		P->A: Abolishes translation arrest. {ECO:0000269|PubMed:10986266}.	
P06959	603	603		H->C: Abolishes catalytic activity. {ECO:0000269|PubMed:2201286}.	
P36683	769	769		C->S: Inhibits the dimer formation. {ECO:0000269|PubMed:15882410}.	
P09158	158	158		D->A: Completely inactive. {ECO:0000269|PubMed:23001854}.	
P09158	159	159		C->A: Reduction of 23% of the aminopropyltransferase activity. {ECO:0000269|PubMed:23001854}.	
P09158	159	159	1	C->S: No influence on aminopropyltransferase activity. {ECO:0000269|PubMed:23001854}.	
P09158	160	160		T->A: Reduction of aminopropyltransferase activity. {ECO:0000269|PubMed:23001854}.	
P09158	161	161		D->A: Completely inactive. {ECO:0000269|PubMed:23001854}.	
P09158	162	162	1	P->A: No influence on aminopropyltransferase activity. {ECO:0000269|PubMed:23001854}.	
P09158	163	163	1	I->A: No influence on aminopropyltransferase activity. {ECO:0000269|PubMed:23001854}.	
P09158	165	165		P->A: Reduction of aminopropyltransferase activity. {ECO:0000269|PubMed:23001854}.	
P36649	500	501		CH->SR: Residual activity and loss of resistance to copper. {ECO:0000269|PubMed:11527384}.	
P0ABS1	71	71	1	D->N: Does not increase ppGpp-dependent inhibition of transcription, but retains its ability to bind to RNAP; when associated with N-74. {ECO:0000269|PubMed:15294156}.	
P0ABS1	74	74	1	D->N: Does not increase ppGpp-dependent inhibition of transcription, but retains its ability to bind to RNAP; when associated with N-71. {ECO:0000269|PubMed:15294156}.	
P37025	43	43		H->A: Lack of CPDase activity. {ECO:0000269|PubMed:25239919}.	
P37025	45	45		T->A: Lack of CPDase activity. {ECO:0000269|PubMed:25239919}.	
P37025	48	48		F->A: Decreases CPDase activity. {ECO:0000269|PubMed:25239919}.	
P37025	125	125		H->A: Lack of CPDase activity. {ECO:0000269|PubMed:25239919}.	
P37025	127	127	1	T->A: Does not affect CPDase activity. {ECO:0000269|PubMed:25239919}.	
P37025	130	130		R->A: Lack of CPDase activity. {ECO:0000269|PubMed:25239919}.	
P02919	233	233		E->Q: Loss of wild-type glycan chain elongation activity. No complementation in strain defective in PBP-1b. {ECO:0000269|PubMed:10564478}.	
P02919	234	234		D->N: 7-fold decrease in catalytic activity. No complementation in strain defective in PBP-1b. {ECO:0000269|PubMed:10564478}.	
P02919	290	290		E->Q: 11-fold decrease in catalytic activity. Shows complementation activity in strain defective in PBP-1b. {ECO:0000269|PubMed:10564478}.	
P23893	265	265		K->R: 2% of wild-type activity. {ECO:0000269|PubMed:1643048}.	
P37019	107	107		S->A: Uncouples chloride transport from proton transport. {ECO:0000269|PubMed:16341087}.	
P37019	148	148		E->A,Q: Abolishes proton transport, but permits the transit of chloride ions. Abolishes gating, permitting continuous rapid transit of chloride ions; when associated with A-445. {ECO:0000269|PubMed:12649487, ECO:0000269|PubMed:14985752, ECO:0000269|PubMed:16341087, ECO:0000269|PubMed:18678918}.	
P37019	203	203		E->A,G,Q,S,T: Abolishes proton transport, and reduces chloride transport. {ECO:0000269|PubMed:19139174}.	
P37019	203	203		E->C,I,L,V: Abolishes proton and chloride transport. {ECO:0000269|PubMed:19139174}.	
P37019	203	203	1	E->D,H: No effect on proton and chloride transport. {ECO:0000269|PubMed:19139174}.	
P37019	203	203		E->K,R: Decreased proton and chloride transport. {ECO:0000269|PubMed:19139174}.	
P37019	445	445		Y->A: Abolishes gating, permitting continuous rapid transit of chloride ions; when associated with A-148. {ECO:0000269|PubMed:16341087, ECO:0000269|PubMed:16949616, ECO:0000269|PubMed:18678918}.	
P37019	445	445	1	Y->F,W: No effect. {ECO:0000269|PubMed:16341087, ECO:0000269|PubMed:16949616, ECO:0000269|PubMed:18678918}.	
P37019	445	445		Y->L: Alters stoichiometry of proton/chloride exchange. {ECO:0000269|PubMed:16341087, ECO:0000269|PubMed:16949616, ECO:0000269|PubMed:18678918}.	
P0ACC3	42	42		C->S: Does not complement knockout. {ECO:0000269|PubMed:17698959}.	
P0ACC3	106	106		C->S: Does not complement knockout. {ECO:0000269|PubMed:17698959}.	
P0ACC3	108	108		C->S: Does not complement knockout. {ECO:0000269|PubMed:17698959}.	
P0AF12	9	9		M->A: 13-19% of wild-type catalytic efficiency. {ECO:0000269|PubMed:16101288}.	
P0AF12	12	12		E->A,Q: Loss of catalytic activity. {ECO:0000269|PubMed:16101288}.	
P0AF12	50	50		I->A: 12-23% of wild-type catalytic efficiency. {ECO:0000269|PubMed:16101288}.	
P0AF12	76	76		S->A: 13-23% of wild-type catalytic efficiency. {ECO:0000269|PubMed:16101288}.	
P0AF12	151	151		F->A: 0.5% of wild-type catalytic efficiency. {ECO:0000269|PubMed:16101288}.	
P0AF12	173	173		M->A: 0.5% of wild-type catalytic efficiency. {ECO:0000269|PubMed:16101288}.	
P0AF12	174	174		E->A,Q: Loss of catalytic activity. {ECO:0000269|PubMed:16101288}.	
P0AF12	193	193		R->A: 13-28% of wild-type catalytic efficiency. {ECO:0000269|PubMed:16101288}.	
P0AF12	196	196		S->A: 2-4% of wild-type catalytic efficiency. {ECO:0000269|PubMed:16101288}.	
P0AF12	197	197		D->A,N: Loss of catalytic activity. {ECO:0000269|PubMed:16101288}.	
P0AF12	207	207		F->A: 2% of wild-type catalytic efficiency. {ECO:0000269|PubMed:16101288}.	
P0C0V0	131	131		H->R: Loss of peptidase activity with no detectable changes in secondary structure. {ECO:0000269|PubMed:7557477}.	
P0C0V0	236	236		S->A: Loss of peptidase activity with no detectable changes in secondary structure. {ECO:0000269|PubMed:12730160, ECO:0000269|PubMed:7557477}.	
P0C0V0	254	254		I->N: It does not affect the proteolytic activity. {ECO:0000269|PubMed:20515644}.	
P0C0V0	255	255		L->N: Loss of proteolytic activity. {ECO:0000269|PubMed:20515644}.	
P0C0V0	258	258	1	D->V: Increases the proteolytic activity. {ECO:0000269|PubMed:20515644}.	
P0C0V0	261	261		N->I: Loss of proteolytic activity. {ECO:0000269|PubMed:20515644}.	
P0C0V0	262	262		I->N: Stimulates the proteolytic activity at low temperatures (20-30 degrees Celsius), whereas at higher temperatures (above 35 degrees Celsius), the proteolytic activity is less efficient. {ECO:0000269|PubMed:20515644}.	
P0C0V0	264	264		I->N: Loss of proteolytic activity. {ECO:0000269|PubMed:20515644}.	
P27249	93	93		G->L,V: Loss of UTase activity, while no significant effect on UR activity. {ECO:0000269|PubMed:20363937}.	
P27249	94	94		G->D: Loss of UTase activity, while no significant effect on UR activity. {ECO:0000269|PubMed:20363937}.	
P27249	107	107		D->A,V,Y: Loss of UTase activity, while no significant effect on UR activity. {ECO:0000269|PubMed:20363937}.	
P27249	514	515		HD->AA,QN: Loss of UR activity, while no significant effect on UTase activity. {ECO:0000269|PubMed:20363937}.	
P0AE18	79	79		H->A: Reduces activity 100000-fold for the Co(2+)-complexed enzyme, but only 2.6-fold for the Mn(2+)-complexed enzyme. {ECO:0000269|PubMed:10387007, ECO:0000269|PubMed:18855426}.	
P0AE18	97	97		D->A,E,N: Reduces activity 50- to 580- fold depending on the metal ion bound. Binds only one equivalent of the divalent metal cation with affinities identical to the wild-type enzyme. {ECO:0000269|PubMed:19019076}.	
P0AE18	178	178		H->A: Reduces activity 9000-fold for the Co(2+)-complexed enzyme. Binds only one equivalent of the divalent metal cation with affinities identical to the wild- type enzyme. {ECO:0000269|PubMed:10387007, ECO:0000269|PubMed:12755633}.	
P0A6P1	24	24		K->A: No change in binding to EF-Tu and in promoting GDP exchange. {ECO:0000269|PubMed:9468511}.	
P0A6P1	81	81		D->A: 2 to 3-fold less active in promoting GDP exchange and slightly lower binding constant for interaction with EF- Tu. {ECO:0000269|PubMed:9468511}.	
P0A6P1	82	82		F->A: 2 to 3-fold less active in promoting GDP exchange and 6-fold less active in binding to EF-Tu. {ECO:0000269|PubMed:9468511}.	
P0A6P1	148	148		H->A: At least 100-fold decrease in affinity between EF-Ts and EF-Tu and only small amount of GDP exchange activity. {ECO:0000269|PubMed:9468511}.	
P0A7E9	62	62		R->H: Loss of activation by GTP and decreased affinity for UTP. {ECO:0000269|PubMed:9457846}.	
P0A7E9	77	77		D->N: Loss of activation by GTP and decreased affinity for UTP. {ECO:0000269|PubMed:9457846}.	
P0A7E9	138	138		T->A: Loss of activation by GTP. Moderate loss of sensitivity to UTP inhibition. 4- fold and 2-fold decrease in affinity for UMP and ATP, respectively. {ECO:0000269|PubMed:15857829}.	
P0A7E9	140	140		N->A: Loss of activation by GTP. Moderate loss of sensitivity to UTP inhibition. {ECO:0000269|PubMed:15857829}.	
P0A7E9	146	146		D->N: Drastically reduced activity. {ECO:0000269|PubMed:9457846}.	
P0A7E9	159	159		D->N: Increased solubility at neutral pH. Nearly no change in kinetic properties and stability. {ECO:0000269|PubMed:9457846}.	
P0A7E9	174	174		D->N: Reduced UMP-binding affinity. {ECO:0000269|PubMed:9457846}.	
P0A7E9	201	201		D->N: Loss of activation by GTP. {ECO:0000269|PubMed:7711027, ECO:0000269|PubMed:9457846}.	
P45568	14	14		G->D: Loss of solubility and activity. {ECO:0000269|PubMed:10787409}.	
P45568	153	153		H->Q: Increase in KM for substrate. Reduces activity 35-fold. {ECO:0000269|PubMed:10787409}.	
P45568	209	209		H->Q: Increase in KM for substrate. Reduces activity 5000-fold. {ECO:0000269|PubMed:10787409}.	
P45568	231	231		E->K: No effect on KM for substrate. Reduces activity by over 99.9%. {ECO:0000269|PubMed:10787409}.	
P45568	257	257		H->Q: Strong increase in KM for substrate. Loss of activity. {ECO:0000269|PubMed:10787409}.	
P60472	26	26		D->A: Great decrease in activity. {ECO:0000269|PubMed:11076526}.	
P60472	31	31		W->F: Decrease in activity; reduced affinity for decaprenyl diphosphate substrate analog. {ECO:0000269|PubMed:11744728}.	
P60472	43	43		H->A: Great decreases in the catalytic efficiency and the affinity for FPP and IPP. {ECO:0000269|PubMed:12756244}.	
P60472	62	62		I->A: Formation predominantly of C(60) and C(65) polymers rather than the C(55) polymer. {ECO:0000269|PubMed:11581264}.	
P60472	69	69		A->L: Produces shorter polymers. {ECO:0000269|PubMed:11581264}.	
P60472	71	71		S->A: Decrease in activity. {ECO:0000269|PubMed:11581264}.	
P60472	73	73		E->A: Slight decrease in activity. {ECO:0000269|PubMed:11076526, ECO:0000269|PubMed:11581264}.	
P60472	74	74		N->A: Decrease in activity. {ECO:0000269|PubMed:11581264}.	
P60472	75	75		W->A,F: Decrease in activity; reduced affinity for decaprenyl diphosphate substrate analog. {ECO:0000269|PubMed:11581264, ECO:0000269|PubMed:11744728}.	
P60472	77	77		R->A: Decrease in activity. {ECO:0000269|PubMed:11581264}.	
P60472	81	81		E->A: Slight decrease in activity. {ECO:0000269|PubMed:11581264}.	
P60472	91	91		W->F: Decrease in affinity for IPP. {ECO:0000269|PubMed:11744728}.	
P60472	103	103	1	H->A: No effect. {ECO:0000269|PubMed:11581264}.	
P60472	105	105		V->A: Formation predominantly of C(60), C(65) and C(70) polymers rather than the C(55) polymer. {ECO:0000269|PubMed:11581264}.	
P60472	137	137		L->A: Formation predominantly of a C(70) polymer rather than the C(55) polymer. {ECO:0000269|PubMed:11581264}.	
P60472	143	143	1	A->V: No effect on polymer length. {ECO:0000269|PubMed:11581264}.	
P60472	149	149		W->F: Decrease in affinity for IPP. {ECO:0000269|PubMed:11744728}.	
P60472	150	150		D->A: Great decrease in affinity for the substrate. {ECO:0000269|PubMed:11076526}.	
P60472	190	190	1	D->A: No effect. {ECO:0000269|PubMed:11076526}.	
P60472	198	198	1	E->A: No effect. {ECO:0000269|PubMed:11076526}.	
P60472	199	199		H->A: Great decreases in the catalytic efficiency and in the affinity for IPP; when associated with A-213. {ECO:0000269|PubMed:12756244}.	
P60472	207	207		W->F: Decrease in affinity for both IPP and decaprenyl diphosphate substrate analog. {ECO:0000269|PubMed:11744728}.	
P60472	213	213		E->A: Great decrease in activity; reduced affinity for IPP. Great decreases in the catalytic efficiency and in the affinity for IPP; when associated with A-199. {ECO:0000269|PubMed:11076526, ECO:0000269|PubMed:12756244}.	
P60472	218	218		D->A: Slight decrease in activity. {ECO:0000269|PubMed:11076526}.	
P60472	221	221		W->F: Decrease in affinity for IPP. {ECO:0000269|PubMed:11744728}.	
P60472	223	223	1	D->A: No effect. {ECO:0000269|PubMed:11076526}.	
P0AEH1	22	22		H->A: Loss of protease activity. {ECO:0000269|PubMed:11689431, ECO:0000269|PubMed:11750129, ECO:0000269|PubMed:12183368, ECO:0000269|PubMed:15496982, ECO:0000269|PubMed:18268014, ECO:0000269|PubMed:21810987}.	
P0AEH1	22	22		H->F: Loss of protease activity of RseA and signal peptides, does not complement deletion mutant. Binds substrate. {ECO:0000269|PubMed:11689431, ECO:0000269|PubMed:11750129, ECO:0000269|PubMed:12183368, ECO:0000269|PubMed:15496982, ECO:0000269|PubMed:18268014, ECO:0000269|PubMed:21810987}.	
P0AEH1	23	23		E->A: Low basal sigma-E activity, sigma-E not induced. No proteolysis of RseA. {ECO:0000269|PubMed:11750129, ECO:0000269|PubMed:12183369, ECO:0000269|PubMed:18268014}.	
P0AEH1	23	23		E->D: Behaves like wild-type in vivo, slight reduction in RseA cleavage in vitro. {ECO:0000269|PubMed:11750129, ECO:0000269|PubMed:12183369, ECO:0000269|PubMed:18268014}.	
P0AEH1	23	23		E->Q: Does not complement deletion mutant. {ECO:0000269|PubMed:11750129, ECO:0000269|PubMed:12183369, ECO:0000269|PubMed:18268014}.	
P0AEH1	23	23		E->S: Loss of protease activity. {ECO:0000269|PubMed:11750129, ECO:0000269|PubMed:12183369, ECO:0000269|PubMed:18268014}.	
P0AEH1	26	26		H->F: Does not complement deletion mutant. {ECO:0000269|PubMed:11750129}.	
P0AEH1	115	115		A->V: No effect. Cleaves RseA without previous DegS cleavage; when associated with R-214. {ECO:0000269|PubMed:18945679}.	
P0AEH1	145	145		I->N: Cuts RseA without previous DegS cleavage. {ECO:0000269|PubMed:18945679}.	
P0AEH1	151	151		L->P: Cuts RseA without previous DegS cleavage. {ECO:0000269|PubMed:18945679}.	
P0AEH1	162	162		W->R: Cuts RseA without previous DegS cleavage. {ECO:0000269|PubMed:18945679}.	
P0AEH1	169	169		L->S: Cuts RseA without previous DegS cleavage. {ECO:0000269|PubMed:18945679}.	
P0AEH1	213	213		L->P: Cuts RseA without previous DegS cleavage. {ECO:0000269|PubMed:18945679}.	
P0AEH1	214	214		G->E,Q: Cuts RseA without previous DegS cleavage. {ECO:0000269|PubMed:14633997, ECO:0000269|PubMed:18945679}.	
P0AEH1	214	214	1	G->R: Weakly cuts RseA without previous DegS cleavage. Stronger cleavage; when associated with V-115. {ECO:0000269|PubMed:14633997, ECO:0000269|PubMed:18945679}.	
P0AEH1	215	215		I->A: No cleavage of RseA in vitro (PubMed:19706448), cleavage of RseA (PubMed:23016873) in vivo. {ECO:0000269|PubMed:19706448, ECO:0000269|PubMed:23016873}.	
P0AEH1	234	235		AA->KK: Cuts RseA without previous DegS cleavage. {ECO:0000269|PubMed:14633997}.	
P0AEH1	243	243		G->Q: Cuts RseA without previous DegS cleavage. {ECO:0000269|PubMed:14633997}.	
P0AEH1	244	244		D->K: Cuts RseA without previous DegS cleavage. {ECO:0000269|PubMed:14633997}.	
P0AEH1	246	246		I->Y: Cuts RseA without previous DegS cleavage. {ECO:0000269|PubMed:14633997}.	
P0AEH1	261	261		V->VTDSYTQVASWTEPFPFSIQGDPRSDQETAFV: Does not complement deletion mutant. {ECO:0000269|PubMed:11750129}.	
P0AEH1	304	304		I->A: No cleavage of RseA in vitro (PubMed:19706448), cleavage of RseA (PubMed:23016873) in vivo. {ECO:0000269|PubMed:19706448, ECO:0000269|PubMed:23016873}.	
P0AEH1	389	389		N->C,G,L: Decreased substrate binding, retains some proteolytic activity. {ECO:0000269|PubMed:18268014}.	
P0AEH1	389	389	1	N->Q: No effect. {ECO:0000269|PubMed:18268014}.	
P0AEH1	394	394		N->C: Decreased substrate binding, retains some proteolytic activity. {ECO:0000269|PubMed:18268014}.	
P0AEH1	397	397		P->C: Decreased substrate binding, retains some proteolytic activity. {ECO:0000269|PubMed:18268014}.	
P0AEH1	399	399		P->C: Decreased substrate binding, retains some proteolytic activity. {ECO:0000269|PubMed:18268014}.	
P0AEH1	402	402		D->N: Does not complement deletion mutant, loss of protease activity. {ECO:0000269|PubMed:11750129, ECO:0000269|PubMed:12183368}.	
P0A940	435	435		E->L: Very minor growth defect. Lethal; when associated with L-800. {ECO:0000269|PubMed:24619089}.	
P0A940	464	464		D->L: Very minor growth defect. {ECO:0000269|PubMed:24619089}.	
P0A940	500	500		D->L: Very minor growth defect. {ECO:0000269|PubMed:24619089}.	
P0A940	547	547		R->A: Lethal. {ECO:0000269|PubMed:24619089}.	
P0A940	554	562		EHPSTSDQD->VDYPYDVPDYA: Loop 4 to HA epitope; still susceptible to CdiA-EC93. {ECO:0000269|PubMed:23882017}.	
P0A940	556	563		PSTSDQDN->G: Delta loop 4; slight increase in resistance to CdiA-EC93, forms aggregates with CdiA-EC93 cells. {ECO:0000269|PubMed:23882017}.	
P0A940	661	661		R->A: Slow growth on solid and liquid media, less protein accumulates which is more proteinase sensitive. {ECO:0000269|PubMed:24619089}.	
P0A940	673	702		Missing: Lethal. {ECO:0000269|PubMed:24619089}.	
P0A940	675	701		FPHQASNYDPDYDYECATQDGAKDLCK->G: Delta loop 6; fully resistant to CdiA-EC93, does not form aggregates with CdiA-EC93 cells. {ECO:0000269|PubMed:23882017}.	
P0A940	677	685		HQASNYDPD->VDYPYDVPDYA: Loop 6 to HA epitope; still susceptible to CdiA-EC93. {ECO:0000269|PubMed:23882017}.	
P0A940	740	740		D->A: Slow growth on solid and liquid media, less protein accumulates which is more proteinase sensitive. {ECO:0000269|PubMed:24619089}.	
P0A940	754	755		YS->VDYPYDVPDYA: Loop 7 to HA epitope; fully resistant to CdiA-EC93, does not form aggregates with CdiA-EC93 cells. {ECO:0000269|PubMed:23882017}.	
P0A940	800	800		E->L: Very minor growth defect. Lethal; when associated with L-435. {ECO:0000269|PubMed:24619089}.	
P21645	41	41		F->A: 30-fold decrease in affinity for UDP-3-O-((3R)-hydroxytetradecanoyl)-GlcN and 5-fold decrease in catalytic activity. {ECO:0000269|PubMed:18422345}.	
P21645	165	165		Q->R: In firA200; confers temperature sensitivity and reverses the rifampicin resistance of rpoB mutants. {ECO:0000269|PubMed:1987124}.	
P21645	172	172		I->F: In firA201; confers temperature sensitivity.	
P21645	228	228		G->D: In firA200 and firA201; confers temperature sensitivity. {ECO:0000269|PubMed:1987124}.	
P21645	239	239		H->A: 1000-fold reduction in catalytic activity with very little effect on substrate affinity. {ECO:0000269|PubMed:18422345}.	
P21645	252	252		G->S: In firA200 and firA201; confers temperature sensitivity. {ECO:0000269|PubMed:1987124}.	
P21645	271	271		S->N: In omsA; confers temperature sensitivity. {ECO:0000269|PubMed:1429432}.	
P21645	276	276		H->A: 30-fold reduction in catalytic activity. {ECO:0000269|PubMed:18422345}.	
P21645	290	290		M->A: Change in the acyl donor selectivity, showing a preference for 3- hydroxypalmitoyl-ACP over 3- hydroxytetradecanoyl-ACP as substrate. Produces a lipid A with longer acyl chains. {ECO:0000269|PubMed:19655786}.	
P21645	292	292	1	M->A: No change in the acyl donor selectivity. {ECO:0000269|PubMed:19655786}.	
P0A6Q6	85	85		L->P: In sfhC21; suppresses an ftsH deletion mutant as well as an ftsH temperature-sensitive mutation. Probably stabilizes the enzyme. {ECO:0000269|PubMed:10048027}.	
P40711	26	27		GG->VA: Strong decrease in activity. {ECO:0000269|PubMed:21051357}.	
P40711	27	28		GQ->AE: Strong decrease in activity. {ECO:0000269|PubMed:21051357}.	
P40711	27	27		G->A: Decrease in activity. {ECO:0000269|PubMed:21051357, ECO:0000269|PubMed:21418110}.	
P40711	28	28		Q->E: Decrease in activity. {ECO:0000269|PubMed:21051357}.	
P16659	257	257		T->A: Reduces the posttransfer editing activity 5-fold, with little change in both the aminoacylation and the pretransfer editing activities. {ECO:0000269|PubMed:12033945}.	
P16659	279	279		K->A: Severely affects the posttransfer editing activity, with little change in both the aminoacylation and the pretransfer editing activities. {ECO:0000269|PubMed:12033945}.	
P16659	350	350		D->A: Abolishes the pretransfer editing activity and reduces the aminoacylation activity 20-fold and the posttransfer editing activity 5-fold. {ECO:0000269|PubMed:12033945}.	
P16659	369	369		H->A: Reduces both the aminoacylation and the pretransfer editing activities 2.5- fold, and the posttransfer editing activity 5-fold. Loss of specificity in deacylation. {ECO:0000269|PubMed:12033945}.	
P16659	378	378		D->A: Little change in both the aminoacylation and the editing activities. {ECO:0000269|PubMed:12033945}.	
P16659	386	386		D->A: Reduces the posttransfer editing activity approximately 2-fold, with little change in both the aminoacylation and the pretransfer editing activities. {ECO:0000269|PubMed:12033945}.	
P16659	394	394		D->A: Reduces the posttransfer editing activity approximately 2-fold, with little change in both the aminoacylation and the pretransfer editing activities. {ECO:0000269|PubMed:12033945}.	
P16659	443	443		C->G: 150-fold decrease in posttransfer editing activity against alanine, without change neither in pretransfer editing nor in aminoacylation. {ECO:0000269|PubMed:10922054}.	
P69411	7	7	1	C->S: Does not affect exopolysaccharide biosynthesis. {ECO:0000269|PubMed:21471196}.	
P69411	16	16		C->S: Strongly decreases exopolysaccharide biosynthesis. {ECO:0000269|PubMed:21471196}.	
P69411	74	74		C->S: Mucoid phenotype. Decreases exopolysaccharide biosynthesis. {ECO:0000269|PubMed:21454485, ECO:0000269|PubMed:21471196}.	
P69411	89	89	1	R->A: Does not affect exopolysaccharide biosynthesis; when associated with A-90. {ECO:0000269|PubMed:21471196}.	
P69411	90	90	1	K->A: Does not affect exopolysaccharide biosynthesis; when associated with A-89. {ECO:0000269|PubMed:21471196}.	
P69411	109	109		C->S: Does not activate the production of capsule polysaccharides. {ECO:0000269|PubMed:21454485, ECO:0000269|PubMed:21471196}.	
P69411	118	118		C->S: Mucoid phenotype. Decreases exopolysaccharide biosynthesis. {ECO:0000269|PubMed:21454485, ECO:0000269|PubMed:21471196}.	
P69411	124	124		C->S: Does not activate the production of capsule polysaccharides. {ECO:0000269|PubMed:21454485, ECO:0000269|PubMed:21471196}.	
P63228	11	11		D->N: Inactive. {ECO:0000269|PubMed:20050699}.	
P63228	13	13		D->A: Inactive. {ECO:0000269|PubMed:20050614, ECO:0000269|PubMed:20050699}.	
P63228	13	13		D->N: Inactive. {ECO:0000269|PubMed:20050614, ECO:0000269|PubMed:20050699}.	
P63228	92	92		C->A: Reduces the catalytic efficiencies towards the alpha and beta-anomers of HBP. {ECO:0000269|PubMed:20050614}.	
P63228	107	107		C->A: More than 3-fold reduction in the affinity binding of HBP. Reduces the catalytic efficiencies towards the alpha and beta-anomers of HBP. {ECO:0000269|PubMed:20050614, ECO:0000269|PubMed:20050699}.	
P63228	109	109		C->A: Reduces the catalytic efficiencies towards the alpha and beta-anomers of HBP. {ECO:0000269|PubMed:20050614}.	
P63228	110	110		R->A: Significant reduction in the catalytic efficiency of hydrolysis of the physiological substrate HBP. {ECO:0000269|PubMed:20050614}.	
P63228	111	111		K->N: Inactive. {ECO:0000269|PubMed:20050699}.	
P63228	137	137		K->A: 8-fold reduction in the affinity binding of HBP. {ECO:0000269|PubMed:20050614}.	
P0A7Y4	10	10		D->N: Loss of activity. {ECO:0000269|PubMed:1689729}.	
P0A7Y4	48	48		E->Q: Loss of activity. {ECO:0000269|PubMed:1689729}.	
P0A7Y4	70	70		D->N: Loss of activity. {ECO:0000269|PubMed:1689729}.	
P0A7Y4	124	124		H->A: Reduces activity. {ECO:0000269|PubMed:1689729, ECO:0000269|PubMed:8931125, ECO:0000269|PubMed:9852071}.	
P0A7Y4	130	130		N->A: Reduces activity. {ECO:0000269|PubMed:1689729}.	
P0A7Y4	134	134		D->A: Loss of activity. {ECO:0000269|PubMed:1689729, ECO:0000269|PubMed:8931125, ECO:0000269|PubMed:9852071}.	
P0A7Y4	134	134		D->H,N: Slight decrease of activity. {ECO:0000269|PubMed:1689729, ECO:0000269|PubMed:8931125, ECO:0000269|PubMed:9852071}.	
P63224	61	61	1	H->Q: Almost no effect. {ECO:0000269|PubMed:18056714}.	
P63224	65	65		E->N,Q: No activity. {ECO:0000269|PubMed:18056714}.	
P63224	69	69	1	R->Q: Almost no effect. {ECO:0000269|PubMed:18056714}.	
P63224	94	94		D->N: No activity. {ECO:0000269|PubMed:18056714}.	
P63224	120	120		T->A: No activity. {ECO:0000269|PubMed:18056714}.	
P63224	169	169		D->N: No activity. {ECO:0000269|PubMed:18056714}.	
P63224	172	172		Q->E: No activity. {ECO:0000269|PubMed:18056714}.	
P63224	180	180		H->Q: No activity. {ECO:0000269|PubMed:18056714}.	
Q47149	87	87		H->Q: Loss of mRNA cleavage, loss of toxic effect. Still associates with the ribosome. {ECO:0000269|PubMed:19210620}.	
Q47155	8	8		D->A,H: Loss of function. {ECO:0000269|PubMed:10488344}.	
Q47155	49	49		R->A,F: Loss of function. {ECO:0000269|PubMed:10488344}.	
Q47155	103	103		D->A,N: Loss of function. {ECO:0000269|PubMed:10488344}.	
Q47155	104	104		E->A: Loss of function. {ECO:0000269|PubMed:10488344}.	
P0A9M5	59	59	1	C->A: No effect on catalytic activity; increased stability. {ECO:0000269|PubMed:8812991}.	
P02932	351	351		F->Y,N,S,V: Less resistant to trypsin. {ECO:0000269|PubMed:1848301}.	
P71301	179	179		H->P: Slightly increases motility. {ECO:0000269|PubMed:22422754}.	
P77379	21	21		C->A: Does not induce expression of target genes in response to HOCl. {ECO:0000269|PubMed:24078635}.	
P77379	42	42		H->A: Increases expression of the target genes in the absence of HOCl. {ECO:0000269|PubMed:24078635}.	
P77379	75	75		H->A: Increases expression of the target genes in the absence of HOCl. In vitro, increases DNA binding under reducing conditions. {ECO:0000269|PubMed:24078635}.	
P77379	89	89		C->A: Does not induce expression of target genes in response to HOCl. {ECO:0000269|PubMed:24078635}.	
P77541	123	123		C->S: Inactive. {ECO:0000269|PubMed:15723538}.	
P25524	157	157		Q->A,N: Less than 0.01% of wild-type enzymatic activity. {ECO:0000269|PubMed:21545144}.	
P25524	218	218		E->A,Q: Less than 0.01% of wild-type enzymatic activity. {ECO:0000269|PubMed:21545144}.	
P25524	247	247		H->A,N: Less than 0.01% of wild-type enzymatic activity. {ECO:0000269|PubMed:21545144}.	
P25524	247	247	1	H->Q: 200-fold decrease in catalytic efficiency. {ECO:0000269|PubMed:21545144}.	
P25524	314	314		D->A: 17-fold decrease in catalytic efficiency with cytosine as substrate and 2-fold increase in that with 5FC as substrate. Shows increased sensitivity to 5FC. {ECO:0000269|PubMed:15381761}.	
P25524	314	314		D->A: Less than 0.01% of wild-type enzymatic activity. {ECO:0000269|PubMed:21545144}.	
P25524	314	314	1	D->G,S: Still active towards cytosine. Shows increased sensitivity to 5FC. {ECO:0000269|PubMed:15381761}.	
P25524	314	314		D->K,R,H: Loss of enzymatic activity. {ECO:0000269|PubMed:15381761}.	
P25524	314	314		D->N: 35000-fold decrease in catalytic efficiency. {ECO:0000269|PubMed:21545144}.	
P02920	237	237		D->N,G: Defect in melibiose transport.	
P02920	358	358		K->T: Defect in melibiose transport.	
P00722	202	202		D->E,N: Causes a significant decrease in binding affinity in the absence of monovalent cations or in the presence of potassium ions, but only a moderate decrease in the presence of sodium ions. {ECO:0000269|PubMed:15060622}.	
P00722	202	202		D->F: Obliterates all binding and catalysis. {ECO:0000269|PubMed:15060622}.	
P00722	358	358		H->D,F,L,N: Less stable to heat than wild-type. Causes significant destabilizations of the first transition state. {ECO:0000269|PubMed:9665715}.	
P00722	392	392		H->E,F,K: Essentially inactive unless very rapid purification. Causes very large destabilizations of the transition state. {ECO:0000269|PubMed:11310566}.	
P00722	462	462		E->H: Slowly inactivates galactosidase activity by reducing the binding of magnesium. It increases binding specificity. {ECO:0000269|PubMed:7577931}.	
P00722	538	538		E->Q: 10000-fold decrease in the beta- galactosidase activity. {ECO:0000269|PubMed:11732897}.	
P00722	541	541		H->E,F,N: Poorly reactive with galactosyl substrates. Less stable to heat than wild-type. {ECO:0000269|PubMed:8662937}.	
P00722	602	602		F->A: Decreases the stability of the loop 794-804. {ECO:0000269|PubMed:11732897}.	
P00722	795	795		G->A: It forces the apoenzyme to adopt the closed rather than the open conformation. Reduces the binding affinity. {ECO:0000269|PubMed:14621996}.	
P00722	798	798		E->A,L: The catalytic efficiency is not increased, when the sodium concentration increases. {ECO:0000269|PubMed:17126292}.	
P00722	798	798		E->D,Q: Small increase of the catalytic efficiency, when the sodium concentration increases. {ECO:0000269|PubMed:17126292}.	
P00722	1000	1000		W->F,G,L,T: Decreases affinity for substrate. {ECO:0000269|PubMed:12578395}.	
P03023	17	17		Y->H: Broadening of specificity.	
P03023	22	22		R->N: Recognizes an operator variant.	
P0ABR9	114	114		D->A: Complete loss of extradiol cleavage activity. {ECO:0000269|PubMed:15491145}.	
P0ABR9	114	114		D->N: Low level of catalytic activity, 600-fold lower than the wild-type enzyme. More than 8000-fold decrease in affinity. {ECO:0000269|PubMed:15491145}.	
P0ABR9	115	115		H->A: Complete loss of extradiol cleavage activity. {ECO:0000269|PubMed:15491145}.	
P0ABR9	115	115		H->Q: Complete loss of activity. {ECO:0000269|PubMed:15491145}.	
P0ABR9	115	115		H->Y: Complete loss of activity. {ECO:0000269|PubMed:15491145}.	
P0ABR9	179	179		H->A: Complete loss of activity. {ECO:0000269|PubMed:15491145}.	
P0ABR9	179	179		H->Q: Complete loss of activity. {ECO:0000269|PubMed:15491145}.	
P0ABR9	179	179		H->Y: Complete loss of activity. {ECO:0000269|PubMed:15491145}.	
P0ABR9	181	181		P->A: More than 2-fold decrease in catalytic activity and 100-fold decrease in affinity. {ECO:0000269|PubMed:15491145}.	
P0ABR9	181	181		P->H: More than 60-fold decrease in catalytic activity and affinity. {ECO:0000269|PubMed:15491145}.	
P77044	44	44		S->A: 2-fold decrease in catalytic efficiency and more than 5-fold increase in affinity for the natural substrate. {ECO:0000269|PubMed:15663941}.	
P77044	113	113		N->A: 200-fold decrease in catalytic activity and almost 2-fold increase in affinity. {ECO:0000269|PubMed:17029402}.	
P77044	113	113		N->H: 350-fold decrease in catalytic activity and almost 2-fold increase in affinity. {ECO:0000269|PubMed:17029402}.	
P77044	114	114		S->A: Weakly active. 3-fold decrease in affinity. Fast ketonisation and slow C-C cleavage. {ECO:0000269|PubMed:15663941}.	
P77044	114	114		S->G: Weakly active. 3-fold decrease in affinity. Fast ketonisation and slow C-C cleavage. {ECO:0000269|PubMed:15663941}.	
P77044	118	118		H->A: More than 2-fold decrease in catalytic efficiency and 3-fold increase affinity. {ECO:0000269|PubMed:15663941}.	
P77044	177	177		F->D: 100-fold decrease in catalytic activity. {ECO:0000269|PubMed:17029402}.	
P77044	177	177		F->G: 4-fold and 8-fold decrease in catalytic activity and affinity, respectively. {ECO:0000269|PubMed:17029402}.	
P77044	192	192		R->K: 40-fold and 5-fold decrease in catalytic activity and affinity, respectively. {ECO:0000269|PubMed:17029402}.	
P77044	192	192		R->Q: 280-fold and 10-fold decrease in catalytic activity and affinity, respectively. {ECO:0000269|PubMed:17029402}.	
P77044	265	265		C->A: 2-fold decrease in catalytic activity and almost 2-fold increase in affinity. {ECO:0000269|PubMed:17029402}.	
P77044	267	267		H->A: Weakly active, 1000-fold decrease in catalytic efficiency. Very slow ketonisation and C-C cleavage. {ECO:0000269|PubMed:15663941}.	
P77044	268	268		W->G: 10-fold and 20-fold decrease in catalytic activity and affinity, respectively. {ECO:0000269|PubMed:17029402}.	
P77589	27	27		E->A: Lack of 3HPP transport activity. {ECO:0000269|PubMed:23934492}.	
P77589	27	27		E->D: Slight decrease in 3HPP transport activity. {ECO:0000269|PubMed:23934492}.	
P77589	75	75		D->A,E: Lack of 3HPP transport activity. {ECO:0000269|PubMed:23934492}.	
P77589	272	272		A->H: 30% increase in 3HPP transport activity. {ECO:0000269|PubMed:23934492}.	
P77589	276	276		K->D: Lack of 3HPP transport activity. {ECO:0000269|PubMed:23934492}.	
P0ACB2	127	127	1	H->A: No significant effect on activity; when associated with A-129. {ECO:0000269|PubMed:7592604}.	
P0ACB2	129	129	1	H->A: No significant effect on activity; when associated with A-127. {ECO:0000269|PubMed:7592604}.	
P0AAN9	9	9		L->S: Loss of ability to interact with RssB. {ECO:0000269|PubMed:16600914}.	
P0AAP1	291	292		DE->AA: No c-di-GMP produced in an overexpressing strain. {ECO:0000269|PubMed:19707751}.	
P0A847	28	28		C->A: Slight loss of activity. {ECO:0000269|PubMed:7893665}.	
P0A847	90	90		S->A: Loss of activity. {ECO:0000269|PubMed:8003468}.	
P0A847	90	90		S->C: Loss of activity. {ECO:0000269|PubMed:8003468}.	
P0A847	90	90		S->F: Loss of activity. {ECO:0000269|PubMed:8003468}.	
P0A847	145	145	1	C->A: No loss of activity. {ECO:0000269|PubMed:7893665}.	
P0A847	232	232		C->A: Slight loss of activity. {ECO:0000269|PubMed:7893665}.	
P0A847	265	265		C->A: Significant loss of activity. {ECO:0000269|PubMed:7893665}.	
P0A847	302	302		C->A: Loss of activity. {ECO:0000269|PubMed:7893665}.	
P0A847	304	304		C->A: Loss of activity. {ECO:0000269|PubMed:7893665}.	
P0A847	307	307		C->A: Loss of activity. {ECO:0000269|PubMed:7893665}.	
P0A847	316	316		H->A: Slight loss of activity. {ECO:0000269|PubMed:7893665}.	
P0A847	317	317		H->A: Loss of activity. {ECO:0000269|PubMed:7893665}.	
P0A847	321	321	1	C->A: No loss of activity. {ECO:0000269|PubMed:7893665}.	
P0AG90	519	519		D->N: Abolishes protein translocation. {ECO:0000269|PubMed:21562494}.	
P0AG93	213	213		D->M: Abolishes protein translocation. {ECO:0000269|PubMed:21562494}.	
P0AG93	247	247		R->M: Abolishes protein translocation. {ECO:0000269|PubMed:21562494}.	
P77488	370	370		E->A: Loss of activity. {ECO:0000269|PubMed:17135236}.	
P77488	392	392	1	Y->A: Slightly increases activity. {ECO:0000269|PubMed:17135236}.	
P77488	392	392		Y->F: Increases activity 3-fold. {ECO:0000269|PubMed:17135236}.	
P77488	398	398		R->A: Loss of activity. {ECO:0000269|PubMed:17135236}.	
P77488	431	431	1	H->A: No effect on activity. {ECO:0000269|PubMed:17135236}.	
P77488	478	478		R->A: Loss of activity. {ECO:0000269|PubMed:17135236}.	
P77718	108	108	1	C->A: No effect. {ECO:0000269|PubMed:11443125}.	
P77718	189	189		D->A: No activity. {ECO:0000269|PubMed:10595545}.	
P77718	202	202	1	C->A: No effect. {ECO:0000269|PubMed:11443125}.	
P77718	207	207		C->A: Enables partial functional complementation in vivo. Four-fold reduction in activity. {ECO:0000269|PubMed:11443125}.	
P77718	321	321		K->M: No activity. {ECO:0000269|PubMed:10595545}.	
P77718	321	321		K->R: Approximately half of wild-type activity. {ECO:0000269|PubMed:10595545}.	
P77718	344	344		C->A: Cannot functionally complement for wild-type enzyme in vivo. 2700-fold reduction in activity. {ECO:0000269|PubMed:11443125}.	
P77718	456	456		C->A: No activity. {ECO:0000269|PubMed:10722656}.	
Q46948	47	47	1	C->A: Is not impaired in the formation of mixed disulfide with a sulfenylated protein. Has a monomeric quaternary structure. {ECO:0000269|PubMed:22157000, ECO:0000269|PubMed:22321799}.	
Q46948	106	106		C->A: Is impaired in the formation of mixed disulfide with cytoplasmic and sulfenylated proteins. Does not complement a disruption mutant. {ECO:0000269|PubMed:20124404, ECO:0000269|PubMed:22157000, ECO:0000269|PubMed:22321799}.	
Q46948	106	106		C->D: Does not complement a disruption mutant. {ECO:0000269|PubMed:20124404}.	
P0A9J4	31	31	1	R->A: Increases KM for NADP 4-fold. {ECO:0000269|PubMed:16884311}.	
P0A9J4	72	72	1	K->A: Increases KM for NADP 10-fold. {ECO:0000269|PubMed:17229734}.	
P0A9J4	98	98		N->A: Increases KM for ketopantoate 140- fold. Strongly decreases catalytic activity. {ECO:0000269|PubMed:16884311, ECO:0000269|PubMed:17242510}.	
P0A9J4	176	176		K->A: Increases KM for ketopantoate 1400- fold. Decreases Vmax 230-fold. Loss of activity; when associated with A-256. {ECO:0000269|PubMed:11123955, ECO:0000269|PubMed:17242510}.	
P0A9J4	244	244	1	S->A: Increases KM for ketopantoate 230- fold. {ECO:0000269|PubMed:17229734}.	
P0A9J4	256	256		E->A: Increases KM for ketopantoate 1100- fold. Decreases Vmax 40-fold. Loss of activity; when associated with A-176. {ECO:0000269|PubMed:11123955, ECO:0000269|PubMed:17242510}.	
P0ABI8	54	54		H->A: 50% quinol oxidase activity. {ECO:0000269|PubMed:1309808}.	
P0ABI8	55	55	1	K->Q: No effect. {ECO:0000269|PubMed:9378723}.	
P0ABI8	71	71		R->H: No quinol oxidase activity. {ECO:0000269|PubMed:11017202, ECO:0000269|PubMed:12186553}.	
P0ABI8	71	71		R->Q,L: Abolishes quinol oxidase activity. {ECO:0000269|PubMed:11017202, ECO:0000269|PubMed:12186553}.	
P0ABI8	75	75	1	D->E: Very similar to wild-type. {ECO:0000269|PubMed:11017202, ECO:0000269|PubMed:12186553, ECO:0000269|PubMed:17267395}.	
P0ABI8	75	75		D->H: No quinol oxidase activity, altered binding of a semiquinone intermediate at the QH site. {ECO:0000269|PubMed:11017202, ECO:0000269|PubMed:12186553, ECO:0000269|PubMed:17267395}.	
P0ABI8	75	75		D->N: Abolishes quinol oxidase activity. {ECO:0000269|PubMed:11017202, ECO:0000269|PubMed:12186553, ECO:0000269|PubMed:17267395}.	
P0ABI8	80	80		R->Q: Abolishes quinol oxidase activity. {ECO:0000269|PubMed:9378723}.	
P0ABI8	98	98		H->F: About 1% quinol oxidase activity. {ECO:0000269|PubMed:11017202, ECO:0000269|PubMed:12186553}.	
P0ABI8	98	98		H->N: Abolishes enzyme activity. {ECO:0000269|PubMed:11017202, ECO:0000269|PubMed:12186553}.	
P0ABI8	101	101		Q->N: Reduces quinol oxidase activity by 75%, decreased affinity for ubiquinol-1. {ECO:0000269|PubMed:11017202}.	
P0ABI8	102	102		I->W: No quinol oxidase activity. {ECO:0000269|PubMed:12186553}.	
P0ABI8	106	106		H->A: 2% quinol oxidase activity, loss of heme b, loss of heme o, loss of Cu(B). {ECO:0000269|PubMed:1309808}.	
P0ABI8	135	135		D->N: Abolishes quinol oxidase activity. {ECO:0000269|PubMed:9378723}.	
P0ABI8	173	173	1	Y->F: No effect. {ECO:0000269|PubMed:9378723}.	
P0ABI8	188	188	1	D->N: No effect. {ECO:0000269|PubMed:9378723}.	
P0ABI8	256	256	1	D->N: No effect.	
P0ABI8	257	257		R->Q: Abolishes quinol oxidase activity.	
P0ABI8	284	284		H->A: 1% quinol oxidase activity, loss of heme o. {ECO:0000269|PubMed:1309808}.	
P0ABI8	286	286		E->Q,D: Great decrease in quinol oxidase activity. {ECO:0000269|PubMed:9378723}.	
P0ABI8	288	288		Y->F: Great decrease in activity, 100- fold decrease in heme b-to-heme o electron transfer. {ECO:0000269|PubMed:9378723}.	
P0ABI8	333	333		H->A: 2% quinol oxidase activity, loss of Cu(B). {ECO:0000269|PubMed:1309808}.	
P0ABI8	334	334		H->A: 1% quinol oxidase activity, loss of Cu(B). {ECO:0000269|PubMed:1309808}.	
P0ABI8	362	362		K->Q: Abolishes quinol oxidase activity, 100-fold decrease in heme b-to-heme o electron transfer. {ECO:0000269|PubMed:9378723}.	
P0ABI8	407	407		D->N: Abolishes quinol oxidase activity. {ECO:0000269|PubMed:9378723}.	
P0ABI8	411	411		H->A: 50% quinol oxidase activity. {ECO:0000269|PubMed:1309808}.	
P0ABI8	419	419		H->A: 3% quinol oxidase activity, loss of heme o, loss of Cu(B). {ECO:0000269|PubMed:1309808}.	
P0ABI8	421	421		H->A: 1% quinol oxidase activity, loss of heme b, some loss of Cu(B). {ECO:0000269|PubMed:1309808}.	
P0ABI8	481	481	1	R->Q: No effect.	
P0ABI8	482	482	1	R->Q: No effect.	
P0ABI8	540	540		E->Q: Abolishes quinol oxidase activity. {ECO:0000269|PubMed:9378723}.	
P0A850	44	46		FRK->AAA: Decreases association with ribosomes. {ECO:0000269|PubMed:12226666}.	
P0A850	140	140		M->E: Significantly decreases antiaggregation activity. {ECO:0000269|PubMed:24812405}.	
P0A850	374	387		MASAYEDPKEVIEF->AASAAEDPKEAIEA: Significantly decreased affinity for substrate PhoA, significantly decreases antiaggregation activity. {ECO:0000269|PubMed:24812405}.	
P0A6G7	17	17		V->A: No ClpA-ClpP, little ClpX-ClpP complex forms. {ECO:0000269|PubMed:16406682}.	
P0A6G7	18	18		P->A: Reduced processing, no ClpA-ClpP complex forms. {ECO:0000269|PubMed:16406682}.	
P0A6G7	19	19		M->A: No ClpA-ClpP, little ClpX-ClpP complex forms. {ECO:0000269|PubMed:16406682}.	
P0A6G7	20	20		V->A: No ClpA-ClpP or ClpX-ClpP complex forms. {ECO:0000269|PubMed:16406682}.	
P0A6G7	21	21		I->A: No ClpA-ClpP or ClpX-ClpP complex forms. {ECO:0000269|PubMed:16406682}.	
P0A6G7	24	24		T->A: No ClpA-ClpP, little ClpX-ClpP complex forms. {ECO:0000269|PubMed:16406682}.	
P0A6G7	27	27		G->A: No ClpA-ClpP, little ClpX-ClpP complex forms. {ECO:0000269|PubMed:16406682}.	
P0A6G7	32	32		D->A: No ClpA-ClpP or ClpX-ClpP complex forms. {ECO:0000269|PubMed:16406682}.	
P0A6G7	33	33		I->A: No ClpA-ClpP or ClpX-ClpP complex forms. {ECO:0000269|PubMed:16406682}.	
P0A6G7	34	34		Y->A: No ClpA-ClpP or ClpX-ClpP complex forms. {ECO:0000269|PubMed:16406682}.	
P0A6G7	126	126		F->A: Little ClpA-ClpP or ClpX-ClpP complex forms. {ECO:0000269|PubMed:16406682}.	
P0A6G7	185	185		D->A: Loss of protease activity, forms ClpA-ClpP complex. {ECO:0000269|PubMed:16406682}.	
P0A6H1	185	185		E->Q: No ATP hydrolyis. {ECO:0000269|PubMed:23622246}.	
P0A6H1	370	370		R->K: No ATP hydrolyis. {ECO:0000269|PubMed:23622246}.	
P0A9M0	362	362		K->A: Loss of proteolytic activity and ATP-binding. {ECO:0000269|PubMed:7988699}.	
P0A9M0	665	665		H->Y: Loss of proteolytic activity. {ECO:0000269|PubMed:9490010}.	
P0A9M0	667	667		H->Y: Loss of proteolytic activity. {ECO:0000269|PubMed:9490010}.	
P0A9M0	676	676		D->N: Loss of proteolytic activity. {ECO:0000269|PubMed:9490010}.	
P0A9M0	679	679		S->A: Loss of proteolytic activity. {ECO:0000269|PubMed:8226758}.	
P0A9M0	743	743	1	D->N: No effect. {ECO:0000269|PubMed:9490010}.	
P0ACF4	30	30	1	A->D: No effect. {ECO:0000269|PubMed:2265752}.	
P0ACF4	37	37	1	K->Q: No effect. {ECO:0000269|PubMed:2265752}.	
P0ACF4	47	47		F->T: Reduced DNA-binding. {ECO:0000269|PubMed:2265752}.	
P0ACF4	58	61		RTGR->GTGG: Reduced DNA-binding. {ECO:0000269|PubMed:2265752}.	
P0ADY1	312	312		G->A,R: Loss of activity. {ECO:0000269|PubMed:9670013}.	
P0ADY1	313	313		G->A,R: Loss of activity. {ECO:0000269|PubMed:9670013}.	
P0ADY1	347	347		G->A: Loss of activity. {ECO:0000269|PubMed:9670013}.	
P0ADY1	350	350		I->A,F: Loss of activity. {ECO:0000269|PubMed:9670013}.	
P0AFP2	83	83		W->C: Does not confer alkyltransferase activity. {ECO:0000269|PubMed:16027108}.	
P0ACE3	10	10		D->N: Does not affect H-NS binding ability. {ECO:0000269|PubMed:21600204}.	
P0ACE3	22	22		D->N: Does not affect H-NS binding ability. {ECO:0000269|PubMed:21600204}.	
P0ACE3	25	25		E->Q: Affects H-NS binding ability. Decrease in the ability to repress the expression of the hly operon. {ECO:0000269|PubMed:21600204}.	
P0ACE3	29	29		E->Q: Does not affect H-NS binding ability. {ECO:0000269|PubMed:21600204}.	
P0ACE3	34	34		E->Q: Does not affect H-NS binding ability. {ECO:0000269|PubMed:21600204}.	
P0ACE3	37	37		D->N: Does not affect H-NS binding ability. {ECO:0000269|PubMed:21600204}.	
P0ACE3	39	39		E->Q: Does not affect H-NS binding ability. {ECO:0000269|PubMed:21600204}.	
P0ACE3	48	48		D->E,R: Abolishes the interaction with H- NS. {ECO:0000269|PubMed:21600204}.	
P0ACE3	48	48		D->N: Abolishes the interaction with H- NS. Loss of the ability to repress the expression of the hly operon. {ECO:0000269|PubMed:21600204}.	
P0ACE3	61	61		D->N: Does not affect H-NS binding ability. {ECO:0000269|PubMed:21600204}.	
P31224	526	526	1	H->Y: Partially restores chloramphenicol resistance to an AcrZ G30R mutant. {ECO:0000269|PubMed:23010927}.	
P0AE06	1	25	1	MNKNRGFTPLAVVLMLSGSLALTGC->MKKTAIAIAVALAG FATVAQA: Fully functional (replaces endogenous signal and lipid anchor with periplasmic signal for OmpA).	
P0AE06	223	224		FL->MM: Wild-type resistance to efflux substrates. Protein unstable; when associated with 287-M-M-288. {ECO:0000269|PubMed:16531241}.	
P0AE06	287	288		LL->MM: Wild-type resistance to efflux substrates. Protein unstable; when associated with 223-M-M-224. {ECO:0000269|PubMed:16531241}.	
P77338	922	922		G->S: Prevents growth in medium containing high levels of potassium in the presence of betaine. {ECO:0000269|PubMed:11985727}.	
P69441	9	9	1	P->G: No loss of enzyme activity.	
P69441	10	10	1	G->V: No loss of enzyme activity.	
P69441	13	13		K->Q: Drastic reduction in enzyme activity.	
P23872	103	103		H->A: Reduces enzymatic efficiency. {ECO:0000269|PubMed:10431819}.	
P23872	128	128		E->A: Reduces enzymatic efficiency. {ECO:0000269|PubMed:10431819}.	
P23872	163	163		G->A: Diminishes catalytic efficiency. {ECO:0000269|PubMed:10431819}.	
P23872	164	164		D->A: Strongly reduces enzymatic activity. {ECO:0000269|PubMed:10431819}.	
P23872	165	165		S->A: Abolishes enzymatic activity. {ECO:0000269|PubMed:10431819}.	
P23872	167	167		G->A: Diminishes substrate affinity. {ECO:0000269|PubMed:10431819}.	
P23872	262	262		D->A: Strongly reduces enzymatic activity. {ECO:0000269|PubMed:10431819}.	
P23872	266	266		D->A: Reduces enzymatic efficiency. {ECO:0000269|PubMed:10431819}.	
P23872	292	292		H->A: Abolishes enzymatic activity. {ECO:0000269|PubMed:10431819}.	
P0AAR3	30	30		G->C,I,V: >100-fold decrease in Cys- tRNA(Pro) deacylation activity. Fails to gain Ala-tRNA(Pro) deacylation activity. {ECO:0000269|PubMed:23185990}.	
P0AAR3	136	136		D->A,C: 6-fold decrease in Cys-tRNA(Pro) deacylation activity. {ECO:0000269|PubMed:23185990}.	
Q59385	8	150		Missing: Loss of activity.	
Q59385	14	14	1	C->A: No effect. {ECO:0000269|PubMed:11500054}.	
Q59385	17	17	1	C->A: No effect. {ECO:0000269|PubMed:11500054}.	
Q59385	110	110	1	C->A: No effect. {ECO:0000269|PubMed:11500054}.	
Q59385	113	113	1	C->A: No effect. {ECO:0000269|PubMed:11500054}.	
Q59385	479	479		C->A: Loss of copper resistance, transport and phosphoenzyme formation. {ECO:0000269|PubMed:12351646}.	
Q59385	481	481		C->A,H: Loss of copper resistance, transport and phosphoenzyme formation. {ECO:0000269|PubMed:12351646}.	
P77454	69	69		K->A: Loss of activity. {ECO:0000269|PubMed:18459799}.	
P77454	117	117		N->A: Loss of activity. {ECO:0000269|PubMed:18459799}.	
P77454	160	160		S->A: Loss of activity. {ECO:0000269|PubMed:18459799}.	
P77454	161	161		E->A: Strongly reduced activity. {ECO:0000269|PubMed:18459799}.	
P77454	162	162	1	Q->A: No effect. {ECO:0000269|PubMed:18459799}.	
P77454	168	168		N->A: Loss of activity. {ECO:0000269|PubMed:18459799}.	
P77454	192	192		Y->A: Loss of activity. {ECO:0000269|PubMed:18459799}.	
P77454	244	244		Y->A: Loss of activity. {ECO:0000269|PubMed:18459799}.	
P77454	260	260		S->A: Reduced activity. {ECO:0000269|PubMed:18459799}.	
P0A9G4	112	112		C->S: Loss of sensitivity to copper. {ECO:0000269|PubMed:12446701, ECO:0000269|PubMed:14518983}.	
P0A9G4	120	120		C->S: Loss of sensitivity to copper. {ECO:0000269|PubMed:12446701, ECO:0000269|PubMed:14518983}.	
P0A9G4	129	129	1	C->S: No effect on response to copper. {ECO:0000269|PubMed:12446701, ECO:0000269|PubMed:14518983}.	
P0A9G4	130	130	1	C->S: No effect on response to copper. {ECO:0000269|PubMed:12446701, ECO:0000269|PubMed:14518983}.	
P0ADA1	36	36		S->A: Reduces activity by over 99%. {ECO:0000269|PubMed:16515533}.	
P0ADA1	70	70		G->A: Reduces activity by over 75%. {ECO:0000269|PubMed:16515533}.	
P0ADA1	99	99		N->A: Reduces activity by over 60%. {ECO:0000269|PubMed:16515533}.	
P0ADA1	135	135		L->P: Lowers activity towards substrates with long acyl chains.	
P0ADA1	180	180		D->A: Reduces activity by over 70%. {ECO:0000269|PubMed:16515533}.	
P0ADA1	183	183		H->A: Reduces activity by over 99%. {ECO:0000269|PubMed:16515533}.	
P33667	96	96	1	C->S: No change in activity. {ECO:0000269|PubMed:14594807}.	
P33667	97	97		C->S: In vivo, abolishes 2-selenouridine synthase activity. In vitro, reduces activity by only 50%. {ECO:0000269|PubMed:14594807}.	
P0ACN4	135	142		CKSMVRMC->APA: Loss of repressor activity. Loss of DNA binding. Reduces assembly into functionally active tetramers. {ECO:0000269|PubMed:16546208}.	
P0ACN4	141	141		M->A: No effect on repressor activity. Loss of glyoxylate-triggered dissociation from DNA. {ECO:0000269|PubMed:16546208}.	
P0ACN4	142	142		C->W: Strongly reduced repressor activity. Reduces DNA binding. Prevents assembly into functionally active tetramers. {ECO:0000269|PubMed:16546208}.	
P0ACN4	215	215		L->A: Reduced repressor activity. Loss of glyoxylate-triggered dissociation from DNA. {ECO:0000269|PubMed:16546208}.	
P0ACN4	217	217		C->A,S: Slightly reduced repressor activity. Loss of glyoxylate-triggered dissociation from DNA. {ECO:0000269|PubMed:16546208}.	
P0ACN4	234	234		S->A,N: Reduced repressor activity. Loss of glyoxylate-triggered dissociation from DNA. {ECO:0000269|PubMed:16546208}.	
P0ACN4	236	236		S->A,M: Slightly reduced repressor activity. Loss of glyoxylate-triggered dissociation from DNA. {ECO:0000269|PubMed:16546208}.	
P23895	4	4		Y->C: Still binds substrate. No transport activity in the presence of a proton gradient, but still transports substrate in the absence of a proton gradient. Resistance to toxicants is abolished. {ECO:0000269|PubMed:16672221}.	
P23895	4	4	1	Y->F,W: No effect on resistance to toxicants. {ECO:0000269|PubMed:16672221}.	
P23895	6	6	1	Y->C,F,L: No effect on resistance to toxicants. {ECO:0000269|PubMed:16672221}.	
P23895	7	7		L->C: No substrate binding. Resistance to toxicants is abolished. {ECO:0000269|PubMed:12590142}.	
P23895	10	10		A->C: Still binds substrate, with lower affinity. Resistance to toxicants is abolished. {ECO:0000269|PubMed:12590142}.	
P23895	11	11		I->C: Still binds substrate, with lower affinity. Resistance to toxicants is abolished. {ECO:0000269|PubMed:12590142}.	
P23895	14	14		E->C: No substrate binding. No transport activity. Resistance to toxicants is abolished. {ECO:0000269|PubMed:10681497, ECO:0000269|PubMed:12590142}.	
P23895	14	14		E->D: Still binds substrate. No transport activity in the presence of a proton gradient, but still transports substrate in the absence of a proton gradient. Resistance to toxicants is abolished. {ECO:0000269|PubMed:10681497, ECO:0000269|PubMed:12590142}.	
P23895	17	17		G->C: No substrate binding. Resistance to toxicants is abolished. {ECO:0000269|PubMed:12590142}.	
P23895	18	18		T->C: Still binds substrate, with lower affinity. Resistance to toxicants is abolished. {ECO:0000269|PubMed:12590142}.	
P23895	40	40		Y->C,F,L,M,S,T,V: Modifies substrate specificity. {ECO:0000269|PubMed:16672221}.	
P23895	53	53	1	Y->C: No effect on resistance to toxicants. {ECO:0000269|PubMed:16672221}.	
P23895	60	60		Y->C,F: Still binds substrate, with lower affinity. Resistance to toxicants is abolished. {ECO:0000269|PubMed:16672221}.	
P23895	63	63		W->C,Y: No transport activity. Resistance to toxicants is abolished. {ECO:0000269|PubMed:15882076}.	
P23895	63	63		W->F: Still binds substrate, with two- fold reduction in substrate affinity. Resistance to toxicants is abolished. {ECO:0000269|PubMed:15882076}.	
P0AG74	16	16	1	R->Q: No effect on ability to promote DNA repair. {ECO:0000269|PubMed:11080453}.	
P0AG74	17	17	1	Y->L: No effect on ability to promote DNA repair. {ECO:0000269|PubMed:11080453}.	
P0AG74	19	19	1	R->Q: No effect on ability to promote DNA repair. {ECO:0000269|PubMed:11080453}.	
P0AG74	58	58	1	R->Q: No effect on ability to promote DNA repair. {ECO:0000269|PubMed:11080453}.	
P0AG74	68	68	1	R->Q: No effect on ability to promote DNA repair. {ECO:0000269|PubMed:11080453}.	
P0AG74	69	69		R->Q,A: Loss of ability to promote DNA repair. Great loss of Holliday junction resolvase activity. No effect on DNA binding. {ECO:0000269|PubMed:11080453}.	
P0AG74	70	70		D->N: Reduces junction resolution 80- fold. No effect on DNA binding. {ECO:0000269|PubMed:9571038, ECO:0000269|PubMed:9973560}.	
P0AG74	72	72		D->N: Loss of ability to resolve junctions. No effect on DNA binding. {ECO:0000269|PubMed:9973560}.	
P0AG74	73	73		N->A: Slight reduction in ability to promote DNA repair. Great reduction in Holliday junction resolution activity. {ECO:0000269|PubMed:11080453}.	
P0AG74	76	76		K->Q: Loss of ability to promote DNA repair. Loss of Holliday junction resolvase activity. No effect on DNA binding. {ECO:0000269|PubMed:11080453}.	
P0AG74	76	76		K->R: Loss of ability to promote DNA repair. Less than 2% activity of Holliday junction resolvase. No effect on DNA binding. {ECO:0000269|PubMed:11080453}.	
P0AG74	80	80		D->N: Slight reduction in ability to resolve junctions. No effect on DNA binding. {ECO:0000269|PubMed:9973560}.	
P0AG74	87	87	1	F->Y,V: No effect on ability to promote DNA repair. {ECO:0000269|PubMed:11080453}.	
P0AG74	90	90		D->N: Slight reduction in ability to resolve junctions. No effect on DNA binding. {ECO:0000269|PubMed:9973560}.	
P0AG74	91	91		D->N: Loss of ability to resolve junctions. No effect on DNA binding. {ECO:0000269|PubMed:9973560}.	
P0AG74	101	101	1	K->Q: No effect on ability to promote DNA repair. {ECO:0000269|PubMed:11080453}.	
P0AG74	111	111	1	E->Q: No effect on resolvase activity or DNA binding. {ECO:0000269|PubMed:9973560}.	
P0AG74	116	116	1	E->Q: No effect on resolvase activity or DNA binding. {ECO:0000269|PubMed:9973560}.	
P09169	103	103		D->A: Loss of activity. {ECO:0000269|PubMed:11576541}.	
P09169	105	105		D->A: Loss of activity. {ECO:0000269|PubMed:11576541}.	
P09169	230	230		D->A: Loss of activity. {ECO:0000269|PubMed:11576541}.	
P09169	236	237		GK->KG: 70% of wild-type enzymatic activity.	
P09169	237	237		K->T: 40% of wild-type enzymatic activity. {ECO:0000269|PubMed:10651827}.	
P09169	238	238		R->L: Loss of activity.	
P77214	25	27	1	HHH->QQQ: No change in copper resistance. {ECO:0000269|PubMed:12813074}.	
P77214	48	48	1	D->N: No change in copper resistance. {ECO:0000269|PubMed:12813074}.	
P77214	57	58		HH->QQ: Slight decrease in copper resistance. {ECO:0000269|PubMed:12813074}.	
P77214	69	69		M->I: Loss of copper resistance and strong decrease in copper binding; when associated with I-71. {ECO:0000269|PubMed:12813074}.	
P77214	71	71		M->I: Loss of copper resistance and strong decrease in copper binding; when associated with I-69. {ECO:0000269|PubMed:12813074}.	
P77214	73	73	1	F->Y: No change in copper resistance. {ECO:0000269|PubMed:12813074}.	
P38054	399	399		A->D: Strong decrease in copper resistance. {ECO:0000269|PubMed:12813074}.	
P38054	405	405		D->N: Loss of copper resistance. {ECO:0000269|PubMed:12813074}.	
P38054	412	412		E->D: Slight decrease in copper resistance. {ECO:0000269|PubMed:12813074}.	
P38054	412	412		E->Q: Loss of copper resistance. {ECO:0000269|PubMed:12813074}.	
P38054	573	573		M->I: Loss of copper resistance. {ECO:0000269|PubMed:12813074}.	
P38054	623	623		M->I: Loss of copper resistance. {ECO:0000269|PubMed:12813074}.	
P38054	640	640	1	M->I: No change in copper resistance. {ECO:0000269|PubMed:12813074}.	
P38054	672	672		M->I: Loss of copper resistance. {ECO:0000269|PubMed:12813074}.	
P38054	738	738	1	M->I: No change in copper resistance. {ECO:0000269|PubMed:12813074}.	
P38054	755	755		M->I: Slight decrease in copper resistance. {ECO:0000269|PubMed:12813074}.	
P38054	792	792	1	M->I: No change in copper resistance. {ECO:0000269|PubMed:12813074}.	
P38054	812	812		M->I: Slight decrease in copper resistance. {ECO:0000269|PubMed:12813074}.	
P38054	833	833		M->I: Slight decrease in copper resistance. {ECO:0000269|PubMed:12813074}.	
P11454	1138	1138		S->A: No enterobactin synthase activity. This mutant holo-EntF is still able to adenylate serine and to autoacylate itself with serine. {ECO:0000269|PubMed:9485415}.	
P0AEJ2	303	303		A->T: Loss of mutase activity. {ECO:0000269|PubMed:20079748}.	
P0AEJ2	304	304		L->A: Loss of mutase activity. {ECO:0000269|PubMed:20079748}.	
P0AEJ2	327	327		F->Y: Loss of mutase activity. {ECO:0000269|PubMed:20079748}.	
P0AEJ2	346	346		I->L: Loss of mutase activity. {ECO:0000269|PubMed:20079748}.	
P0AEJ2	359	359		F->Q: Loss of mutase activity. {ECO:0000269|PubMed:20079748}.	
P10378	437	437		R->D: Catalyzes the adenylation reaction with 10% reduction of activity compared to the wild-type. 3% reduction of activity compared to the wild-type; when associated with D-473. {ECO:0000269|PubMed:16632253}.	
P10378	473	473	1	K->D: Catalyzes the adenylation reaction with same activity as the wild-type. 3% reduction of activity compared to the wild-type; when associated with D-437. {ECO:0000269|PubMed:16632253}.	
P10378	494	494	1	R->D: Catalyzes the adenylation reaction with same activity as the wild-type. {ECO:0000269|PubMed:16632253}.	
P0ADI4	240	240		D->R: The catalytic efficiency slightly increases, but a 8-fold decrease of the affinity for the S- dihydroxybenzoyltransferase EntE is observed. {ECO:0000269|PubMed:16632253}.	
P0ADI4	242	242		G->A: Not efficiently phosphopantetheinylated by EntD. {ECO:0000269|PubMed:16925399}.	
P0ADI4	244	244	1	D->A: Efficiently phosphopantetheinylated by EntD. {ECO:0000269|PubMed:16925399}.	
P0ADI4	244	244		D->R: Not efficiently phosphopantetheinylated by EntD. {ECO:0000269|PubMed:16925399}.	
P0ADI4	249	249		M->A: Unable to recognize EntE and EntF. Exhibits a decrease in the enterobactin production compared to the wild-type. Still able to be phosphopantetheinylated. {ECO:0000269|PubMed:16567620}.	
P0ADI4	263	263		D->R: The catalytic efficiency is the same as the wild-type, but a 3-fold decrease of the affinity for the S- dihydroxybenzoyltransferase EntE is observed. {ECO:0000269|PubMed:16632253}.	
P0ADI4	264	264		F->E: The affinity for EntE and catalytic efficiency of the S- dihydroxybenzoyltransferase EntE are below that of the wild-type. {ECO:0000269|PubMed:16567620, ECO:0000269|PubMed:16632253}.	
P0ADI4	268	268		A->Q: Unable to recognize EntE and EntF. Exhibits a decrease in the enterobactin production compared to the wild-type. Still able to be phosphopantetheinylated. {ECO:0000269|PubMed:16567620}.	
P0ADI4	269	269	1	K->A: Behaves similarly to the wild-type. {ECO:0000269|PubMed:16567620}.	
P0A8Y8	48	48		Q->A: Loss of activity. {ECO:0000269|PubMed:19193103, ECO:0000269|PubMed:25010423}.	
P0A8Y8	48	48		Q->N: 290-fold decrease in activity toward salicylyl-CoA. {ECO:0000269|PubMed:19193103}.	
P0A8Y8	54	54		H->A: 229-fold decrease in activity toward salicylyl-CoA. Loss of activity toward benzoyl-CoA. {ECO:0000269|PubMed:19193103, ECO:0000269|PubMed:25010423}.	
P0A8Y8	63	63		E->A,D,Q: Loss of activity. {ECO:0000269|PubMed:19193103, ECO:0000269|PubMed:25010423}.	
P0A8Y8	64	64		T->S: 13-fold decrease in activity toward salicylyl-CoA. {ECO:0000269|PubMed:19193103}.	
P0A8Y8	67	67		S->A: 140-fold decrease in activity toward salicylyl-CoA. {ECO:0000269|PubMed:19193103}.	
P0A8Y8	67	67		S->C: 104-fold decrease in activity toward salicylyl-CoA. {ECO:0000269|PubMed:19193103}.	
P0A8Y8	68	68		M->A: 130-fold decrease in activity toward salicylyl-CoA. {ECO:0000269|PubMed:19193103}.	
P0A8Y8	68	68		M->V: 47-fold increase in catalytic efficiency toward 1,4-dihydroxy-2- naphthoyl-CoA and 10-fold increase in catalytic efficiency toward lauroyl-CoA. Does not affect catalytic efficiency toward benzoyl-CoA. {ECO:0000269|PubMed:24992697, ECO:0000269|PubMed:25010423}.	
P77202	126	126		C->A: Complete loss of redox activity. {ECO:0000269|PubMed:10788443}.	
P77202	126	126	1	C->S: No loss of chaperone activity; when associated with S-129. {ECO:0000269|PubMed:10788443}.	
P77202	129	129		C->A: Partial loss of redox activity. Traps the protein in complex with ErfK, YbiS and YnhG. {ECO:0000269|PubMed:10788443, ECO:0000269|PubMed:19965429}.	
P77202	129	129	1	C->S: No loss of chaperone activity; when associated with S-126. {ECO:0000269|PubMed:10788443, ECO:0000269|PubMed:19965429}.	
P77510	138	138		G->R: Reduces strongly citrate binding. {ECO:0000269|PubMed:11889485}.	
P77510	478	478		C->A: Loss of autophosphorylation. {ECO:0000269|PubMed:19202292}.	
P77510	517	517		C->A: Decrease in autophosphorylation. {ECO:0000269|PubMed:19202292}.	
P77510	529	529		C->A: Constitutively active. {ECO:0000269|PubMed:19202292}.	
P37001	58	58		H->F: Drastically reduces palmitoyltransferase activity while leaving expression and membrane insertion intact. {ECO:0000269|PubMed:12357033}.	
P37001	58	58		H->N: Drastically reduces palmitoyltransferase activity while leaving expression and membrane insertion intact. {ECO:0000269|PubMed:12357033}.	
P37001	101	101		D->A: Drastically reduces palmitoyltransferase activity while leaving expression and membrane insertion intact. {ECO:0000269|PubMed:12357033}.	
P37001	101	101		D->N: Drastically reduces palmitoyltransferase activity while leaving expression and membrane insertion intact. {ECO:0000269|PubMed:12357033}.	
P37001	102	102		S->A: Drastically reduces palmitoyltransferase activity while leaving expression and membrane insertion intact. {ECO:0000269|PubMed:12357033}.	
P37001	113	113		G->A: Mutant with longer amino-acid side chains at position 113 preferentially transfers pentadecane chain (15:0). {ECO:0000269|PubMed:15272304}.	
P37001	113	113		G->C: Mutants with longer amino-acid side chains at position 113 preferentially transfers myristate chain (14:0). {ECO:0000269|PubMed:15272304}.	
P37001	113	113		G->M: Mutants with longer amino-acid side chains at position 113 preferentially transfers laurate chain (12:0). {ECO:0000269|PubMed:15272304}.	
P37001	155	155	1	S->A: Fully functional. {ECO:0000269|PubMed:12357033}.	
P37001	172	172		Y->A: Does not cause significant structural perturbations of the enzyme, but induces a 2-fold increase in the palmitoyltransferase activity. {ECO:0000269|PubMed:20826347}.	
P37001	172	172		Y->F: Does not cause significant structural perturbations of the enzyme, but induces a 2.3-fold increase in the palmitoyltransferase activity. {ECO:0000269|PubMed:20826347}.	
P60716	68	79		CEEASCPNLAEC->AEEASAPNLAEA: Loss of 1 4Fe-4S cluster binding. Loss of activity. {ECO:0000269|PubMed:15362861}.	
P60716	94	101		CTRRCPFC->ATRRAPFA: Loss of 1 4Fe-4S cluster binding. Loss of activity. {ECO:0000269|PubMed:15362861}.	
P60720	137	137	1	C->A: No effect on activity.	
P60720	147	147	1	C->A: No effect on activity.	
P60720	169	169		C->A: 1% of wild-type activity. {ECO:0000269|PubMed:16342964}.	
P60720	169	169		C->S: Loss of activity. {ECO:0000269|PubMed:16342964}.	
P0AEB2	101	121		Missing: Complete loss of enzyme activity. No effect on penicillin binding. {ECO:0000269|PubMed:14555648}.	
P0AEB2	213	213		K->R: Complete loss of enzyme activity. No effect on penicillin binding. {ECO:0000269|PubMed:1597468}.	
P0AEB2	213	213		K->X: Complete loss of activity. {ECO:0000269|PubMed:1597468}.	
P0AD65	330	330		S->C: No longer binds penicillin. {ECO:0000269|PubMed:3148617}.	
P0ADC1	117	119		PIS->R: Affects interaction with LptD and LptD biogenesis. Increases outer membrane permeability. {ECO:0000269|PubMed:21257909}.	
P0A898	59	59		R->A,E: Loss of activity. {ECO:0000269|PubMed:20807199, ECO:0000269|PubMed:23273979}.	
P0A898	114	114		H->A: Loss of activity. {ECO:0000269|PubMed:20807199, ECO:0000269|PubMed:23273979}.	
P0A898	118	118	1	H->A: No change in activity. {ECO:0000269|PubMed:20807199}.	
P0A898	124	124	1	H->A: No change in activity. {ECO:0000269|PubMed:20807199}.	
P0AEI1	157	157		C->A: Loss of activity. {ECO:0000269|PubMed:11882645}.	
P0AEI1	161	161		C->A: Loss of activity. {ECO:0000269|PubMed:11882645}.	
P0AEI1	164	164		C->A: Loss of activity. {ECO:0000269|PubMed:11882645}.	
P22106	2	2		C->A,S: Loss of glutamine-dependent activity but no effect on ammonia- dependent asparagine synthetase activity. {ECO:0000269|PubMed:7907328}.	
P22106	30	30		H->A: 4,5-fold decrease in glutamine affinity. {ECO:0000269|PubMed:7907328}.	
P22106	34	34		D->N,E: Little effect on the kinetic properties. {ECO:0000269|PubMed:7907328}.	
P22106	81	81		H->A: 5-fold decrease in glutamine affinity. {ECO:0000269|PubMed:7907328}.	
P22106	105	105		A->H: Little effect on the kinetic properties. {ECO:0000269|PubMed:7907328}.	
P22106	349	349		E->A,Q: Loss of glutamine- and ammonia- dependent synthetase activity, but still exhibits glutaminase activity. {ECO:0000269|PubMed:20853825}.	
P22106	349	349		E->D: 5-fold increase in affinity for asparate when assaying both the glutamine- and ammonia-dependent synthetase reactions, and 2-fold decrease in kcat for these reactions. Modifies the product glutamate/asparagine stoichiometry. {ECO:0000269|PubMed:20853825}.	
P0AF18	59	59		Q->H: Large decrease in catalytic activity and substrate affinity, and increase in the average amount of Zn bound to the protein, suggesting that an additional metal ion can bind to this mutant; when associated with H-61. {ECO:0000269|PubMed:17567047, ECO:0000269|PubMed:17567048}.	
P0AF18	61	61		N->H: Large decrease in catalytic activity and substrate affinity, and increase in the average amount of Zn bound to the protein, suggesting that an additional metal ion can bind to this mutant; when associated with H-59. {ECO:0000269|PubMed:17567047}.	
P0AF18	131	131		E->Q,A: Large reduction in the amount of the metal cofactor bound to the enzyme. {ECO:0000269|PubMed:17567047}.	
P0AF18	143	143		H->N: Dramatic decrease in catalytic activity and moderate decrease in substrate affinity, producing a 6000-fold decrease in catalytic efficiency. {ECO:0000269|PubMed:17567047}.	
P0AF18	143	143		H->Q: 180-fold decrease in catalytic efficiency. {ECO:0000269|PubMed:17567047}.	
P0AF18	251	251		H->N: 500-fold decrease in catalytic efficiency. {ECO:0000269|PubMed:17567047}.	
P0AF18	273	273		D->N,A: Loss of catalytic activity. {ECO:0000269|PubMed:17567047}.	
P0A759	118	118		C->S: 50% of wild-type activity, but 2- fold decrease in substrate affinity. {ECO:0000269|PubMed:1734962}.	
P0A759	141	141		D->N: Large decrease in activity. {ECO:0000269|PubMed:11513596}.	
P0A759	143	143		H->Q: Loss of activity for the deamination reaction but not for the reverse reaction; complete loss of the homotropic cooperativity. {ECO:0000269|PubMed:11513596}.	
P0A759	148	148		E->Q: Large decrease in activity. {ECO:0000269|PubMed:11513596}.	
P0A759	174	174		F->A: Loss of activity in the absence of the allosteric activator.	
P0A759	239	239		C->S: 50% of wild-type activity, but 2- fold decrease in substrate affinity; decrease in allosteric interaction energy. {ECO:0000269|PubMed:1734962}.	
P0AFY8	116	116		R->A: Strongly reduced DNA binding. {ECO:0000269|PubMed:14704346}.	
P0AFY8	118	118		R->A: Strongly reduced DNA binding. {ECO:0000269|PubMed:14704346}.	
P0AFY8	149	149		T->A: Strongly reduced DNA binding. {ECO:0000269|PubMed:14704346}.	
P0AFY8	150	150		N->A,D: Strongly reduced DNA binding. {ECO:0000269|PubMed:14704346}.	
P0AFY8	151	151		T->A: Reduced DNA binding. {ECO:0000269|PubMed:14704346}.	
P0AFY8	152	152		N->D: Strongly reduced DNA binding. {ECO:0000269|PubMed:14704346}.	
P0AFY8	155	155		R->A: Strongly reduced DNA binding. {ECO:0000269|PubMed:14704346}.	
P0AFY8	156	156		K->A: Strongly reduced DNA binding. {ECO:0000269|PubMed:14704346}.	
P00914	278	278		W->X: Reduces DNA-binding affinity. {ECO:0000269|PubMed:2200511}.	
P00914	383	383		W->F: Abolishes photolyase activity. {ECO:0000269|PubMed:12835419}.	
P50465	2	2		P->T: Loss of glycosylase and AP lyase activity. {ECO:0000269|PubMed:11711552}.	
P50465	3	3		E->A,Q: Loss of glycosylase activity. No effect on AP lyase activity. {ECO:0000269|PubMed:11711552, ECO:0000269|PubMed:11847126}.	
P50465	3	3		E->D: Much reduced glycosylase activity. No effect on AP lyase activity. {ECO:0000269|PubMed:11711552, ECO:0000269|PubMed:11847126}.	
P50465	6	6		E->Q: Reduced glycosylase activity. No effect on AP lyase activity. {ECO:0000269|PubMed:11711552}.	
P50465	53	53		K->A: Loss of DNA cleavage at sites containing oxidized pyrimidine. No effect on AP lyase activity. {ECO:0000269|PubMed:11847126}.	
P50465	129	129		D->N: Reduced glycosylase activity. No effect on AP lyase activity. {ECO:0000269|PubMed:11711552}.	
P50465	160	160	1	D->N: No effect on glycosylase and AP lyase activity. {ECO:0000269|PubMed:11711552}.	
P50465	174	174		E->Q: Loss of glycosylase activity. No effect on AP lyase activity. {ECO:0000269|PubMed:11711552}.	
P50465	213	213		R->A: Slightly reduced activity. {ECO:0000269|PubMed:11847126}.	
P50465	253	253		R->A: Reduced DNA cleavage at sites containing oxidized pyrimidine. No effect on AP lyase activity. {ECO:0000269|PubMed:11847126}.	
P0ABH7	207	207		C->S: Weakened NADH binding and inhibition. {ECO:0000269|PubMed:1939121}.	
P0ABH7	208	208		E->A: Weakened NADH binding and inhibition. {ECO:0000269|PubMed:1939121}.	
P0ABJ9	19	19		H->L,R: Loss of cytochrome b595 and heme d, no aerobic growth, complex assembles. {ECO:0000269|PubMed:2656671}.	
P0ABJ9	86	86	1	H->R: No effect. {ECO:0000269|PubMed:2656671}.	
P0ABJ9	126	126		H->P: Loss of all cofactors, no aerobic growth, complex assembles. {ECO:0000269|PubMed:2656671}.	
P0ABJ9	126	126	1	H->R: No effect. {ECO:0000269|PubMed:2656671}.	
P0ABJ9	186	186		H->L: Loss of cytochrome b558, no aerobic growth, complex assembles, this subunit is more susceptible to proteolysis. {ECO:0000269|PubMed:2656671}.	
P0ABJ9	314	314		H->L: Grows aerobically, has altered cytochrome b/d ratio, complex assembles. {ECO:0000269|PubMed:2656671}.	
P0ABJ9	314	314		H->P: Loss of cytochrome b595 and heme d, no aerobic growth, loss of complex. {ECO:0000269|PubMed:2656671}.	
P0ABJ9	393	393		M->L: Cytochrome b558 shifts to a high spin configuration, complex assembles. Retains about 1% quinol oxidoreductase activity after purification.	
P0ABJ9	510	510	1	H->L: No effect. {ECO:0000269|PubMed:2656671}.	
P0ABK2	56	56	1	H->L: No effect. {ECO:0000269|PubMed:2656671}.	
P0ABK2	197	197	1	H->L: No effect. {ECO:0000269|PubMed:2656671}.	
P0ABK2	237	237	1	H->L,R: No effect. {ECO:0000269|PubMed:2656671}.	
P0ABK2	376	376	1	H->P: No effect. {ECO:0000269|PubMed:2656671}.	
P56100	1	1		M->Q: Does not restore reductant (beta- mercapoethanol) resistance. {ECO:0000269|PubMed:23749980}.	
P56100	4	4		F->A: Does not restore reductant (beta- mercapoethanol) resistance. {ECO:0000269|PubMed:23749980}.	
P56100	7	7		I->A: Does not restore reductant (beta- mercapoethanol) resistance. {ECO:0000269|PubMed:23749980}.	
P56100	12	12		L->A: Does not restore reductant (beta- mercapoethanol) resistance. {ECO:0000269|PubMed:23749980}.	
P56100	14	14	1	C->S: Restores reductant (beta- mercapoethanol) resistance. {ECO:0000269|PubMed:23749980}.	
P56100	21	21		A->G: Does not restore reductant (beta- mercapoethanol) resistance. {ECO:0000269|PubMed:23749980}.	
P11458	291	291		C->S: Activity is 3.3-fold lower under oxic conditions than under anoxic conditions. {ECO:0000269|PubMed:18651751}.	
P11458	294	294		C->S: Activity is 13-fold lower under oxic conditions than under anoxic conditions. {ECO:0000269|PubMed:18651751}.	
P0A6T3	371	371		Y->H: Displays relaxed substrate specificity since it gains kinase activity toward sugars as diverse as D- galacturonic acid, D-talose, L-altrose, and L-glucose. Also shows enhanced turnover of the small pool of sugars converted by the wild-type enzyme. {ECO:0000269|PubMed:14612558}.	
P09148	160	160		C->S,A: Slight inhibition of enzymatic activity. {ECO:0000269|PubMed:10820011}.	
P09148	161	161		S->A: 7000-fold reduction in specific activity. {ECO:0000269|PubMed:10820011}.	
P09148	166	166		H->G: Abolishes enzymatic activity. {ECO:0000269|PubMed:9063869}.	
P09147	124	124		S->A: No major structural changes. Catalytic efficiency is very low and affinity binding is 21% of the wild-type enzyme. {ECO:0000269|PubMed:9271498, ECO:0000269|PubMed:9271499, ECO:0000269|PubMed:9708982}.	
P09147	124	124		S->T: No major structural changes. Catalytic efficiency is about 30% of that of the wild-type enzyme, and affinity binding is similar to that of the native enzyme. {ECO:0000269|PubMed:9271498, ECO:0000269|PubMed:9271499, ECO:0000269|PubMed:9708982}.	
P09147	149	149		Y->F: No major structural changes. Catalytic efficiency is very low and affinity binding is 12% of the wild-type enzyme. {ECO:0000269|PubMed:9271498, ECO:0000269|PubMed:9708982}.	
P09147	153	153		K->A: Decreases the catalytic activity. Not reduced by sugars in the presence or absence of UMP. It contains very little NADH. {ECO:0000269|PubMed:8241178}.	
P09147	153	153		K->M: Decreases the catalytic activity. Not reduced by sugars in the presence or absence of UMP. It contains very little NADH. {ECO:0000269|PubMed:8241178}.	
P09147	299	299		Y->C: Loss of epimerase activity with UDP-Gal by almost 5-fold, but it results in a gain of epimerase activity with uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) by 230-fold with minimal changes in its three-dimensional structure. {ECO:0000269|PubMed:12019271}.	
P0A9G8	76	76		A->V: Partial loss of repression by ModE. {ECO:0000269|PubMed:8550508}.	
P0A9G8	125	125		T->I: Transcription repression by ModE even in the absence of molybdate. {ECO:0000269|PubMed:8550508}.	
P0A9G8	133	133		G->D: Transcription repression by ModE even in the absence of molybdate. {ECO:0000269|PubMed:8550508}.	
P0A9G8	216	262		Missing: Transcription repression by ModE even in the absence of molybdate.	
P0AAW9	30	30		G->R: Loss of chloramphenicol resistance, does not bind AcrB (dominant-negative to wild-type). Partially suppressed by AcrB H526Y. {ECO:0000269|PubMed:23010927}.	
P0AAW9	46	49		Missing: Loss of chloramphenicol resistance, still binds AcrB (dominant- negative to wild-type). {ECO:0000269|PubMed:23010927}.	
P12995	17	17		Y->F: Severely reduces the aminotransferase activity. {ECO:0000269|PubMed:14756557}.	
P12995	144	144		Y->F: Severely reduces the aminotransferase activity. {ECO:0000269|PubMed:14756557}.	
P12995	147	147		D->N: Loss of aminotransferase activity. {ECO:0000269|PubMed:14756557}.	
P12995	253	253		R->A: Has only a small effect on the rate of reaction with DAPA. {ECO:0000269|PubMed:14756557}.	
P12995	253	253		R->K: Increases aminotransferase activity toward SAM. {ECO:0000269|PubMed:14756557}.	
P12995	253	253		R->M: Loss of aminotransferase activity. {ECO:0000269|PubMed:14756557}.	
P12995	253	253		R->Q: Increases aminotransferase activity toward SAM. {ECO:0000269|PubMed:14756557}.	
P12995	391	391		R->A: Reduces aminotransferase activity. {ECO:0000269|PubMed:12379100}.	
P12996	53	53		C->A: Total loss of activity. {ECO:0000269|PubMed:11834738, ECO:0000269|PubMed:11862544}.	
P12996	57	57		C->A: Total loss of activity. {ECO:0000269|PubMed:11834738, ECO:0000269|PubMed:11862544}.	
P12996	60	60		C->A: Total loss of activity. {ECO:0000269|PubMed:11834738, ECO:0000269|PubMed:11862544}.	
P12996	97	97		C->A: Total loss of activity. {ECO:0000269|PubMed:11834738, ECO:0000269|PubMed:11862544}.	
P12996	128	128		C->A: Total loss of activity. {ECO:0000269|PubMed:11834738, ECO:0000269|PubMed:11862544}.	
P12996	151	151		N->A: Total loss of activity. {ECO:0000269|PubMed:17014080}.	
P12996	152	152		H->A: Weak activity. {ECO:0000269|PubMed:17014080}.	
P12996	153	153		N->A: Total loss of activity. {ECO:0000269|PubMed:17014080}.	
P12996	155	155		D->A: Total loss of activity. {ECO:0000269|PubMed:17014080}.	
P12996	188	188		C->A: Total loss of activity. {ECO:0000269|PubMed:11834738, ECO:0000269|PubMed:11862544}.	
P13000	12	12		T->V: Strong decreased in the affinity for ATP; essential role for this residue in the steady-state affinity for ATP. {ECO:0000269|PubMed:9125495}.	
P13000	13	13	1	E->A,D: Almost no change in activity. {ECO:0000269|PubMed:9125495}.	
P13000	16	16		K->Q: Complete loss of activity. {ECO:0000269|PubMed:9125495}.	
P13000	38	38		K->L,Q,R: Complete loss of activity. {ECO:0000269|PubMed:9125495}.	
P13000	42	42	1	S->A,C: Almost no change in activity. {ECO:0000269|PubMed:9125495}.	
P0A8F8	95	96		YY->AA: Defective in DNA-unwinding activity. {ECO:0000269|PubMed:11689453}.	
P0A8F8	101	101		Y->A: Defective in DNA-unwinding activity; when associated with A-108. {ECO:0000269|PubMed:11689453}.	
P0A8F8	108	108		F->A: Defective in DNA-unwinding activity; when associated with A-101. {ECO:0000269|PubMed:11689453}.	
P0A738	51	51		K->A: Reduced activity. {ECO:0000269|PubMed:10903949}.	
P0A738	52	52		G->A: Reduced activity. {ECO:0000269|PubMed:10903949}.	
P0A738	67	67		K->A: Reduced activity. {ECO:0000269|PubMed:10903949}.	
P0A738	76	76		C->A: Reduced activity. {ECO:0000269|PubMed:10903949}.	
P0A738	77	77		H->A: Reduced activity. {ECO:0000269|PubMed:10903949}.	
P0A738	110	110		G->A: Reduced activity. {ECO:0000269|PubMed:10903949}.	
P0A738	112	112		E->A: Reduced activity. {ECO:0000269|PubMed:10903949}.	
P0A738	117	117		T->P: Strongly reduced activity. {ECO:0000269|PubMed:10903949}.	
P0A738	128	128		D->A: Loss of activity. {ECO:0000269|PubMed:10903949}.	
P0A738	131	131		K->A: Reduced activity. {ECO:0000269|PubMed:10903949}.	
P30749	34	34		F->A: 4-fold lower activity than wild- type. {ECO:0000269|PubMed:12571226}.	
P30749	39	39		R->A: 24-fold lower activity than wild- type. {ECO:0000269|PubMed:12571226}.	
P30749	115	115		M->A: 4-fold lower activity than wild- type. {ECO:0000269|PubMed:12571226}.	
P30749	119	119		K->A: No activity. {ECO:0000269|PubMed:12571226}.	
P30749	126	126		K->A: 58-fold lower activity than wild- type. Accumulates large quantities of reaction intermediate. {ECO:0000269|PubMed:12571226}.	
P30749	128	128		E->K: 17-fold lower activity than wild- type. {ECO:0000269|PubMed:12571226}.	
P30749	140	140		R->A: 2-fold lower activity than wild- type. {ECO:0000269|PubMed:12571226}.	
P27296	120	120		C->S: Abolishes iron-sulfur-binding. {ECO:0000269|PubMed:19074432}.	
P27296	194	194		C->S: Abolishes iron-sulfur-binding. {ECO:0000269|PubMed:19074432}.	
P27296	199	199		C->S: Abolishes iron-sulfur-binding. {ECO:0000269|PubMed:19074432}.	
P27296	205	205		C->S: Abolishes iron-sulfur-binding. {ECO:0000269|PubMed:19074432}.	
P0AAX8	210	210		C->A: Protein is unable to form sulfenic acid adducts. {ECO:0000269|PubMed:19965429}.	
P78055	85	85		K->R: Loss of activity. {ECO:0000269|PubMed:11120740}.	
P12282	14	14	1	R->A,K: No effect. {ECO:0000269|PubMed:11713534}.	
P12282	14	14	1	R->A: No activity; when associated with A-73. {ECO:0000269|PubMed:11713534}.	
P12282	44	44	1	C->A: No effect. {ECO:0000269|PubMed:11463785}.	
P12282	73	73	1	R->A: No effect. No activity; when associated with A-14. {ECO:0000269|PubMed:11713534}.	
P12282	73	73		R->K: Substantially reduced activity. {ECO:0000269|PubMed:11713534}.	
P12282	128	128	1	C->A: No effect. {ECO:0000269|PubMed:11463785}.	
P12282	128	128		C->Y: No activity. {ECO:0000269|PubMed:11463785}.	
P12282	130	130		D->A: No activity. {ECO:0000269|PubMed:11713534}.	
P12282	130	130		D->E: Substantially reduced activity. {ECO:0000269|PubMed:11713534}.	
P12282	142	142	1	C->A: No effect. {ECO:0000269|PubMed:11463785}.	
P12282	172	172		C->A: No zinc bound and no enzyme activity. {ECO:0000269|PubMed:11463785}.	
P12282	175	175		C->A: No zinc bound and no enzyme activity. {ECO:0000269|PubMed:11463785}.	
P12282	187	187	1	C->A: No effect. {ECO:0000269|PubMed:11463785}.	
P12282	231	231	1	C->A: No effect. {ECO:0000269|PubMed:11463785}.	
P12282	244	244		C->A: No zinc bound and almost no enzyme activity. {ECO:0000269|PubMed:11463785}.	
P12282	247	247		C->A: No zinc bound and almost no enzyme activity. {ECO:0000269|PubMed:11463785}.	
P37595	179	179		T->A: Catalytically inactive.	
P0AEY8	26	26		E->A: Loss of ethidium bromide efflux activity. {ECO:0000269|PubMed:14717607}.	
P0AEY8	26	26		E->D: No change in ethidium bromide efflux activity. {ECO:0000269|PubMed:14717607}.	
P0AEY8	26	26		E->H: Almost no chloramphenicol efflux activity. Loss of ethidium bromide efflux activity. {ECO:0000269|PubMed:14717607}.	
P0AEY8	26	26		E->I,V: Slight decrease in chloramphenicol efflux activity. Exhibits low ethidium bromide efflux activity. {ECO:0000269|PubMed:14717607}.	
P0AEY8	26	26		E->K: Decrease in TPP efflux activity. Exhibits low ethidium bromide efflux activity. {ECO:0000269|PubMed:14717607}.	
P0AEY8	26	26		E->L,N: Strong decrease in chloramphenicol efflux activity. Loss of ethidium bromide and TPP efflux activities. {ECO:0000269|PubMed:14717607}.	
P0AEY8	26	26		E->Q: Slight decrease in chloramphenicol efflux activity. Loss of ethidium bromide efflux activity. {ECO:0000269|PubMed:14717607}.	
P0AEY8	26	26		E->T: Strong decrease in chloramphenicol efflux activity. Loss of ethidium bromide efflux activity. {ECO:0000269|PubMed:14717607}.	
P07003	533	533		A->T: In poxB11. {ECO:0000269|PubMed:2663858}.	
P07003	549	572		Missing: In poxB6. {ECO:0000269|PubMed:2663858}.	
P07003	553	553		A->V: In poxB14. {ECO:0000269|PubMed:2663858}.	
P07003	560	560		D->P: In poxB15; normal activity. {ECO:0000269|PubMed:2663858}.	
P07003	564	572		Missing: In poxB7. {ECO:0000269|PubMed:2663858}.	
P07003	564	564		E->P: In poxB16; loss of activity. {ECO:0000269|PubMed:2663858}.	
P07003	570	572		Missing: In poxB8. {ECO:0000269|PubMed:2663858}.	
P07003	572	572		R->G: In poxB10; reduced activity; may interact less with membranes. {ECO:0000269|PubMed:2663858}.	
P60844	9	9	1	C->S: No effect. {ECO:0000269|PubMed:10518952}.	
P60844	20	20		C->S: Loss of oligomerization; no alteration of water permeability. {ECO:0000269|PubMed:10518952}.	
P60844	183	183	1	T->C: No effect. {ECO:0000269|PubMed:10518952}.	
P60844	189	189		R->V,S: Loss of function. {ECO:0000269|PubMed:10518952}.	
P75830	353	353		G->A: 2-fold increase in susceptibility to macrolides. Does not affect oligomerization and ability to interact with MacB and TolC, but changes the structure of the MP region. Does not stimulate MacB ATPase activity. {ECO:0000269|PubMed:21696464}.	
P75830	353	353		G->C: 4-fold increase in susceptibility to macrolides. Does not stimulate MacB ATPase activity. {ECO:0000269|PubMed:21696464}.	
P75830	353	353		G->S: 2-fold increase in susceptibility to macrolides. {ECO:0000269|PubMed:21696464}.	
P75830	357	357		G->A: 2-fold increase in susceptibility to macrolides. Does not stimulate MacB ATPase activity. {ECO:0000269|PubMed:21696464}.	
P75830	357	357		G->C,S: Does not affect susceptibility to macrolides. {ECO:0000269|PubMed:21696464}.	
P75831	47	47		K->L: Lack of activity. {ECO:0000269|PubMed:17214741}.	
P75831	169	169		D->N: Lack of activity. {ECO:0000269|PubMed:17214741}.	
P46889	58	58		E->A: Loss of function. {ECO:0000269|PubMed:10922461}.	
P46889	80	80		G->A: In Toe44; loss of function under extreme conditions.	
P46889	135	135		D->C: Impairs the ability of FtsK to function in cell division. Uncouples invagination of the inner and outer membranes and results in cellular voids. {ECO:0000269|PubMed:25002583}.	
P46889	136	136		D->C: Impairs the ability of FtsK to function in cell division. Uncouples invagination of the inner and outer membranes and results in cellular voids. {ECO:0000269|PubMed:25002583}.	
P46889	137	137		I->C: Impairs the ability of FtsK to function in cell division. Uncouples invagination of the inner and outer membranes and results in cellular voids. {ECO:0000269|PubMed:25002583}.	
P46889	138	138		W->C: Impairs the ability of FtsK to function in cell division. Uncouples invagination of the inner and outer membranes and results in cellular voids. {ECO:0000269|PubMed:25002583}.	
P46889	997	997		K->A: Does not activate Xer recombination. {ECO:0000269|PubMed:15522074}.	
P61316	64	64		R->L: Loss of ability to transfer lipoproteins to LolB. {ECO:0000269|PubMed:11587539}.	
P61316	68	68		F->E: Loss of ability to bind lipoproteins. {ECO:0000269|PubMed:12297303}.	
P0AAZ4	156	156		R->A: Lack of ATPase activity. {ECO:0000269|PubMed:21297161}.	
P0A8L1	355	355		E->Q: Loss of serine activation activity. {ECO:0000269|PubMed:7537870}.	
P18775	17	17		R->S: Not targeted to the membrane, does not support anaerobic growth. {ECO:0000269|PubMed:10801884}.	
P18775	57	57		K->D: No alteration of the growth, expression, or catalytic activities. {ECO:0000269|PubMed:8125918}.	
P18775	67	67		C->S: Electron transfer from the 4Fe-4S clusters of DmsB to the Mo-bisMGD of DmsA is blocked. Little effect on the coordination sphere of the molybdenum and only minor effects on its redox chemistry. {ECO:0000269|PubMed:10224050, ECO:0000269|PubMed:8125918}.	
P18775	71	71		C->S: Can not support growth. {ECO:0000269|PubMed:8125918}.	
P18775	104	104		C->S: No alteration of the growth, expression, or catalytic activities. {ECO:0000269|PubMed:8125918}.	
P18775	106	106		R->S: Electron transfer from the 4Fe-4S clusters of DmsB to the Mo-bisMGD of DmsA is blocked. Little effect on the coordination sphere of the molybdenum and only minor effects on its redox chemistry. {ECO:0000269|PubMed:10224050, ECO:0000269|PubMed:8125918}.	
P18776	102	102		C->F,S,W,Y: Loss of electron transfer from menaquinol to DMSO. {ECO:0000269|PubMed:1653010}.	
P0A6D3	96	96		G->A: Insensitive to glyphosate with unaltered affinity for its first substrate S3P, but displays a 30-fold lower affinity for its second substrate PEP. {ECO:0000269|PubMed:12430021}.	
P0A6D3	97	97		T->I: This mutant is sensitive to glyphosate and causes a substantial decrease in the affinity for PEP. Insensitive to glyphosate but maintains high affinity for PEP. It causes a shift of residue G96 toward the glyphosate binding site, impairing efficient binding of glyphosate, while the side chain of I97 points away from the substrate binding site, facilitating PEP utilization; when associated with S-101. {ECO:0000269|PubMed:19211556}.	
P0A6D3	101	101		P->A: Displays a slight decrease of the affinity binding for both S3P and PEP. Decreases the binding affinity of glyphosate, reducing the potency of this inhibitor. {ECO:0000269|PubMed:17855366, ECO:0000269|PubMed:19211556}.	
P0A6D3	101	101		P->G: Displays a slight decrease of the affinity binding for both S3P and PEP. Decreases the binding affinity of glyphosate, reducing the potency of this inhibitor. {ECO:0000269|PubMed:17855366, ECO:0000269|PubMed:19211556}.	
P0A6D3	101	101		P->L: Displays a 2-fold lower affinity binding for both S3P and PEP. Decreases the binding affinity of glyphosate, reducing the potency of this inhibitor. {ECO:0000269|PubMed:17855366, ECO:0000269|PubMed:19211556}.	
P0A6D3	101	101		P->S: Displays a slight decrease of the affinity binding for both S3P and PEP. Decreases the binding affinity of glyphosate, reducing the potency of this inhibitor. Insensitive to glyphosate but maintains high affinity for PEP. It causes a shift of residue G96 toward the glyphosate binding site, impairing efficient binding of glyphosate, while the side chain of I97 points away from the substrate binding site, facilitating PEP utilization; when associated with I- 97. {ECO:0000269|PubMed:17855366, ECO:0000269|PubMed:19211556}.	
P0A6D3	313	313		D->A: The enolpyruvyl transfer reaction is halted after formation of the tetrahedral adduct of the substrates. {ECO:0000269|PubMed:13129913}.	
P0A6Y1	44	44		E->G,K,V: Altered DNA-binding specificity. {ECO:0000269|PubMed:1531459}.	
P60752	270	270		A->T: Loss of lipid export. {ECO:0000269|PubMed:11278265}.	
P60752	511	511		L->P: Loss of ATPase activity; ATP is still bound. {ECO:0000269|PubMed:8809774}.	
P60752	512	512		D->G: Loss of ATPase activity; ATP is still bound. {ECO:0000269|PubMed:8809774}.	
P60293	233	233		L->P: Abolishes function. {ECO:0000269|PubMed:8602138}.	
P22523	33	33	1	S->F: In mukB106; no effect. {ECO:0000269|PubMed:10545099}.	
P22523	40	40	1	K->L: No effect. {ECO:0000269|PubMed:10545099}.	
P22523	688	688		E->A: Does not rescue a ts-mutant of MukB. {ECO:0000269|PubMed:20921377}.	
P22523	692	692		D->A: Does not rescue a ts-mutant of MukB; less binding of ParC. {ECO:0000269|PubMed:20921377}.	
P22523	1201	1201	1	D->N: In mukB33; no effect. {ECO:0000269|PubMed:10545099}.	
P22523	1381	1381		V->L: Abolishes DNA-binding, but remains associated with MukE and MukF. {ECO:0000269|PubMed:10545099}.	
P22523	1403	1403		L->P: Abolishes association with MukE and MukF, but still binds DNA. {ECO:0000269|PubMed:10545099}.	
P22523	1404	1404	1	F->L: No effect. {ECO:0000269|PubMed:10545099}.	
P22523	1406	1406	1	D->N: No effect. {ECO:0000269|PubMed:10545099}.	
P22523	1428	1428	1	M->L: No effect. {ECO:0000269|PubMed:10545099}.	
P22523	1429	1429		Q->R: Abolishes association with MukE and MukF, but still binds DNA. {ECO:0000269|PubMed:10545099}.	
P00509	65	65		Y->F,S: Slight changes in activity. {ECO:0000269|PubMed:1868057}.	
P00509	133	133		H->A: Slight increase in maximum velocity of the overall transamination reaction between aspartate and 2-oxoglutarate. {ECO:0000269|PubMed:2007566}.	
P00509	133	133		H->N: Decreases to 60% in maximum rate of the overall reactions in both directions. {ECO:0000269|PubMed:2007566}.	
P00509	280	280		R->V: Reduces first-order rate constant over 25000-fold. {ECO:0000269|PubMed:10556573}.	
P00509	374	374		R->A: Reduces first-order rate constant about 10000-fold. {ECO:0000269|PubMed:10556573, ECO:0000269|PubMed:1993208}.	
P00509	374	374		R->F,Y: Second-order rate constants are reduced by >5 orders of magnitude. {ECO:0000269|PubMed:10556573, ECO:0000269|PubMed:1993208}.	
P0A8M0	426	426	1	Y->F: No effect.	
P0A8M0	426	426		Y->S: 15-fold increase in Km for ATP.	
P80645	298	298		R->C: Loss of activity. {ECO:0000269|PubMed:10480865}.	
P0A7E1	175	175		S->A: Almost no activity. {ECO:0000269|PubMed:10074342}.	
P0A7E1	175	175		S->C: 500-fold reduction in activity. {ECO:0000269|PubMed:10074342}.	
P75862	22	22		L->P: Does not interact with FtsZ, but shows affinity for itself. Reduces GTPase activity by less than 10%. {ECO:0000269|PubMed:21216997}.	
P75864	195	195		D->A: Does not affect methyltransferase activity. {ECO:0000269|PubMed:22210896}.	
P75864	309	309		N->A: Impairs m2G2445 formation, but does not affect m7G2069 formation. {ECO:0000269|PubMed:22210896}.	
P75864	397	397		N->A: Impairs m2G2445 formation, but does not affect m7G2069 formation. {ECO:0000269|PubMed:22210896}.	
P75864	530	530		R->A: Does not affect methyltransferase activity. {ECO:0000269|PubMed:22210896}.	
P75864	568	568		D->A: Impairs m7G2069 formation, but does not affect m2G2445 formation. {ECO:0000269|PubMed:22210896}.	
P75864	597	597		D->A: Does not affect methyltransferase activity. {ECO:0000269|PubMed:22210896}.	
P0AFZ5	39	39		R->A: No effect on degradation by Lon protease. {ECO:0000269|PubMed:9180687}.	
P0AFZ5	62	62		R->A: Loss of degradation by Lon protease. {ECO:0000269|PubMed:8752322, ECO:0000269|PubMed:9180687}.	
P0AFZ5	62	62		R->C,H,S: Loss of activity due to loss of ability to bind to FtsZ. {ECO:0000269|PubMed:8752322, ECO:0000269|PubMed:9180687}.	
P0AFZ5	67	67		L->A: Loss of degradation by Lon protease. {ECO:0000269|PubMed:9180687}.	
P0AFZ5	72	72	1	K->A: No effect on degradation by Lon protease. {ECO:0000269|PubMed:9180687}.	
P0AFZ5	75	75	1	R->A: No effect on degradation by Lon protease. {ECO:0000269|PubMed:9180687}.	
P0AFZ5	76	76	1	E->A: No effect on degradation by Lon protease. {ECO:0000269|PubMed:9180687}.	
P0AFZ5	77	77		W->A: Loss of degradation by Lon protease. {ECO:0000269|PubMed:9180687}.	
P0AFZ5	83	83		L->R: Loss of activity due to loss of ability to bind to FtsZ. {ECO:0000269|PubMed:8752322}.	
P0AFZ5	87	87		K->A: Loss of degradation by Lon protease. {ECO:0000269|PubMed:9180687}.	
P0AFZ5	98	98	1	H->A: No effect on degradation by Lon protease. {ECO:0000269|PubMed:9180687}.	
P0AFZ5	105	105	1	R->A: No effect on degradation by Lon protease. {ECO:0000269|PubMed:9180687}.	
P0AFZ5	108	108	1	R->A: No effect on degradation by Lon protease. {ECO:0000269|PubMed:9180687}.	
P0AFZ5	115	115	1	V->A: No effect on degradation by Lon protease. {ECO:0000269|PubMed:9180687}.	
P0AFZ5	117	117	1	G->A: No effect on degradation by Lon protease. {ECO:0000269|PubMed:9180687}.	
P0AFZ5	126	126	1	E->A: No effect on degradation by Lon protease. {ECO:0000269|PubMed:9180687}.	
P0AFZ5	128	128	1	H->A: No effect on degradation by Lon protease. {ECO:0000269|PubMed:9180687}.	
P0AFZ5	163	163		I->A: Slight decrease in degradation by Lon protease. {ECO:0000269|PubMed:10788793}.	
P0AFZ5	164	164		H->A: No effect on degradation by Lon protease. {ECO:0000269|PubMed:10788793}.	
P0AFZ5	167	167		L->A: Slight decrease in degradation by Lon protease. {ECO:0000269|PubMed:10788793}.	
P0AFZ5	169	169		H->A: Great decrease in degradation by Lon protease. {ECO:0000269|PubMed:10788793}.	
P0AB65	5	5		C->A: No change in secondary structure. Nearly identical enzymatic properties. Loss of activity in 8.0 M urea. Reduced thermodynamic activity. Inactivated after 3 hours of incubation at 90 degrees Celsius. {ECO:0000269|PubMed:17134700}.	
P0AB18	108	108		C->S: Loss of activity. {ECO:0000269|PubMed:16387657}.	
P0AAC6	1	12		MDRIVSSSHDRT->MTMITPSLHDRI: Protein is as sensitive to FtsH degradation as the wild-type. {ECO:0000269|PubMed:10357810}.	
P0AAC6	5	12		Missing: In yccA11; increases the half- life of overexpressed SecY, F(0) ATP synthase subunit a and itself in an HflKC-dependent fashion, but has no effect on degradation of cytosolic substrates sigma-32 or the phage lambda cII protein. Partially dominant over the wild-type allele. This protein interacts with but is not degraded by FtsH. {ECO:0000269|PubMed:9636708}.	
P39453	453	453		H->Q: Loss of activity. {ECO:0000269|PubMed:9135110}.	
P39453	733	733		D->A,E: Loss of activity. {ECO:0000269|PubMed:9135110}.	
P39453	860	860		H->Q: Decrease in activity. {ECO:0000269|PubMed:9135110}.	
P38684	53	53		D->A: Loss of phosphorylation. {ECO:0000269|PubMed:9135110}.	
P33226	329	329		C->S: Decrease in expression of the torCAD operon. {ECO:0000269|PubMed:11562502}.	
P07117	257	257		R->C: Sodium-independent binding affinity for proline.	
P07117	376	376	1	R->E,Q: No change in activity. {ECO:0000269|PubMed:8119910}.	
P07117	376	376		R->K: Loss of activity. {ECO:0000269|PubMed:8119910}.	
P75906	115	115		D->A: High decrease in catalytic activity. Unable to support biofilm formation and PGA secretion. {ECO:0000269|PubMed:18359807}.	
P75906	184	184		H->A: Unable to support biofilm formation and PGA secretion. {ECO:0000269|PubMed:18359807}.	
P75908	359	360		GG->AA: Cells overexpressing this mutant are no longer swimming suppressed. {ECO:0000269|PubMed:18713317}.	
P0A8D6	124	124		G->E: Abolishes enzyme activity. {ECO:0000269|PubMed:21257746}.	
P75919	130	130		H->A: Lack of activity. {ECO:0000269|PubMed:22988102}.	
P75919	369	369		H->A: Lack of activity. {ECO:0000269|PubMed:22988102}.	
P0ACV0	132	132		H->A: Almost loss of activity. {ECO:0000269|PubMed:18656959}.	
P0ACV0	137	137		E->A: Almost loss of activity. {ECO:0000269|PubMed:18656959}.	
P0ACV0	169	169		R->A: 169-fold decrease in activity. {ECO:0000269|PubMed:18656959}.	
P0ACV0	200	200		D->A: 14-fold decrease in activity. {ECO:0000269|PubMed:18656959}.	
P0ACV0	238	238		P->A: Slight decrease in activity. {ECO:0000269|PubMed:18656959}.	
P0AF16	18	18		R->A,C: Lack of activity. {ECO:0000269|PubMed:23935042}.	
P0AF16	24	24		R->A,C: Lack of activity. {ECO:0000269|PubMed:23935042}.	
P0AF16	39	39		D->A,C: Lack of activity. {ECO:0000269|PubMed:23935042}.	
P0AF16	52	52		R->A: Decrease in activity. {ECO:0000269|PubMed:23935042}.	
P0AF16	52	52		R->C: Lack of activity. {ECO:0000269|PubMed:23935042}.	
P0AF16	270	270		R->A,C: Lack of activity. {ECO:0000269|PubMed:23935042}.	
P21513	57	57		F->A: Reduces RNA cleavage by over 98%. {ECO:0000269|PubMed:16237448}.	
P21513	66	66		G->S: Disrupts folding of the S1 motif. {ECO:0000269|PubMed:15312761}.	
P21513	67	67		F->A: Reduces RNA cleavage by over 98%. Reduces affinity for RNA. {ECO:0000269|PubMed:16237448}.	
P21513	112	112		K->A: Reduces RNA cleavage by 98%. Loss of RNA-binding. {ECO:0000269|PubMed:16237448}.	
P21513	170	170		T->V: Abolishes enzyme activity toward RNA substrates with a 5' monophosphate (PubMed:16237448). Strongly reduces enzyme activity toward cspA mRNA (PubMed:19889093). {ECO:0000269|PubMed:16237448, ECO:0000269|PubMed:19889093}.	
P21513	303	303		D->N: Reduces RNA cleavage by over 96%. {ECO:0000269|PubMed:16237448}.	
P21513	305	305		N->D,L: Reduces RNA cleavage by over 96%. {ECO:0000269|PubMed:16237448}.	
P21513	346	346		D->N: Reduces RNA cleavage by over 96%. Reduces affinity for RNA. {ECO:0000269|PubMed:16237448}.	
P21513	373	373		R->A,D: Reduces RNA cleavage by 89%. {ECO:0000269|PubMed:16237448}.	
P21513	404	404		C->A: Reduces zinc-binding. Abolishes homotetramerization and enzyme activity. {ECO:0000269|PubMed:15779893}.	
P21513	407	407		C->A: Reduces zinc-binding. Abolishes homotetramerization and enzyme activity. {ECO:0000269|PubMed:15779893}.	
P0A6R0	112	112		C->S: Loss of activity.	
P0A6R0	214	214		K->E,A: Strongly reduces the binding to malonyl-ACP but not that of the substrate. {ECO:0000269|PubMed:11078736}.	
P0A6R0	244	244		H->A: Loss of activity.	
P0A6R0	249	249		R->E,A: Abolishes the binding to malonyl- ACP but not that of the substrate. {ECO:0000269|PubMed:11078736}.	
P0A6R0	253	253		A->Y: Abolishes both binding to malonyl- ACP and binding to substrate. {ECO:0000269|PubMed:11078736}.	
P0A6R0	256	257		KK->AA: Strongly reduces both binding to malonyl-ACP and binding to substrate. {ECO:0000269|PubMed:11078736}.	
P0A6R0	256	257		KK->EE: Abolishes the binding to malonyl- ACP but not that of the substrate. {ECO:0000269|PubMed:11078736}.	
P0A6R0	274	274		N->A: Loss of activity.	
P0AEK2	151	151		Y->F: Defect in the affinity for NADPH. {ECO:0000269|PubMed:15016358}.	
P0AEK2	154	154		A->T: Decreases in the thermolability of the reductase; when associated with K- 233. {ECO:0000269|PubMed:14996818}.	
P0AEK2	155	155		K->A: Defect in the affinity for NADPH. {ECO:0000269|PubMed:15016358}.	
P0AEK2	233	233		E->K: Decreases in the thermolability of the reductase; when associated with T- 154. {ECO:0000269|PubMed:14996818}.	
P0A6A8	37	37		S->A,T: Loss of phosphopantetheinylation, and inhibition of cell growth. {ECO:0000269|PubMed:7673201}.	
P16869	44	44		V->P: Abolishes transport activity. {ECO:0000269|PubMed:2162465}.	
P16869	46	46		V->P: Abolishes transport activity. {ECO:0000269|PubMed:2162465}.	
P16869	163	163		G->A,V,N,D,H: Impaired transport and growth. {ECO:0000269|PubMed:2162465}.	
P0ACE7	101	101		H->A,G: Abolishes enzyme activity. {ECO:0000269|PubMed:15703176, ECO:0000269|PubMed:20934431, ECO:0000269|PubMed:21754980}.	
P0ACE7	114	119		Missing: Strongly reduces enzyme activity. {ECO:0000269|PubMed:20934431}.	
P0ACE7	117	119		Missing: Abolishes enzyme activity. {ECO:0000269|PubMed:20934431}.	
P75957	42	42		G->D: Loss of lipoprotein release when overexpressed. {ECO:0000269|PubMed:10783239}.	
P75960	55	55		Y->F: 42-fold decrease in desuccinylase activity. 3-fold decrease in deacetylase activity. {ECO:0000269|PubMed:24176774}.	
P75960	58	58		R->M: 100-fold decrease in desuccinylase activity. 3-fold decrease in deacetylase activity. {ECO:0000269|PubMed:24176774}.	
P69874	26	26		C->A: Lower ATPase activity and transport efficiency. {ECO:0000269|PubMed:7592703}.	
P69874	27	27		F->L: Lower ATPase activity and transport efficiency. {ECO:0000269|PubMed:11976340}.	
P69874	45	45		F->L: Lower ATPase activity and transport efficiency. {ECO:0000269|PubMed:11976340}.	
P69874	54	54		C->T: Loss of ATPase activity and transport. {ECO:0000269|PubMed:7592703}.	
P69874	60	60		L->F: Lower ATPase activity and transport efficiency. {ECO:0000269|PubMed:11976340}.	
P69874	76	76		L->P: Lower ATPase activity and transport efficiency. {ECO:0000269|PubMed:11976340}.	
P69874	135	135		V->M: Loss of ATPase activity and transport. {ECO:0000269|PubMed:11976340, ECO:0000269|PubMed:8366082}.	
P69874	172	172		D->N: Loss of ATPase activity and transport. {ECO:0000269|PubMed:11976340}.	
P69874	276	276		C->A: Lower ATPase activity and transport efficiency. {ECO:0000269|PubMed:7592703}.	
P69874	297	297		E->K,D: Lower ATPase activity and transport efficiency. {ECO:0000269|PubMed:11976340}.	
P69874	297	297		E->Q: Loss of ATPase activity and transport. {ECO:0000269|PubMed:11976340}.	
P23837	27	27		V->N: Shows Mg(2+)-dependent signaling and partial gene activation activity; when associated with A-202. {ECO:0000269|PubMed:20404199}.	
P23837	30	30		L->N: Shows Mg(2+)-dependent signaling and displays higher gene activation activity than wild-type; when associated with A-202. {ECO:0000269|PubMed:20404199}.	
P23837	47	47	1	T->L: No significant effect (with or without MgCl(2) or CaCl(2)). {ECO:0000269|PubMed:16041131}.	
P23837	48	48	1	T->A,C,E,M,N,Q,S,V: No significant effect (with or without MgCl(2) or CaCl(2)). {ECO:0000269|PubMed:12218035}.	
P23837	48	48		T->D,G,H,I,K,L,P,R: Confers less than 30% of the wild-type levels of PhoP/PhoQ- signaling cascade in absence of CaCl(2) or MgCl(2). {ECO:0000269|PubMed:12218035}.	
P23837	48	48		T->F,W: Decreased sensitivity to repression by calcium but not by magnesium. {ECO:0000269|PubMed:12218035}.	
P23837	48	48	1	T->Y: Higher activity than wild-type (with or without MgCl(2) or CaCl(2)). {ECO:0000269|PubMed:12218035}.	
P23837	50	50		R->D: Large decrease in the transcriptional activation of PhoQ- dependent genes. {ECO:0000269|PubMed:18348979}.	
P23837	54	54		G->D: Very large decrease in the transcriptional activation of PhoQ- dependent genes. {ECO:0000269|PubMed:18348979}.	
P23837	68	68	1	N->L: No significant effect (with or without MgCl(2) or CaCl(2)). {ECO:0000269|PubMed:16041131}.	
P23837	90	90	1	D->A: No significant effect (with or without MgCl(2) or CaCl(2)). {ECO:0000269|PubMed:16041131}.	
P23837	148	154		EDDDDAE->QNNNNAQ: Unable to bind divalent cations in vitro and impaired in the ability to respond to Mg(2+) deprivation in vivo. {ECO:0000269|PubMed:8900137}.	
P23837	149	149		D->A: Wild-type effect concerning mgrB transcription. {ECO:0000269|PubMed:16041131}.	
P23837	150	150		D->I: Wild-type effect concerning mgrB transcription. {ECO:0000269|PubMed:16041131}.	
P23837	151	151		D->I: Wild-type effect concerning mgrB transcription. {ECO:0000269|PubMed:16041131}.	
P23837	152	152		D->F: Wild-type effect concerning mgrB transcription. {ECO:0000269|PubMed:16041131}.	
P23837	179	179		D->L,A: Locked-on mutant defective in Mg(2+)-sensing and unable to control its phosphorylation state and phosphotransfer to phoP. {ECO:0000269|PubMed:16041131, ECO:0000269|PubMed:18348979}.	
P23837	179	179		D->R: Very large decrease in the transcriptional activation of PhoQ- dependent genes. {ECO:0000269|PubMed:16041131, ECO:0000269|PubMed:18348979}.	
P23837	199	199	1	L->N: Shows Mg(2+)-dependent signaling and partial gene activation activity; when associated with A-202. {ECO:0000269|PubMed:20404199}.	
P23837	202	202		N->A: Is blind to signal, fails to activate transcription of PhoQ-dependent genes, and abrogates transcription when coexpressed with wild-type PhoQ. Shows no detectable autophosphorylation. Still displays phosphatase activity. Recovers Mg(2+)-dependent signaling and partial gene activation activity; when associated with N-27 or N-199 or N-203 or N-205. Recovers Mg(2+)-dependent signaling and displays higher gene activation activity than wild-type; when associated with N- 30. {ECO:0000269|PubMed:20404199}.	
P23837	202	202		N->I,L,M,F,W,Y,V,C,G,P: Is blind to signal, fails to activate transcription of PhoQ-dependent genes, and abrogates transcription when coexpressed with wild- type PhoQ. {ECO:0000269|PubMed:20404199}.	
P23837	202	202	1	N->R,D,Q,E,H: Shows similar activity profile to wild-type. {ECO:0000269|PubMed:20404199}.	
P23837	203	203		L->N: Shows Mg(2+)-dependent signaling and partial gene activation activity; when associated with A-202. {ECO:0000269|PubMed:20404199}.	
P23837	205	205		L->N: Shows Mg(2+)-dependent signaling and partial gene activation activity; when associated with A-202. {ECO:0000269|PubMed:20404199}.	
P23837	392	392		K->A: 44-fold decrease in ATP affinity and 6-fold decrease in activity. {ECO:0000269|PubMed:11493605}.	
P23837	434	434		R->A: 2-fold decrease in ATP affinity and 51-fold decrease in activity. {ECO:0000269|PubMed:11493605}.	
P23837	439	439		R->A: 3-fold decrease in ATP affinity and 2-fold increase in activity. {ECO:0000269|PubMed:11493605}.	
P0AB89	171	171		H->A,N: Reduces catalytic activity about 500-fold. {ECO:0000269|PubMed:17531264}.	
P0AB89	295	295		S->A: Reduces catalytic activity about 1000-fold. {ECO:0000269|PubMed:17531264}.	
P25745	17	17		D->A: Loss of activity. {ECO:0000269|PubMed:16871210}.	
P25745	37	37		M->A: Reduces activity by 60%. {ECO:0000269|PubMed:16871210}.	
P25745	97	97		N->A: Loss of activity. {ECO:0000269|PubMed:16871210}.	
P25745	99	99		D->A: Loss of activity. {ECO:0000269|PubMed:16871210}.	
P25745	102	102		C->A: Loss of activity. {ECO:0000269|PubMed:16871210}.	
P25745	107	107		K->M: Reduces activity by 75%. {ECO:0000269|PubMed:16871210}.	
P25745	128	128		H->A: Reduces activity by 90%. {ECO:0000269|PubMed:16871210}.	
P25745	149	149		K->A: Loss of activity. {ECO:0000269|PubMed:16871210}.	
P25745	151	151		Q->E: Loss of activity. {ECO:0000269|PubMed:16871210}.	
P25745	199	199		C->A: Abolishes the incorporation of sulfur from the sulfur-relay system; loss of activity. {ECO:0000269|PubMed:16871210}.	
P25745	200	200		F->A: Reduces activity by 60%. {ECO:0000269|PubMed:16871210}.	
P25745	239	239		T->A: Reduces activity by 50%. {ECO:0000269|PubMed:16871210}.	
P25745	311	311		R->A: Reduces activity by 75%. {ECO:0000269|PubMed:16871210}.	
P25745	344	344		Q->A: Loss of activity. {ECO:0000269|PubMed:16871210}.	
P75966	79	79		D->N,T: Loss of activity. {ECO:0000269|PubMed:11720289}.	
P08200	100	100		K->R,E: Abolishes enzymatic activity. {ECO:0000269|PubMed:21151122}.	
P08200	113	113		S->D,E: Reduced affinity for isocitrate. {ECO:0000269|PubMed:2204109}.	
P08200	160	160		Y->F: Large decrease in activity and a small increase in substrate affinity. {ECO:0000269|PubMed:7761851, ECO:0000269|PubMed:7819221}.	
P08200	230	230		K->M: Decrease in activity and substrate affinity. {ECO:0000269|PubMed:7761851, ECO:0000269|PubMed:7819221}.	
P08200	242	242		K->E: Strongly impairs enzymatic activity. {ECO:0000269|PubMed:21151122}.	
P08200	242	242		K->R: Impairs enzymatic activity. {ECO:0000269|PubMed:21151122}.	
P75990	193	195		IVQ->LVR: Does not confer c-di-GMP phosphodiesterase activity. {ECO:0000269|PubMed:19240136}.	
P0AEZ3	15	15		G->S: Less effective then wild-type. {ECO:0000269|PubMed:1836760}.	
P0AEZ3	16	17		KT->QR: Loss of activity. {ECO:0000269|PubMed:1836760}.	
P0AEZ3	16	16		K->Q: Loss of activity. {ECO:0000269|PubMed:1836760}.	
P77335	88	90		GVA->DVD: Abolishes cytotoxic activity. {ECO:0000269|PubMed:10383763}.	
P77335	97	97		Y->H: Strongly reduces cytotoxic activity. {ECO:0000269|PubMed:11006277}.	
P77335	143	144		NA->DD: Abolishes cytotoxic activity. {ECO:0000269|PubMed:10383763}.	
P77335	157	157		N->H: Strongly reduces cytotoxic activity. {ECO:0000269|PubMed:11006277}.	
P77335	165	165		Y->C: Strongly reduces cytotoxic activity. {ECO:0000269|PubMed:11006277}.	
P77335	183	186		Missing: In PMWK16; retained in cytosol. Loss of function.	
P77335	183	184		AG->DD: Abolishes cytotoxic activity. {ECO:0000269|PubMed:10383763}.	
P77335	187	188		AG->DD: Abolishes cytotoxic activity. {ECO:0000269|PubMed:10383763}.	
P77335	261	261		R->K: Strongly reduces cytotoxic activity. {ECO:0000269|PubMed:11006277}.	
P77335	268	268		D->A: Strongly reduces cytotoxic activity. {ECO:0000269|PubMed:10383763}.	
P77335	293	294		GK->DA: Strongly reduces cytotoxic activity. {ECO:0000269|PubMed:10383763}.	
P0AG11	27	27		P->D: In umuD1; non-cleavable. {ECO:0000269|PubMed:1320188}.	
P0AG11	65	65		G->R: In umuD44; non-cleavable. {ECO:0000269|PubMed:1320188}.	
P0AG11	92	92		G->D: In umuD77; non-cleavable. {ECO:0000269|PubMed:1320188}.	
P04152	75	75		E->K: In umuC36; non-mutable. {ECO:0000269|PubMed:1320188}.	
P04152	101	101		D->N: In umuC104; non-mutable. {ECO:0000269|PubMed:1320188}.	
P04152	290	290		T->K: In umuC25; non-mutable. {ECO:0000269|PubMed:1320188}.	
P76010	42	42		K->D: Suppression of the yhjH disruption motility phenotype. {ECO:0000269|PubMed:20346719}.	
P76010	62	62		N->W: Signficant suppression of the yhjH disruption motility phenotype, less binding to FliG. {ECO:0000269|PubMed:20346719}.	
P76010	81	81		K->D: Signficant suppression of the yhjH disruption motility phenotype, less binding to FliG. {ECO:0000269|PubMed:20346719}.	
P76010	118	118		R->D: Complete loss of c-di-GMP binding in vitro, suppresses yhjH disruption (PubMed:16920715). Somewhat reduced binding to FliM, stimulated by c-di-GMP, greatly reduced binding to FliG (PubMed:20346719). {ECO:0000269|PubMed:16920715, ECO:0000269|PubMed:20346719}.	
P76010	147	147	1	S->A: Slight increase in affinity for c- di-GMP. {ECO:0000269|PubMed:16920715}.	
P76010	223	223		Q->P: Signficant suppression of the yhjH disruption motility phenotype, no binding to FliM. {ECO:0000269|PubMed:20346719}.	
P76010	223	223		Q->W: Signficant suppression of the yhjH disruption motility phenotype. {ECO:0000269|PubMed:20346719}.	
P76010	227	227		I->W: Some suppression of the yhjH disruption motility phenotype, no binding to FliM. {ECO:0000269|PubMed:20346719}.	
P37349	9	9		H->A: Loss of activity. {ECO:0000269|PubMed:11350937}.	
P37349	169	169		H->A: Loss of activity. {ECO:0000269|PubMed:11350937}.	
P37349	430	430		H->A: Loss of activity. {ECO:0000269|PubMed:11350937}.	
P76015	218	218		H->A,K: Loss of kinase activity. {ECO:0000269|PubMed:12813127}.	
P0ABU2	12	12	1	N->A: Shows similar hydrolysis activities in the presence of K(+) or Na(+). {ECO:0000269|PubMed:21527254}.	
P0ABU2	78	78	1	K->A: Shows similar hydrolysis activities in the presence of K(+) or Na(+). {ECO:0000269|PubMed:21527254}.	
P0ABU2	78	78	1	K->R: Retains K(+)-dependent stimulation of ATPase activity and differentiates between K(+) and Na(+). {ECO:0000269|PubMed:21527254}.	
P0A7D1	101	101		G->D: Pth(ts) mutants synthesize thermosensitive PTH and die at 42 degrees Celsius from a defect in protein synthesis.	
P0A7D1	134	134		R->H: Rap mutants do not support vegetative growth of bacteriophage lambda and die upon transcription of lambda DNA bar sites.	
P0A717	220	220		D->E: 4-fold decrease in the affinity binding for Rib-5-P in the presence of magnesium ions. In the presence of cobalt ions, it shows a 15-fold decrease in the affinity binding for Rib-5-P. {ECO:0000269|PubMed:8679571}.	
P0A717	220	220	1	D->F: With magnesium or manganese ions, the affinity binding values for ATP and Rib-5-P are comparable to those of the wild-type. {ECO:0000269|PubMed:8679571}.	
P0A717	221	221		D->A: The affinity binding for ATP is comparable to those of the wild-type, apart from a slight decrease in the presence of manganese ions. The affinity binding for Rib-5-P is greatly decreased in the presence of both manganese and cobalt ions but only about 2-fold in the presence of magnesium ions. {ECO:0000269|PubMed:8679571}.	
P0A717	224	224	1	D->A: With magnesium or manganese ions, the affinity binding values for ATP and Rib-5-P are comparable to those of the wild-type. {ECO:0000269|PubMed:8679571}.	
P0A717	224	224	1	D->S: With magnesium or manganese ions, the affinity binding values for ATP and Rib-5-P are comparable to those of the wild-type. {ECO:0000269|PubMed:8679571}.	
P62615	239	239		G->R: Loss of activity. {ECO:0000269|PubMed:12859972}.	
P62615	240	240		T->I: Loss of activity. {ECO:0000269|PubMed:12859972}.	
P0A6X1	7	7		G->D: Loss of activity. {ECO:0000269|PubMed:12370189}.	
P0A6X1	49	49		T->V: 10% and 5% of wild-type reductase and esterase activity, respectively. {ECO:0000269|PubMed:17697121}.	
P0A6X1	50	50		C->S: Loss of activity. {ECO:0000269|PubMed:12370189}.	
P0A6X1	52	52		R->K: 5% and 4% of wild-type reductase and esterase activity, respectively. {ECO:0000269|PubMed:17697121}.	
P0A6X1	52	52		R->Q: Loss of activity. {ECO:0000269|PubMed:17697121}.	
P0A6X1	54	54		E->K: 6% and 2% of wild-type reductase and esterase activity, respectively. {ECO:0000269|PubMed:17697121}.	
P0A6X1	74	74	1	C->S: No effect. {ECO:0000269|PubMed:12370189}.	
P0A6X1	99	99		H->N: 5% and 4% of wild-type reductase and esterase activity, respectively. {ECO:0000269|PubMed:17697121}.	
P0A6X1	106	106		G->N: Loss of activity. {ECO:0000269|PubMed:12370189}.	
P0A6X1	109	109		S->A: 28% and 25% of wild-type reductase and esterase activity, respectively. {ECO:0000269|PubMed:17697121}.	
P0A6X1	114	114		E->K: Loss of activity. {ECO:0000269|PubMed:12370189}.	
P0A6X1	116	116		Q->L: Loss of reductase activity. 30% of wild-type esterase activity. {ECO:0000269|PubMed:17697121}.	
P0A6X1	145	145		S->F: Loss of activity. {ECO:0000269|PubMed:12370189}.	
P0A6X1	170	170	1	C->S: No effect. {ECO:0000269|PubMed:12370189}.	
P0A6X1	191	191		G->D: Loss of reductase activity. Retains esterase activity. {ECO:0000269|PubMed:12370189}.	
P0A6X1	314	314		R->C: Loss of activity. {ECO:0000269|PubMed:12370189}.	
P0A7I0	235	235		Q->E,A: Loss of methylation. {ECO:0000269|PubMed:11847124}.	
P0ACC1	36	36		R->A: 17% of wild-type RF1 methylation activity. {ECO:0000269|PubMed:16364916}.	
P0ACC1	40	40		L->A: 60% of wild-type RF1 methylation activity. {ECO:0000269|PubMed:16364916}.	
P0ACC1	41	41		A->R: 7% of wild-type RF1 methylation activity. Strongly reduced affinity for S-adenosyl-L-methionine. {ECO:0000269|PubMed:16364916}.	
P0ACC1	42	42		F->A: 40% of wild-type RF1 methylation activity. {ECO:0000269|PubMed:16364916}.	
P0ACC1	44	44		E->A: 62% of wild-type RF1 methylation activity. {ECO:0000269|PubMed:16364916}.	
P0ACC1	44	44		E->R: 33% of wild-type RF1 methylation activity. {ECO:0000269|PubMed:16364916}.	
P0ACC1	183	183		N->A: Less than 2% of wild-type RF1 methylation activity. {ECO:0000269|PubMed:16364916}.	
P09152	50	50		H->S: Loss of activity. {ECO:0000269|PubMed:9585550}.	
P0AEV1	58	58		D->P,Q,R: Lack of phosphorylation. Cannot bind RpoS. {ECO:0000269|PubMed:11442836, ECO:0000269|PubMed:24352426, ECO:0000269|PubMed:9515704}.	
P0AEV1	67	67		L->A: Lack of phosphorylation. {ECO:0000269|PubMed:24352426}.	
P0AEV1	109	109		P->S: Resistant to IraP but not to IraD. Increases stabilization by IraM. Decreases phosphorylation. {ECO:0000269|PubMed:24352426}.	
P0AEV1	143	143		W->R: Resistant to both IraP and IraD. Increases stabilization by IraM. {ECO:0000269|PubMed:24352426}.	
P0AEV1	214	214		L->H: Resistant to IraP and IraD. {ECO:0000269|PubMed:24352426}.	
P0AEV1	216	216		A->T: Resistant to IraP, IraD and IraM. {ECO:0000269|PubMed:24352426}.	
P0AEV1	218	218		L->V: Resistant to IraP, IraD and IraM. {ECO:0000269|PubMed:24352426}.	
P0AEV1	255	255		A->V: Resistant to IraM. {ECO:0000269|PubMed:24352426}.	
P0ACF8	12	12		R->K: Abolishes the interaction with Hha. {ECO:0000269|PubMed:21600204}.	
P0A6H8	2	60		Missing: Remains membrane associated and retains in vitro and in vivo activity. {ECO:0000269|PubMed:22988102}.	
P0A6H8	7	8		LV->SS: Retains in vitro activity, but loses most of its in vivo activity. Higher apparent molecular mass than wild- type protein. {ECO:0000269|PubMed:22988102}.	
P0A6H8	30	32		KRR->TTT: Undergoes altered post- translational processing and has much lower in vivo and in vitro activity. {ECO:0000269|PubMed:22988102}.	
P0A6H8	59	59	1	G->A: Does not affect CL synthase processing or activity. {ECO:0000269|PubMed:22988102}.	
P37765	110	110		D->N,T: Loss of activity. {ECO:0000269|PubMed:11720289}.	
P06612	9	9		E->A: Abolishes enzyme activity. {ECO:0000269|PubMed:9497321}.	
P06612	9	9	1	E->Q: No effect on DNA cleavage activity. {ECO:0000269|PubMed:9497321}.	
P06612	111	111		D->A: Abolishes both magnesium binding and enzyme activity; when associated with A-113 and A-115. {ECO:0000269|PubMed:10681504}.	
P06612	113	113		D->A: Abolishes both magnesium binding and enzyme activity; when associated with A-111 and A-115. {ECO:0000269|PubMed:10681504}.	
P06612	115	115		E->A: Abolishes both magnesium binding and enzyme activity; when associated with A-111 and A-113. {ECO:0000269|PubMed:10681504}.	
P06612	168	168		R->A: Abolishes enzyme activity. {ECO:0000269|PubMed:21482796}.	
P06612	172	172		D->A: Abolishes enzyme activity. {ECO:0000269|PubMed:21482796}.	
P06612	319	319		Y->A: Abolishes enzyme activity. {ECO:0000269|PubMed:9497321}.	
P06612	321	321		R->A: Abolishes enzyme activity. {ECO:0000269|PubMed:9497321}.	
P06612	321	321	1	R->K: No effect. {ECO:0000269|PubMed:9497321}.	
P06612	365	365	1	H->A: No effect. {ECO:0000269|PubMed:14604525, ECO:0000269|PubMed:9497321}.	
P06612	365	365		H->R: Increases DNA binding affinity. {ECO:0000269|PubMed:14604525, ECO:0000269|PubMed:9497321}.	
P06612	496	496	1	T->A: No effect. {ECO:0000269|PubMed:9497321}.	
P0A7I7	54	54		C->S: Loss of zinc binding. Loss of ring- opening activity. Can still remove phosphate from GTP. {ECO:0000269|PubMed:12392559}.	
P0A7I7	65	65		C->S: Loss of zinc binding. Loss of ring- opening activity. Can still remove phosphate from GTP. {ECO:0000269|PubMed:12392559}.	
P0A7I7	67	67		C->S: Loss of zinc binding. Loss of ring- opening activity. Can still remove phosphate from GTP. {ECO:0000269|PubMed:12392559}.	
P0AB58	184	184	1	C->S: Does not affect metal binding; when associated with S-258. {ECO:0000269|PubMed:24187084}.	
P0AB58	258	258	1	C->S: Does not affect metal binding; when associated with S-184. {ECO:0000269|PubMed:24187084}.	
P0AB58	357	357	1	C->S: Lack of activity; when associated with S-360; S-371 and S-374. {ECO:0000269|PubMed:24187084}.	
P0AB58	360	360	1	C->S: Lack of activity; when associated with S-357; S-371 and S-374. {ECO:0000269|PubMed:24187084}.	
P0AB58	371	371		C->R: Lack of activity. {ECO:0000269|PubMed:24722986}.	
P0AB58	371	371	1	C->S: Lack of activity; when associated with S-357; S-360 and S-374. {ECO:0000269|PubMed:24187084}.	
P0AB58	372	372		P->L: Lack of activity. {ECO:0000269|PubMed:24722986}.	
P0AB58	374	374	1	C->S: Lack of activity; when associated with S-357; S-360 and S-371. {ECO:0000269|PubMed:24187084}.	
P0AB58	378	378		S->P: Lack of activity. {ECO:0000269|PubMed:24722986}.	
P0AEK4	93	93		G->S: Diazaborine resistance. {ECO:0000269|PubMed:1364817, ECO:0000269|PubMed:9707111}.	
P0AEK4	93	93		G->V: Triclosan resistance. {ECO:0000269|PubMed:1364817, ECO:0000269|PubMed:9707111}.	
P0AEK4	146	146		Y->F: Large impact on catalysis, with kcat and kcat/Km for DD-ACP decreasing by around 50-fold compared with wild-type. {ECO:0000269|PubMed:17012233}.	
P0AEK4	156	156	1	Y->F: No effect on substrate reduction. {ECO:0000269|PubMed:17012233}.	
P0AEK4	159	159		M->T: Triclosan resistance. {ECO:0000269|PubMed:9707111}.	
P0AEK4	201	201	1	K->A: No effect on substrate reduction. {ECO:0000269|PubMed:17012233}.	
P0AEK4	201	201		K->E: Little activity toward DD-CoA and DD-ACP. {ECO:0000269|PubMed:17012233}.	
P0AEK4	203	203		F->L: Triclosan resistance. {ECO:0000269|PubMed:9707111}.	
P0AEK4	204	204	1	R->A: No effect on substrate reduction. {ECO:0000269|PubMed:17012233}.	
P0AEK4	204	204		R->E: Causes a further reduction in kcat/Km for reduction of DD-ACP without affecting kcat/Km for the DD-CoA substrate. {ECO:0000269|PubMed:17012233}.	
P0AEK4	205	205	1	K->A: No effect on substrate reduction. {ECO:0000269|PubMed:17012233}.	
P0AEK4	205	205		K->E: Causes a further reduction in kcat/Km for reduction of DD-ACP without affecting kcat/Km for the DD-CoA substrate. Has a larger impact on substrate reduction. {ECO:0000269|PubMed:17012233}.	
P0AEK4	241	241		S->F: Produces temperature-sensitive phenotype.	
P76037	110	110		Y->X: The uptake activity is reduced to one-eighth of that of wild-type. {ECO:0000269|PubMed:19181795}.	
P78061	282	282		H->N: Activity is impaired to 9% of wild- type. {ECO:0000269|PubMed:18495664}.	
P78061	357	357		R->Q: Activity is impaired to 3% of wild- type. {ECO:0000269|PubMed:18495664}.	
P76038	114	114		C->A: Lacks the PuuD activity. The expression level is similar to that of the wild-type. {ECO:0000269|PubMed:16499623}.	
P50457	267	267		K->A: No GABA-AT activity. {ECO:0000269|PubMed:20639325}.	
P0A9E5	16	16	1	C->A: No effect. {ECO:0000269|PubMed:2226775}.	
P0A9E5	20	20		C->S: Loss of activity. {ECO:0000269|PubMed:2226775}.	
P0A9E5	22	22		D->G: Loss of regulation by O(2). {ECO:0000269|PubMed:1898918}.	
P0A9E5	23	23		C->G: Loss of activity. {ECO:0000269|PubMed:2226775}.	
P0A9E5	28	28		L->H: Loss of regulation by O(2). {ECO:0000269|PubMed:1898918}.	
P0A9E5	29	29		C->G: Loss of activity. {ECO:0000269|PubMed:2226775}.	
P0A9E5	43	43		D->G: Decrease in activity; no effect on DNA-binding. {ECO:0000269|PubMed:9321653}.	
P0A9E5	64	64	1	E->Q: No effect. {ECO:0000269|PubMed:2226775}.	
P0A9E5	72	72		R->H: Decrease in activity; no effect on DNA-binding. {ECO:0000269|PubMed:9321653}.	
P0A9E5	73	73		S->F: Decrease in activity; no effect on DNA-binding. {ECO:0000269|PubMed:11115116, ECO:0000269|PubMed:9321653}.	
P0A9E5	81	81		I->T: Decrease in activity; no effect on DNA-binding. {ECO:0000269|PubMed:1762901}.	
P0A9E5	82	82		T->P: Decrease in activity; no effect on DNA-binding. {ECO:0000269|PubMed:1762901}.	
P0A9E5	85	85		G->A: Decrease in activity; no effect on DNA-binding. Trace activity; when associated with P-187. {ECO:0000269|PubMed:11115116, ECO:0000269|PubMed:1762901}.	
P0A9E5	86	86		D->A: Decrease in activity; no effect on DNA-binding. {ECO:0000269|PubMed:1762901}.	
P0A9E5	87	87		E->K: Decrease in activity; no effect on DNA-binding. {ECO:0000269|PubMed:1762901}.	
P0A9E5	88	88		Q->E: Decrease in activity; no effect on DNA-binding. {ECO:0000269|PubMed:1762901}.	
P0A9E5	93	93		H->R: Loss of regulation by O(2). {ECO:0000269|PubMed:1898918}.	
P0A9E5	96	96		G->D: Loss of activity. {ECO:0000269|PubMed:2226775}.	
P0A9E5	118	118		T->A,P: Decrease in activity; no effect on DNA-binding. {ECO:0000269|PubMed:11115116, ECO:0000269|PubMed:9321653}.	
P0A9E5	120	120		M->I,R,T,V: Decrease in activity; no effect on DNA-binding. {ECO:0000269|PubMed:9321653}.	
P0A9E5	122	122		C->A,S: Loss of activity. {ECO:0000269|PubMed:2226775}.	
P0A9E5	140	140		R->A: Decrease in activity.	
P0A9E5	143	143		M->A: Decrease in activity.	
P0A9E5	144	144		M->A: Decrease in activity due to faulty dimerization.	
P0A9E5	145	145		R->A: Decrease in activity.	
P0A9E5	146	146		L->A: Decrease in activity.	
P0A9E5	147	147		M->A: Decrease in activity due to faulty dimerization.	
P0A9E5	150	150		E->K: Loss of regulation by O(2). {ECO:0000269|PubMed:1898918}.	
P0A9E5	151	151		I->A: Decrease in activity due to faulty dimerization.	
P0A9E5	154	154		D->A,G,V: Loss of regulation by O(2). {ECO:0000269|PubMed:1898918, ECO:0000269|PubMed:8406003}.	
P0A9E5	158	158		I->A: Decrease in activity due to faulty dimerization.	
P0A9E5	181	181		F->L: Decrease in activity; no effect on DNA-binding. {ECO:0000269|PubMed:9321653}.	
P0A9E5	186	186		F->S: Decrease in activity; no effect on DNA-binding. {ECO:0000269|PubMed:9321653}.	
P0A9E5	187	187		S->P: Decrease in activity; no effect on DNA-binding. Trace activity; when associated with A-85. {ECO:0000269|PubMed:11115116, ECO:0000269|PubMed:9321653}.	
P0A9E5	191	191		F->L: Decrease in activity; no effect on DNA-binding. {ECO:0000269|PubMed:9321653}.	
P0AFH0	102	102		C->G: Little effect on the activity. {ECO:0000269|PubMed:1520330}.	
P0AFH0	139	139		C->G: Eliminates the activity. {ECO:0000269|PubMed:1520330}.	
P77302	334	335		EE->AA: No longer complements a ydaM disruption, loss of csgB induction. {ECO:0000269|PubMed:17010156}.	
P21693	53	53		K->A: Shows accumulation of partially- assembled 45S particles. {ECO:0000269|PubMed:19734347}.	
P21693	154	154		E->A: Shows accumulation of partially- assembled 45S particles. {ECO:0000269|PubMed:19734347}.	
P21693	331	331		R->A: Shows accumulation of partially- assembled 45S particles. Binds rRNA normally but is severely impaired in ATPase and helicase activities. Overexpression confers a dominant slow growth and cold-sensitive phenotype. {ECO:0000269|PubMed:19734347}.	
P33230	1	1		M->T: No protein should be translated, DNA region still acts as an antitoxin to RalR. {ECO:0000269|PubMed:24748661}.	
P33230	9	69		Missing: No protein should be translated, DNA region still acts as an antitoxin to RalR. {ECO:0000269|PubMed:24748661}.	
P33229	43	46	1	EKEA->AIAE: No longer inhibits growth. {ECO:0000269|PubMed:24748661}.	
P33229	52	52		K->E: No longer inhibits growth, has no DNase activity. {ECO:0000269|PubMed:24748661}.	
P77455	256	256		E->Q: Catalyzes the formation of 3-oxo- 5,6-dehydrosuberyl-CoA semialdehyde instead of 3-oxo-5,6-dehydrosuberyl-CoA. {ECO:0000269|PubMed:21296885}.	
P76084	46	46		N->A: Reduces activity 1000-fold. {ECO:0000269|PubMed:16464851}.	
P76084	52	52		H->A: Reduces activity 100-fold. {ECO:0000269|PubMed:16464851}.	
P76084	61	61		D->A: Loss of activity. {ECO:0000269|PubMed:16464851}.	
P25397	36	36		D->A,N: Loss of tellurite resistance. {ECO:0000269|PubMed:11053398}.	
P25397	59	59		D->A: Loss of tellurite resistance. {ECO:0000269|PubMed:11053398}.	
P25397	96	96		Y->A: Decrease in tellurite resistance. {ECO:0000269|PubMed:11053398}.	
P25397	97	97	1	D->E: No effect on tellurite resistance. {ECO:0000269|PubMed:11053398}.	
P25397	97	97		D->N: Decrease in tellurite resistance. {ECO:0000269|PubMed:11053398}.	
P25397	98	98		F->A,Y: Loss of tellurite resistance. {ECO:0000269|PubMed:11053398}.	
P25397	176	176		H->A: 95% of wild-type methyltransferase activity on tellurite. {ECO:0000269|PubMed:21244361}.	
P25397	177	177		R->A: 35% of wild-type methyltransferase activity on tellurite. {ECO:0000269|PubMed:21244361}.	
P25397	184	184		R->A: 74% of wild-type methyltransferase activity on tellurite. {ECO:0000269|PubMed:21244361}.	
P64453	1	1		M->T: Not toxic as no protein is produced. {ECO:0000269|PubMed:25643179}.	
P64453	38	38		F->R: Reduced toxicity. {ECO:0000269|PubMed:25643179}.	
P76113	247	247		C->A: Exhibits a reduction of about 50% in activity, but is not inhibited by 5,5'-dithio-bis-2-nitrobenzoate. {ECO:0000269|PubMed:21467222}.	
P37758	87	87		R->F,H,K,L,N,P,Q: Loss of activity. {ECO:0000269|PubMed:15667293, ECO:0000269|PubMed:18691156}.	
P37758	99	99	1	G->A: No change in activity. {ECO:0000269|PubMed:18691156}.	
P37758	99	99		G->T: Decrease in activity. {ECO:0000269|PubMed:18691156}.	
P37758	113	113	1	P->A: No change in activity. {ECO:0000269|PubMed:18691156}.	
P37758	113	113		P->C,L: Decrease in activity. {ECO:0000269|PubMed:18691156}.	
P37758	139	139		G->E,I: Loss of activity. {ECO:0000269|PubMed:18691156}.	
P37758	145	145		F->E,W: Loss of activity. {ECO:0000269|PubMed:18691156}.	
P37758	162	162		G->A,S: Loss of activity. {ECO:0000269|PubMed:18691156}.	
P37758	172	172	1	G->A: No change in activity. {ECO:0000269|PubMed:18691156}.	
P37758	172	172		G->V: Loss of activity. {ECO:0000269|PubMed:18691156}.	
P37758	175	175		G->A,S: Loss of activity. {ECO:0000269|PubMed:18691156}.	
P37758	261	261	1	Y->N: No change in activity. {ECO:0000269|PubMed:18691156}.	
P37758	266	266		G->A,P,T: Loss of activity. {ECO:0000269|PubMed:18691156}.	
P37758	303	303		R->C,D,K,L,N,P,Q: Loss of activity. {ECO:0000269|PubMed:15667293, ECO:0000269|PubMed:18691156}.	
P37758	307	307		G->L: Loss of activity. {ECO:0000269|PubMed:18691156}.	
P37758	311	311		D->G,K: Loss of activity. {ECO:0000269|PubMed:18691156}.	
P37758	405	405		G->A,L,V: Loss of activity. {ECO:0000269|PubMed:18691156}.	
P37758	414	414		G->L: No change in activity. {ECO:0000269|PubMed:18691156}.	
P76129	69	69		H->A,G: Loss of heme binding. {ECO:0000269|PubMed:11970957, ECO:0000269|PubMed:14551206}.	
P76129	75	75	1	H->A,G: No loss of heme binding. {ECO:0000269|PubMed:11970957}.	
P76129	87	87		M->A,I: Ferrous heme iron changes from an exclusively hexacoordinate low-spin form to an exclusively pentacoordinate high- spin form. Ferric heme iron remains hexacoordinate but becomes a mixture of high and low spin. Increases c-di-GMP PDE activity 7-fold in absence of O(2), CO or NO, no additional increase upon addition of gases (M-A only). {ECO:0000269|PubMed:12080073, ECO:0000269|PubMed:12081490, ECO:0000269|PubMed:17535805}.	
P76129	87	87		M->H: No change in heme coordination; increases c-di-GMP PDE activity 2-fold in absence of O(2), CO or NO, and 2-fold more upon addition of gases. {ECO:0000269|PubMed:12080073, ECO:0000269|PubMed:12081490, ECO:0000269|PubMed:17535805}.	
P76129	89	89		R->A,E,I: The Fe(2+)-O(2) form loses c- di-GMP PDE activity, due to reduced O(2) affinity and/or increased auto-oxidation. NO and CO forms are less affected. {ECO:0000269|PubMed:12081490, ECO:0000269|PubMed:17535805}.	
P76129	91	91		L->F: Alters O(2) binding, increases auto-oxidation. {ECO:0000269|PubMed:16519686}.	
P76129	91	91		L->T: Increases auto-oxidation. {ECO:0000269|PubMed:16519686}.	
P76129	107	107		L->F: Significantly reduces heme-binding affinity; increases auto-oxidation. {ECO:0000269|PubMed:16519686}.	
P76129	107	107		L->T: Increases auto-oxidation. {ECO:0000269|PubMed:16519686}.	
P76129	582	582		H->A: Loss of cAMP PDE activity. {ECO:0000269|PubMed:14551206}.	
P76129	586	586		H->A: Loss of cAMP PDE activity. {ECO:0000269|PubMed:14551206}.	
P0AA89	43	43		Y->A,L: Same biofilm formation activity as wild-type. Large decrease in O(2) affinity. {ECO:0000269|PubMed:21067162}.	
P0AA89	43	43		Y->F,W: Same biofilm formation activity as wild-type. Markedly enhanced O(2) dissociation but not association rate constants. Highly enhanced autoxidation rate constant. {ECO:0000269|PubMed:21067162}.	
P0AA89	60	60		Q->A,E: Same biofilm formation activity as wild-type. Enhanced O(2) dissociation but not association rate constants. Enhanced autoxidation rate constant. {ECO:0000269|PubMed:21067162}.	
P0AA89	60	60		Q->L: Same biofilm formation activity as wild-type. 5-fold reduction in O(2) dissociation rate constant. Significant decrease in the autoxidation rate constant. {ECO:0000269|PubMed:21067162}.	
P0AA89	65	65	1	L->G,T: Enhanced autoxidation rate constant. Markedly enhanced O(2) association rate constant. {ECO:0000269|PubMed:22005448}.	
P0AA89	65	65	1	L->M,Q: Enhanced autoxidation rate constant. Decrease in O(2) association rate constant. {ECO:0000269|PubMed:22005448}.	
P0AA89	98	98		H->A: Same biofilm formation activity as wild-type. Loss of heme-binding ability. {ECO:0000269|PubMed:21067162}.	
P0AA89	223	223	1	H->A: Same biofilm formation activity as wild-type. {ECO:0000269|PubMed:21067162}.	
P0AA89	365	365	1	R->A: Same biofilm formation activity as wild-type. {ECO:0000269|PubMed:21067162}.	
P0AA89	368	368		D->A: Lacks biofilm formation activity, and thus is probably devoid of diguanylate cyclase activity. {ECO:0000269|PubMed:21067162}.	
P0AA89	376	377		DE->AA: Loss of DGC activity. Stimulation of PNAG production and activation of pgaABCD expression are abolished. {ECO:0000269|PubMed:20576684}.	
P0AA89	376	376		D->A: Lacks biofilm formation activity, and thus is probably devoid of diguanylate cyclase activity. {ECO:0000269|PubMed:21067162}.	
P0AA89	377	377		E->A: Lacks biofilm formation activity, and thus is probably devoid of diguanylate cyclase activity. {ECO:0000269|PubMed:21067162}.	
P69910	276	276		K->A: Strongly reduces pyridoxal phosphate binding and increases stability of the polypeptide. {ECO:0000269|PubMed:12383249}.	
P69910	276	276		K->H: Abolishes pyridoxal phosphate binding. {ECO:0000269|PubMed:12383249}.	
P23874	22	22		G->S: Loss of toxicity, does not confer high persistence. Loss of toxicity, high persistence and cold sensitivity; in hipA7; when associated with A-291. {ECO:0000269|PubMed:14622409}.	
P23874	88	88		D->N: Loss of toxicity, still confers high persistence. {ECO:0000269|PubMed:14622409}.	
P23874	150	150	1	S->A: No phosphorylation; cells grow normally. {ECO:0000269|PubMed:17041039}.	
P23874	291	291		D->A: Retains toxicity and high persistence but not cold-sensitive. Loss of toxicity, high persistence and cold sensitivity; in hipA7; when associated with S-22. {ECO:0000269|PubMed:14622409}.	
P23874	309	309	1	D->Q: Loss of autophosphorylation; cells grow normally; protein can accumulate to high levels in E.coli. {ECO:0000269|PubMed:17041039}.	
P23874	332	332	1	D->Q: Loss of autophosphorylation; cells grow normally. {ECO:0000269|PubMed:17041039}.	
P23873	73	88		Missing: Increased half-life in vivo and in vitro, no change in DNA or HipA- binding. {ECO:0000269|PubMed:22720069}.	
P23873	88	88	1	W->A: No change in DNA or HipA-binding. {ECO:0000269|PubMed:22720069}.	
P27245	45	45	1	V->E: Increased transcription of the region II transcript. {ECO:0000269|PubMed:10760140}.	
P27245	77	77	1	R->L: Increased transcription of the region II transcript. {ECO:0000269|PubMed:10760140}.	
P27245	123	144		Missing: Increased transcription of the region II transcript. {ECO:0000269|PubMed:10760140}.	
P31129	206	207		GG->AA: Cells overexpressing this mutant are no longer swimming suppressed. {ECO:0000269|PubMed:18713317}.	
P31129	208	208		E->Q: Significantly decreased biofilm formation. {ECO:0000269|PubMed:19460094}.	
P0C077	52	52		K->A: Reduces mRNA cleavage rate constant 2100-fold. Reduces mRNA cleavage rate constant 1000000-fold; when associated with F-87. {ECO:0000269|PubMed:24251350}.	
P0C077	54	54		K->A: Reduces mRNA cleavage rate constant 2700-fold. {ECO:0000269|PubMed:24251350}.	
P0C077	61	61		R->A: Reduces mRNA cleavage rate constant 2700000-fold. {ECO:0000269|PubMed:20005802, ECO:0000269|PubMed:24251350}.	
P0C077	81	83		RER->AEA: Significant reduction in endonuclease activity, still binds RelB. {ECO:0000269|PubMed:19297318}.	
P0C077	81	81		R->A: Reduces mRNA cleavage rate constant 60000-fold, significantly less translation inhibition which is countered by RelB. Almost complete loss of mRNA cleavage; when associated with F-87. {ECO:0000269|PubMed:12123459, ECO:0000269|PubMed:20005802, ECO:0000269|PubMed:24251350}.	
P0C077	87	87		Y->A: Reduces mRNA cleavage rate constant 180000-fold. {ECO:0000269|PubMed:20005802, ECO:0000269|PubMed:24251350}.	
P0C077	87	87		Y->F: Reduces mRNA cleavage rate constant 130-fold. Almost complete loss of mRNA cleavage; when associated with A-81 (Ref.20). Reduces mRNA cleavage rate constant 1000000-fold; when associated with A-52 (Ref.18). {ECO:0000269|PubMed:20005802, ECO:0000269|PubMed:24251350}.	
P0C077	90	95	1	AVKRIL->VTVTVT: Does not inhibit translation. {ECO:0000269|PubMed:12123459}.	
P0C079	7	7		R->A: Loss of DNA binding, 100-fold derepression of operon, still binds RelE. {ECO:0000269|PubMed:18501926, ECO:0000269|PubMed:19747491}.	
P0C079	8	8		I->A: 43-fold derepression of operon, partial loss of DNA-binding, still binds RelE. {ECO:0000269|PubMed:19747491}.	
P0C079	13	13		K->A: 83-fold derepression of operon, loss of DNA-binding, still binds RelE. {ECO:0000269|PubMed:19747491}.	
P0C079	28	28		S->L,R: 100-fold derepression of operon, loss of DNA-binding, still binds RelE. {ECO:0000269|PubMed:19747491}.	
P0C079	39	39		A->T: In relB101; a delayed relaxed phenotype. {ECO:0000269|PubMed:2990907}.	
P0C079	45	45		P->L: In relB102; a delayed relaxed phenotype. {ECO:0000269|PubMed:2990907}.	
P0C079	45	45		P->T: In relB35; a delayed relaxed phenotype. {ECO:0000269|PubMed:2990907}.	
P0C079	66	79		Missing: Protein no longer tetramerizes. {ECO:0000269|PubMed:18501926}.	
P0C079	71	79		Missing: Protein still tetramerizes. {ECO:0000269|PubMed:18501926}.	
P69853	72	75		WQRL->HQRY: 1.5-fold increased binding to DmsA signal sequence. {ECO:0000269|PubMed:20169075}.	
P50456	257	257		C->A,S: Strongly reduced activity. {ECO:0000269|PubMed:15929984}.	
P50456	259	259		C->A,S: Strongly reduced activity. {ECO:0000269|PubMed:15929984}.	
P69210	5	5		E->Q: Decrease in spermidine excretion. {ECO:0000269|PubMed:18039771}.	
P69210	19	19		E->Q: Decrease in spermidine excretion. {ECO:0000269|PubMed:18039771}.	
P69210	60	60		D->N: Decrease in spermidine excretion. {ECO:0000269|PubMed:18039771}.	
P69210	68	68		W->L: Decrease in spermidine excretion. {ECO:0000269|PubMed:18039771}.	
P69210	81	81		W->L: Decrease in spermidine excretion. {ECO:0000269|PubMed:18039771}.	
P69212	4	4		Y->L: Decrease in spermidine excretion. {ECO:0000269|PubMed:18039771}.	
P69212	5	5		W->L: Decrease in spermidine excretion. {ECO:0000269|PubMed:18039771}.	
P69212	15	15		E->Q: Decrease in spermidine excretion. {ECO:0000269|PubMed:18039771}.	
P69212	45	45		Y->L: Decrease in spermidine excretion. {ECO:0000269|PubMed:18039771}.	
P69212	61	61		Y->L: Decrease in spermidine excretion. {ECO:0000269|PubMed:18039771}.	
P69212	82	82		E->Q: Decrease in spermidine excretion. {ECO:0000269|PubMed:18039771}.	
P07001	151	161		Missing: Dimerizes; affinity for PntB unchanged, but maximum transhydrogenation rate lowered significantly.	
P05042	126	126		R->A: Reduces enzyme activity 10-fold. {ECO:0000269|PubMed:14990798}.	
P05042	127	127	1	K->D: No effect. {ECO:0000269|PubMed:14990798}.	
P05042	129	129		H->N: No effect on activity, but the carboxyamide group from Asn129 swings into the B site and replaces S-malate by forming a bifurcated hydrogen bond with Asn131 and Asp132. {ECO:0000269|PubMed:14990798, ECO:0000269|PubMed:9098893}.	
P05042	188	188		H->N: Reduces activity 200-fold. {ECO:0000269|PubMed:9098893}.	
P05042	315	315		E->Q: Reduces activity 10-fold. {ECO:0000269|PubMed:12021453}.	
P0AET8	146	146		S->A,H: Reduces activity by over 65%. {ECO:0000269|PubMed:9722677}.	
P0AET8	159	159		Y->F: Loss of activity. {ECO:0000269|PubMed:9722677}.	
P0AET8	159	159		Y->H: Reduces activity by 87%. {ECO:0000269|PubMed:9722677}.	
P0AET8	163	163		K->I: Reduces activity by 95%. {ECO:0000269|PubMed:9722677}.	
P0AET8	163	163		K->R: Reduces activity by 35%. {ECO:0000269|PubMed:9722677}.	
P23256	233	233		K->I: Loss of enzymatic activity; but no loss of repression function. {ECO:0000269|PubMed:7665481}.	
P64467	44	44		D->N: Abolishes heterocomplex formation with H-NS. {ECO:0000269|PubMed:21600204}.	
P0AB83	120	120		K->Q: 100000-fold decrease in activity and slight decrease in substrate affinity. {ECO:0000269|PubMed:7664751}.	
P0AB83	138	138		D->N: 100-fold decrease in activity and 4-fold increase in substrate affinity. {ECO:0000269|PubMed:7664751}.	
P0AB83	191	191		K->E: Slight decrease in activity and 130-fold increase in substrate affinity. {ECO:0000269|PubMed:7664751}.	
P0A9D2	5	5	1	Y->F: Does not significantly affect the activity. {ECO:0000269|PubMed:7798255}.	
P0A9D2	10	10		C->A: 8-fold decrease in affinity for GSH, but 5-fold increase in GSH transferase activity. Loss of thiol:disulfide oxidoreductase activity. {ECO:0000269|PubMed:18778244}.	
P0A9D2	10	10		C->S: 6-fold decrease in affinity for GSH, and decrease in GSH transferase activity. Loss of thiol:disulfide oxidoreductase activity. {ECO:0000269|PubMed:18778244}.	
P0A9D2	106	106		H->A: Decrease in affinity for GSH while nearly no effect on affinity for CDNB, and decrease in GSH transferase activity. {ECO:0000269|PubMed:18778244}.	
P0A9D2	106	106		H->F: Decrease in affinity for GSH, while nearly no effect on affinity for CDNB and on GSH transferase activity. {ECO:0000269|PubMed:18778244}.	
P0AGJ9	37	37		Y->V: Confers specificity for the non- natural amino acid 3-iodo-tyrosine; when associated with C-195.	
P0AGJ9	195	195		Q->C: Confers specificity for the non- natural amino acid 3-iodo-tyrosine; when associated with V-37.	
P0AFI7	14	14		R->E: Reduces affinity for substrate about 7-fold, but has no effect on catalytic activity. {ECO:0000269|PubMed:11786019}.	
P0AFI7	14	14		R->M: Reduces affinity for substrate about 9-fold, but has no effect on catalytic activity. {ECO:0000269|PubMed:11786019}.	
P0AFI7	17	17		Y->F: Reduces affinity for substrate 3- fold, but has about 5-fold increase in catalytic activity. {ECO:0000269|PubMed:11786019}.	
P0AFI7	49	49		D->A: Reduces affinity for substrate 3- fold and catalytic activity 2-fold. {ECO:0000269|PubMed:11786019}.	
P0AFI7	197	197		R->E: Reduces affinity for substrate 8000-fold and catalytic activity 16-fold. {ECO:0000269|PubMed:11786019}.	
P0AFI7	197	197		R->M: Reduces affinity for substrate 300- fold and catalytic activity about 4-fold. {ECO:0000269|PubMed:11786019}.	
P0AFI7	199	199		H->A: Reduces affinity for substrate 230- fold, but has no effect on catalytic activity. {ECO:0000269|PubMed:11786019}.	
P0AFI7	199	199		H->N: Reduces catalytic activity about 4- fold, but has no effect on affinity for substrate. {ECO:0000269|PubMed:11786019}.	
P30014	13	13		R->A: Strongly reduces affinity for RNA. Nearly abolishes enzyme activity. {ECO:0000269|PubMed:12364334}.	
P30014	15	15		R->A: Strongly reduces affinity for RNA. {ECO:0000269|PubMed:12364334}.	
P30014	23	23		D->A: Nearly abolishes enzyme activity. {ECO:0000269|PubMed:12364334}.	
P30014	25	25		E->A: Nearly abolishes enzyme activity. {ECO:0000269|PubMed:12364334}.	
P30014	29	29		F->A: Abolishes enzyme activity; when associated with A-73 and A-77. {ECO:0000269|PubMed:21317904}.	
P30014	73	73		E->A: Reduces enzyme activity. Abolishes enzyme activity; when associated with A- 29 and A-77. {ECO:0000269|PubMed:21317904}.	
P30014	77	77		F->A: Abolishes enzyme activity; when associated with A-29 and A-73. {ECO:0000269|PubMed:21317904}.	
P30014	108	108		K->A: Strongly reduces affinity for RNA. {ECO:0000269|PubMed:12364334}.	
P30014	114	114		R->A: Strongly reduces affinity for RNA. {ECO:0000269|PubMed:12364334}.	
P30014	124	124		F->A: Abolishes enzyme activity; when associated with A-146. {ECO:0000269|PubMed:21317904}.	
P30014	139	139		K->A: Reduces affinity for RNA. {ECO:0000269|PubMed:12364334}.	
P30014	146	146		F->A: Abolishes enzyme activity; when associated with A-124. {ECO:0000269|PubMed:21317904}.	
P30014	150	150		D->A: Nearly abolishes enzyme activity. {ECO:0000269|PubMed:12364334}.	
P30014	181	181		H->A: Nearly abolishes enzyme activity. {ECO:0000269|PubMed:12364334}.	
P30014	186	186		D->A: Nearly abolishes enzyme activity. {ECO:0000269|PubMed:12364334}.	
P0ACP7	54	54		L->M: Slight decrease in operator DNA affinity.	
P0ACP7	55	55		K->A: Decrease in operator DNA affinity. {ECO:0000269|PubMed:10438625}.	
P0ACP7	147	147		W->A: 14-fold increase in corepressor affinity. Large increase in repressor activity. {ECO:0000269|PubMed:11781089}.	
P0ACP7	147	147		W->F: Large decrease in corepressor affinity and in repressor activity. {ECO:0000269|PubMed:11781089}.	
P0ACP7	147	147		W->R: 8-fold increase in corepressor affinity. Large increase in repressor activity. {ECO:0000269|PubMed:11781089}.	
P0ACP7	190	190		R->A: Functional repressor. Corepressor specificity is expanded since it allows binding of adenine and 6-methylpurine. {ECO:0000269|PubMed:9454587}.	
P0ACP7	190	190		R->Q: Functional repressor. Corepressor specificity is expanded since it allows binding of adenine. {ECO:0000269|PubMed:9454587}.	
P69776	22	22		S->D: Localizes to the inner membrane, where it associates with peptidoglycan, thereby preventing separation of the two membranes. Prolonged expression is lethal for the cell. {ECO:0000269|PubMed:9139900}.	
P69776	70	70	1	D->E,G,S: Does not affect the formation of murein-bound lipoprotein. {ECO:0000269|PubMed:1527073}.	
P69776	75	75	1	K->S,T: Does not affect the formation of murein-bound lipoprotein. {ECO:0000269|PubMed:1527073}.	
P69776	76	76		Y->C,D,E,G,N,P,S: Reduces the formation of murein-bound lipoprotein. {ECO:0000269|PubMed:1527073}.	
P69776	76	76	1	Y->F,H,I,L: Does not affect the formation of murein-bound lipoprotein. {ECO:0000269|PubMed:1527073}.	
P69776	77	77		R->D,L: Reduces the formation of murein- bound lipoprotein. {ECO:0000269|PubMed:1527073}.	
P69776	78	78		K->R: Abolishes the formation of murein- bound lipoprotein. {ECO:0000269|PubMed:1527073}.	
P76194	51	51		C->S: Abolishes cysteine desulfurase activity. {ECO:0000269|PubMed:12876288, ECO:0000269|PubMed:12941942, ECO:0000269|PubMed:14644425}.	
P77444	55	55	1	H->A: No effect. {ECO:0000269|PubMed:11983074}.	
P77444	123	123		H->A: Loss of function; possibly due to destabilization of PLP in the active site. {ECO:0000269|PubMed:11983074}.	
P77444	364	364		C->A: Abolishes activity towards L- cysteine but not towards selenocysteine. {ECO:0000269|PubMed:10739946}.	
P77444	379	379		R->A: Loss of function. {ECO:0000269|PubMed:11983074}.	
P77781	48	48		Q->A: Almost loss of activity with benzoyl-CoA as substrate. {ECO:0000269|PubMed:25010423}.	
P77781	48	48		Q->N: 51-fold decrease in catalytic efficiency toward benzoyl-CoA. {ECO:0000269|PubMed:25010423}.	
P77781	54	54		H->A: 514-fold decrease in catalytic efficiency toward benzoyl-CoA. {ECO:0000269|PubMed:25010423}.	
P77781	54	54		H->F: Almost loss of activity with benzoyl-CoA as substrate. {ECO:0000269|PubMed:25010423}.	
P77781	63	63		E->A,Q: Loss of activity with benzoyl-CoA as substrate. {ECO:0000269|PubMed:25010423}.	
P77781	63	63		E->D: Almost loss of activity with benzoyl-CoA as substrate. {ECO:0000269|PubMed:25010423}.	
P77781	64	64	1	S->A: Almost no change in catalytic efficiency toward benzoyl-CoA. {ECO:0000269|PubMed:25010423}.	
P77781	67	67	1	S->A: Almost no change in catalytic efficiency toward benzoyl-CoA. {ECO:0000269|PubMed:25010423}.	
P77781	68	68		V->M: 10-fold decrease in catalytic efficiency toward lauroyl-CoA. Does not affect catalytic efficiency toward 1,4- dihydroxy-2-naphthoyl-CoA and benzoyl- CoA. {ECO:0000269|PubMed:24992697}.	
P77781	71	71		Y->A: Does not affect activity. {ECO:0000269|PubMed:24992697}.	
P77781	89	89		H->A: 156-fold decrease in catalytic efficiency toward benzoyl-CoA. {ECO:0000269|PubMed:25010423}.	
P77781	91	91		R->A: 9-fold decrease in catalytic efficiency toward benzoyl-CoA. {ECO:0000269|PubMed:25010423}.	
P77781	106	106	1	H->A: Almost no change in catalytic efficiency toward benzoyl-CoA. {ECO:0000269|PubMed:25010423}.	
P77781	109	109	1	S->A: Almost no change in catalytic efficiency toward benzoyl-CoA. {ECO:0000269|PubMed:25010423}.	
P0A6D5	22	22	1	S->A: Kinetically unchanged as compared with the wild-type. {ECO:0000269|PubMed:15596430}.	
P0A6D5	39	39	1	Y->F: Kinetically unchanged as compared with the wild-type. {ECO:0000269|PubMed:15596430}.	
P0A6D5	67	67		S->A: Reduces activity towards quinate about 6-fold, but has a little effect on shikimate conversion. {ECO:0000269|PubMed:15596430}.	
P0A6D5	71	71		K->A: 3200-fold decrease in the affinity for quinate. 170-fold decrease in the affinity for shikimate. {ECO:0000269|PubMed:15596430}.	
P0A6D5	71	71		K->G: 10-fold greater reduction in catalytic efficiency is observed with quinate than with shikimate. {ECO:0000269|PubMed:15596430}.	
P0A6D5	92	92		N->A: Alters protein structure. Loss of activity for both substrates. {ECO:0000269|PubMed:15596430}.	
P0A6D5	106	106		T->A: 2000-fold decrease in the affinity for quinate. 70-fold decrease in the affinity for shikimate. 10-fold greater reduction in catalytic efficiency is observed with quinate than with shikimate. {ECO:0000269|PubMed:15596430}.	
P0A6D5	107	107		D->A: Loss of activity towards quinate. 20000-fold decrease in the affinity for shikimate. {ECO:0000269|PubMed:15596430}.	
P0A6D5	262	262		Q->A: 3-fold reduction in catalytic efficiency for both substrates. {ECO:0000269|PubMed:15596430}.	
P05194	143	143		H->A: Loss of dehydratase activity. {ECO:0000269|PubMed:7592767}.	
P05194	146	146	1	H->A: It retains full catalytic activity. {ECO:0000269|PubMed:7592767}.	
P05194	170	170		K->A: Loss of dehydratase activity, but it is still able to bind substrate. {ECO:0000269|PubMed:7592767}.	
P05194	205	205	1	M->L: It has little effect on the catalytic efficiency and affinity for 3- dehydroquinate. {ECO:0000269|PubMed:7592767}.	
P0A6X7	65	65		P->L: Alters DNA-binding specificity. {ECO:0000269|PubMed:1531459}.	
P0A6X7	66	66		K->S: Alters DNA-binding specificity. {ECO:0000269|PubMed:1531459}.	
P0A707	107	107		Y->F,L: Reduced ribosome binding. {ECO:0000269|PubMed:1457399}.	
P0A707	110	110		K->R,L: Reduced ribosome binding. {ECO:0000269|PubMed:1457399}.	
P0A8M3	334	334		C->S: Activity very strongly affected.	
P0A8M3	385	385		H->A,N: Activity very strongly affected.	
P0A8M3	511	511		H->A,N: Activity very strongly affected.	
P06999	190	190		E->Q: Causes a 50-fold decrease in the kcat value and a 15-fold increment in the apparent KM for ATP. {ECO:0000269|PubMed:16866375}.	
P77247	13	13		D->A: Loss of the phosphatase activity. {ECO:0000269|PubMed:16990279}.	
P37794	11	11		D->A: Unable to induce CnbR and to grow on chitobiose. {ECO:0000269|PubMed:22797760}.	
P37794	61	61		H->A: Unable to induce CnbR and to grow on chitobiose. {ECO:0000269|PubMed:22797760}.	
P37794	125	125		H->A: Unable to induce CnbR and to grow on chitobiose. {ECO:0000269|PubMed:22797760}.	
P76216	365	365		C->S: Large decrease in activity. {ECO:0000269|PubMed:15703173}.	
P78067	385	385		C->A: Loss of activity. {ECO:0000269|PubMed:19798741}.	
P77788	33	33		E->A,Q: Increases enzyme activity with 2- hydroxy-ATP. Decreases enzyme activity with dCTP, 5-methyl-dCTP and 8-hydroxy- ATP. {ECO:0000269|PubMed:15823026}.	
P77788	33	33		E->D: Decreases enzyme activity with 2- hydroxy-ATP, dCTP, 5-dmethyl-CTP and 8- hydroxy-ATP. {ECO:0000269|PubMed:15823026}.	
P77788	36	36		G->A: Abolishes enzyme activity. {ECO:0000269|PubMed:15381107}.	
P77788	37	37		G->A: Abolishes enzyme activity. {ECO:0000269|PubMed:15381107}.	
P77788	38	38		K->A,R: Strongly reduces enzyme activity with dCTP, and to a lesser degree with 5- methyl-dCTP. {ECO:0000269|PubMed:15381107}.	
P77788	43	43		E->A: Abolishes enzyme activity with dCTP and reduces enzyme activity with 5- methyl-dCTP. {ECO:0000269|PubMed:15381107}.	
P77788	51	51		R->A: Abolishes enzyme activity with dCTP. Nearly abolishes enzyme activity with 5-methyl-dCTP. {ECO:0000269|PubMed:15381107}.	
P77788	52	52		E->A,D,Q: Abolishes enzyme activity. {ECO:0000269|PubMed:15381107}.	
P77788	53	53		L->A: Reduces enzyme activity. {ECO:0000269|PubMed:15381107}.	
P77788	55	55		E->A: Abolishes enzyme activity with dCTP and reduces enzyme activity with 5- methyl-dCTP. {ECO:0000269|PubMed:15381107}.	
P77788	55	55		E->D,Q: Abolishes enzyme activity with dCTP and reduces enzyme activity with 5- methyl-dCTP. {ECO:0000269|PubMed:15381107}.	
P77788	56	56		E->A,D,Q: Abolishes enzyme activity. {ECO:0000269|PubMed:15381107}.	
P77788	72	72		R->A: Strongly decreases the activity with 2-hydroxy-ATP. {ECO:0000269|PubMed:15823026}.	
P77788	77	77	1	R->A: No effect. {ECO:0000269|PubMed:15823026}.	
P77788	118	118		D->A,N: Abolishes enzyme activity with 2- hydroxy-ATP. No effect on activity with dCTP, 5-methyl-dCTP and 8-hydroxy-ATP. {ECO:0000269|PubMed:15823026}.	
P77788	118	118		D->A: Abolishes enzyme activity with dCTP and 2-hydroxy-ATP and decreases activity with 5-methyl-dCTP. Increases activity with 8-hydroxy-ATP. {ECO:0000269|PubMed:15823026}.	
P77788	118	118		D->E: Increases the activity with 2- hydroxy-ATP. Strongly decreases activity with 8-hydroxy-ATP. {ECO:0000269|PubMed:15823026}.	
P00370	92	92		K->S: Complete loss of dehydrogenase activity. {ECO:0000269|PubMed:8355660}.	
P00370	128	128		K->H: Reduces catalytic activity and increases pH optima for activity. Increases relative activity with amino acid substrates other than glutamate, especially L-norvaline. {ECO:0000269|PubMed:3149742}.	
P00370	128	128		K->R: Reduced catalytic activity and increases pH optima for activity. NADP- specific glutamate dehydrogenase. {ECO:0000269|PubMed:3149742}.	
P16456	13	13	1	H->N: No loss of activity. {ECO:0000269|PubMed:8262938}.	
P16456	17	17		C->S: Complete loss of activity. {ECO:0000269|PubMed:1527085}.	
P16456	18	18		G->V: Partial loss of activity. {ECO:0000269|PubMed:8262938}.	
P16456	19	19	1	C->S: No loss of activity. {ECO:0000269|PubMed:1527085}.	
P16456	20	20		K->Q: Complete loss of activity. {ECO:0000269|PubMed:8262938}.	
P16456	20	20		K->R: Marked loss of activity. {ECO:0000269|PubMed:8262938}.	
P08395	209	209		K->A: Loss of activity. {ECO:0000269|PubMed:18476724}.	
P08395	366	366		K->A: Reduced activity. {ECO:0000269|PubMed:18476724}.	
P08395	409	409		S->A: Loss of activity. {ECO:0000269|PubMed:18476724}.	
P08395	410	410		G->A: Reduced activity. {ECO:0000269|PubMed:18476724}.	
P08395	412	412	1	Y->F: No effect on activity. {ECO:0000269|PubMed:18476724}.	
P08395	510	510		H->A: Reduced activity. {ECO:0000269|PubMed:18476724}.	
P08395	524	524		D->N: Increased activity. {ECO:0000269|PubMed:18476724}.	
P0A962	14	14		T->A,V: Loss of enzyme activity. {ECO:0000269|PubMed:17451745}.	
P0A962	61	61		S->Q: Loss of enzyme activity.	
P0A962	91	91		T->A,V: Loss of enzyme activity. {ECO:0000269|PubMed:17451745}.	
P0A962	118	118		Q->D: Loss of enzyme activity. {ECO:0000269|PubMed:17451745}.	
P0A962	162	162		T->A: No effect on activity at saturating substrate concentration. Abolishes cooperativity. {ECO:0000269|PubMed:17451745}.	
P0A962	240	240		R->A: No effect on activity at saturating substrate concentration. Reduced activity at lower substrate concentrations. {ECO:0000269|PubMed:17451745}.	
P0A746	46	46		C->D: Loss of activity; when associated with S-49; S-95 and S-98. {ECO:0000269|PubMed:16251365}.	
P0A746	49	49		C->S: Loss of activity; when associated with S-46; S-95 and S-98. {ECO:0000269|PubMed:16251365}.	
P0A746	95	95		C->S: Loss of activity; when associated with S-46; S-49 and S-98. {ECO:0000269|PubMed:16251365}.	
P0A746	98	98		C->S: Loss of activity; when associated with S-46; S-49 and S-95. {ECO:0000269|PubMed:16251365}.	
P0A9B2	177	177		H->N: Reduces activity about 50-fold. {ECO:0000269|PubMed:2659073}.	
P69451	213	213		Y->A: Loss of activity. {ECO:0000269|PubMed:12034706}.	
P69451	214	214		T->A: 10% of wild-type activity. {ECO:0000269|PubMed:12034706}.	
P69451	216	216		G->A: Decreases activity. {ECO:0000269|PubMed:12034706}.	
P69451	217	217		T->A: Decreases activity. {ECO:0000269|PubMed:12034706}.	
P69451	219	219		G->A: Decreases activity. {ECO:0000269|PubMed:12034706}.	
P69451	222	222		K->A: Decreases activity. {ECO:0000269|PubMed:12034706}.	
P69451	361	361		E->A: Loss of activity. {ECO:0000269|PubMed:12034706}.	
P05041	258	258		E->A: The reaction is extremely slow. {ECO:0000269|PubMed:16605270}.	
P05041	258	258		E->D: The reaction is extremely slow. {ECO:0000269|PubMed:16605270}.	
P05041	274	274		K->A: Absence of covalent intermediate. Addition of ammonia allows the formation of the covalent intermediate and shows that ammonia can replace the function of K-274. Reduced catalytic efficiency. {ECO:0000269|PubMed:14982443, ECO:0000269|PubMed:16605270}.	
P05041	274	274		K->R: Absence of covalent intermediate. {ECO:0000269|PubMed:14982443, ECO:0000269|PubMed:16605270}.	
P05041	274	274		K->R: Reduced catalytic efficiency. {ECO:0000269|PubMed:14982443, ECO:0000269|PubMed:16605270}.	
P05041	275	275		G->S: Catalytically inactive for both the glutamine-dependent and ammonia-dependent reactions and fails to interact with PabA. {ECO:0000269|PubMed:8679677}.	
P05041	311	311		R->K: Catalytically active in the NH3- dependent, but inactive for the glutamine-dependent reactions and fails to complex with PabA. {ECO:0000269|PubMed:8679677}.	
P05041	316	316		R->H: Catalytically inactive for both the glutamine-dependent and ammonia-dependent reactions and fails to interact with PabA. {ECO:0000269|PubMed:8679677}.	
P05041	322	322		S->T: Complete loss of aminodeoxychorismate synthase activity. {ECO:0000269|PubMed:8679677}.	
P05041	339	339		H->W: Catalytically inactive for both the glutamine-dependent and ammonia-dependent reactions and fails to interact with PabA. {ECO:0000269|PubMed:8679677}.	
P64512	16	16	1	C->A: Still represses PhoP-regulated transcription. {ECO:0000269|PubMed:22267510}.	
P64512	28	28		C->A: No longer represses PhoP-regulated transcription. {ECO:0000269|PubMed:22267510}.	
P64512	39	39		C->A: No longer represses PhoP-regulated transcription. {ECO:0000269|PubMed:22267510}.	
P23894	105	105		N->D: Does not complement a double ftsH/htpX disruption mutant. {ECO:0000269|PubMed:12081643}.	
P23894	107	107		F->A: Does not complement a double ftsH/htpX disruption mutant. {ECO:0000269|PubMed:12081643}.	
P23894	139	139		H->F: Does not complement a double ftsH/htpX disruption mutant. No self- degradation. {ECO:0000269|PubMed:12081643}.	
P23894	140	140		E->Q: Does not complement a double ftsH/htpX disruption mutant. {ECO:0000269|PubMed:12081643}.	
P23894	222	222		E->Q: Does not complement a double ftsH/htpX disruption mutant. {ECO:0000269|PubMed:12081643}.	
P23894	226	226		D->N: Does not complement a double ftsH/htpX disruption mutant. {ECO:0000269|PubMed:12081643}.	
P23894	276	276		H->F: Does not complement a double ftsH/htpX disruption mutant. {ECO:0000269|PubMed:12081643}.	
P23865	397	397		G->A: Loss of activity. Perturbs protein structure. {ECO:0000269|PubMed:7499412}.	
P23865	398	398		G->A: Loss of activity. Perturbs protein structure. {ECO:0000269|PubMed:7499412}.	
P23865	452	452		S->A: Loss of activity. {ECO:0000269|PubMed:7499412}.	
P23865	452	452		S->C: Reduces activity by over 90%. {ECO:0000269|PubMed:7499412}.	
P23865	455	455		E->A: Loss of activity. Perturbs protein structure. {ECO:0000269|PubMed:7499412}.	
P23865	463	463		D->A: Loss of activity. {ECO:0000269|PubMed:7499412}.	
P23865	463	463		D->N: Reduces activity by 90%. {ECO:0000269|PubMed:7499412}.	
P23865	474	474		T->A: Loss of activity. Perturbs protein structure. {ECO:0000269|PubMed:7499412}.	
P23865	477	477		K->A,H: Loss of activity. No apparent effect on protein structure. {ECO:0000269|PubMed:7499412}.	
P23865	477	477		K->R: Loss of activity. Perturbs protein structure. {ECO:0000269|PubMed:7499412}.	
P55798	24	24		D->V: Loss of function. {ECO:0000269|PubMed:9130712}.	
P55798	26	26		H->L: Loss of function. {ECO:0000269|PubMed:9130712}.	
P55798	26	26		H->N: Loss of function. {ECO:0000269|PubMed:9130712}.	
P55798	107	107		L->Q: Loss of function. {ECO:0000269|PubMed:9130712}.	
P0A955	45	45		E->N: 50-fold decrease in catalytic efficiency and 6-fold decrease of binding affinity. {ECO:0000269|PubMed:16403639, ECO:0000269|PubMed:17981470}.	
P0A955	133	133		K->Q: Absence of aldolase activity. Shows a markedly altered substrate specificity relative to the wild-type, with an enhanced activity against pyridine carboxaldehyde, benzaldehyde, and alpha- ketobutyrate; when associated with k-161. {ECO:0000269|PubMed:11342129}.	
P0A955	161	161		T->K: Shows activity significantly greater than wild-type. Shows a markedly altered substrate specificity relative to the wild-type, with an enhanced activity against pyridine carboxaldehyde, benzaldehyde, and alpha-ketobutyrate; when associated with Q-133. {ECO:0000269|PubMed:11342129, ECO:0000269|PubMed:17981470}.	
P0A955	161	161		T->V: Little stereoselectivity, accepting KDPG and KDPGal as substrate with roughly equal efficacy. It strongly diminishes the activity against KDPG and slightly increases activity against KDPGal. {ECO:0000269|PubMed:11342129, ECO:0000269|PubMed:17981470}.	
P0A955	168	168		N->S: Shows activity significantly greater than wild-type. {ECO:0000269|PubMed:11342129}.	
P0A9H9	21	21		I->T: Gain of function, increased counterclockwise rotation of flagella. {ECO:0000269|PubMed:17998207}.	
P0A9H9	65	65		A->V: Loss of function, fails to oligomerize. {ECO:0000269|PubMed:10852888}.	
P0A9H9	90	90		L->S: Loss of localization to the cell pole. Fails to oligomerize. {ECO:0000269|PubMed:10852888, ECO:0000269|PubMed:12644507}.	
P0A9H9	94	94		W->R: Loss of localization to the cell pole. {ECO:0000269|PubMed:12644507}.	
P0A9H9	117	117		F->S: Loss of localization to the cell pole. {ECO:0000269|PubMed:10852888, ECO:0000269|PubMed:12644507}.	
P0A9H9	143	143		D->G: Loss of function. Fails to oligomerize. {ECO:0000269|PubMed:10852888}.	
P0A9H9	147	147		Q->A: Severely diminished function, exclusive clockwise flagellar rotation. {ECO:0000269|PubMed:12080332}.	
P0A9H9	188	188		G->E: Diminished ability to stimulate dephosphorylation of CheY-P. {ECO:0000269|PubMed:10852888}.	
P0A9H9	205	205		V->E: Severely impairs the interaction the interaction with CheY-P. {ECO:0000269|PubMed:10852888}.	
P0AE67	12	12		D->A: Abolishes magnesium binding. {ECO:0000269|PubMed:11023787}.	
P0AE67	13	13	1	D->A: No effect on magnesium binding. {ECO:0000269|PubMed:11023787}.	
P0AE67	57	57		D->A: Abolishes magnesium binding. {ECO:0000269|PubMed:11023787}.	
P0AE67	87	87		T->I: Impairs chemotaxis; when associated with W-106.	
P0AE67	92	92	1	K->R: No effect on chemotaxis. {ECO:0000269|PubMed:9560203}.	
P0AE67	95	95		I->A,V: Enhanced CW flagellar rotational signaling activity.	
P0AE67	95	95		I->D,K,M: Loss of CW flagellar rotational signaling activity.	
P0AE67	106	106		Y->W: Impairs chemotaxis; when associated with I-87.	
P0AF06	31	31		A->T: Complete loss of motility.	
P0AF06	32	32		D->N: Complete loss of motility. {ECO:0000269|PubMed:2061285}.	
P0AF06	39	39		A->V: Complete loss of motility. {ECO:0000269|PubMed:2061285}.	
P0AF06	159	159		P->I: Decreased motility, subnormal torque, tethered strains rotate very slowly. {ECO:0000269|PubMed:2061285}.	
P0AF06	164	164		G->D: Complete loss of motility. {ECO:0000269|PubMed:2061285}.	
P0AF06	196	196		T->I: Complete loss of motility. {ECO:0000269|PubMed:2061285}.	
P0AF06	197	197		D->N: Complete loss of motility. {ECO:0000269|PubMed:2061285}.	
P0AF06	205	205		E->K: Decreased motility, subnormal torque, tethered strains rotate very slowly, maybe reduced affinity for the motor. {ECO:0000269|PubMed:2061285}.	
P0AF06	214	214		S->F: Complete loss of motility. {ECO:0000269|PubMed:2061285}.	
P0AF06	217	217		R->W: Complete loss of motility. {ECO:0000269|PubMed:2061285}.	
P0AF06	222	222		R->H: Complete loss of motility. {ECO:0000269|PubMed:2061285}.	
P0AF06	240	240		G->D: Decreased motility, subnormal torque, tethered strains rotate very slowly. {ECO:0000269|PubMed:2061285}.	
P0AF06	242	242		A->T,V: Complete loss of motility. {ECO:0000269|PubMed:2061285}.	
P0AF06	258	258		R->C,H: Complete loss of motility. {ECO:0000269|PubMed:2061285}.	
P09348	93	93		G->E: Suppresses yhjH disruption motility mutant, swimming velocity is wild-type. {ECO:0000269|PubMed:20303158}.	
P09348	93	93		G->R: Suppresses yhjH disruption motility mutant, swimming velocity is between disruption and wild-type. {ECO:0000269|PubMed:20303158}.	
P09348	93	93		G->V: Suppresses yhjH disruption motility mutant, swimming velocity is between disruption and wild-type. In the wt background velocity is reduced. {ECO:0000269|PubMed:20303158}.	
P09348	96	96		S->L: Suppresses yhjH disruption motility mutant, swimming velocity is between disruption and wild-type. In the wt background velocity is reduced. {ECO:0000269|PubMed:20303158}.	
P0A8S9	2	2		H->A: Partial swarming phenotype. {ECO:0000269|PubMed:11169100}.	
P0A8S9	28	28		D->A: Partial swarming phenotype. Affects FlhD/FlhC complex formation. {ECO:0000269|PubMed:11169100}.	
P0A8S9	34	34		F->A: Partial swarming phenotype. Affects FlhD/FlhC complex formation. {ECO:0000269|PubMed:11169100}.	
P0A8S9	35	35		R->A: Partial swarming phenotype. Affects FlhD/FlhC complex formation. {ECO:0000269|PubMed:11169100}.	
P0A8S9	61	61		N->A: Partial swarming phenotype. Affects FlhD/FlhC complex formation. {ECO:0000269|PubMed:11169100}.	
P0A8S9	82	82		S->A: Partial swarming phenotype. Does not affect FlhD/FlhC complex formation, but affects DNA binding. {ECO:0000269|PubMed:11169100}.	
P0A8S9	83	83		R->A: Partial swarming phenotype. Does not affect FlhD/FlhC complex formation, but affects DNA binding. {ECO:0000269|PubMed:11169100}.	
P0A8S9	84	84		V->A: Partial swarming phenotype. Does not affect FlhD/FlhC complex formation, but affects DNA binding. {ECO:0000269|PubMed:11169100}.	
P0A8S9	91	91		H->A: Partial swarming phenotype. Affects FlhD/FlhC complex formation. {ECO:0000269|PubMed:11169100}.	
P0A8S9	92	92		T->A: Non-swarming phenotype. Affects FlhD/FlhC complex formation. {ECO:0000269|PubMed:11169100}.	
P0A8S9	94	94		I->A: Non-swarming phenotype. Affects FlhD/FlhC complex formation. {ECO:0000269|PubMed:11169100}.	
P0A8S9	96	96		L->A: Partial swarming phenotype. Affects FlhD/FlhC complex formation. {ECO:0000269|PubMed:11169100}.	
P02924	277	277	1	P->G: Improves binding to galactose.	
P0A998	17	17		E->A: Initially 100-fold slower Fe(2+) oxidation rate. {ECO:0000269|PubMed:24380371}.	
P0A998	24	24		Y->F: Initially reduces Fe(2+)/O(2) stoichiometry from 3.1 to 2.2. {ECO:0000269|PubMed:24380371}.	
P0A998	49	49		E->A: Initially reduces Fe(2+)/O(2) stoichiometry from ~3 to ~2. {ECO:0000269|PubMed:24380371}.	
P0A998	53	53		H->A: Initially 6000-fold slower Fe(2+) oxidation rate. {ECO:0000269|PubMed:24380371}.	
P0A998	94	94		E->A: Initially 200-fold slower Fe(2+) oxidation rate. {ECO:0000269|PubMed:24380371}.	
P0A998	126	126		E->A: Initially reduces Fe(2+)/O(2) stoichiometry from ~3 to ~2. {ECO:0000269|PubMed:24380371}.	
P0A998	130	130		E->A: Initially reduces Fe(2+)/O(2) stoichiometry from ~3 to ~2. {ECO:0000269|PubMed:24380371}.	
P0ABF8	60	60		T->P: In pgsA3; lower activity.	
P0ABF8	92	92		T->I: In pgsA10; lower activity.	
P0A8G0	42	42		R->A: Defective in 3' incision but not in 5' incision. {ECO:0000269|PubMed:10671556}.	
P0A8G0	399	399		D->A,N: Defective in 5' incision but not in 3' incision. {ECO:0000269|PubMed:1387639}.	
P0A8G0	438	438		D->A,N: Defective in 5' incision but not in 3' incision. {ECO:0000269|PubMed:1387639}.	
P0A8G0	466	466		D->A,N: Defective in 5' incision but not in 3' incision. {ECO:0000269|PubMed:1387639}.	
P0A8G0	538	538		H->F,Y: Defective in 5' incision but not in 3' incision. {ECO:0000269|PubMed:1387639}.	
P0AEM6	73	73	1	Q->A: No change in activity. {ECO:0000269|PubMed:19400790}.	
P0AEM6	74	74		R->A,W: Decrease in activity. {ECO:0000269|PubMed:19400790}.	
P0AEM6	78	78		A->E: Decrease in activity. {ECO:0000269|PubMed:19400790}.	
P0AEM6	81	81		D->A: Loss of activity. {ECO:0000269|PubMed:19400790}.	
P0AEM6	84	84		R->A: Loss of activity. {ECO:0000269|PubMed:19400790}.	
P0AEM6	91	91		R->A: Loss of activity. {ECO:0000269|PubMed:19400790}.	
P0AEM6	92	92	1	S->A: No change in activity. {ECO:0000269|PubMed:19400790}.	
P0AEM6	94	94		R->A: Decrease in activity. {ECO:0000269|PubMed:19400790}.	
P0AEM6	95	95	1	R->A: No change in activity. {ECO:0000269|PubMed:19400790}.	
P0AEM6	96	96	1	N->A: No change in activity. {ECO:0000269|PubMed:19400790}.	
P0AEM6	98	98		R->A: Strong decrease in activity. {ECO:0000269|PubMed:19400790}.	
P0ABZ1	252	252		Q->W: Decreases binding to YcgR, significantly improves motility in a yhjH disruption mutant. {ECO:0000269|PubMed:20346719}.	
P0ABZ1	284	284	1	D->W: Slightly improves motility in a yhjH disruption mutant. {ECO:0000269|PubMed:20346719}.	
P0ABZ1	292	292		N->W: Decreases binding to YcgR, significantly improves motility in a yhjH disruption mutant. {ECO:0000269|PubMed:20346719}.	
P0ABZ1	295	295		P->W: Decreases binding to YcgR, significantly improves motility in a yhjH disruption mutant. {ECO:0000269|PubMed:20346719}.	
P0ABZ1	298	298	1	L->W: Slightly improves motility in a yhjH disruption mutant. {ECO:0000269|PubMed:20346719}.	
P06974	153	153		V->D: Decreases binding to YcgR. {ECO:0000269|PubMed:20346719}.	
P06974	155	155		N->E: Decreases binding to YcgR. {ECO:0000269|PubMed:20346719}.	
P06974	156	156	1	R->D: Obviates binding to YcgR. {ECO:0000269|PubMed:20346719}.	
P06974	160	160	1	L->E: Obviates binding to YcgR. {ECO:0000269|PubMed:20346719}.	
P06974	167	167		D->R: Decreases binding to YcgR. {ECO:0000269|PubMed:20346719}.	
P06974	176	176		E->R: Decreases binding to YcgR. {ECO:0000269|PubMed:20346719}.	
P31658	77	77		E->A: Almost completely abolishes glyoxalase activity. {ECO:0000269|PubMed:21696459}.	
P31658	185	185		C->A: Almost completely abolishes glyoxalase and aminopeptidase activities. {ECO:0000269|PubMed:12939276, ECO:0000269|PubMed:21696459}.	
P31658	186	186		H->A: Shows approximately 17% remaining glyoxalase activity compared with that of the wild-type. {ECO:0000269|PubMed:21696459}.	
P76342	146	146		C->S: Loss of enzymatic activity. Enhances binding to YedZ and targeting to the inner membrane. {ECO:0000269|PubMed:16042411}.	
P64524	1	15		Missing: No longer toxic, cells become lemon-shaped more quickly than wild-type on overexpression. {ECO:0000269|PubMed:21166897}.	
P04995	148	148		R->A: Strongly reduced ssb-binding. Reduced ssb-dependent nuclease activity. {ECO:0000269|PubMed:18591666}.	
P04995	150	150	1	E->A: About 2-fold increased ssb-binding. Weakly increased ssb-independent and ssb- dependent nuclease activity. {ECO:0000269|PubMed:18591666}.	
P04995	181	181		H->A: Residual nuclease activity. {ECO:0000269|PubMed:23609540}.	
P04995	207	207		Y->A: Strongly reduced ssb-binding. Reduced ssb-dependent nuclease activity. {ECO:0000269|PubMed:18591666}.	
P04995	227	227		K->A: 7-fold reduced ssb-binding. Reduced ssb-dependent nuclease activity. {ECO:0000269|PubMed:18591666}.	
P04995	311	311		Q->A: 2-fold reduced ssb-binding. Weakly reduced ssb-dependent nuclease activity. {ECO:0000269|PubMed:18591666}.	
P04995	316	316		R->A: Strongly reduced ssb-binding. Strongly reduced ssb-dependent nuclease activity. {ECO:0000269|PubMed:18591666}.	
P04995	318	318	1	E->A: About 2-fold increased ssb-binding. No effect on ssb-dependent nuclease activity. {ECO:0000269|PubMed:18591666}.	
P04995	319	319		D->A: 2-fold reduced ssb-binding. No effect on ssb-dependent nuclease activity. {ECO:0000269|PubMed:18591666}.	
P04995	327	327	1	R->A: No effect on ssb-binding and on ssb-dependent nuclease activity. {ECO:0000269|PubMed:18591666}.	
P04995	331	331	1	L->A: No effect on ssb-binding and on ssb-dependent nuclease activity. {ECO:0000269|PubMed:18591666}.	
P04995	338	338		R->A: 3-fold reduced ssb-binding. Reduced ssb-dependent nuclease activity. {ECO:0000269|PubMed:18591666}.	
P04995	448	448	1	Q->A: No effect on ssb-binding and on ssb-dependent nuclease activity. {ECO:0000269|PubMed:18591666}.	
P04995	452	452	1	Q->A: No effect on ssb-binding and on ssb-dependent nuclease activity. {ECO:0000269|PubMed:18591666}.	
P69348	65	65		R->A: Loss of RNase activity. {ECO:0000269|PubMed:16109374}.	
P69348	83	83		H->Q: Loss of RNase activity; still see mRNA cleavage in association with 70S ribosomes. {ECO:0000269|PubMed:16109374, ECO:0000269|PubMed:19124462}.	
P69348	84	84		Y->A: Loss of RNase activity. {ECO:0000269|PubMed:16109374}.	
P69346	10	10		R->A: Loss of DNA-binding and transcriptional repression. {ECO:0000269|PubMed:19028895}.	
P69346	31	31		R->A: Loss of DNA-binding and transcriptional repression. {ECO:0000269|PubMed:19028895}.	
P60664	5	5		R->A: Loss of activity. {ECO:0000269|PubMed:11208798}.	
P60664	5	5		R->H: Loss of IGP synthase activity. Weak IGP synthase activity and reduced HisH activity in vitro. {ECO:0000269|PubMed:11208798}.	
P60664	46	46		E->A: Loss of activity. {ECO:0000269|PubMed:11208798}.	
P60664	46	46		E->G: Loss of IGP synthase activity. Weak IGP synthase and HisH activities in vitro. {ECO:0000269|PubMed:11208798}.	
P60664	123	123		Q->A: Decrease in activity. {ECO:0000269|PubMed:11208798}.	
P60664	123	123		Q->R: Loss of IGP synthase activity. Weak HisH activity in vitro. {ECO:0000269|PubMed:11208798}.	
P60664	124	124	1	C->A: No change in activity. {ECO:0000269|PubMed:11208798}.	
P60664	124	124		C->R: Loss of IGP synthase activity. Weak HisH activity in vitro. {ECO:0000269|PubMed:11208798}.	
P37747	151	151		Y->F: 3-fold decrease in the mutase activity. {ECO:0000269|PubMed:11573090}.	
P37747	156	156		W->A: Loss of mutase activity. {ECO:0000269|PubMed:11573090}.	
P37747	156	156		W->Y: 2-fold decrease in the mutase activity. {ECO:0000269|PubMed:11573090}.	
P37747	181	181		Y->F: Increase in the mutase activity. {ECO:0000269|PubMed:11573090}.	
P37747	311	311		Y->F: Loss of mutase activity. {ECO:0000269|PubMed:11573090}.	
P37747	346	346		Y->F: Loss of mutase activity. {ECO:0000269|PubMed:11573090}.	
P32056	21	21		D->A: Increases Km for GDP-mannose 5- fold. Reduces activity 120-fold. {ECO:0000269|PubMed:15966723}.	
P32056	21	21		D->N: Increases Km for GDP-mannose 9- fold. Reduces activity 400-fold. {ECO:0000269|PubMed:15966723}.	
P32056	36	36		R->Q: Increases Km for GDP-mannose 9- fold. Reduces activity 24-fold. {ECO:0000269|PubMed:15966723}.	
P32056	51	51		R->K: Increases Km for GDP-mannose 40- fold. Reduces activity 10-fold. {ECO:0000269|PubMed:12196023}.	
P32056	51	51		R->Q: Increases Km for GDP-mannose 40- fold. Reduces activity 300-fold. {ECO:0000269|PubMed:12196023}.	
P32056	64	64		R->Q: Increases Km for GDP-mannose 80- fold. Reduces activity 24-fold. {ECO:0000269|PubMed:12196023}.	
P32056	69	69		E->Q: Increases Km for GDP-mannose 10- fold. Increases Km for magnesium 40-fold. Reduces activity 150-fold.	
P32056	87	87		H->Q: Increases Km for GDP-mannose 4- fold. Reduces activity 200-fold. {ECO:0000269|PubMed:12196023}.	
P32056	101	101		H->Q: Increases Km for GDP-mannose 14- fold. Reduces activity 7-fold. {ECO:0000269|PubMed:12196023}.	
P32056	102	102		Y->F: Increases Km for GDP-mannose 7- fold. Reduces activity 100-fold. {ECO:0000269|PubMed:15966723}.	
P32056	123	123		H->Q: Increases Km for GDP-mannose 5- fold. Reduces activity 2000-fold. {ECO:0000269|PubMed:12196023}.	
P32055	107	107		S->A: Nearly abolishes catalytic activity. Minor effect of affinity for NADPH and substrate. {ECO:0000269|PubMed:11021971}.	
P32055	109	109		C->A: Nearly abolishes catalytic activity.	
P32055	136	136		Y->E: Abolishes enzyme activity. {ECO:0000269|PubMed:11021971}.	
P32055	140	140		K->R: Reduces catalytic activity 20-fold. {ECO:0000269|PubMed:11021971}.	
P32055	140	140		K->S: Nearly abolishes catalytic activity. {ECO:0000269|PubMed:11021971}.	
P32055	179	179		H->N: Nearly abolishes catalytic activity. {ECO:0000269|PubMed:11021971}.	
P32055	187	187		R->A: Decreases affinity for the substrate GDP-4-keto-6-deoxymannose. {ECO:0000269|PubMed:11021971}.	
P0AC88	133	133		T->V: Strongly reduces activity. {ECO:0000269|PubMed:10673432}.	
P0AC88	135	135		E->Q: Strongly reduces activity.	
P0AC88	157	157		Y->F: Strongly reduces activity. {ECO:0000269|PubMed:10673432}.	
P0AC88	161	161		K->A: Strongly reduces activity. {ECO:0000269|PubMed:10673432}.	
P76387	467	467	1	Y->F: No loss of autophosphorylation. {ECO:0000269|PubMed:11751920}.	
P76387	491	491	1	Y->F: No loss of autophosphorylation. {ECO:0000269|PubMed:11751920}.	
P76387	540	540		K->M: Loss of autophosphorylation. {ECO:0000269|PubMed:11751920}.	
P76387	569	569		Y->F: Loss of autophosphorylation. {ECO:0000269|PubMed:11751920}.	
P76387	636	636	1	Y->F: No loss of autophosphorylation. {ECO:0000269|PubMed:11751920}.	
P76387	668	668	1	Y->F: No loss of autophosphorylation. {ECO:0000269|PubMed:11751920}.	
P04395	124	124		Q->A: Methylmethane sulfonate-resistant. {ECO:0000269|PubMed:8706135}.	
P04395	218	218		W->A: No catalytic activity, methylmethane sulfonate-sensitive. {ECO:0000269|PubMed:8706135}.	
P04395	237	237		D->N: More than 30% catalytic activity, methylmethane sulfonate-resistant. {ECO:0000269|PubMed:8706135}.	
P04395	238	238		D->N: No catalytic activity, methylmethane sulfonate-sensitive. {ECO:0000269|PubMed:8706135}.	
P0A991	237	237		K->A: Loss of activity.	
P0A991	239	239	1	K->A: No change in activity.	
P00959	336	336		K->Q,A,E,R: Loss of activity. {ECO:0000269|PubMed:1959615, ECO:0000269|PubMed:8515465}.	
P0AFT5	54	54		D->E: 2-fold increase in yjiY induction. {ECO:0000269|PubMed:22685278}.	
P0AFT5	54	54		D->N: 10-fold decrease in yjiY induction. {ECO:0000269|PubMed:22685278}.	
P0AD14	382	382		H->Q: Lack of activity. {ECO:0000269|PubMed:22685278}.	
C1P609	2	2		K->G: Protein mostly C-terminus inside. Both orientations found; when associated with 24-G. {ECO:0000269|PubMed:21778229}.	
C1P609	24	24		K->G: Protein mostly C-terminus outside. Both orientations found; when associated with 2-G. {ECO:0000269|PubMed:21778229}.	
P0AEE5	97	97		G->D: Improductive interaction with trg.	
P33018	26	26		C->A: Reduces catalytic efficiency, but has no effect on affinity for substrate. {ECO:0000269|PubMed:16567800}.	
P33018	54	54		C->A: Reduces affinity for substrate and catalytic efficiency. {ECO:0000269|PubMed:16567800}.	
P33018	80	80		D->A: Increases affinity for substrate, but reduces catalytic efficiency. {ECO:0000269|PubMed:16567800}.	
P33018	145	145		S->A: Loss of activity. {ECO:0000269|PubMed:16567800}.	
P33018	199	199		D->A: Reduces catalytic efficiency, but has no effect on affinity for substrate. {ECO:0000269|PubMed:16567800}.	
P33018	218	218		D->A: Reduces affinity for substrate and catalytic efficiency. {ECO:0000269|PubMed:16567800}.	
P33018	223	223		D->A: Loss of activity. {ECO:0000269|PubMed:16567800}.	
P33018	255	255		D->A: Increases affinity for substrate, but reduces catalytic efficiency. {ECO:0000269|PubMed:16567800}.	
P33018	256	256		H->A: Loss of activity. {ECO:0000269|PubMed:16567800}.	
P33022	82	82		H->N: Increases KM for uridine 2-fold. Increases Kcat 3-fold. {ECO:0000269|PubMed:15130467}.	
P33022	239	239		H->A: Increases KM for uridine 13-fold. No effect on Kcat. {ECO:0000269|PubMed:15130467}.	
P33025	31	31		E->A: 7500-fold decrease in reaction rate while little change in substrate affinity. {ECO:0000269|PubMed:23066817}.	
P33025	93	93		K->A: 17-fold decrease in reaction rate while modest decrease in substrate affinity. {ECO:0000269|PubMed:23066817}.	
P33025	149	149		D->A: Loss of activity. {ECO:0000269|PubMed:23066817}.	
P33025	166	166		K->A: 2900-fold decrease in reaction rate while no change in substrate affinity. {ECO:0000269|PubMed:23066817}.	
P33025	289	289		N->A: 17-fold decrease in reaction rate while modest decrease in substrate affinity. {ECO:0000269|PubMed:23066817}.	
P76445	190	190		H->A: Lack of activity. {ECO:0000269|PubMed:20384697}.	
P0AFV4	94	94		C->A: Loss of DD-endopeptidase activity, no complementation of double mepS-mepM deletion mutants. {ECO:0000269|PubMed:23062283}.	
P0AA43	102	102		D->N,T: Loss of activity. {ECO:0000269|PubMed:10376875}.	
P0AA86	80	80		C->S: Drastic decrease in activity. {ECO:0000269|PubMed:9537397}.	
P0AA86	83	83		C->S: Drastic decrease in activity. {ECO:0000269|PubMed:9537397}.	
P69490	130	130		H->A: Abolishes heme binding. {ECO:0000269|PubMed:12486054}.	
P69490	130	130		H->C: Can still form a covalent bond with heme, but blocks heme release transfer to cytochrome c. {ECO:0000269|PubMed:12486054}.	
P05050	51	51		T->A: Slighly reduced activity towards single-stranded DNA containing 1- methyladenine. Reduces affinity for undamaged DNA. {ECO:0000269|PubMed:20084272}.	
P05050	69	69		W->A: Abolishes activity towards single- stranded DNA containing 1-methyladenine. {ECO:0000269|PubMed:20084272}.	
P05050	76	76		Y->A: Reduces affinity for damaged DNA and activity towards single-stranded DNA containing 1-methyladenine. {ECO:0000269|PubMed:20084272}.	
P05050	135	135		D->A: Abolishes activity towards single- stranded DNA containing 1-methyladenine. Alters substrate specificity, so that the enzyme gains activity towards single- stranded DNA containing 1-methylguanine. {ECO:0000269|PubMed:20084272}.	
P05050	161	161		R->A: No effect on enzyme activity. Decreases affinity for damaged DNA. {ECO:0000269|PubMed:20084272}.	
P39838	842	842		H->R: Lack of activity. {ECO:0000269|PubMed:11309126}.	
P0AES4	32	32		R->A,Q: Nearly abolishes DNA supercoiling. Reduces DNA cleavage and relaxation. {ECO:0000269|PubMed:12051842}.	
P0AES4	47	47		R->Q: Nearly abolishes DNA supercoiling. Reduces DNA cleavage. Slightly reduces DNA relaxation. {ECO:0000269|PubMed:12051842}.	
P0AES4	78	78		H->A: Nearly abolishes DNA supercoiling. Reduces DNA cleavage and DNA relaxation. {ECO:0000269|PubMed:12051842}.	
P0AES4	80	80		H->A: Reduces DNA supercoiling. Slightly reduces DNA cleavage. No effect on DNA relaxation. {ECO:0000269|PubMed:12051842}.	
P0AES4	83	83	1	S->A: Resistant to fluoroquinolones. {ECO:0000269|PubMed:1850970}.	
P0AES4	106	106	1	Q->R: Resistant to fluoroquinolones. {ECO:0000269|PubMed:1850970}.	
P0AES4	462	462		R->C: In gyrA462; resistant to cytotoxic protein CcdB, but not to the quinoline antibiotic enoxacin, has no effect on DNA supercoiling. Does not interact with CcdB. {ECO:0000269|PubMed:1324324, ECO:0000269|PubMed:8254658}.	
P00452	441	441		E->A,Q: Loss of activity. {ECO:0000269|PubMed:9395490}.	
P00452	441	441		E->D: Decrease in activity. {ECO:0000269|PubMed:9395490}.	
P00452	730	730		Y->F: Loss of activity. {ECO:0000269|PubMed:8702814}.	
P00452	731	731		Y->F: Loss of activity. {ECO:0000269|PubMed:8702814}.	
P76469	49	49		H->A: Loss of activity. {ECO:0000269|PubMed:18754683}.	
P76469	74	74		R->A: Loss of activity. {ECO:0000269|PubMed:18754683}.	
P77215	29	29		H->N: Loss of activity due to absence of substrate binding. {ECO:0000269|PubMed:18754693}.	
P77215	277	277		H->N: 35-fold decrease in activity. 59- fold decrease in substrate affinity. {ECO:0000269|PubMed:18754693}.	
P77215	325	325		H->N: Loss of activity. 2-fold decrease in substrate affinity. {ECO:0000269|PubMed:18754693}.	
P77398	102	102		N->A: No activity. {ECO:0000269|PubMed:15807526}.	
P77398	104	104		H->A: 25-fold lower activity. {ECO:0000269|PubMed:15807526}.	
P77398	104	104		H->K: Less than 1% residual activity. {ECO:0000269|PubMed:15807526}.	
P77398	140	140		D->A,N: Less than 1% residual activity. {ECO:0000269|PubMed:15807526}.	
P77398	433	433		S->A: 40-fold lower specific activity. {ECO:0000269|PubMed:15809294, ECO:0000269|PubMed:15939024}.	
P77398	433	433		S->T: No activity. {ECO:0000269|PubMed:15809294, ECO:0000269|PubMed:15939024}.	
P77398	434	434		E->A: 100-fold lower specific activity. {ECO:0000269|PubMed:15809294}.	
P77398	434	434		E->Q: No activity. {ECO:0000269|PubMed:15809294}.	
P77398	619	619		R->E,Y: No activity. {ECO:0000269|PubMed:15939024}.	
P77398	619	619		R->M: 400-fold lower activity. {ECO:0000269|PubMed:15939024}.	
P0ABU0	89	89		K->A: Strongly decreases affinity for substrate and DHNA-CoA synthase activity. {ECO:0000269|PubMed:23658663}.	
P0ABU0	91	91		R->A: Loss of DHNA-CoA synthase activity. {ECO:0000269|PubMed:23658663}.	
P0ABU0	97	97		Y->F: Loss of DHNA-CoA synthase activity. {ECO:0000269|PubMed:21830810}.	
P0ABU0	154	154		Q->A: Reduces the specific DHNA-CoA synthase activity by 15-fold, whereas its affinity for bicarbonate is reduced by 36-fold. {ECO:0000269|PubMed:20643650}.	
P0ABU0	156	156		G->D: Loss of DHNA-CoA synthase activity. {ECO:0000269|PubMed:20643650, ECO:0000269|PubMed:21830810}.	
P0ABU0	184	184		W->F: Reduces the specific DHNA-CoA synthase activity by 530-fold, whereas its affinity for bicarbonate is reduced by 20-fold. {ECO:0000269|PubMed:20643650}.	
P0ABU0	267	267		R->A: Strongly decreases affinity for substrate and DHNA-CoA synthase activity. {ECO:0000269|PubMed:23658663}.	
P0ABU0	270	270		F->A: Strongly decreases affinity for substrate and DHNA-CoA synthase activity. {ECO:0000269|PubMed:23658663}.	
P0ABU0	273	273		K->A: Impairs protein folding. {ECO:0000269|PubMed:23658663}.	
P37355	86	86		S->A: 1400-fold decrease in catalytic activity. {ECO:0000269|PubMed:18284213}.	
P37355	210	210		D->A: Loss of activity. {ECO:0000269|PubMed:18284213}.	
P37355	232	232		H->A: Loss of activity. {ECO:0000269|PubMed:18284213}.	
P17109	55	55		E->Q: Loss of activity. {ECO:0000269|PubMed:14621995}.	
P38051	190	190		K->A: Lack of activity. {ECO:0000269|PubMed:17240978}.	
P38051	240	240		E->Q: Lack of activity. {ECO:0000269|PubMed:17240978}.	
P38051	255	255		L->A: Decrease in activity. {ECO:0000269|PubMed:17240978}.	
P38051	344	344		A->T: Lack of activity. {ECO:0000269|PubMed:17240978}.	
P38051	387	387		R->A: Lack of activity. {ECO:0000269|PubMed:17240978}.	
Q47013	313	313		C->S: Abolishes deubiquitinating activity. {ECO:0000269|PubMed:17440617}.	
P0AFF0	1	1		M->H: Shows 20% of the wild-type rate of deamino-NADH oxidase. {ECO:0000269|PubMed:12718520}.	
P0AFF0	158	158		K->C: Shows 50% of the wild-type rate of deamino-NADH oxidase. Inhibited by 30-50% upon addition of 0.25 mM of decylubiquinone. {ECO:0000269|PubMed:12718520}.	
P0AFF0	217	217		K->C: Loss of activity. {ECO:0000269|PubMed:12718520}.	
P0AFF0	217	217		K->R: Shows 40% of the wild-type rate of deamino-NADH oxidase. {ECO:0000269|PubMed:12718520}.	
P0AFF0	224	224		H->K: Shows 40% of the wild-type rate of deamino-NADH oxidase. Inhibited by 20-30% upon addition of 0.25 mM of decylubiquinone. {ECO:0000269|PubMed:12718520}.	
P0AFF0	247	247		K->C: Shows 7% of the wild-type rate of deamino-NADH oxidase. {ECO:0000269|PubMed:12718520}.	
P0AFF0	391	391		G->S: Shows 90% of the wild-type rate of deamino-NADH oxidase. {ECO:0000269|PubMed:12718520}.	
P0AFF0	395	395		K->C: Shows 5% of the wild-type rate of deamino-NADH oxidase. {ECO:0000269|PubMed:12718520}.	
P0AFF0	395	395		K->R: Shows 30% of the wild-type rate of deamino-NADH oxidase. {ECO:0000269|PubMed:12718520}.	
P0AFE4	25	26		RR->AA: Retains 14% dNADH oxidase and dNADH-DB reductase activity. {ECO:0000269|PubMed:15996109}.	
P0AFE4	36	36		E->A: Retains 2% dNADH oxidase and dNADH- DB reductase activity. {ECO:0000269|PubMed:15996109}.	
P0AFE4	36	36		E->Q: Retains 2% dNADH oxidase and dNADH- DB reductase activity, neither a membrane potential nor a proton gradient can be formed by isolated membranes. {ECO:0000269|PubMed:15996109}.	
P0AFE4	72	72		E->A: Retains 43% dNADH oxidase and dNADH-DB reductase activity. {ECO:0000269|PubMed:15996109}.	
P0AFE4	72	72		E->Q: Retains 22% dNADH oxidase and dNADH-DB reductase activity. {ECO:0000269|PubMed:15996109}.	
P76491	18	18		R->A: Shows negligible enzymatic activity. {ECO:0000269|PubMed:18353368}.	
P76491	30	30		V->A: Shows reduced activity and affinity compared to the wild-type. {ECO:0000269|PubMed:18353368}.	
P76491	33	33		H->A: Shows negligible enzymatic activity. {ECO:0000269|PubMed:18353368}.	
P76491	68	68		H->A: Shows negligible enzymatic activity. {ECO:0000269|PubMed:18353368}.	
P76491	69	69		D->A: Shows negligible enzymatic activity. {ECO:0000269|PubMed:18353368}.	
P76491	72	72		E->A: Shows negligible enzymatic activity. {ECO:0000269|PubMed:18353368}.	
P76491	72	72		E->V: Shows wild-type activity and substrate affinity. {ECO:0000269|PubMed:18353368}.	
P76491	77	77		D->A: Shows negligible enzymatic activity. {ECO:0000269|PubMed:18353368}.	
P76491	122	122		E->A: Shows reduced activity and affinity compared to the wild-type. {ECO:0000269|PubMed:18353368}.	
P76491	137	137		D->A: Shows negligible enzymatic activity. {ECO:0000269|PubMed:18353368}.	
P77544	10	10	1	S->A: Nearly no effect on GSH transferase activity. {ECO:0000269|PubMed:17018556}.	
P77544	16	16		S->G: 2% of wild-type GSH transferase activity. {ECO:0000269|PubMed:17018556}.	
P77526	9	9	1	T->A: No effect on GSH transferase activity. {ECO:0000269|PubMed:17018556}.	
P77526	11	11		N->A: Loss of GSH transferase activity. {ECO:0000269|PubMed:17018556}.	
P77526	14	14		K->A: 10-fold reduction in GSH transferase activity. {ECO:0000269|PubMed:17018556}.	
P77526	166	166	1	C->A: No effect on disulfide-bond reductase activity. {ECO:0000269|PubMed:19537707}.	
P0A9Q5	27	27		C->A: Vmax decreases 9-fold. {ECO:0000269|PubMed:19965770}.	
P0A9Q5	30	30		C->A: Vmax decreases 140-fold. Loss of nucleic acid-binding. {ECO:0000269|PubMed:19965770}.	
P0A9Q5	46	46		C->A: Vmax decreases 11-fold. {ECO:0000269|PubMed:19965770}.	
P0A9Q5	49	49		C->A: Vmax decreases 8-fold. {ECO:0000269|PubMed:19965770}.	
P07649	58	58		R->A: Loss of activity. {ECO:0000269|PubMed:17466622}.	
P77182	64	64		E->A: Loss of methyltransferase activity. {ECO:0000269|PubMed:18186482}.	
P77182	178	178		D->A: Strong decrease in methyltransferase activity. {ECO:0000269|PubMed:18186482}.	
P77182	180	180		F->A: Strong decrease in methyltransferase activity. {ECO:0000269|PubMed:18186482}.	
P77182	271	271		G->Q: 4-fold decrease in activity, but no change in FAD binding. {ECO:0000269|PubMed:18186482}.	
P77182	567	567		R->A: Loss of activity, but no change in FAD binding. {ECO:0000269|PubMed:18186482}.	
P77182	618	618		R->A: Loss of activity, but no change in FAD binding. {ECO:0000269|PubMed:18186482}.	
P0C0T5	113	113		H->A: Strongly reduces enzyme activity. {ECO:0000269|PubMed:15292190}.	
P0C0T5	120	120		D->A: Strongly reduces enzyme activity. {ECO:0000269|PubMed:15292190}.	
P0C0T5	209	209		H->A: Strongly reduces enzyme activity. {ECO:0000269|PubMed:15292190}.	
P0C0T5	211	211		H->A: Strongly reduces enzyme activity. {ECO:0000269|PubMed:15292190}.	
Q2EES9	28	28		Y->F,S: Loss of all excisionase activity. {ECO:0000269|PubMed:16079126}.	
Q2EES9	45	45		R->K,Q: Retains approximately 10% excisionase activity. {ECO:0000269|PubMed:16079126}.	
P0AA93	371	371		H->Q: Lack of activity. {ECO:0000269|PubMed:23222720}.	
P0AE39	53	53		D->E: Strong induction of yhjX. {ECO:0000269|PubMed:23222720}.	
P0AE39	53	53		D->N: Prevents yhjX induction. {ECO:0000269|PubMed:23222720}.	
P0A769	34	34		D->E,N: Loss of function. {ECO:0000269|PubMed:15630547}.	
P0A769	35	35		P->N,Q: Loss of function. {ECO:0000269|PubMed:15630547}.	
P0A769	36	36		G->P: Loss of function. {ECO:0000269|PubMed:15630547}.	
P0A769	37	37		N->D: Loss of function. {ECO:0000269|PubMed:15630547}.	
P0A769	102	102		E->D,Q: Loss of function. {ECO:0000269|PubMed:15630547}.	
P0A769	109	109		D->E,N: Transports manganese to a very low level. {ECO:0000269|PubMed:15630547}.	
P0A769	112	112		E->D,Q: Transports manganese to a very low level. {ECO:0000269|PubMed:15630547}.	
P0A769	115	115		G->A,P: Loss of function. {ECO:0000269|PubMed:15630547}.	
P0A769	154	154		E->Q: Transports manganese to a level half of that of wild-type. {ECO:0000269|PubMed:15630547}.	
P0A769	238	238		D->N: Transports manganese to a very low level. {ECO:0000269|PubMed:15630547}.	
P04805	98	98		C->S: 10-fold decrease in activity. Strong decrease in zinc content. {ECO:0000269|PubMed:7797500}.	
P04805	100	100		C->S: Loss of activity. Strong decrease in zinc content. {ECO:0000269|PubMed:14764088, ECO:0000269|PubMed:7797500}.	
P04805	100	100		C->Y: Does not prevent zinc binding. Reduces only 2-fold the binding affinity for tRNA(Glu), but reduces more than 10- fold the affinity for glutamate in the presence of tRNA(Glu). {ECO:0000269|PubMed:14764088, ECO:0000269|PubMed:7797500}.	
P04805	125	125		C->S: Loss of activity. Strong decrease in zinc content. {ECO:0000269|PubMed:7797500}.	
P04805	127	127		H->Q: 10-fold decrease in activity. Strong decrease in zinc content. {ECO:0000269|PubMed:7797500}.	
P04805	129	129	1	H->Q: No change in activity or in zinc content. {ECO:0000269|PubMed:7797500}.	
P04805	131	131	1	H->Q: No change in activity or in zinc content. {ECO:0000269|PubMed:7797500}.	
P04805	132	132	1	H->Q: No change in activity or in zinc content. {ECO:0000269|PubMed:7797500}.	
P04805	138	138	1	C->S: No change in activity or in zinc content. {ECO:0000269|PubMed:7797500}.	
P04805	239	239		S->D: Does not aminoacylate tRNA(Glu), not phosphorylated by HipA. {ECO:0000269|PubMed:24095282}.	
P45563	191	191		Y->L: No detectable activity with xanthosine as substrate, but largely retains its activity against other substrates, namely inosine and guanosine, although with altered affinities, higher and lower respectively, and clearly reduced maximal velocities for both. {ECO:0000269|PubMed:15808857}.	
P45563	239	239		N->D: Catalyzes the phosphorolysis of adenosine with moderate efficiency, and essentially has lost all activity against the 6-oxo-purine substrates xanthosine, inosine and guanosine. {ECO:0000269|PubMed:15808857}.	
P15042	10	10	1	E->A: No effect. {ECO:0000269|PubMed:11781321}.	
P15042	22	22		Y->A,S: Reduces nick joining activity by 99.9%. {ECO:0000269|PubMed:11781321}.	
P15042	22	22		Y->F: Reduces nick joining activity by 91%. {ECO:0000269|PubMed:11781321}.	
P15042	23	23		H->A,Y: Reduces nick joining activity by 90%. {ECO:0000269|PubMed:11781321}.	
P15042	32	32		D->A,E: Reduces nick joining activity by 99%. {ECO:0000269|PubMed:11781321}.	
P15042	32	32		D->N: Reduces nick joining activity by 91%. {ECO:0000269|PubMed:11781321}.	
P15042	35	35		Y->A: Reduces nick joining activity by 98%. {ECO:0000269|PubMed:11781321}.	
P15042	35	35		Y->F: Reduces nick joining activity by 77%. {ECO:0000269|PubMed:11781321}.	
P15042	35	35		Y->S: Reduces nick joining activity by 99.9%. {ECO:0000269|PubMed:11781321}.	
P15042	36	36		D->A: Reduces nick joining activity by 99.8%. {ECO:0000269|PubMed:11781321}.	
P15042	36	36		D->E: Reduces nick joining activity by 96%. {ECO:0000269|PubMed:11781321}.	
P15042	36	36		D->N: Reduces nick joining activity by 88%. {ECO:0000269|PubMed:11781321}.	
P15042	115	115		K->Q,R: Reduces nick joining activity by 99.9%. {ECO:0000269|PubMed:15671015}.	
P15042	117	117		D->E: Reduces nick joining activity by 97%. {ECO:0000269|PubMed:15671015}.	
P15042	117	117		D->N: Reduces nick joining activity by 99.9%. {ECO:0000269|PubMed:15671015}.	
P15042	118	118		G->A: Reduces nick joining activity by 99.9%. {ECO:0000269|PubMed:15671015}.	
P15042	138	138		D->A: Reduces nick joining activity by 63%. {ECO:0000269|PubMed:15671015}.	
P15042	143	143		E->A: Reduces nick joining activity by 48%. {ECO:0000269|PubMed:15671015}.	
P15042	172	172		G->A: Reduces nick joining activity by 64%. {ECO:0000269|PubMed:15671015}.	
P15042	173	173		E->A,D,Q: Reduces nick joining activity by 99.9%. {ECO:0000269|PubMed:15671015}.	
P15042	198	198		N->A: Reduces nick joining activity by 74%. {ECO:0000269|PubMed:15671015}.	
P15042	200	200		R->A,K,Q: Reduces nick joining activity by 99.9%. {ECO:0000269|PubMed:15671015}.	
P15042	208	208		R->A,K,Q: Reduces nick joining activity by 99%. {ECO:0000269|PubMed:15671015}.	
P15042	277	277		R->A: Reduces nick joining activity by 99%. {ECO:0000269|PubMed:15671015}.	
P15042	285	285		D->E: Reduces nick joining activity by 96%. {ECO:0000269|PubMed:15671015}.	
P15042	285	285		D->N: Reduces nick joining activity by 99%. {ECO:0000269|PubMed:15671015}.	
P15042	286	286		G->A: Reduces nick joining activity by 86%. {ECO:0000269|PubMed:15671015}.	
P15042	288	288		V->A: Reduces nick joining activity by 25%. {ECO:0000269|PubMed:15671015}.	
P15042	290	290		K->A: Reduces nick joining activity by 87%. {ECO:0000269|PubMed:15671015}.	
P15042	314	314		K->Q: Reduces nick joining activity by 99%. {ECO:0000269|PubMed:15671015}.	
P15042	314	314		K->R: Reduces nick joining activity by 95%. {ECO:0000269|PubMed:15671015}.	
P15042	333	333		R->A,Q: Reduces nick joining activity by over 95%. Abolishes nick joining activity; when associated with A-334. {ECO:0000269|PubMed:18515356}.	
P15042	334	334		T->A: Abolishes nick joining activity; when associated with A-333. {ECO:0000269|PubMed:18515356}.	
P15042	342	342		R->A: Reduces nick joining activity by 80%. {ECO:0000269|PubMed:18515356}.	
P15042	379	379		R->A,Q: Reduces nick joining activity by over 95%. {ECO:0000269|PubMed:18515356}.	
P15042	383	384		VI->AA: Reduces nick joining activity by 95%. {ECO:0000269|PubMed:18515356}.	
P15042	446	447		RR->AA: Reduces nick joining activity by 95%. {ECO:0000269|PubMed:18515356}.	
P15042	455	455		G->A: Reduces nick joining activity by 50%. {ECO:0000269|PubMed:18515356}.	
P15042	455	455		G->D,V: Reduces nick joining activity by 95%. {ECO:0000269|PubMed:18515356}.	
P15042	487	487		R->A: Reduces nick joining activity by over 90%. {ECO:0000269|PubMed:18515356}.	
P15042	489	489		G->D,V: Reduces nick joining activity by 95%. {ECO:0000269|PubMed:18515356}.	
P15042	521	521		G->A: Reduces nick joining activity by 95%. {ECO:0000269|PubMed:18515356}.	
P15042	521	521		G->D,V: Loss of nick joining activity. {ECO:0000269|PubMed:18515356}.	
P15042	553	553		G->D,V: Reduces nick joining activity by 95%. {ECO:0000269|PubMed:18515356}.	
P15042	614	614		R->A: Reduces nick joining activity by 85%. {ECO:0000269|PubMed:18515356}.	
P0ABK5	42	42		K->A: Still stimulates tRNase activity of CdiA-CT in vitro and in vivo. {ECO:0000269|PubMed:22333533}.	
P76535	83	83		E->A: 10000-fold reduction in catalytic activity. {ECO:0000269|PubMed:18837509}.	
P76535	83	83		E->Q: Loss of catalytic activity. {ECO:0000269|PubMed:18837509}.	
P76535	114	114		E->Q: 2000-fold reduction in catalytic activity and 4-fold increase in substrate affinity. {ECO:0000269|PubMed:18837509}.	
P76535	115	115		D->N: 7-fold reduction in catalytic activity and 1.5-fold increase in substrate affinity. {ECO:0000269|PubMed:18837509}.	
P76536	215	215		H->A: Strong decrease in affinity for heme and protoporphyrin. {ECO:0000269|PubMed:19564607}.	
P36553	96	96		H->L: Complete loss of oxidase activity and absence of manganese ions. {ECO:0000269|PubMed:12975365}.	
P36553	106	106		H->L: Complete loss of oxidase activity and absence of manganese ions. {ECO:0000269|PubMed:12975365}.	
P36553	145	145		H->L: Complete loss of oxidase activity and absence of manganese ions. {ECO:0000269|PubMed:12975365}.	
P36553	175	175		H->L: Complete loss of oxidase activity and absence of manganese ions. {ECO:0000269|PubMed:12975365}.	
P36553	274	274		W->L: Complete loss of oxidase activity.	
P76562	287	287		T->A: Loss of ATPase activity, but no change in tRNA-binding. {ECO:0000269|PubMed:19322199}.	
P76562	291	291		Y->A: Loss of ATPase activity, but no change in tRNA-binding. {ECO:0000269|PubMed:19322199}.	
P76562	292	292		E->A: Loss of ATPase activity, but no change in tRNA-binding. {ECO:0000269|PubMed:19322199}.	
P76562	296	296		R->A: Decrease in ATPase activity and loss of tRNA-binding. {ECO:0000269|PubMed:19322199}.	
P76562	301	301		K->A: Decrease in ATPase activity and loss of tRNA-binding. {ECO:0000269|PubMed:19322199}.	
P76562	319	319		R->A: Loss of ATPase activity, but no change in tRNA-binding. {ECO:0000269|PubMed:19322199}.	
P76562	327	327		E->A: Loss of ATPase activity, but no change in tRNA-binding. {ECO:0000269|PubMed:19322199}.	
P76562	377	377		H->A: Decrease in ATPase activity and loss of tRNA-binding. {ECO:0000269|PubMed:19322199}.	
P76562	387	387		R->A: Abolishes the tRNA-binding capacity, but no loss of activity. {ECO:0000269|PubMed:19322199}.	
P76562	460	460		R->A: Loss of tRNA-binding. {ECO:0000269|PubMed:19322199}.	
P0A6L2	44	44		T->S: 8% of wild-type activity. 4-fold decrease in affinity for pyruvate, but nearly no change in that for (S)-ASA. {ECO:0000269|PubMed:15066435, ECO:0000269|PubMed:19505526}.	
P0A6L2	44	44		T->V: Reduced kcat by 99.9%. {ECO:0000269|PubMed:15066435, ECO:0000269|PubMed:19505526}.	
P0A6L2	107	107		Y->F: Reduced kcat by 90%. {ECO:0000269|PubMed:15066435, ECO:0000269|PubMed:18937497}.	
P0A6L2	107	107		Y->W: Reduced activity by 95%. Reduced affinity for both substrates. Exists as a mixture of monomer, dimer and tetramer in solution. Has significantly lower thermal stability than the wild-type enzyme. {ECO:0000269|PubMed:15066435, ECO:0000269|PubMed:18937497}.	
P0A6L2	133	133		Y->F: Reduced kcat by 99.7%. Reduced affinity for both substrates. {ECO:0000269|PubMed:15066435}.	
P0A6L2	138	138		R->A,H: Strongly increased KM for L- aspartate 4-semialdehyde. No effect on KM for pyruvate. Reduced activity by 99.7%. {ECO:0000269|PubMed:16185069}.	
P0A6L2	161	161		K->A: 0.1% of wild-type activity. 3-fold decrease in affinity for pyruvate, and 2- fold decrease in that for (S)-ASA. {ECO:0000269|PubMed:20353808}.	
P0A6L2	161	161		K->R: 0.35% of wild-type activity. 3-fold decrease in affinity for pyruvate, but nearly no change in that for (S)-ASA. {ECO:0000269|PubMed:20353808}.	
P0A6L2	197	197		L->Y,D: 1.4 to 2.5% of wild-type activity. Decrease in affinity for pyruvate, but nearly no change in that for (S)-ASA. Exists as a dimer in solution. {ECO:0000269|PubMed:18556019}.	
P66948	136	136		H->R: Lack of protease activity. Increases sensitivity to erythromycin. {ECO:0000269|PubMed:24003122}.	
P66948	137	137		E->Q: Lack of protease activity. Increases sensitivity to erythromycin. {ECO:0000269|PubMed:24003122}.	
P69931	6	6		Q->A: Severely impaired in beta clamp binding and DnaA-ATP hydrolysis, very poor growth at 30 degrees Celsius. {ECO:0000269|PubMed:15611053, ECO:0000269|PubMed:22716942}.	
P69931	7	11		LSLPL->ASAPA: Decreased binding to beta clamp. {ECO:0000269|PubMed:15150238}.	
P69931	9	10		LP->AA: Decreased binding to beta clamp. {ECO:0000269|PubMed:15150238}.	
P69931	9	9		L->A: Impaired in beta clamp binding and DnaA-ATP hydrolysis, very poor growth at 30 degrees Celsius. {ECO:0000269|PubMed:15611053, ECO:0000269|PubMed:22716942}.	
P69931	56	56		R->A: Severely impaired in ADP-binding but still has beta clamp-binding activity in vitro, defective in DnaA-ATP hydrolysis in vivo; when associated with 102-A-A-103. {ECO:0000269|PubMed:18977760}.	
P69931	98	98		L->P: No growth at 30 degrees Celsius, impaired RIDA. {ECO:0000269|PubMed:22716942}.	
P69931	102	103		DN->AA: Impaired in ADP-binding, has beta clamp-binding activity in vitro. {ECO:0000269|PubMed:18977760}.	
P69931	136	136		G->D: No growth at 30 degrees Celsius, impaired RIDA. {ECO:0000269|PubMed:22716942}.	
P69931	153	153		R->A,M: Defective in DnaA-ATP hydrolysis, binds beta clamp normally, no growth at 30 degrees Celsius. {ECO:0000269|PubMed:15611053, ECO:0000269|PubMed:22716942}.	
P69931	157	157		G->V: Grows at 30 degrees Celsius, impaired RIDA. {ECO:0000269|PubMed:22716942}.	
P69931	167	167		D->N: Grows at 30 degrees Celsius, impaired RIDA. {ECO:0000269|PubMed:22716942}.	
P69931	196	196		R->Q: Grows at 30 degrees Celsius, impaired RIDA. {ECO:0000269|PubMed:22716942}.	
P69931	208	210		Missing: No growth at 30 degrees Celsius, impaired RIDA. {ECO:0000269|PubMed:22716942}.	
P69931	210	210		Q->QLDQ: No growth at 30 degrees Celsius, impaired RIDA. {ECO:0000269|PubMed:22716942}.	
P69931	212	212		D->N: Grows at 30 degrees Celsius, impaired RIDA. {ECO:0000269|PubMed:22716942}.	
P69931	233	233		L->F: No growth at 30 degrees Celsius, impaired RIDA. {ECO:0000269|PubMed:22716942}.	
P0AGM7	73	73		F->A: Slightly decreased uracil uptake. {ECO:0000269|PubMed:21423164}.	
P0AGM7	241	241		E->A: Abolishes uracil uptake. Abolishes uracil binding. {ECO:0000269|PubMed:21423164}.	
P0AGM7	245	245		H->A: Abolishes uracil uptake. Abolishes uracil binding. {ECO:0000269|PubMed:21423164}.	
P0AGM7	288	288	1	Y->A: No effect on uracil uptake. {ECO:0000269|PubMed:21423164}.	
P0AGM7	290	290		E->A: Abolishes uracil uptake. Abolishes uracil binding. {ECO:0000269|PubMed:21423164}.	
P0AGM7	291	291		N->A: Slightly decreased uracil uptake. {ECO:0000269|PubMed:21423164}.	
P0AGM7	342	342		Y->A: Slightly decreased uracil uptake. {ECO:0000269|PubMed:21423164}.	
P0A8F0	131	131		P->D: 60-fold reduction of the catalytic rate, and large decrease in uracil- binding affinity. {ECO:0000269|PubMed:10079076}.	
P08179	70	70		E->A: Loss of homodimerization. No effect on activity. {ECO:0000269|PubMed:9698564}.	
P08179	106	106		N->A,D,G,S: Reduces activity about 2000- fold. {ECO:0000269|PubMed:8688421}.	
P08179	106	106		N->E,H,I,K,L,Y: Loss of activity. {ECO:0000269|PubMed:8688421}.	
P08179	108	108		H->A,G,M,N,Q,R: Loss of activity. {ECO:0000269|PubMed:10433709, ECO:0000269|PubMed:8688421}.	
P08179	108	108		H->E,S,T: Reduces activity about 1000- fold. {ECO:0000269|PubMed:8688421}.	
P08179	119	119	1	H->A: No effect. {ECO:0000269|PubMed:8688421}.	
P08179	121	121		H->Q: Increases Km for 5'- phosphoribosylglycinamide 4-fold. {ECO:0000269|PubMed:10433709}.	
P08179	135	135		S->A,L: Reduces activity about 1000-fold. {ECO:0000269|PubMed:8688421}.	
P08179	137	137	1	H->F,Q: No effect. {ECO:0000269|PubMed:8688421}.	
P08179	144	144		D->A,E,S,Y: Reduces activity about 1000- fold. {ECO:0000269|PubMed:10433709, ECO:0000269|PubMed:8688421}.	
P08179	144	144		D->C,F,H,K,L,N,P,Q,R,T,V: Loss of activity. {ECO:0000269|PubMed:2204419, ECO:0000269|PubMed:8688421}.	
P0ADG7	13	13		D->A: Causes a 38-fold increase in the value of Km for K(+). No change is observed in the value of Km for IMP. {ECO:0000269|PubMed:9341229}.	
P0ADG7	50	50		D->A: Causes a 17-fold increase in the value of Km for K(+). {ECO:0000269|PubMed:9341229}.	
P0ADG7	54	54	1	E->A: No effect. {ECO:0000269|PubMed:9341229}.	
P0ADG7	138	138	1	D->A: No effect. {ECO:0000269|PubMed:9341229}.	
P0ADG7	200	200	1	D->A: No effect. {ECO:0000269|PubMed:9341229}.	
P0ADG7	243	243	1	D->A: No effect. {ECO:0000269|PubMed:9341229}.	
P0ADG7	248	248		D->A: Causes a 130-fold decrease in the value of kcat. {ECO:0000269|PubMed:9341229}.	
P0ADG7	338	338		D->A: Decreases the value of kcat by 600- fold. Increases the value of Km for IMP by 12-fold. {ECO:0000269|PubMed:9341229}.	
P0ADG7	369	369	1	E->A: No effect. {ECO:0000269|PubMed:9341229}.	
P0ADG7	373	373	1	E->A: No effect. {ECO:0000269|PubMed:9341229}.	
P0ADG7	469	469		E->A: Increases the value of Km for K(+) by 17-fold. {ECO:0000269|PubMed:9341229}.	
P0A6P5	15	15		K->A: Complements a disruption mutant, KM for GTP 695 uM. {ECO:0000269|PubMed:16963571}.	
P0A6P5	16	16		S->A: Does not complement a disruption mutant, KM for GTP 4.9 mM. Decreased GTPase activity, no stimulation by YihI. {ECO:0000269|PubMed:16963571, ECO:0000269|PubMed:20434458}.	
P0A6P5	118	118		N->D: Complements a disruption mutant at 42 degrees Celsius, very poor complementation at 30 degrees Celsius. Reduces affinity for the 50S ribosomal subunit at 30 degrees Celsius. RelA suppresses this point mutation at 30 degrees Celsius. {ECO:0000269|PubMed:16930151}.	
P0A6P5	118	118		N->D: Does not complement a disruption mutant at 42 degrees Celsius, diminished association with 50S ribosomal subunits; when associated with D-321. {ECO:0000269|PubMed:16930151}.	
P0A6P5	215	215		K->A: Does not complement a disruption mutant, KM for GTP 6.7 mM. {ECO:0000269|PubMed:16963571}.	
P0A6P5	216	216		S->A: Does not complement a disruption mutant, considerably decreased GTPase activity, KM for GTP 4.8 mM, no stimulation by YihI. {ECO:0000269|PubMed:16963571, ECO:0000269|PubMed:20434458}.	
P0A6P5	321	321		N->D: Complements a disruption mutant at 42 degrees Celsius, no complementation at 30 degrees Celsius. Greatly reduces affinity for the 50S ribosomal subunit at 30 degrees Celsius. RelA suppresses this point mutation at 30 degrees Celsius. {ECO:0000269|PubMed:16930151}.	
P0A6P5	414	414		G->R: Does not complement rrmJ deletion, complements der disruption at 42 degrees Celsius. {ECO:0000269|PubMed:20172997}.	
P0A6P5	424	424		G->D: Does not complement rrmJ deletion, nor the der disruption at 42 degrees Celsius. {ECO:0000269|PubMed:20172997}.	
P0A6P5	469	469		N->K: Does not complement rrmJ deletion, complements der disruption at 42 degrees Celsius. {ECO:0000269|PubMed:20172997}.	
P0A6P5	472	472		T->A: Does not complement rrmJ deletion, complements der disruption at 42 degrees Celsius. {ECO:0000269|PubMed:20172997}.	
P62620	322	322		G->D: Loss of activity. {ECO:0000269|PubMed:12859972}.	
P62620	328	328		G->D: Loss of activity. {ECO:0000269|PubMed:12859972}.	
P62620	335	335		R->C: Loss of activity. {ECO:0000269|PubMed:12859972}.	
P36979	118	118	1	C->A: No change in iron-sulfur cluster content. No effect on methylation of Cys- 355. {ECO:0000269|PubMed:21916495}.	
P36979	125	132		CALECKFC->AALEAKFA: Loss of iron-sulfur cluster binding. No methylation of Cys- 355. {ECO:0000269|PubMed:21916495}.	
P36979	355	355	1	C->A: No change in iron-sulfur cluster content. {ECO:0000269|PubMed:21916495}.	
P31142	240	240		S->A: Decrease in 3-mercaptopyruvate cyanide sulfurtransferase activity; abolition of thiosulfate binding. {ECO:0000269|PubMed:11445076}.	
P31142	240	240		S->K: Decrease in 3-mercaptopyruvate cyanide sulfurtransferase activity; increased affinity for thiosulfate. {ECO:0000269|PubMed:11445076}.	
P0AAC8	35	35		C->S: Decrease of iron binding activity. {ECO:0000269|PubMed:15247288}.	
P0AAC8	99	99		C->S: Loss of iron binding activity. {ECO:0000269|PubMed:15247288}.	
P0AAC8	101	101		C->S: Loss of iron binding activity. {ECO:0000269|PubMed:15247288}.	
P0ACD4	39	39		D->A,L,V: Stabilizes apo-protein in the S-state (structured). {ECO:0000269|PubMed:22203963, ECO:0000269|PubMed:22734684}.	
P0ACD4	39	39	1	D->G: No effect on equilibrium between S- and D-state (disordered). {ECO:0000269|PubMed:22203963, ECO:0000269|PubMed:22734684}.	
P0ACD4	89	89		K->A: Stabilizes apo-protein in the D- state; Fe-S cluster assembly 3-fold slower than wild-type. {ECO:0000269|PubMed:22203963}.	
P0ACD4	90	90		N->A: Stabilizes apo-protein in the S- state; biphasic Fe-S cluster assembly 7- fold slower than wild-type. {ECO:0000269|PubMed:22203963, ECO:0000269|PubMed:22734684}.	
P0ACD4	90	90		N->D: Stabilizes apo-protein in the D- state; Fe-S cluster assembly 3-fold slower than wild-type. {ECO:0000269|PubMed:22203963, ECO:0000269|PubMed:22734684}.	
P0ACD4	107	107		S->A: Stabilizes apo-protein in the S- state; biphasic Fe-S cluster assembly 7- fold slower than wild-type. {ECO:0000269|PubMed:22203963, ECO:0000269|PubMed:22734684}.	
P0ACD4	111	111		E->A: Stabilizes apo-protein in the S- state; biphasic Fe-S cluster assembly 7- fold slower than wild-type. {ECO:0000269|PubMed:22203963, ECO:0000269|PubMed:22734684}.	
P0A6B7	328	328		C->A: Loss of cysteine desulfurization. {ECO:0000269|PubMed:10739946}.	
P0A6B7	376	404		Missing: Normal cysteine desulfurase activity, decreased binding to IscU, decreased sulfur transfer to IscU, decreased Fe-S cluster assembly. {ECO:0000269|PubMed:11577100}.	
P0AGK8	92	92	1	C->A: No effect on activation of the suf operon, no effect on repression of rnlA. {ECO:0000269|PubMed:16824106, ECO:0000269|PubMed:20421606}.	
P0AGK8	98	98	1	C->A: No effect on activation of the suf operon, no effect on repression of rnlA. {ECO:0000269|PubMed:16824106, ECO:0000269|PubMed:20421606}.	
P0AGK8	104	104	1	C->A: No effect on activation of the suf operon, no effect on repression of rnlA. {ECO:0000269|PubMed:16824106, ECO:0000269|PubMed:20421606}.	
P0A825	55	55		Y->F: 50 and 15-fold increase in the affinity for serine and tetrahydrofolate, respectively, and 4-fold decrease in the catalytic efficiency. {ECO:0000269|PubMed:19883126}.	
P0A825	65	65		Y->F: Decrease in catalytic activity. {ECO:0000269|PubMed:10858298}.	
P0A825	85	85		L->A: Alteration of the dimer-monomer equilibrium accompanied by minor changes in the catalytic properties and whitout any significant change of tertiary structure. In the monomeric state; when associated with A-276. {ECO:0000269|PubMed:19019081}.	
P0A825	214	214	1	P->A: No significant difference in catalytic efficiency and affinity compared to the wild-type. {ECO:0000269|PubMed:12773539}.	
P0A825	214	214	1	P->G: No significant difference in catalytic efficiency and affinity compared to the wild-type. {ECO:0000269|PubMed:12773539}.	
P0A825	216	216	1	P->A: No significant difference in catalytic efficiency and affinity compared to the wild-type. Alteration in the folding rate. {ECO:0000269|PubMed:12773539}.	
P0A825	216	216		P->G: Important decrease in affinity and catalytic efficiency. Severely compromised in folding into a catalytically competent enzyme. {ECO:0000269|PubMed:12773539}.	
P0A825	218	218	1	P->A: No significant difference in catalytic efficiency and affinity compared to the wild-type. {ECO:0000269|PubMed:12773539}.	
P0A825	218	218	1	P->G: No significant difference in catalytic efficiency and affinity compared to the wild-type. {ECO:0000269|PubMed:12773539}.	
P0A825	235	235		R->K: 1500- and 20-fold increase in the affinity for serine and tetrahydrofolate, respectively, and 15-fold decrease in the catalytic efficiency. {ECO:0000269|PubMed:19883126}.	
P0A825	235	235		R->L: 450- and 11-fold increase in the affinity for serine and tetrahydrofolate, respectively, and 60-fold decrease in the catalytic efficiency. {ECO:0000269|PubMed:19883126}.	
P0A825	235	235		R->Q: 900- and 17-fold increase in the affinity for serine and tetrahydrofolate, respectively, and 30-fold decrease in the catalytic efficiency. {ECO:0000269|PubMed:19883126}.	
P0A825	258	258		P->A: Important decrease in affinity and catalytic efficiency. Reduced thermal stability. {ECO:0000269|PubMed:12773539}.	
P0A825	258	258		P->G: Important decrease in affinity and catalytic efficiency. {ECO:0000269|PubMed:12773539}.	
P0A825	264	264		P->A: Important decrease in affinity and catalytic efficiency. {ECO:0000269|PubMed:12773539}.	
P0A825	264	264		P->G: Important decrease in affinity and catalytic efficiency. {ECO:0000269|PubMed:12773539}.	
P0A825	276	276		L->A: Alteration of the dimer-monomer equilibrium accompanied by minor changes in the catalytic properties and whitout any significant change of tertiary structure. In the monomeric state; when associated with A-85. {ECO:0000269|PubMed:19019081}.	
P0A825	363	363		R->A: It does not bind serine and glycine and shows no activity with serine as the substrate. {ECO:0000269|PubMed:7925461}.	
P0A825	363	363		R->K: Exhibits only 0.03% of the catalytic activity of the wild-type and a 15-fold reduction in affinity for glycine and serine. {ECO:0000269|PubMed:7925461}.	
P0A825	372	372	1	R->A: No significant difference compared to the wild-type. {ECO:0000269|PubMed:7925461}.	
P0A825	372	372	1	R->K: No significant difference compared to the wild-type. {ECO:0000269|PubMed:7925461}.	
P24232	29	29		Y->E,H: 15 to 35-fold reduction in NO dioxygenase activity. {ECO:0000269|PubMed:10777548}.	
P24232	29	29		Y->F: 30-fold reduction in NO dioxygenase activity, and 80-fold increase in the O(2) dissociation rate constant. {ECO:0000269|PubMed:10777548}.	
P68398	53	53		D->E: Resistance to the cell-killing function encoded by the gef gene family.	
P24224	5	5		G->D: 5-fold reduction in catalytic activity. {ECO:0000269|PubMed:10625633}.	
P06616	8	8		C->A: In era770; 20-fold reduction in GTP-binding. Confers growth sensitivity at 42 degrees Celsius; when associated with an unpublished 22 residue replacement in the C-terminus. {ECO:0000269|PubMed:2527846}.	
P06616	17	17		P->R: In era1; suppresses a number of temperature-sensitive mutations affecting cell cycle. {ECO:0000269|PubMed:1526446, ECO:0000269|PubMed:9515700}.	
P06616	17	17		P->V: Confers sensitivity to cold. {ECO:0000269|PubMed:1526446, ECO:0000269|PubMed:9515700}.	
P06616	26	26		N->S: Confers sensitivity to cold; overexpression does not suppress an rbfA disruption. {ECO:0000269|PubMed:7729673}.	
P06616	39	49		KAQTTRHRIVG->R: In Era-de; does not complement a disruption mutant, overexpression in a wt cells inhibits growth. Binds GTP poorly, Km for GTP increases 5-fold, Vmax for GTPase is 55% that of wt. Does not autophosphorylate. Complements cold-sensitivity and 16S rRNA processing in an rbfA disruption mutant.	
P06616	42	43		TT->AA: Does not complement a disruption mutant, Km for GTP increases 12-fold, Vmax for GTPase is 49% that of wt. Overexpression partially suppresses an rbfA disruption. {ECO:0000269|PubMed:12753192, ECO:0000269|PubMed:8919456}.	
P06616	156	156		A->D: Confers sensitivity to cold; overexpression partially suppresses an rbfA disruption. {ECO:0000269|PubMed:7729673}.	
P06616	200	200		E->K: Confers sensitivity to cold, cells do not divide properly but do replicate DNA and segregate nucleoids normally. 16S rRNA processing is decreased, ribosome assembly is defective. Suppressed by overexpression of RsmA. Overexpression does not suppress an rbfA disruption, while at 37 degrees Celsius the rbfA/era E220K mutant grows very poorly, a dominant-negative effect. This mutant still binds 30S ribosomes. {ECO:0000269|PubMed:12753192, ECO:0000269|PubMed:7729673}.	
P0A7Y0	38	38		E->A: Reduced affinity for Mg(2+), no catalytic defect at 10 mM Mg(2+). {ECO:0000269|PubMed:15476399}.	
P0A7Y0	40	40		L->G,D,R: Loss of activity. {ECO:0000269|PubMed:11738048}.	
P0A7Y0	40	40	1	L->M,W: No effect. {ECO:0000269|PubMed:11738048}.	
P0A7Y0	41	41		E->A: Reduced affinity for Mg(2+), catalytic defect. 85-fold reduced affinity for Mg(2+); when associated with A-114. {ECO:0000269|PubMed:15476399}.	
P0A7Y0	44	44		G->S: In rnc-105; slower growth, loss of RNase activity. {ECO:0000269|PubMed:3903434, ECO:0000269|PubMed:9632264}.	
P0A7Y0	45	45		D->A,E,N: 30000-fold reduction in catalytic efficiency, binds RNA normally. Partially rescued by Mn(2+). {ECO:0000269|PubMed:15476399}.	
P0A7Y0	65	65		E->A: Reduced affinity for Mg(2+), no catalytic defect at 10 mM Mg(2+). {ECO:0000269|PubMed:15476399}.	
P0A7Y0	100	100		E->A: Reduced affinity for Mg(2+) and RNA. {ECO:0000269|PubMed:15476399}.	
P0A7Y0	114	114		D->A: Reduced affinity for Mg(2+), no catalytic defect at 10 mM Mg(2+). 85-fold reduced affinity for Mg(2+); when associated with A-41. {ECO:0000269|PubMed:15476399}.	
P0A7Y0	117	117		E->D: Nearly complete loss of RNase activity, still binds RNA. Partially rescued by Mn(2+). {ECO:0000269|PubMed:11305928, ECO:0000269|PubMed:9632264}.	
P0A7Y0	117	117		E->K: In rnc70; slower growth, loss of RNase activity. Dominant over wild-type. Binds ds-RNA. {ECO:0000269|PubMed:11305928, ECO:0000269|PubMed:9632264}.	
P0A7Y0	117	117		E->Q: Loss of RNase activity, still binds RNA. {ECO:0000269|PubMed:11305928, ECO:0000269|PubMed:9632264}.	
P00803	62	62	1	E->V: Indifferent.	
P00803	78	78	1	R->E,N,L: Indifferent.	
P00803	91	91		S->A: Loss of activity.	
P00803	125	125	1	H->N: Indifferent.	
P00803	128	128		R->Q: Small effect.	
P00803	130	130	1	D->A: Indifferent.	
P00803	144	144	1	Y->F: Indifferent.	
P00803	146	146		K->M,D,G,S: Loss of activity.	
P00803	147	147		R->Q: Small effect.	
P00803	154	154		D->A: Loss of activity.	
P00803	154	154	1	D->N: Indifferent.	
P00803	159	159		D->N: Small effect.	
P00803	171	171	1	C->A: Indifferent.	
P00803	177	177	1	C->A: Indifferent.	
P00803	236	236	1	H->N: Indifferent.	
P00803	269	269	1	Y->F: Indifferent.	
P00803	274	274	1	D->A: Indifferent.	
P00803	276	276		R->Q: Small effect.	
P00803	281	281	1	D->A: Indifferent.	
P00803	283	283		R->Q: Small effect.	
P0AFX7	1	28		Missing: Loss of anti-sigma factor activity. {ECO:0000269|PubMed:9159522}.	
P0AFX7	11	11		D->H: Loss of anti-sigma factor activity. {ECO:0000269|PubMed:9159522}.	
P0AFX7	19	19		L->P: Loss of anti-sigma factor activity. {ECO:0000269|PubMed:9159522}.	
P0AFX7	33	33		W->C: Loss of anti-sigma factor activity. {ECO:0000269|PubMed:9159522}.	
P0AFX7	79	79		Q->A: No binding of N-terminal fragment to SspB. {ECO:0000269|PubMed:15880122}.	
P0AFX7	85	85		W->A: No binding of N-terminal fragment to SspB. {ECO:0000269|PubMed:15880122}.	
P0AFX7	88	88		M->A: Reduced binding of N-terminal fragment to SspB. {ECO:0000269|PubMed:15880122}.	
P0AFX7	107	108		AA->DD: Significantly less degradation by ClpX-ClpP when present as a 1-108 peptide fragment. {ECO:0000269|PubMed:15371343}.	
P0AFX7	146	146	1	S->X: No effect on protein cleavage. {ECO:0000269|PubMed:19706448}.	
P0AFX7	147	147	1	P->X: No effect on protein cleavage in vitro and in vivo. {ECO:0000269|PubMed:19706448, ECO:0000269|PubMed:23016873}.	
P0AFX7	148	148		V->A,C,I,L,M,N,T: Normal cleavage by DegS and RseP in vitro (PubMed:19706448), for A-148 decreased cleavage by DegS in vivo (PubMed:23016873). {ECO:0000269|PubMed:19706448, ECO:0000269|PubMed:23016873}.	
P0AFX7	148	148		V->D,E,G,F,P: Not cleaved by DegS nor RseP in vitro (PubMed:19706448). {ECO:0000269|PubMed:19706448, ECO:0000269|PubMed:23016873}.	
P0AFX7	148	148		V->H,K,Q,R,S,Y: Cleaved by DegS but not by RseP in vitro (PubMed:19706448), for R-148 and S-148 decreased cleavage by DegS in vivo (PubMed:23016873). {ECO:0000269|PubMed:19706448, ECO:0000269|PubMed:23016873}.	
P0AFX7	162	169		QQQQVQEQ->AAAAVAEA: RseA is degraded by RseP in the absence of DegS. {ECO:0000269|PubMed:14633997}.	
P0AFX7	172	172		R->A: Still binds RseB. No binding to RseB; when associated with A-185. {ECO:0000269|PubMed:17496148}.	
P0AFX7	172	172		R->D: No binding to RseB. {ECO:0000269|PubMed:17496148}.	
P0AFX7	185	185		R->A: Still binds RseB. No binding to RseB; when associated with A-172. {ECO:0000269|PubMed:17496148}.	
P0AFX7	185	185		R->E: No binding to RseB. {ECO:0000269|PubMed:17496148}.	
P0AFX7	190	200		QLQFEQAQTQQ->ALAFFAAATAA: RseA is degraded by RseP in the absence of DegS. {ECO:0000269|PubMed:14633997}.	
P0AGB6	25	25		L->P: In SR1576; loss of sigma factor activity. {ECO:0000269|PubMed:7889935}.	
P0AGB6	165	165	1	C->A: Binds RNAP and RseA normally. {ECO:0000269|PubMed:12016219}.	
P0AGB6	172	172		S->P: In SR1723; loss of sigma factor activity. {ECO:0000269|PubMed:7889935}.	
P0AGB6	178	178		R->G: In SR1502; decreased sigma factor activity. Does not bind RseA, still binds RNAP. {ECO:0000269|PubMed:12016219, ECO:0000269|PubMed:7889935}.	
P0AGB6	181	181		I->A: In SR1503; decreased sigma factor activity. Does not bind RseA, still binds RNAP. {ECO:0000269|PubMed:12016219}.	
P0AGB6	185	185		V->A: In SR1504; decreased sigma factor activity. Does not bind RseA, still binds RNAP. {ECO:0000269|PubMed:12016219}.	
P63284	7	7		T->A: Loss of chaperone activity. {ECO:0000269|PubMed:12139937}.	
P63284	84	84	1	S->A: No effect. {ECO:0000269|PubMed:12139937}.	
P63284	93	93		L->Q: Loss of chaperone activity. Retains ATPase activity. {ECO:0000269|PubMed:12623019}.	
P63284	97	97		L->Q: 75% decrease in chaperone activity; retains ATPase activity. {ECO:0000269|PubMed:12623019}.	
P63284	103	103		D->A: Loss of chaperone activity. {ECO:0000269|PubMed:12139937}.	
P63284	109	109		E->A: Loss of chaperone activity. {ECO:0000269|PubMed:12139937}.	
P63284	110	110		L->Q: 30% decrease in chaperone activity; retains ATPase activity. {ECO:0000269|PubMed:12623019}.	
P63284	212	212		K->T: Loss of ability to form oligomers even in the presence of ATP. Loss of chaperone activity. {ECO:0000269|PubMed:11061966, ECO:0000269|PubMed:12220194, ECO:0000269|PubMed:12624113}.	
P63284	251	251		Y->A: Decrease in ability to disaggregate proteins due to decreased substrate- binding activity. Retains hexameric quaternary structure and ATPase activity. {ECO:0000269|PubMed:15208691}.	
P63284	254	254		E->A: Decrease in ability to disaggregate proteins due to decreased substrate- binding activity. Retains hexameric quaternary structure and ATPase activity; when associated with A-257. {ECO:0000269|PubMed:15208691}.	
P63284	257	257		E->A: Decrease in ability to disaggregate proteins due to decreased substrate- binding activity. Retains hexameric quaternary structure and ATPase activity; when associated with A-254. {ECO:0000269|PubMed:15208691}.	
P63284	279	279	1	E->A: No effect on oligomerization. {ECO:0000269|PubMed:12624113}.	
P63284	332	332		R->A: Loss of ability to form oligomers. {ECO:0000269|PubMed:12624113}.	
P63284	543	543	1	W->F: No effect on chaperone activity or ability to form oligomers. {ECO:0000269|PubMed:12624113}.	
P63284	611	611		K->T: No effect on ability to form oligomers. Loss of chaperone activity. {ECO:0000269|PubMed:11061966, ECO:0000269|PubMed:12220194, ECO:0000269|PubMed:12624113}.	
P63284	678	678	1	E->A: No effect on oligomerization. {ECO:0000269|PubMed:12624113}.	
P63284	756	756		R->A: No effect on oligomerization. Loss of ATPase activity. {ECO:0000269|PubMed:12624113}.	
P63284	797	797	1	D->A: No effect. {ECO:0000269|PubMed:12220194}.	
P63284	813	815	1	GAR->AAA: No effect on oligomerization. {ECO:0000269|PubMed:12624113}.	
P63284	815	815		R->A: Loss of ability to form oligomers; loss of chaperone activity. {ECO:0000269|PubMed:12220194}.	
P63284	819	819		R->A: Loss of ability to form oligomers; loss of chaperone activity. {ECO:0000269|PubMed:12220194}.	
P63284	826	826	1	E->A: No effect. {ECO:0000269|PubMed:12220194}.	
P33643	139	139		D->N,T: Loss of activity. {ECO:0000269|PubMed:11453071}.	
P0A9J8	11	11		R->A: Important decrease in catalytic efficiency and affinity. {ECO:0000269|Ref.8}.	
P0A9J8	11	11		R->K: Important decrease in catalytic efficiency and affinity. {ECO:0000269|Ref.8}.	
P0A9J8	28	28		R->A: Important decrease in catalytic efficiency and affinity. {ECO:0000269|Ref.8}.	
P0A9J8	28	28		R->K: Important decrease in catalytic efficiency and affinity. {ECO:0000269|Ref.8}.	
P0A9J8	39	39		K->A: Important decrease in catalytic efficiency and affinity. {ECO:0000269|Ref.8}.	
P0A9J8	39	39		K->Q: Important decrease in catalytic efficiency and affinity. {ECO:0000269|Ref.8}.	
P0A9J8	39	39		K->R: Important decrease in catalytic efficiency and affinity. {ECO:0000269|Ref.8}.	
P0A9J8	52	52		E->A: Important decrease in catalytic efficiency and affinity. {ECO:0000269|Ref.8}.	
P0A9J8	52	52		E->D: Important decrease in catalytic efficiency and affinity. {ECO:0000269|Ref.8}.	
P0A9J8	52	52		E->Q: Important decrease in catalytic efficiency and affinity. {ECO:0000269|Ref.8}.	
P0A9J8	88	88		Q->A: Important decrease in catalytic efficiency and affinity. {ECO:0000269|Ref.8}.	
P0A9J8	88	88		Q->E: Important decrease in catalytic efficiency and affinity. {ECO:0000269|Ref.8}.	
P0A9J8	88	88		Q->K: Important decrease in catalytic efficiency and affinity. {ECO:0000269|Ref.8}.	
P0A873	59	59		G->A: Loss of activity. {ECO:0000269|PubMed:14583191}.	
P0A873	91	91		G->A: Loss of activity; no effect on tRNA binding. {ECO:0000269|PubMed:14583191}.	
P0A873	114	114		R->A: Loss of activity. {ECO:0000269|PubMed:14583191}.	
P0A873	115	115		Y->A: Increases Km for S-adenosyl-L- methionine 24-fold. {ECO:0000269|PubMed:14583191}.	
P0A873	117	117		G->A: Loss of activity. {ECO:0000269|PubMed:14583191}.	
P0A873	119	119		D->A: Loss of activity. {ECO:0000269|PubMed:14583191}.	
P0A873	121	121		R->A: Loss of activity; no effect on tRNA binding. {ECO:0000269|PubMed:14583191}.	
P0A873	128	128		D->A: Loss of activity. {ECO:0000269|PubMed:14583191}.	
P0A873	135	135		D->A: Loss of activity; no effect on tRNA binding. {ECO:0000269|PubMed:14583191}.	
P0A873	136	136		Y->A: Increases Km for S-adenosyl-L- methionine 68-fold. {ECO:0000269|PubMed:14583191}.	
P0A873	141	141		G->A: Increases Km for S-adenosyl-L- methionine 82-fold. {ECO:0000269|PubMed:14583191}.	
P0A873	154	154		R->A: Loss of activity; no effect on tRNA binding. {ECO:0000269|PubMed:14583191}.	
P0A873	169	169		D->A: Loss of activity. {ECO:0000269|PubMed:14583191}.	
P0A873	171	171		F->A: Loss of activity. {ECO:0000269|PubMed:14583191}.	
P0A873	184	184		P->A: Loss of activity; no effect on tRNA binding. {ECO:0000269|PubMed:14583191}.	
P0A873	192	192		V->A: Loss of activity; no effect on tRNA binding. {ECO:0000269|PubMed:14583191}.	
P0A873	193	193		P->A: Loss of activity; no effect on tRNA binding. {ECO:0000269|PubMed:14583191}.	
P0A873	196	196		L->A: Loss of activity; no effect on tRNA binding. {ECO:0000269|PubMed:14583191}.	
P0A873	197	197		L->A: Loss of activity; no effect on tRNA binding. {ECO:0000269|PubMed:14583191}.	
P0A873	204	204		I->A: Loss of activity; no effect on tRNA binding. {ECO:0000269|PubMed:14583191}.	
P0A873	207	207		W->A: Loss of activity; no effect on tRNA binding. {ECO:0000269|PubMed:14583191}.	
P0A873	207	207		W->F,H: Small decrease in activity. {ECO:0000269|PubMed:14583191}.	
P0A873	208	208		R->A: Loss of activity; no effect on tRNA binding. {ECO:0000269|PubMed:14583191}.	
P0A7X6	106	107		YY->AA: 3-fold decreased growth rate; loss of association with 30S ribosomal subunit; loss of interaction with S19. {ECO:0000269|PubMed:11514519}.	
P09372	73	73		R->A: Great decrease in ability to interact with DnaK. {ECO:0000269|PubMed:15136046}.	
P09372	74	74		R->A: Great decrease in ability to interact with DnaK. {ECO:0000269|PubMed:15136046}.	
P09372	82	82		K->A: Great decrease in ability to interact with DnaK. {ECO:0000269|PubMed:15136046}.	
P09372	86	86	1	F->A: No effect in ability to interact with DnaK. {ECO:0000269|PubMed:12885238}.	
P09372	104	104	1	R->A: No effect in ability to interact with DnaK. {ECO:0000269|PubMed:15136046}.	
P09372	107	107	1	E->A: No effect in ability to interact with DnaK. {ECO:0000269|PubMed:15136046}.	
P09372	108	108	1	V->A: No effect in ability to interact with DnaK. {ECO:0000269|PubMed:15136046}.	
P09372	122	122		G->D: Temperature-sensitive phenotype. {ECO:0000269|PubMed:9103205}.	
P09372	149	149	1	L->A: No effect in ability to interact with DnaK. {ECO:0000269|PubMed:15136046}.	
P09372	151	151	1	P->A: No effect in ability to interact with DnaK. {ECO:0000269|PubMed:15136046}.	
P09372	155	155	1	Q->A: No effect in ability to interact with DnaK. {ECO:0000269|PubMed:15136046}.	
P09372	157	157	1	I->A: No effect in ability to interact with DnaK. {ECO:0000269|PubMed:15136046}.	
P09372	159	159	1	M->A: No effect in ability to interact with DnaK. {ECO:0000269|PubMed:15136046}.	
P09372	174	174	1	M->A: No effect in ability to interact with DnaK. {ECO:0000269|PubMed:15136046}.	
P09372	183	183		R->A: Loss of ability to interact with DnaK. {ECO:0000269|PubMed:12885238, ECO:0000269|PubMed:15136046}.	
P09372	186	186	1	R->A: No effect in ability to interact with DnaK. {ECO:0000269|PubMed:8890154}.	
P09372	189	189	1	M->A: No effect in ability to interact with DnaK. {ECO:0000269|PubMed:8890154}.	
P09372	192	192		V->A: Loss of ability to interact with DnaK. {ECO:0000269|PubMed:12885238, ECO:0000269|PubMed:15136046}.	
P0A7B3	175	175		R->E: Does not exhibit NADH kinase activity in addition to NAD kinase activity. {ECO:0000269|PubMed:15855156}.	
P0A7B3	175	175		R->G: Exhibits NADH kinase activity in addition to NAD kinase activity. Reduces the Vmax of the NAD kinase activity. {ECO:0000269|PubMed:15855156}.	
P0A7B3	175	175		R->H: Exhibits NADH kinase activity in addition to NAD kinase activity. {ECO:0000269|PubMed:15855156}.	
P0A7B3	175	175		R->I: Does not exhibit NADH kinase activity in addition to NAD kinase activity. {ECO:0000269|PubMed:15855156}.	
P0A7B3	175	175		R->K: Does not exhibit NADH kinase activity in addition to NAD kinase activity. {ECO:0000269|PubMed:15855156}.	
P0A7B3	175	175		R->Q: Exhibits NADH kinase activity in addition to NAD kinase activity. {ECO:0000269|PubMed:15855156}.	
P0A7B3	175	175		R->T: Exhibits NADH kinase activity in addition to NAD kinase activity. {ECO:0000269|PubMed:15855156}.	
P52129	188	196		EKVLIRQED->KKVLIRQEN: In rnlA5; strongly reduces RNase LS activity. {ECO:0000269|PubMed:15677746}.	
P00957	179	179		C->S: Inactivates the enzyme. {ECO:0000269|PubMed:1712632}.	
P00957	182	182	1	C->S: No inactivation. {ECO:0000269|PubMed:1712632}.	
P00957	184	184	1	E->Q: No inactivation. {ECO:0000269|PubMed:1712632}.	
P00957	188	188	1	D->N: No inactivation. {ECO:0000269|PubMed:1712632}.	
P00957	189	189		H->Q: Inactivates the enzyme. {ECO:0000269|PubMed:1712632}.	
P00957	191	191	1	D->N: No inactivation. {ECO:0000269|PubMed:1712632}.	
P00957	192	192		H->Q: Inactivates the enzyme. {ECO:0000269|PubMed:1712632}.	
P00957	236	236		D->A,N: Decreases affinity for alanine without improving discrimination against serine. {ECO:0000269|PubMed:20010690}.	
P00957	238	238		G->A: Greatly decreases affinity for alanine with only small changes in affinity for serine and glycine, in a 2- 442 residue construct. {ECO:0000269|PubMed:20010690}.	
P00957	564	564	1	H->A: No effect on tRNA editing. {ECO:0000269|PubMed:12554667}.	
P00957	568	568	1	H->A: No effect on tRNA editing. {ECO:0000269|PubMed:12554667}.	
P00957	584	584	1	Q->H: Loss of mischarged tRNA editing activity; when associated with A-666. {ECO:0000269|PubMed:12554667, ECO:0000269|PubMed:18723508}.	
P00957	666	666		C->A: Loss of mischarged tRNA editing activity; when associated with H-584 the effect is more pronounced. {ECO:0000269|PubMed:12554667, ECO:0000269|PubMed:18723508}.	
P00957	670	670	1	H->A: No effect on tRNA editing. {ECO:0000269|PubMed:12554667}.	
P00957	693	693		R->K: Reduces specificity of editing activity for tRNA(Ala), allows editing of tRNA(Thr). {ECO:0000269|PubMed:18172502}.	
Q46877	413	479		Missing: Unable to accept electrons from nitric oxide reductase FlrD-NAD(+) reductase (norW). {ECO:0000269|PubMed:11123953}.	
P30131	23	23		R->E,H,K: Loss of activity. {ECO:0000269|PubMed:15291820}.	
P30131	23	23		R->Q: Diminishes activity. {ECO:0000269|PubMed:15291820}.	
P30131	112	112		C->A: Loss of activity. {ECO:0000269|PubMed:12377778}.	
P30131	162	162		C->A: Loss of activity. {ECO:0000269|PubMed:12377778}.	
P30131	475	475		H->A: Loss of activity. {ECO:0000269|PubMed:12377778}.	
P30131	476	476		H->A: Carbamoyl phosphate-dependent ATP hydrolysis activity diminished in vitro but sufficient for wild-type-like phenotype. {ECO:0000269|PubMed:15291820}.	
P0AEV9	16	16		D->N: No protease activity. {ECO:0000269|PubMed:10727938}.	
P0AEV9	62	62		D->N,M: No protease activity. {ECO:0000269|PubMed:10727938}.	
P0AEV9	90	90		H->Q: A little protease activity remaining. {ECO:0000269|PubMed:10727938}.	
P0AAN3	117	117		K->N: Important decrease in GTPase activity. {ECO:0000269|PubMed:7601092}.	
P0AAN3	241	241		D->N: 85-fold decrease in Kcat/KM value of GTPase activity and loss of the specificity for GTP. {ECO:0000269|PubMed:7601092}.	
P55799	78	78		H->N: In prpB17; loss of function. {ECO:0000269|PubMed:9130712}.	
P13445	173	173		K->E: Eliminates RpoS proteolysis. Lack of interaction with RssB. {ECO:0000269|PubMed:10339606}.	
P13445	174	174		E->T: 2-fold increase in RpoS half-life. Does not affect interaction with RssB. {ECO:0000269|PubMed:10339606}.	
P13445	177	177		V->K: 3-fold increase in RpoS half-life. {ECO:0000269|PubMed:10339606}.	
P13445	178	178	1	Y->L: Does not affect RpoS half-life. {ECO:0000269|PubMed:10339606}.	
Q57261	31	31		E->D: 3-fold decrease in activity. {ECO:0000269|PubMed:19664587}.	
Q57261	31	31		E->Q: Loss of activity. {ECO:0000269|PubMed:19664587}.	
Q57261	79	79		K->L: 20-fold decrease in activity. {ECO:0000269|PubMed:19664587}.	
Q57261	79	79		K->R: 10-fold decrease in activity. {ECO:0000269|PubMed:19664587}.	
Q57261	80	80		D->N,T: Loss of activity. {ECO:0000269|PubMed:12756329}.	
Q57261	87	87		Q->E: 3-fold decrease in activity. {ECO:0000269|PubMed:19664587}.	
Q57261	129	129		N->K: Loss of activity. {ECO:0000269|PubMed:19664587}.	
Q57261	131	131		F->Y: 1.5-fold decrease in activity. {ECO:0000269|PubMed:19664587}.	
P62617	8	8		D->S: Loss of activity. {ECO:0000269|PubMed:11829504}.	
P62617	42	42		H->S: Loss of activity. {ECO:0000269|PubMed:11829504}.	
P62617	56	56		D->S: 35% decrease of activity. {ECO:0000269|PubMed:11829504}.	
P62617	142	142		R->M: Little effect on the overall structure; when associated with L-144. {ECO:0000269|PubMed:16511114}.	
P62617	144	144		E->L: Little effect on the overall structure; when associated with M-142. {ECO:0000269|PubMed:16511114}.	
Q46893	27	27		K->A,S: Strong decrease in activity. {ECO:0000269|PubMed:11427897}.	
Q46893	140	140		T->I: Loss of activity. {ECO:0000269|PubMed:12859972}.	
Q46893	191	191		E->K: Loss of activity. {ECO:0000269|PubMed:12859972}.	
Q46893	213	213		K->S: Decrease in activity. {ECO:0000269|PubMed:11427897}.	
P45956	9	9	1	E->A,R: No effect on spacer acquisition, Cas1-Cas2 complex formation or CRISPR DNA-binding by complex. {ECO:0000269|PubMed:24793649}.	
P45956	10	10	1	N->A: No effect on spacer acquisition. {ECO:0000269|PubMed:24793649}.	
P45956	14	14		R->A: Slight decrease in spacer acquisition. {ECO:0000269|PubMed:24793649}.	
P45956	16	16		R->A: Slight decrease in spacer acquisition. {ECO:0000269|PubMed:24793649}.	
P45956	18	18		R->A: Very little spacer acquisition. {ECO:0000269|PubMed:24793649}.	
P45956	27	27		R->A: Slight decrease in spacer acquisition. {ECO:0000269|PubMed:24793649}.	
P45956	65	65	1	E->A: No effect on spacer acquisition. {ECO:0000269|PubMed:24793649}.	
P45956	65	65		E->R: Slight decrease in spacer acquisition, Cas1-Cas2 complex formation or CRISPR DNA-binding by complex. Loss of spacer acquisition; when associated with R-84. {ECO:0000269|PubMed:24793649}.	
P45956	79	94		Missing: Loss of spacer acquisition, no Cas1-Cas2 complex formation, loss of CRISPR DNA-binding by complex. {ECO:0000269|PubMed:24793649}.	
P45956	84	84	1	D->A: No effect on spacer acquisition. {ECO:0000269|PubMed:24793649}.	
P45956	84	84		D->R: Slight decrease in spacer acquisition. Loss of spacer acquisition; when associated with R-65. {ECO:0000269|PubMed:24793649}.	
Q46896	141	141		E->A: No cleavage of any substrates, no restoration of UV or mitomycin C (MMC) resistance (PubMed:21219465). Loss of spacer acquisition (PubMed:24793649). {ECO:0000269|PubMed:21219465, ECO:0000269|PubMed:24793649}.	
Q46896	184	184		T->A: No cleavage of any substrates. {ECO:0000269|PubMed:21219465}.	
Q46896	188	188		Y->A: Partial inhibition of cleavage. {ECO:0000269|PubMed:21219465}.	
Q46896	208	208		H->A: No cleavage of any substrates, no restoration of UV or MMC resistance (PubMed:21219465). Loss of spacer acquisition (PubMed:24793649). {ECO:0000269|PubMed:21219465, ECO:0000269|PubMed:24793649}.	
Q46896	211	211		K->A: No cleavage of any substrates. {ECO:0000269|PubMed:21219465}.	
Q46896	218	218		D->A: No cleavage of any substrates, no restoration of UV or MMC resistance (PubMed:21219465). Loss of spacer acquisition (PubMed:24793649). {ECO:0000269|PubMed:21219465, ECO:0000269|PubMed:24793649}.	
Q46896	221	221		D->A: No cleavage of any substrates (PubMed:21219465). Loss of spacer acquisition (PubMed:24793649). {ECO:0000269|PubMed:21219465, ECO:0000269|PubMed:24793649}.	
Q46896	224	224		K->A: No cleavage of any substrates (PubMed:21219465). Loss of spacer acquisition (PubMed:24793649). {ECO:0000269|PubMed:21219465, ECO:0000269|PubMed:24793649}.	
Q46896	245	245		R->A: No effect on spacer acquisition. {ECO:0000269|PubMed:24793649}.	
Q46896	245	245		R->D: Decreased spacer acquisition. {ECO:0000269|PubMed:24793649}.	
Q46896	252	252		R->A: No effect on spacer acquisition. {ECO:0000269|PubMed:24793649}.	
Q46896	252	252		R->E: Loss of spacer acquisition, no Cas1-Cas2 complex formation, loss of CRISPR DNA-binding by complex. Protein is stable and dimerizes. {ECO:0000269|PubMed:24793649}.	
Q46896	256	256		R->A: No effect on spacer acquisition. {ECO:0000269|PubMed:24793649}.	
Q46896	256	256		R->E: Loss of spacer acquisition. {ECO:0000269|PubMed:24793649}.	
Q46896	282	305		Missing: No effect on spacer acquisition, Cas1-Cas2 complex formation or CRISPR DNA-binding by complex. {ECO:0000269|PubMed:24793649}.	
Q46896	291	291		I->G,R: No effect on spacer acquisition. {ECO:0000269|PubMed:24793649}.	
Q46897	20	20		H->A: Loss of pre-crRNA cleavage. {ECO:0000269|PubMed:18703739, ECO:0000269|PubMed:21255106}.	
Q46901	129	129		F->A: 80% increase in phage sensitivity; 500-fold decrease in affinity for target dsDNA. {ECO:0000269|PubMed:22521690}.	
Q46901	130	130		V->A: 20% increase in phage sensitivity; no change in binding of target dsDNA. {ECO:0000269|PubMed:22521690}.	
Q46901	131	131		N->A: 45% increase in phage sensitivity; 60-fold decrease in affinity for target dsDNA. {ECO:0000269|PubMed:22521690}.	
P38036	74	74		H->A: Loss of CRISPR immunity to lambda DNA and of CRISPR-mediated plasmid curing. {ECO:0000269|PubMed:21699496, ECO:0000269|PubMed:22521689}.	
P38036	74	74		H->G: 75% R-loop formation. {ECO:0000269|PubMed:21699496, ECO:0000269|PubMed:22521689}.	
P38036	75	75		D->A: Loss of CRISPR immunity to lambda DNA and of CRISPR-mediated plasmid curing. {ECO:0000269|PubMed:21699496, ECO:0000269|PubMed:22521689}.	
P38036	75	75		D->G: 10% R-loop formation. {ECO:0000269|PubMed:21699496, ECO:0000269|PubMed:22521689}.	
P38036	78	78		K->A: Loss of CRISPR immunity to lambda DNA and of CRISPR-mediated plasmid curing. {ECO:0000269|PubMed:21699496, ECO:0000269|PubMed:22521689}.	
P38036	78	78		K->L: Less than 5% R-loop formation, binds DNA normally. 100-fold greater senstivity to bacteriophage lambda. No effect on R-loop formation; when associated with L-320. {ECO:0000269|PubMed:21699496, ECO:0000269|PubMed:22521689}.	
P38036	317	318		GS->SY: No effect on R-loop formation. Impaired R-loop unwinding. {ECO:0000269|PubMed:21699496}.	
P38036	320	320		K->L: Double R-loop formation. 2-4 fold decreased ATPase. No effect on R-loop formation; when associated with L-78. {ECO:0000269|PubMed:21699496, ECO:0000269|PubMed:22521689}.	
P38036	320	320		K->N: Loss of CRISPR immunity to lambda DNA and of CRISPR-mediated plasmid curing. Nicks target plasmid DNA but does not degrade it. {ECO:0000269|PubMed:21699496, ECO:0000269|PubMed:22521689}.	
P38036	452	452		D->N: Loss of CRISPR immunity to lambda DNA and of CRISPR-mediated plasmid curing. {ECO:0000269|PubMed:22521689}.	
P38036	455	455		H->L: Loss of R-loop unwinding. {ECO:0000269|PubMed:21699496}.	
P38036	483	485		SAT->AAA: Retains CRISPR immunity to lambda DNA and CRISPR-mediated plasmid curing. {ECO:0000269|PubMed:22521689}.	
P17854	209	209		Y->F: Reduction in Vmax. {ECO:0000269|PubMed:7588765}.	
P17854	239	239		C->S: 5-fold reduction in Vmax. {ECO:0000269|PubMed:7588765}.	
P0A6P9	168	168		E->Q: 5% activity; not secreted. {ECO:0000269|PubMed:15003462}.	
P0A6P9	209	209		E->Q: 1% activity; not secreted. {ECO:0000269|PubMed:15003462}.	
P0A6P9	342	342		K->A,Q,R: 1% activity; not secreted. {ECO:0000269|PubMed:15003462}.	
P0A6P9	342	342		K->E: 94% activity; not secreted. {ECO:0000269|PubMed:15003462}.	
P0A7E5	349	349		V->S: 30% increase in both glutamine- dependent and ammonia-dependent activities. {ECO:0000269|PubMed:3298209}.	
P0A7E5	352	352		G->P: Loss of glutamine-dependent activity, but no change in ammonia- dependent activity. {ECO:0000269|PubMed:3298209}.	
P0A7E5	379	379		C->A,S: Loss of glutamine-dependent activity, but no change in ammonia- dependent activity. {ECO:0000269|PubMed:11336655}.	
P0AEY3	95	95	1	R->A: Does not affect nucleotide pyrophosphohydrolysis activity. {ECO:0000269|PubMed:18353782}.	
P0AEY3	119	119	1	K->A: Does not affect the nucleotide pyrophosphohydrolysis activity. {ECO:0000269|PubMed:18353782}.	
P0AEY3	168	168	1	K->A: Does not affect nucleotide pyrophosphohydrolysis activity. {ECO:0000269|PubMed:18353782}.	
P0AEY3	171	171	1	E->A: Does not affect nucleotide pyrophosphohydrolysis activity. {ECO:0000269|PubMed:18353782}.	
P0AEY3	172	172		E->A: Loss of pyrophosphohydrolysis activity against both ATP and dTTP. {ECO:0000269|PubMed:18353782}.	
P0AEY3	175	175	1	E->A: Does not affect nucleotide pyrophosphohydrolysis activity. {ECO:0000269|PubMed:18353782}.	
P0AEY3	189	189	1	K->A: Does not affect nucleotide pyrophosphohydrolysis activity. {ECO:0000269|PubMed:18353782}.	
P0AEY3	192	192	1	E->A: Does not affect nucleotide pyrophosphohydrolysis activity. {ECO:0000269|PubMed:18353782}.	
P0AEY3	193	193		E->A: Loss of pyrophosphohydrolysis activity against both ATP and dTTP. {ECO:0000269|PubMed:18353782}.	
P0AEY3	196	196		D->A: Loss of pyrophosphohydrolysis activity against both ATP and dTTP. {ECO:0000269|PubMed:18353782}.	
P0AEY3	222	222		K->A: Loss of pyrophosphohydrolysis activity against both ATP and dTTP. {ECO:0000269|PubMed:18353782}.	
P0AEY3	226	226		R->A: Loss of pyrophosphohydrolysis activity against both ATP and dTTP. {ECO:0000269|PubMed:18353782}.	
P0AEY3	253	253		W->A: Loss of pyrophosphohydrolysis activity against both ATP and dTTP. {ECO:0000269|PubMed:18353782}.	
P0AEY3	257	257		K->A: Loss of pyrophosphohydrolysis activity against both ATP and dTTP. {ECO:0000269|PubMed:18353782}.	
P0AE70	17	28		FDPTKGSEQAGH->GGGGGGGGGGG: Changes loop 1 to poly-G; loss of endoribonuclease activity. {ECO:0000269|PubMed:23280569}.	
P0AE70	17	28		FDPTKGSEQAGH->LGPPSGSQPAKR: Changes loop 1 to MazF6 M.tuberculosis sequence; loss of endoribonuclease activity. {ECO:0000269|PubMed:23280569}.	
P0AE70	17	28		FDPTKGSEQAGH->PDDSRGPVPSYS: Changes loop 1 to MazF M.xanthus sequence; loss of endoribonuclease activity. {ECO:0000269|PubMed:23280569}.	
P0AE70	24	24		E->A: Greatly reduces toxicity, about 10- fold less RNA cleavage activity. Expression in the presence of wt MazF has a dominant-negative phenotype, causing cell death as it titrates out the MazE antitoxin; still activates operon transcription. {ECO:0000269|PubMed:16413577, ECO:0000269|PubMed:24375411}.	
P0AE70	28	28	1	H->A: No changes in toxicity. {ECO:0000269|PubMed:24375411}.	
P0AE70	53	61		TQSKGYPFE->GGGGGGGG,GGGGGGGGGGG: Changes loop 2 to poly-G; reduces endoribonuclease activity, alters cleavage sites. {ECO:0000269|PubMed:23280569}.	
P0AE70	53	61		TQSKGYPFE->SNLHRASEPGN: Changes loop 2 to MazF M.xanthus sequence; reduces endoribonuclease activity, alters cleavage sites. {ECO:0000269|PubMed:23280569}.	
P0AE70	53	61		TQSKGYPFE->SNTALAAMPGN: Changes loop 2 to MazF6 M.tuberculosis sequence; reduces endoribonuclease activity, alters cleavage sites. {ECO:0000269|PubMed:23280569}.	
P0AE72	8	8		R->A: Binds poorly to DNA. {ECO:0000269|PubMed:12743116}.	
P0AE72	16	16		R->A: Does not bind to DNA. {ECO:0000269|PubMed:12743116}.	
P0AES2	150	150		Y->F: Reduces activity 100-fold. {ECO:0000269|PubMed:10769114}.	
P0AES2	207	207		K->Q: Reduces activity 1000-fold. {ECO:0000269|PubMed:10769114}.	
P0AES2	207	207		K->R: Reduces activity 10000-fold. {ECO:0000269|PubMed:10769114}.	
P0AES2	339	339		H->A: Loss of activity. {ECO:0000269|PubMed:10769114}.	
P0AES2	339	339		H->N: Reduces activity 10000-fold. {ECO:0000269|PubMed:10769114}.	
P0AES2	339	339		H->Q: Reduces activity 1000-fold. {ECO:0000269|PubMed:10769114}.	
P0AES2	366	366		D->A,N: Reduces activity over 100-fold. {ECO:0000269|PubMed:10769114}.	
P0AA41	54	54		D->T: Loss of activity. {ECO:0000269|PubMed:11720289}.	
Q46920	89	89		E->A,L: Drastic decrease in activity. {ECO:0000269|PubMed:23595998}.	
Q46920	90	90		S->A: 9-fold decrease in specific activity. {ECO:0000269|PubMed:23595998}.	
Q46920	190	190		C->A: Loss of catalytic activity. {ECO:0000269|PubMed:23595998}.	
Q46920	197	197		D->N: Loss of catalytic activity. {ECO:0000269|PubMed:23595998}.	
Q46920	228	228		F->W: 11-fold decrease in specific activity. {ECO:0000269|PubMed:23595998}.	
Q46920	229	229		H->A: 6.5-fold decrease in specific activity. {ECO:0000269|PubMed:23595998}.	
Q46920	230	230		E->Q: 26-fold decrease in specific activity. {ECO:0000269|PubMed:23595998}.	
P38506	67	67		K->A: Strongly reduces flap endonuclease activity. {ECO:0000269|PubMed:23821668}.	
P0A9S1	1	9		MANRMILNE->M: Loss of enzyme activity, loss of dimerization. {ECO:0000269|PubMed:15995211}.	
P0A9S1	16	16	1	G->D: No effect on enzyme activity. {ECO:0000269|PubMed:15995211}.	
P0A9S1	38	38		D->G: Enzyme can now use NADP. {ECO:0000269|PubMed:15995211}.	
P0A9S1	96	96		G->E: Loss of NAD binding and enzyme activity. {ECO:0000269|PubMed:15995211}.	
P0A9S1	195	195		D->L: Complete loss of iron-binding. {ECO:0000269|PubMed:15995211}.	
P0A9S1	199	199		H->A,F: Complete loss of iron-binding. {ECO:0000269|PubMed:15995211}.	
Q46925	100	100	1	C->A: No loss of activity. {ECO:0000269|PubMed:9278392}.	
Q46925	176	176	1	C->A: No loss of activity. {ECO:0000269|PubMed:9278392}.	
Q46925	323	323	1	C->A: No loss of activity. {ECO:0000269|PubMed:9278392}.	
Q46925	358	358		C->A: Loss of cysteine desulfurization. {ECO:0000269|PubMed:10739946}.	
P0AGF2	61	61		C->S: Unable to exert a stimulatory effect on the cysteine desulfurase activity of CsdA and to accept sulfur. Retains the ability to interact with CsdA. {ECO:0000269|PubMed:15901727}.	
P0A6C5	15	15	1	H->Y: In EE17. {ECO:0000269|PubMed:9572954}.	
P0A6C5	19	19	1	Y->C: In EE51. {ECO:0000269|PubMed:9572954}.	
P0A6C5	54	54	1	S->N: In PT2M217. {ECO:0000269|PubMed:9572954}.	
P0A6C5	58	58	1	R->H: In EE11. {ECO:0000269|PubMed:9572954}.	
P0A6C5	287	287	1	G->S: In PT2M216. {ECO:0000269|PubMed:9572954}.	
P0A6C5	432	432	1	Q->R: In PT2M217. {ECO:0000269|PubMed:9572954}.	
P04993	177	177		K->Q: Loss of ATP-dependent exonuclease activity in holoenzyme. Subunit loses ATPase and 5'-3' helicase activity, holoenzyme has 2-fold less helicase activity, 5-fold less processivity. {ECO:0000269|PubMed:12815438, ECO:0000269|PubMed:16041061, ECO:0000269|PubMed:1618858}.	
P08394	29	29		K->Q: Subunit loses ATPase and 3'-5' helicase activity, holoenzyme has 3-fold less helicase activity, 20-fold less processivity. {ECO:0000269|PubMed:16041061}.	
P08394	807	807		T->I: In recB-2109; absence of nuclease modification at chi sites. {ECO:0000269|PubMed:10766864}.	
P08394	1067	1067		D->A: Subunit loses nuclease activity. {ECO:0000269|PubMed:16388588}.	
P08394	1080	1080		D->A: Loss of holoenzyme nuclease activity, retains full helicase activity, does not recognize chi, no loading of RecA on ssDNA and no recombinational repair. {ECO:0000269|PubMed:10518611, ECO:0000269|PubMed:16388588, ECO:0000269|PubMed:9790841}.	
P05458	88	88		H->R: Loss of activity and of Zn-binding.	
P05458	91	91		E->Q: Loss of activity.	
P05458	92	92		H->R: Loss of activity and of Zn-binding.	
P05458	162	162		E->Q: 20% loss of activity.	
P05458	169	169		E->Q: Loss of activity and of Zn-binding.	
P05458	204	204	1	E->Q: No loss of activity.	
P07648	38	38		Q->A: Recognizes variant chi sequences. {ECO:0000269|PubMed:22603794}.	
P07648	64	64		L->A: No recognition of chi. {ECO:0000269|PubMed:22603794}.	
P07648	70	70		W->A: No recognition of chi. {ECO:0000269|PubMed:22603794}.	
P07648	133	133		D->A: No recognition of chi. {ECO:0000269|PubMed:22603794}.	
P07648	134	134		L->A: Recognizes variant chi sequences. {ECO:0000269|PubMed:22603794}.	
P07648	136	136		D->A: No recognition of chi. {ECO:0000269|PubMed:22603794}.	
P07648	137	137	1	Q->A: Recognizes variant chi sequences. {ECO:0000269|PubMed:22603794}.	
P07648	142	142	1	R->A: Recognizes variant chi sequences. {ECO:0000269|PubMed:22603794}.	
P07648	186	186		R->A,C,H: No recognition of chi. {ECO:0000269|PubMed:22603794}.	
P07648	705	705	1	D->A,H: Recognizes variant chi sequences. {ECO:0000269|PubMed:22603794}.	
P60955	7	7	1	H->Q: No effect. {ECO:0000269|PubMed:9139912}.	
P60955	24	24	1	H->Q: No effect. {ECO:0000269|PubMed:9139912}.	
P60955	26	26		Y->A: Loss of activity. {ECO:0000269|PubMed:22287519}.	
P60955	26	26	1	Y->F: No effect. {ECO:0000269|PubMed:9139912}.	
P60955	62	62	1	Y->F: No effect. {ECO:0000269|PubMed:9139912}.	
P60955	76	76	1	Y->F: No effect. {ECO:0000269|PubMed:9139912}.	
P60955	98	98	1	G->A: No effect. {ECO:0000269|PubMed:22287519}.	
P60955	103	103		H->N: Loss of activity. {ECO:0000269|PubMed:9139912}.	
P60955	103	103		H->Q: Loss of activity (PubMed:9139912). No effect (PubMed:22287519). {ECO:0000269|PubMed:22287519, ECO:0000269|PubMed:9139912}.	
P60955	104	104	1	G->A: No effect. {ECO:0000269|PubMed:22287519}.	
P60955	129	129	1	D->A: No effect. {ECO:0000269|PubMed:22287519}.	
P60955	143	143		R->A: Decrease in activity. {ECO:0000269|PubMed:22287519}.	
P60955	146	146		N->A: Loss of activity. {ECO:0000269|PubMed:22287519}.	
P60955	151	151		E->A: Decrease in activity. {ECO:0000269|PubMed:22287519}.	
P60955	154	154		G->A: Loss of activity. {ECO:0000269|PubMed:22287519}.	
P60955	190	190	1	Y->F: No effect. {ECO:0000269|PubMed:9139912}.	
P60955	196	196	1	H->N,L: No effect. {ECO:0000269|PubMed:9139912}.	
P60955	196	196		H->Q,R: 50% decrease in activity. {ECO:0000269|PubMed:9139912}.	
P60955	201	201	1	Y->F: No effect. {ECO:0000269|PubMed:9139912}.	
P60955	235	235		Y->F,T: Loss of activity. {ECO:0000269|PubMed:9139912}.	
P60955	235	235		Y->S: 37% decrease in activity. {ECO:0000269|PubMed:9139912}.	
P60955	239	239		R->A: Decrease in activity. {ECO:0000269|PubMed:22287519}.	
P60955	243	243		E->A: Decrease in activity. {ECO:0000269|PubMed:22287519}.	
P60955	282	282	1	Y->F: No effect. {ECO:0000269|PubMed:9139912}.	
P60955	289	289	1	H->Q: No effect. {ECO:0000269|PubMed:9139912}.	
P0A776	53	53		E->A: Loss of function. {ECO:0000269|PubMed:18202662}.	
P06722	28	28		T->L: In TS7; temperature-sensitive.	
P06722	157	157		D->N: In TS28; temperature-sensitive.	
P31119	36	36		H->A: Loss of 2-acyl-GPE acyltransferase activity; retains acyl-ACP synthetase activity. {ECO:0000269|PubMed:9515909}.	
P66899	77	77		K->H,R: No longer binds cofactor, loss of enzymatic activity. {ECO:0000269|PubMed:22505717}.	
P66899	120	120		D->N: No activity on D-DAP, 150-fold reduced catalytic efficiency for L-DAP; alters substrate stereospecificity. {ECO:0000269|PubMed:22505717}.	
P66899	189	189		D->N: 10000-fold reduced catalytic efficiency for both D- and L-DAP. {ECO:0000269|PubMed:22505717}.	
Q46810	9	11		TAA->LAG: 12-fold decrease in affinity for CTP and 3-fold decrease in catalytic activity. Displays a 3-fold decrease in activity with CTP and gains a low activity with GTP as substrate; when associated with 79-P--G-82. {ECO:0000269|PubMed:21081498}.	
Q46810	79	82		LLTS->PLAG: 15-fold decrease in affinity for CTP and 1.5-fold decrease in catalytic activity. Displays a 3-fold decrease in activity with CTP and gains a low activity with GTP as substrate; when associated with 9-L--G-11. {ECO:0000269|PubMed:21081498}.	
P67444	31	31		H->C,L: Decrease in activity. {ECO:0000269|PubMed:19581302}.	
P67444	31	31		H->K,R: Strong decrease in activity. {ECO:0000269|PubMed:19581302}.	
P67444	31	31	1	H->N: No change in activity. {ECO:0000269|PubMed:19581302}.	
P67444	31	31		H->Q: Increase of activity. {ECO:0000269|PubMed:19581302}.	
P67444	93	93		N->A: Highly active. {ECO:0000269|PubMed:19581302}.	
P67444	93	93		N->C,D,T: Strong decrease in activity. {ECO:0000269|PubMed:19581302}.	
P67444	93	93		N->Q: Loss of activity. {ECO:0000269|PubMed:19581302}.	
P67444	93	93		N->S: Increase of activity. {ECO:0000269|PubMed:19581302}.	
P67444	164	164	1	K->C,R: Highly active. {ECO:0000269|PubMed:19581302}.	
P67444	232	232		D->C: Decrease in activity. {ECO:0000269|PubMed:19581302}.	
P67444	232	232	1	D->E: Highly active. {ECO:0000269|PubMed:19581302}.	
P67444	258	258		Q->C: Decrease in activity. {ECO:0000269|PubMed:19581302}.	
P67444	258	258	1	Q->N: Highly active. {ECO:0000269|PubMed:19581302}.	
P67444	272	272		E->C: Loss of activity. {ECO:0000269|PubMed:19581302}.	
P67444	272	272		E->D: Strong decrease in activity. {ECO:0000269|PubMed:19581302}.	
P67444	304	304		D->C: Loss of activity. {ECO:0000269|PubMed:19581302}.	
P67444	304	304		D->E: Strong decrease in activity. {ECO:0000269|PubMed:19581302}.	
P67444	385	385		R->C: Decrease in activity. {ECO:0000269|PubMed:19581302}.	
P67444	385	385	1	R->K: Highly active. {ECO:0000269|PubMed:19581302}.	
P67444	421	421		P->C: Strong decrease in activity. {ECO:0000269|PubMed:18359771}.	
P67444	421	421	1	P->G: Highly active. {ECO:0000269|PubMed:18359771}.	
P67444	423	423	1	S->C: Highly active. {ECO:0000269|PubMed:18359771}.	
P67444	424	424	1	I->C: Highly active. {ECO:0000269|PubMed:18359771}.	
P67444	425	425		Y->C: Strong decrease in activity. {ECO:0000269|PubMed:18359771}.	
P67444	427	427		L->C: Decrease in activity. {ECO:0000269|PubMed:18359771}.	
P67444	430	430		N->T: Loss of activity. {ECO:0000269|PubMed:18359771}.	
P67444	432	432		I->A,S,T,V: Strong decrease in activity. {ECO:0000269|PubMed:18359771}.	
P67444	432	432		I->L,M,E,F: Loss of activity. {ECO:0000269|PubMed:18359771}.	
P67444	432	432	1	I->N,Q: Highly active. {ECO:0000269|PubMed:18359771}.	
P67444	436	436	1	G->C: Highly active. {ECO:0000269|PubMed:18359771}.	
Q46821	37	37		H->K,L: Lack of activity. {ECO:0000269|PubMed:22437829}.	
Q46821	37	37		H->N: Strong decrease in activity. {ECO:0000269|PubMed:22437829}.	
Q46821	100	100		T->A: Decrease in activity with uric acid. Highly active with xanthine. {ECO:0000269|PubMed:22437829}.	
Q46821	100	100		T->S: Decrease in activity. {ECO:0000269|PubMed:22437829}.	
Q46821	256	256	1	S->Q: Almost no change in activity. {ECO:0000269|PubMed:22437829}.	
Q46821	259	259	1	T->V: Almost no change in activity. {ECO:0000269|PubMed:22437829}.	
Q46821	270	270		E->D,N,Q: Lack of activity. {ECO:0000269|PubMed:22437829}.	
Q46821	278	278	1	L->T: Almost no change in activity. {ECO:0000269|PubMed:22437829}.	
Q46821	298	298		D->E: Strong decrease in activity. {ECO:0000269|PubMed:22437829}.	
Q46821	298	298		D->N: Lack of activity. {ECO:0000269|PubMed:22437829}.	
Q46821	317	317		S->A: Decrease in activity. {ECO:0000269|PubMed:22437829}.	
Q46821	318	318		Q->E,N: Strong decrease in activity. {ECO:0000269|PubMed:22437829}.	
Q46821	319	319		N->D,Q: Lack of activity. {ECO:0000269|PubMed:22437829}.	
Q46821	320	320		V->N: Lack of activity. {ECO:0000269|PubMed:22437829}.	
Q46821	327	327	1	R->G: Almost no change in activity. {ECO:0000269|PubMed:22437829}.	
Q46821	426	426	1	S->N: Almost no change in activity. {ECO:0000269|PubMed:22437829}.	
Q46822	104	104		Y->A: Reduces activity by 99%.	
Q46822	104	104		Y->F: Reduces activity by 97%.	
P07012	252	252		Q->E: Loss of methylation. {ECO:0000269|PubMed:11847124}.	
P0AEG6	118	118		C->T,A: Loss of activity. {ECO:0000269|PubMed:8168498}.	
P0AEG6	121	121		C->A: Partial loss of activity. {ECO:0000269|PubMed:8168498}.	
P0AEG6	121	121		C->V: Loss of activity. {ECO:0000269|PubMed:8168498}.	
P0AEG6	161	161		C->S: Destabilization of protein. {ECO:0000269|PubMed:8168498}.	
P0AEG6	183	183		C->L: Destabilization of protein. {ECO:0000269|PubMed:8168498}.	
P0A8P8	148	148		R->K: Abolishes DNA cleavage activity. {ECO:0000269|PubMed:9268326}.	
P0A8P8	244	244		H->L: Abolishes DNA religation activity. {ECO:0000269|PubMed:9268326}.	
P0A8P8	247	247		R->Q: Abolishes DNA cleavage activity. {ECO:0000269|PubMed:8402918, ECO:0000269|PubMed:9268326}.	
P0A8P8	256	258		NHG->ESS: Abolishes plasmid resolution but not chromosomal recombination. {ECO:0000269|PubMed:10635320}.	
P0A8P8	279	279		Y->F: Abolishes DNA cleavage activity. {ECO:0000269|PubMed:7744017, ECO:0000269|PubMed:9268326}.	
P0A8P8	294	294		H->Q,E: Abolishes DNA recombination (in vitro). {ECO:0000269|PubMed:10361305}.	
P0A8P8	295	295		H->E: Abolishes DNA recombination (in vitro). {ECO:0000269|PubMed:10361305}.	
P0A8P8	297	297		R->E: Abolishes DNA recombination (in vitro). {ECO:0000269|PubMed:10361305}.	
P0A8P8	298	298		A->Q: Reduces chromosomal recombination but not plasmid resolution. {ECO:0000269|PubMed:10361305}.	
P25535	301	303		GVN->AVD: Leads to the same phenotype as the ubiI deletion mutant, indicating a strongly impaired catalytic activity. {ECO:0000269|PubMed:23709220}.	
P0A7Z0	81	81		D->A: Catalytic efficiency decreases by 10,000-fold, with no measurable effect on affinity binding. {ECO:0000269|PubMed:12517338}.	
P0A7Z0	84	84		D->A: Activity decreases by 250-fold, with little change on affinity binding. {ECO:0000269|PubMed:12517338}.	
P0A7Z0	94	94		K->A: Has a 1500-fold lower Catalytic efficiency than the wild-type, but affinity binding is increased by a factor of seven. {ECO:0000269|PubMed:12517338}.	
P0C0S1	40	40	1	V->C,G,N: No detectable phenotype. {ECO:0000269|PubMed:12015316}.	
P0C0S1	40	40		V->D,K: Normal growth stops, without cell death, due to increased membrane permeability to potassium ions and protons (permeability tested only for D substitutions). {ECO:0000269|PubMed:12015316}.	
P0C0S1	58	58		S->C: Readily forms disulfide bonds with cross-linkers, suggesting that individual S-58 are only 3 Angstroms apart in the closed state, versus 33 Angstroms apart in the open state crystal structure. {ECO:0000269|PubMed:12767977}.	
P0C0S1	266	286		ISFPYPQMDVNFKRVKEDKAA->HHHHHHLE: Normal levels of channels are expressed; they recover more slowly than wild-type cells after desensitization. {ECO:0000269|PubMed:15665866}.	
P0C0S1	266	286		ISFPYPQMDVNFKRVKEDKAA->LE: Fewer channels present in the membrane, they require slightly more pressure to open and do not recover after desensitization. {ECO:0000269|PubMed:15665866}.	
P0C0S1	267	267		S->C: Provides biochemical evidence for heptameric structure upon cross-linking. {ECO:0000269|PubMed:12767977}.	
P0AB71	36	36		N->A: 1.5% of wild-type activity. 5-fold decrease in FBP affinity. {ECO:0000269|PubMed:10712619}.	
P0AB71	60	60		Q->A: 81% of wild-type activity. 1.3-fold decrease in FBP affinity. {ECO:0000269|PubMed:10712619}.	
P0AB71	62	62		S->A: 8% of wild-type activity. 16-fold decrease in FBP affinity. {ECO:0000269|PubMed:10712619}.	
P0AB71	62	62		S->T: 60% of wild-type activity. 2.5-fold decrease in FBP affinity. {ECO:0000269|PubMed:10712619}.	
P0AB71	108	108		H->A: Loss of activity. {ECO:0000269|PubMed:8436219}.	
P0AB71	111	111		H->A: Loss of activity. {ECO:0000269|PubMed:8436219}.	
P0AB71	112	112		C->A: Partial loss of activity. {ECO:0000269|PubMed:8436219}.	
P0AB71	326	326		K->A: 6% of wild-type activity. 2.2-fold decrease in FBP affinity. {ECO:0000269|PubMed:10712619}.	
P0A9B6	155	155		C->A,G,V: No significant activity. {ECO:0000269|PubMed:9182530}.	
P0A9B6	182	182		H->N: 10-fold reduction in activity. Increases affinity for D-erythrose-4- phosphate and reduces affinity for glyceraldehyde 3-phosphate. {ECO:0000269|PubMed:9182530}.	
P0A9B6	316	316		C->A,Y: Reduces activity and affinity for D-erythrose-4-phosphate and increases affinity for glyceraldehyde 3-phosphate. {ECO:0000269|PubMed:9182530}.	
P60651	163	163		H->F: Loss of activity. {ECO:0000269|PubMed:10527864}.	
P0A817	15	15		H->N: Loss of activity. {ECO:0000269|PubMed:10660564}.	
P0A817	17	17		D->N,A: Loss of activity. {ECO:0000269|PubMed:10551856}.	
P0A817	43	43		E->K: Misfolding and subject to proteolytic degradation. {ECO:0000269|PubMed:7629147}.	
P0A817	43	43		E->Q: Loss of stimulation by potassium. {ECO:0000269|PubMed:7629147}.	
P0A817	90	90		C->A,S: Decrease in the homotetramer formation capability. Enhanced thermal stability. {ECO:0000269|PubMed:7629176}.	
P0A817	119	119		D->N: Decrease of both AdoMet synthesis and AdoMet-activated tripolyphosphate hydrolysis. {ECO:0000269|PubMed:10551856}.	
P0A817	166	166		K->M: Decrease in AdoMet synthesis. {ECO:0000269|PubMed:10660564}.	
P0A817	239	239		D->N: Decrease in AdoMet synthesis. {ECO:0000269|PubMed:10551856}.	
P0A817	240	240		C->A: Decrease in AdoMet synthesis. {ECO:0000269|PubMed:7629176}.	
P0A817	245	245		R->H,L: Loss of activity. {ECO:0000269|PubMed:9753435}.	
P0A817	246	246		K->M: Loss of activity. modification in protein conformation. {ECO:0000269|PubMed:10660564}.	
P0A817	266	266		K->A: Loss of activity. {ECO:0000269|PubMed:10660564}.	
P0A817	266	266		K->M: Unstable; trace activity. {ECO:0000269|PubMed:10660564}.	
P0A817	270	270		K->M: Decrease in activity. {ECO:0000269|PubMed:10660564}.	
P0A817	272	272		D->N,A: Loss of activity. {ECO:0000269|PubMed:10551856}.	
P04425	122	122	1	C->A: No loss of activity. {ECO:0000269|PubMed:3042775}.	
P04425	195	195	1	C->A: No loss of activity. {ECO:0000269|PubMed:3042775}.	
P04425	222	222	1	C->A: No loss of activity. {ECO:0000269|PubMed:3042775}.	
P04425	227	227		P->V: Loss of activity. {ECO:0000269|PubMed:8241129}.	
P04425	233	233		R->A,K: Loss of activity. {ECO:0000269|PubMed:1540581}.	
P04425	240	240		G->V: Loss of activity. {ECO:0000269|PubMed:8241129}.	
P04425	241	241	1	R->A,K: No loss of activity. {ECO:0000269|PubMed:1540581}.	
P04425	289	289	1	C->A: No loss of activity. {ECO:0000269|PubMed:3042775}.	
P00805	34	34		T->A: Loss of enzyme activity. {ECO:0000269|PubMed:1906013}.	
P00805	111	111		T->S: Reduced enzyme activity. {ECO:0000269|PubMed:8706862}.	
P00805	111	111		T->V: Loss of enzyme activity. {ECO:0000269|PubMed:8706862}.	
P0A8I5	26	26		R->A: Reduces catalytic activity over 10- fold. {ECO:0000269|PubMed:15789416}.	
P0A8I5	144	144		D->A: Loss of activity. {ECO:0000269|PubMed:15789416}.	
P0A8I5	150	150		R->A: Reduces catalytic activity about 3- fold. {ECO:0000269|PubMed:15789416}.	
P0A8I5	151	151		H->A: Reduces catalytic activity over 10- fold. {ECO:0000269|PubMed:15789416}.	
P0A8I5	152	152	1	N->A: No effect. {ECO:0000269|PubMed:15789416}.	
P0A8I5	154	154		R->A: Loss of activity. {ECO:0000269|PubMed:15789416}.	
P0A8I5	155	155		R->A: Loss of activity. {ECO:0000269|PubMed:15789416}.	
P0A8I5	180	180		D->A: Reduces catalytic activity over 10- fold. {ECO:0000269|PubMed:15789416}.	
P0A8I5	217	217		T->A: Reduces catalytic activity over 10- fold. {ECO:0000269|PubMed:15789416}.	
P0A8I5	220	220		E->A: Reduces catalytic activity 10-fold. {ECO:0000269|PubMed:15789416}.	
P37330	338	338		R->K: Has a specific activity which is only 6.6% of the wild-type activity. {ECO:0000269|PubMed:12930982}.	
P37330	617	617		C->S: Affinity binding for acetyl-CoA is more than five times greater than that of wild-type, although its specific activity is comparable. {ECO:0000269|PubMed:12930982}.	
P37330	631	631		D->N: Absence of malate synthase activity. {ECO:0000269|PubMed:12930982}.	
P0AES0	59	59		C->A: Loss of amidase activity. {ECO:0000269|PubMed:9398217}.	
P0AES0	173	173	1	C->A: No effect on amidase activity. {ECO:0000269|PubMed:9398217}.	
P0AES0	316	316		R->E: Loss of synthetase activity.	
P0AES0	335	335		S->A: 3.6-fold decrease in GSH affinity, 1.6-fold decrease in spermidine activity, and 1.3-fold decrease in synthetase activity. {ECO:0000269|PubMed:17124497}.	
P0AES0	337	337		S->A: No effect on GSH and spermidine affinity, but 2-fold decrease in synthetase activity. {ECO:0000269|PubMed:17124497}.	
P0AES0	338	338		C->A: 10-fold decrease in GSH affinity, 5-fold decrease in spermidine activity, but no effect on synthetase activity. {ECO:0000269|PubMed:17124497}.	
P0AES0	391	391		E->A: 2-fold decrease in GSH affinity, 60-fold decrease in spermidine activity, and 10-fold decrease in synthetase activity. {ECO:0000269|PubMed:17124497}.	
P0AES0	392	392		E->A: 33-fold decrease in GSH affinity, 13-fold decrease in spermidine activity, and 6-fold decrease in synthetase activity. {ECO:0000269|PubMed:17124497}.	
P0AES0	441	441		T->A: 3-fold decrease in GSH affinity, 21-fold decrease in spermidine activity, and 17-fold decrease in synthetase activity. {ECO:0000269|PubMed:17124497}.	
P0AES0	538	538		R->A: 6-fold decrease in GSH affinity, 2.4-fold decrease in spermidine activity, and 4-fold decrease in synthetase activity. {ECO:0000269|PubMed:17124497}.	
P0AES0	598	598		R->A: 10-fold increase in GSH affinity, 9-fold decrease in spermidine activity, and 15-fold decrease in synthetase activity. {ECO:0000269|PubMed:17124497}.	
P0AA60	39	39		E->A: Abolishes the ability to restore growth, cell division or drug resistance in double mutant. {ECO:0000269|PubMed:24277026}.	
P0AA60	51	51		D->A: Abolishes the ability to restore growth, cell division or drug resistance in double mutant. {ECO:0000269|PubMed:24277026}.	
P0AFI2	80	80	1	S->L: Confers resistance to quinolones. No effect on catalytic activity. {ECO:0000269|PubMed:12269820}.	
P0AFI2	84	84		E->K: Strongly reduced enzyme activity. Increases stability of covalent reaction intermediate with DNA. Confers resistance to quinolones. {ECO:0000269|PubMed:12269820}.	
P0AFI2	84	84	1	E->P: Confers resistance to quinolones. {ECO:0000269|PubMed:12269820}.	
Q46864	61	61		R->A,D: Decreases DNA-binding, decreases thermostability of MqsR-MqsA complex. {ECO:0000269|PubMed:23172222}.	
Q46864	97	101		NAFSR->AAFSA: Abolishes DNA-binding, including binding to the rpoS promoter. {ECO:0000269|PubMed:21068382, ECO:0000269|PubMed:21516113}.	
Q46864	97	97		N->A: 50-fold reduction in DNA-binding. {ECO:0000269|PubMed:21068382}.	
Q46864	101	101		R->A: 10-fold reduction in DNA-binding. {ECO:0000269|PubMed:21068382}.	
Q46865	55	55	1	Y->A: No change in toxicity. {ECO:0000269|PubMed:20041169}.	
Q46865	56	56		K->A: Loss of toxicity. {ECO:0000269|PubMed:20041169}.	
Q46865	58	58	1	M->A: No change in toxicity. {ECO:0000269|PubMed:20041169}.	
Q46865	68	68		Q->A: Loss of toxicity. {ECO:0000269|PubMed:20041169}.	
Q46865	72	72	1	R->A: No change in toxicity. {ECO:0000269|PubMed:20041169}.	
Q46865	81	81		Y->A: Loss of toxicity. {ECO:0000269|PubMed:20041169}.	
Q46865	96	96		K->A: Loss of toxicity. {ECO:0000269|PubMed:20041169}.	
P02930	384	384		Y->F: Partial channel opening. Increases sensitivity to vancomycin, by allowing its passive diffusion across the outer membrane; when associated with E-389. {ECO:0000269|PubMed:18406332}.	
P02930	389	389		R->E: Partial channel opening. Increases sensitivity to vancomycin, by allowing its passive diffusion across the outer membrane; when associated with F-382. {ECO:0000269|PubMed:18406332}.	
P02930	393	393		D->A: Decreases inhibition by hexaamminecobalt(3+). {ECO:0000269|PubMed:15342230}.	
P02930	396	396		D->A: Decreases inhibition by hexaamminecobalt(3+). {ECO:0000269|PubMed:15342230}.	
P0A7J0	33	33		D->S: Loss of activity. {ECO:0000269|PubMed:11687623}.	
P0A7J0	35	35		E->S: Reduces activity by 85%. {ECO:0000269|PubMed:11687623}.	
P0A7J0	37	37		R->E: Loss of activity. {ECO:0000269|PubMed:11687623}.	
P0A7J0	38	38		E->S: Loss of activity. {ECO:0000269|PubMed:11687623}.	
P0A7J0	40	40		E->S: Loss of activity. {ECO:0000269|PubMed:11687623}.	
P0A7J0	42	42		D->S: Loss of activity. {ECO:0000269|PubMed:11687623}.	
P0A7J0	67	67		C->S: Reduces activity by 80%. {ECO:0000269|PubMed:11687623}.	
P0A7J0	107	107		T->S: Loss of activity. {ECO:0000269|PubMed:11687623}.	
P0A7J0	110	110		S->A: Reduces activity by 85%. {ECO:0000269|PubMed:11687623}.	
P0A7J0	113	113		D->S: Reduces activity by 88%. {ECO:0000269|PubMed:11687623}.	
P0A7J0	117	117		T->A: Reduces activity by 75%. {ECO:0000269|PubMed:11687623}.	
P0A7J0	136	136		H->S: Loss of activity. {ECO:0000269|PubMed:11687623}.	
P0A7J0	150	150		R->S: Loss of activity. {ECO:0000269|PubMed:11687623}.	
P0A7J0	153	153		H->S: Loss of activity. {ECO:0000269|PubMed:11687623}.	
P0A7J0	155	155		E->S: Reduces activity by 83%. {ECO:0000269|PubMed:11687623}.	
P0A7J0	174	174		E->S: Loss of activity. {ECO:0000269|PubMed:11687623}.	
P76658	195	195		N->D: Loss of activity. {ECO:0000269|PubMed:16030223}.	
P76658	198	198		E->D: Loss of activity. {ECO:0000269|PubMed:16030223}.	
P76658	264	264		D->E: Loss of activity. {ECO:0000269|PubMed:16030223}.	
P76658	264	264		D->N: Loss of activity. {ECO:0000269|PubMed:16030223}.	
P06961	21	21	1	D->A: No effect on phosphodiesterase and phosphatase activities. {ECO:0000269|PubMed:15210699}.	
P06961	23	23	1	D->A: No effect on phosphodiesterase and phosphatase activities. {ECO:0000269|PubMed:15210699}.	
P06961	70	70		G->D: Lowered AMP incorporation. {ECO:0000269|PubMed:3533927}.	
P06961	255	255		H->A: Loss of phosphodiesterase and phosphatase activities. {ECO:0000269|PubMed:15210699}.	
P06961	256	256		D->A: Loss of phosphodiesterase and phosphatase activities. {ECO:0000269|PubMed:15210699}.	
P06961	305	305		H->A: Loss of phosphodiesterase and phosphatase activities. {ECO:0000269|PubMed:15210699}.	
P06961	306	306	1	D->A: Still possesses phosphodiesterase and phosphatase activities. {ECO:0000269|PubMed:15210699}.	
P0ABS5	165	165		W->A: Abolishes DNA-binding and primer synthesis. {ECO:0000269|PubMed:18193061}.	
P0ABS5	199	199		R->A: Abolishes primer synthesis but can still bind DNA. Abolishes DNA-binding; when associated with A-201. {ECO:0000269|PubMed:18193061}.	
P0ABS5	201	201		R->A: Abolishes primer synthesis but can still bind DNA. Abolishes DNA-binding; when associated with A-199. {ECO:0000269|PubMed:18193061}.	
P0ABS5	576	576		Q->A: Decreases interaction with DnaB and primase activity. {ECO:0000269|PubMed:8917517}.	
P00579	596	596		R->D,E: 2-fold reduction in activation of class II Crp-dependent promoters. {ECO:0000269|PubMed:10860740}.	
P0AA63	39	39		E->A,Q: Abolishes the ability to restore growth, cell division or drug resistance in double mutant. {ECO:0000269|PubMed:24277026}.	
P0AA63	51	51		D->A,N: Abolishes the ability to restore growth, cell division or drug resistance in double mutant. {ECO:0000269|PubMed:24277026}.	
P42615	51	51		D->A: Loss of activity. Decreases interaction with EnvZ. {ECO:0000269|PubMed:20889743}.	
P42615	67	67	1	K->A: No change in activity. {ECO:0000269|PubMed:20889743}.	
P42615	74	74	1	D->A: No change in activity. {ECO:0000269|PubMed:20889743}.	
P42615	78	78		I->F: Loss of activity. Decreases interaction with EnvZ. {ECO:0000269|PubMed:20889743}.	
P42620	63	63		C->A: Loss of GS-hydroquinone reductase activity. {ECO:0000269|PubMed:22955277}.	
P42620	195	195		Y->F: 46-fold reduction in GS- hydroquinone reductase activity. {ECO:0000269|PubMed:22955277}.	
P42620	253	253		Y->F: 55-fold reduction in GS- hydroquinone reductase activity. {ECO:0000269|PubMed:22955277}.	
P42620	296	296		Y->F: 22-fold reduction in GS- hydroquinone reductase activity. {ECO:0000269|PubMed:22955277}.	
P15373	91	111		QGKKLVAGMDVNIDDEIGDDE->HSTRKETCRWHGRQH: In prlF1; suppresses overproduction lethality of lamB-lacZ gene fusions, leads to decreased beta-galactosidase activity. Partially alleviates YhaV toxic activity. {ECO:0000269|PubMed:2152898}.	
P64594	85	94		RVKFGAGRYR->AVKFGAGRYA: Complete loss of toxicity. {ECO:0000269|PubMed:17706670}.	
P64594	85	85		R->A: Partial loss of toxicity. {ECO:0000269|PubMed:17706670}.	
P64594	94	94		R->A: Partial loss of toxicity. {ECO:0000269|PubMed:17706670}.	
P66817	52	52		S->F: Abolishes stimulation of DnaA- dependent DNA synthesis. {ECO:0000269|PubMed:17699754}.	
P66817	71	71		R->Q: Reduces affinity for DnaA. Strongly reduces DnaA-dependent DNA synthesis. {ECO:0000269|PubMed:17699754}.	
P66817	72	72		P->A,S: Strongly reduces affinity for DnaA. Reduces DnaA-dependent DNA synthesis. {ECO:0000269|PubMed:17699754}.	
P66817	83	83		N->D: Abolishes association of homodimers into homotetramers. Reduces affinity for DnaA. Strongly reduces DnaA-dependent DNA synthesis. {ECO:0000269|PubMed:17699754}.	
P66817	101	101		K->E: Abolishes association of homodimers into homotetramers. Strongly reduces DnaA-dependent DNA synthesis. {ECO:0000269|PubMed:17699754}.	
P66817	190	190		L->A,P: Abolishes interaction with DnaA. Strongly reduces DnaA-dependent DNA synthesis. {ECO:0000269|PubMed:17699754}.	
P66817	191	191		F->L,S: Abolishes interaction with DnaA. Strongly reduces DnaA-dependent DNA synthesis. {ECO:0000269|PubMed:17699754}.	
P0A9P6	157	157		E->Q: Abolishes ATPase activity, drastically reduces helicase activity. In vivo acts as a dominant negative mutation in the presence of the wild-type protein at low temperature. {ECO:0000269|PubMed:17259309}.	
P0AFB1	103	103		G->D: Loss of interaction with Prc and IbpB leading to thermosensitivity. {ECO:0000269|PubMed:15047720}.	
P0AFB1	282	294		Missing: Loss of activity leading to thermosensitivity. {ECO:0000269|PubMed:15047720}.	
P0AFB1	283	294	1	Missing: No phenotype. {ECO:0000269|PubMed:15047720}.	
P0AFB1	284	294	1	Missing: No phenotype. {ECO:0000269|PubMed:15047720}.	
P05055	79	80		RR->AA: Strongly reduces RNA binding. Reduces RNA degradation. {ECO:0000269|PubMed:18812438}.	
P05055	83	83		R->A: No effect on RNA-binding. No effect on degradation of long RNA molecules. Impairs degradation of short RNA molecules. {ECO:0000269|PubMed:18812438}.	
P05055	100	100		R->D: Abolishes enzyme activity. {ECO:0000269|PubMed:12162954}.	
P05055	319	319		R->A: Abolishes enzyme activity. {ECO:0000269|PubMed:12162954}.	
P05055	398	399		RR->DD: Abolishes enzyme activity.	
P05055	428	428		V->P: Abolishes enzyme activity. {ECO:0000269|PubMed:12162954}.	
P05055	444	444		C->W: Abolishes enzyme activity. {ECO:0000269|PubMed:12162954}.	
P05055	492	492		D->G: Abolishes enzyme activity. {ECO:0000269|PubMed:12162954}.	
P60340	19	19		K->M,R: Reduced structural stability and decrease in activity. {ECO:0000269|PubMed:10924141}.	
P60340	20	20		P->G,L: Reduced structural stability and no change in activity. {ECO:0000269|PubMed:10924141}.	
P60340	43	43		H->A: 330-fold decrease in catalytic efficiency. {ECO:0000269|PubMed:15581587}.	
P60340	43	43		H->F: 2-fold decrease in catalytic efficiency. {ECO:0000269|PubMed:15581587}.	
P60340	43	43		H->G: 250-fold decrease in catalytic efficiency. {ECO:0000269|PubMed:15581587}.	
P60340	43	43		H->N: 180-fold decrease in catalytic efficiency. {ECO:0000269|PubMed:15581587}.	
P60340	43	43		H->Q: 50-fold decrease in catalytic efficiency. {ECO:0000269|PubMed:15581587}.	
P60340	48	48		D->C: Loss of activity. {ECO:0000269|PubMed:11142385}.	
P60340	58	58	1	C->A: Slight increase in activity. Slight increase in activity; when associated with A-174 and A-193. {ECO:0000269|PubMed:10529181}.	
P60340	174	174	1	C->A: Slight increase in activity. Slight increase in activity; when associated with A-58 and A-193. {ECO:0000269|PubMed:10529181}.	
P60340	193	193	1	C->A: Slight increase in activity; when associated with A-58 and A-174. {ECO:0000269|PubMed:10529181}.	
P60340	193	193	1	C->V: Slight increase in activity. {ECO:0000269|PubMed:10529181}.	
P0AFF6	104	104	1	R->H: In nusA10-1. {ECO:0000269|PubMed:1847365}.	
P0AFF6	181	181		G->D: In nusa11; inability to terminate transcription normally at termination sites. {ECO:0000269|PubMed:1847365}.	
P0AFF6	183	183		L->R: In nusA1; restricts lambda growth by preventing antitermination activity of lambda N protein. {ECO:0000269|PubMed:1847365}.	
P0AFF6	212	212	1	E->K: In nusA10-2. {ECO:0000269|PubMed:1847365}.	
P0AG99	41	41		T->P: Affects activity.	
P0AG99	42	42		L->P: Affects activity.	
P0AG99	43	43		F->S,Y: Affects activity.	
P31120	100	100		S->A: 2% of wild-type activity. {ECO:0000269|PubMed:10231382}.	
P31120	100	100		S->T: 20-fold increase in the non- specific phosphoglucomutase activity towards glucose-phosphate substrates (non aminated). {ECO:0000269|PubMed:10231382}.	
P31120	102	102		S->A: Loss of activity in the absence or presence of glucosamine-1,6-diP. {ECO:0000269|PubMed:10231382}.	
P0AAI3	201	201		L->N: No in vivo protease activity, no in vitro ATPase activity. {ECO:0000269|PubMed:10473576}.	
P0AAI3	225	225		F->A,D,E,G,N,Q,R,S,T: Does not complement ftsH1 at 42 degrees Celsius, no protease activity in vivo. {ECO:0000269|PubMed:14514680}.	
P0AAI3	225	225		F->C,H: Partially complements ftsH1 at 42 degrees Celsius, some protease activity in vivo. {ECO:0000269|PubMed:14514680}.	
P0AAI3	225	225	1	F->I,L,M,V,W,Y: Complements ftsH1 at 42 degrees Celsius, restores protease activity in vivo. {ECO:0000269|PubMed:14514680}.	
P0AAI3	227	227		G->A: Does not complement ftsH1 at 42 degrees Celsius, no protease activity in vivo. {ECO:0000269|PubMed:14514680}.	
P0AAI3	297	297		T->A: Low protease activity in vivo, low ATPase activity in vitro, complements ftsH1 at 42 degrees Celsius. {ECO:0000269|PubMed:10473576}.	
P0AAI3	298	298		N->A: No in vivo protease activity. {ECO:0000269|PubMed:10473576}.	
P0AAI3	304	304		D->A,N: No in vivo protease activity, no in vitro ATPase activity; probably still binds ATP. {ECO:0000269|PubMed:10473576}.	
P0AAI3	304	304		D->E: Low protease activity in vivo, low ATPase activity in vitro, complements ftsH1 at 42 degrees Celsius. {ECO:0000269|PubMed:10473576}.	
P0AAI3	307	307		L->A: Low protease activity in vivo. {ECO:0000269|PubMed:10473576}.	
P0AAI3	309	309		R->A,L,K: No in vivo protease activity, no ATPase activity in vitro; probably still binds ATP. {ECO:0000269|PubMed:10473576}.	
P0AAI3	312	312		R->A,L,K: No in vivo protease activity, no ATPase activity in vitro; probably still binds ATP. {ECO:0000269|PubMed:10473576}.	
P0AAI3	414	418		HEAGH->KEAGK: Loss of protease function.	
P0AAI3	414	414		H->Y: Loss of protease function. {ECO:0000269|PubMed:11827531}.	
P0AAI3	415	415		E->Q: Loss of protease activity in vivo. {ECO:0000269|PubMed:10473576}.	
P0AAI3	418	418		H->Y: In tolZ21; loss of protease function in vivo, retains about 25% ATPase activity, temperature sensitive. {ECO:0000269|PubMed:10473576, ECO:0000269|PubMed:11827531}.	
P0AAI3	463	463		E->K: In ftsH1; a temperature-sensitive mutant which increases the frequency of lysogenization of phage lambda; when associated with A-587. {ECO:0000269|PubMed:8444796}.	
P0AAI3	476	476		E->D,K,V: Severe loss of protease function that is restored by excess Zn. {ECO:0000269|PubMed:11827531}.	
P0AAI3	476	476	1	E->Q: Little effect on protease function. {ECO:0000269|PubMed:11827531}.	
P0AAI3	536	536		H->R: In hflB29; increases the frequency of lysogenization of phage lambda. {ECO:0000269|PubMed:8444796}.	
P0AAI3	582	582	1	E->D,K,Q: No effect on protease function. {ECO:0000269|PubMed:11827531}.	
P0AAI3	582	582		E->V: Decreased protease function. {ECO:0000269|PubMed:11827531}.	
P0C0R7	20	20		D->A: 2-fold decrease in activity. Increase in Km for 50S subunit. {ECO:0000269|PubMed:15375145}.	
P0C0R7	22	22	1	Y->A: No change in activity. {ECO:0000269|PubMed:15375145}.	
P0C0R7	32	32		R->A: 4-fold decrease in activity and increase in Km for 50S subunit; when associated with A-34. {ECO:0000269|PubMed:15375145}.	
P0C0R7	34	34		R->A: 4-fold decrease in activity and increase in Km for 50S subunit; when associated with A-32. {ECO:0000269|PubMed:15375145}.	
P0C0R7	38	38		K->A: Loss of activity. Almost no change in S-adenosyl-L-methionine binding. {ECO:0000269|PubMed:12181314}.	
P0C0R7	83	83		D->A: 5-fold decrease in activity. Increase in Km for 50S subunit and for S- adenosyl-L-methionine. Loss of S- adenosyl-L-methionine binding. {ECO:0000269|PubMed:12181314}.	
P0C0R7	124	124		D->A: Loss of activity. Loss of S- adenosyl-L-methionine binding. {ECO:0000269|PubMed:12181314}.	
P0C0R7	136	136		D->N: 2-fold decrease in activity. {ECO:0000269|PubMed:15375145}.	
P0C0R7	164	164		K->A: Loss of activity. No change in S- adenosyl-L-methionine binding. {ECO:0000269|PubMed:12181314}.	
P0C0R7	189	189		K->A: 9-fold decrease in activity. {ECO:0000269|PubMed:15375145}.	
P0C0R7	194	194	1	R->A: No change in activity. Increase in Km for 50S subunit. {ECO:0000269|PubMed:15375145}.	
P0C0R7	197	197	1	S->A: No change in activity. Increase in Km for 50S subunit. {ECO:0000269|PubMed:15375145}.	
P0C0R7	199	199		E->A: 16-fold decrease in activity. No change in S-adenosyl-L-methionine binding. {ECO:0000269|PubMed:12181314}.	
P0C0R7	201	201		Y->A: 5-fold decrease in activity. Almost no change in S-adenosyl-L-methionine binding. {ECO:0000269|PubMed:12181314}.	
P42641	80	80		G->E: Temperature-sensitive for growth at 42 degrees Celsius, defects in chromosome partitioning; when associated with N-85. {ECO:0000269|PubMed:11555285}.	
P42641	85	85		D->N: Temperature-sensitive for growth at 42 degrees Celsius, defects in chromosome partitioning; when associated with E-80. {ECO:0000269|PubMed:11555285}.	
P42641	168	168		P->V: Increased sensitivity to DNA replication inhibitors upon overexpression. {ECO:0000269|PubMed:15721258}.	
P42641	314	314		S->P: Severe growth defect at 42 degrees Celsius. Decreased levels of some ribosomal proteins, altered PTMs of others. {ECO:0000269|PubMed:15836769}.	
P45395	59	59		K->A: Inactive. {ECO:0000269|PubMed:19664604}.	
P45395	88	88		H->A: Shows 9.5% of residual activity compared to the wild-type. {ECO:0000269|PubMed:20954237}.	
P45395	111	111		E->A: Shows 62% of residual activity compared to the wild-type. {ECO:0000269|PubMed:19664604}.	
P45395	152	152		E->A: Shows 19% of residual activity compared to the wild-type. It is able to support growth. {ECO:0000269|PubMed:19664604}.	
P45395	193	193		H->A: Inactive. {ECO:0000269|PubMed:19664604}.	
P0ADV9	56	56		G->V: Impairs LPS transport. Does not abolish interaction with LptA. {ECO:0000269|PubMed:21169485}.	
P0ADV9	153	153		G->R: Impairs LPS transport. Fails to interacts with LptA. {ECO:0000269|PubMed:21169485}.	
P0ADV9	177	191		Missing: Fails to interact with LptA. {ECO:0000269|PubMed:21169485}.	
P0ADV1	36	36	1	I->D,E: No change in activity. {ECO:0000269|PubMed:18534617}.	
P0ADV1	38	38		I->D: Decrease in activity. {ECO:0000269|PubMed:18534617}.	
P0ADV1	38	38	1	I->E: No change in activity. {ECO:0000269|PubMed:18534617}.	
P0ADV1	76	76	1	R->D,E: No change in activity. {ECO:0000269|PubMed:18534617}.	
P0ADV1	95	95	1	F->A: No change in activity. {ECO:0000269|PubMed:18534617}.	
P0A894	270	270		K->A: Lack of activity. Does not bind GlmY and GlmZ; when associated with A- 281; A-282 and A-283. {ECO:0000269|PubMed:23475961}.	
P0A894	281	281		K->A: Lack of activity. Does not bind GlmY and GlmZ; when associated with A- 270; A-282 and A-283. {ECO:0000269|PubMed:23475961}.	
P0A894	282	282		R->A: Lack of activity. Does not bind GlmY and GlmZ; when associated with A- 270; A-281 and A-283. {ECO:0000269|PubMed:23475961}.	
P0A894	283	283		K->A: Lack of activity. Does not bind GlmY and GlmZ; when associated with A- 270; A-281 and A-282. {ECO:0000269|PubMed:23475961}.	
P0AEC3	292	292		H->Q: Loss of activity. {ECO:0000269|PubMed:10851007}.	
P0AEC3	576	576		D->A: Loss of activity. {ECO:0000269|PubMed:10851007}.	
P0AEC3	717	717		H->Q: Loss of activity. {ECO:0000269|PubMed:10851007}.	
P45425	84	84		L->P: 12-fold increase in catalytic efficiency for glucose phosphorylation. 2-fold decrease in catalytic efficiency for N-acetylmannosamine phosphorylation. {ECO:0000269|PubMed:17979299}.	
P45425	138	138		V->M: 6-fold increase in catalytic efficiency for glucose phosphorylation. No change in catalytic efficiency for N- acetylmannosamine phosphorylation. {ECO:0000269|PubMed:17979299}.	
P0AFZ3	52	52		V->D,M,Q: No folded protein. {ECO:0000269|PubMed:15880122}.	
P0AFZ3	52	52		V->I: 2.5-fold reduction in binding of RseA, no effect on ssrA-tag binding. {ECO:0000269|PubMed:15880122}.	
P0AFZ3	59	59		A->T: 10-fold reduction in binding of ssrA tag and RseA. {ECO:0000269|PubMed:15880122}.	
P0AFZ3	74	74		A->Q: Severe reduction in binding of ssrA tag (40-fold) and RseA (100-fold). {ECO:0000269|PubMed:15880122}.	
P0A7X3	105	130		Missing: Cold sensitive for growth at 30 degrees Celsius. 350-fold reduced affinity of the 30S subunit P site for certain tRNAs in vitro. {ECO:0000269|PubMed:15308780}.	
P0A7X3	128	130		Missing: Very cold sensitive for growth at 30 degrees Celsius. Almost no P site binding of certain tRNAs in vitro. {ECO:0000269|PubMed:15308780}.	
P64612	84	84		K->A: Abolishes ATPase activity. {ECO:0000269|PubMed:24595368}.	
P39099	187	187		S->A: Loss of peptidase activity. {ECO:0000269|PubMed:21685389}.	
P39099	191	191		R->A: Reduces the peptidase activity. {ECO:0000269|PubMed:21685389}.	
P39099	329	329		R->A: Reduces the peptidase activity. {ECO:0000269|PubMed:21685389}.	
P0AEE3	122	122		D->A: Causes substantial reduction of peptidase activity. Binds activator peptides. {ECO:0000269|PubMed:17938245, ECO:0000269|PubMed:17981123}.	
P0AEE3	162	162		Y->A: Loss of peptidase activity. Binds activator peptides. {ECO:0000269|PubMed:15137941, ECO:0000269|PubMed:17938245, ECO:0000269|PubMed:17981123, ECO:0000269|PubMed:20739286}.	
P0AEE3	162	162		Y->F: Loss of 60% of peptidase activity. {ECO:0000269|PubMed:15137941, ECO:0000269|PubMed:17938245, ECO:0000269|PubMed:17981123, ECO:0000269|PubMed:20739286}.	
P0AEE3	178	178		R->A: Causes substantial reduction of peptidase activity. {ECO:0000269|PubMed:17981123, ECO:0000269|PubMed:20739286}.	
P0AEE3	183	183		P->A: Loss of peptidase activity. Also affects an interface contact between the PDZ and protease domains. {ECO:0000269|PubMed:15137941, ECO:0000269|PubMed:17981123}.	
P0AEE3	191	191		Q->A: Loss of peptidase activity. {ECO:0000269|PubMed:20739286}.	
P0AEE3	198	198	1	H->A: Behaves like wild-type. {ECO:0000269|PubMed:19836340, ECO:0000269|PubMed:20739286, ECO:0000269|PubMed:21245315}.	
P0AEE3	198	198		H->P: Partially bypasses the requirement for peptide activation, acts synergistically with mutations that disrupt contacts between the protease and PDZ domains and with an rseB disruption. {ECO:0000269|PubMed:19836340, ECO:0000269|PubMed:20739286, ECO:0000269|PubMed:21245315}.	
P0AEE3	201	201		S->A: Does not restore RseA degradation in a degS disruption. Loss of RseA degradation. {ECO:0000269|PubMed:10500101}.	
P0AEE3	227	227		E->A: Loss of peptidase activity. {ECO:0000269|PubMed:15137941, ECO:0000269|PubMed:17981123}.	
P0AEE3	243	243		K->D: Increases the basal rate of RseA cleavage 3-fold, acts synergistically with an rseB disruption. {ECO:0000269|PubMed:17981123, ECO:0000269|PubMed:21245315}.	
P0AEE3	256	256		R->A: Dramatically increases the basal rate of RseA cleavage. {ECO:0000269|PubMed:17981123}.	
P0AEE3	256	256		R->D: Dramatically increases the basal rate of RseA cleavage. {ECO:0000269|PubMed:17981123}.	
P0AEE3	320	320		D->A: Dramatically increases the basal rate of RseA cleavage. {ECO:0000269|PubMed:17981123}.	
P61889	153	153		R->C: Loss of interaction with substrate. {ECO:0000269|PubMed:11389141}.	
P0A6D0	21	21		E->K: Increased affinity for ARG box in the presence of arginine.	
P0A6D0	44	44		S->F: Defective binding to ARG box.	
P0A6D0	47	47		S->L: Defective binding to ARG box.	
P0A6D0	76	76		P->L: Increased affinity for ARG box in the absence of arginine.	
P0A6D0	105	105		A->V: Defective binding to arginine and to ARG box.	
P0A6D0	123	123		G->D: Defective binding to arginine and to ARG box. Forms dimers not hexamers.	
P13518	584	584		L->A: Decreased transcription of csrB. {ECO:0000269|PubMed:16980588}.	
P24182	19	19		R->E: Loss of homodimerization. No effect on ATP binding. {ECO:0000269|PubMed:16793549}.	
P24182	23	23		E->R: Loss of homodimerization. No effect on ATP binding. {ECO:0000269|PubMed:16793549}.	
P24182	363	363		F->A: Loss of homodimerization. No effect on ATP binding. {ECO:0000269|PubMed:16793549}.	
P24182	366	366		R->E: Loss of homodimerization. No effect on ATP binding. {ECO:0000269|PubMed:16793549}.	
P0A8T1	285	285		W->R: Great decrease in activity. {ECO:0000269|PubMed:7715456}.	
P45748	50	50		K->A: Loss of activity. {ECO:0000269|PubMed:19287007}.	
P45748	52	52		R->A: Loss of activity. {ECO:0000269|PubMed:19287007}.	
P45748	56	56	1	K->A: No change in activity. {ECO:0000269|PubMed:19287007}.	
P45748	110	110	1	R->A: No change in activity. {ECO:0000269|PubMed:19287007}.	
P36929	325	325		C->A: Reduces activity 3-fold. {ECO:0000269|PubMed:10899996, ECO:0000269|PubMed:14656444}.	
P36929	375	375		C->A: Loss of activity. {ECO:0000269|PubMed:10899996, ECO:0000269|PubMed:14656444}.	
P36675	18	18		A->T: Loss of activity. Does not affect binding to the ribosome. {ECO:0000269|PubMed:21062370}.	
P0A7Z4	45	45		R->C: In rpoA112; temperature-sensitive, blocks RNA polymerase assembly. {ECO:0000269|PubMed:2235479}.	
P0A7Z4	162	165		EEDE->AAAA: 5-fold decrease in CRP-class II promoter-dependent transcription. {ECO:0000269|PubMed:8978616}.	
P0A7Z4	165	165		E->K: 5-fold decrease in CRP-class II promoter-dependent transcription. {ECO:0000269|PubMed:8978616}.	
P0A7Z4	191	191		R->C: In rpoA101; temperature-sensitive. {ECO:0000269|PubMed:2235479}.	
P0A7V8	44	47		RKPR->AKPA: Decreases mRNA unwinding ability of the ribosome. {ECO:0000269|PubMed:15652481}.	
P0A7S9	83	118		Missing: Decreased growth rate at all temperatures. Decreased affinity of the 30S subunit P site for tRNA in vitro. {ECO:0000269|PubMed:15308780}.	
P0A7S9	114	118		Missing: Decreased growth rate at all temperatures. Decreased affinity of the 30S subunit P site for tRNA in vitro. {ECO:0000269|PubMed:15308780}.	
P0AGA2	40	40		P->S: In secY100; temperature-sensitive.	
P0AGA2	60	74		Missing: Some loss of viability, supports protein translocation; strongly suppresses defective and missing signal sequences; transient transmembrane channels open. {ECO:0000269|PubMed:17531809, ECO:0000269|PubMed:17531810}.	
P0AGA2	65	70	1	Missing: Grows almost as well as wild- type, supports protein translocation; strongly suppresses defective and missing signal sequences; transient transmembrane channels open. {ECO:0000269|PubMed:17531809, ECO:0000269|PubMed:17531810}.	
P0AGA2	67	67		F->C: In prlA3; altered signal sequence interaction, transient channel opening and closing in presence of oxidant; massive ion flux when cross-linked to SecE C-120 mutation. {ECO:0000269|PubMed:17531809}.	
P0AGA2	167	167		G->E: In secY100; temperature-sensitive.	
P0AGA2	240	240		G->D: In secY24; temperature-sensitive at 42 degrees Celsius, impairs interaction with SecE even at 30 degrees in vitro. {ECO:0000269|PubMed:8183945}.	
P0AGA2	282	282		S->R: In prlA401; altered signal sequence interaction, transient transmembrane channels open.	
P0AGA2	286	286		F->Y: In prlA4-1; altered signal sequence interaction.	
P0AGA2	287	287		P->L: In secY161; altered signal sequence interaction.	
P0AGA2	290	290		I->T: In secY121; altered signal sequence interaction.	
P0AGA2	357	357		R->H: In secY39; cold-sensitive.	
P0AGA2	363	363		A->S: In secY40; cold-sensitive.	
P0AGA2	408	408		I->N: In prlA4-2; altered signal sequence interaction. {ECO:0000269|PubMed:17531809}.	
P0AGA2	424	443		Missing: No longer complements secY24, a temperature-sensitive secY mutation. {ECO:0000269|PubMed:20855604}.	
P0A7W1	20	29		RVSKTVKGGR->AVSKTVKGGA: No effect on mRNA unwinding ability of the ribosome. {ECO:0000269|PubMed:15652481}.	
P0ADY3	97	97		T->A: Reduced RsfS binding. {ECO:0000269|PubMed:22829778}.	
P0ADY3	98	98		R->A: Reduced RsfS binding. {ECO:0000269|PubMed:22829778}.	
P0ADY3	114	114		K->A: Reduced RsfS binding. {ECO:0000269|PubMed:22829778}.	
P0ADY3	117	117	1	S->A: No change in RsfS binding. {ECO:0000269|PubMed:22829778}.	
P0A7V3	131	135		RRAMK->AAAMA: Decreases mRNA unwinding ability of the ribosome. {ECO:0000269|PubMed:15652481}.	
P61175	82	99		Missing: Incorporated into ribosomes in vivo, but is easily removed by a salt wash. {ECO:0000269|PubMed:13130133}.	
P61175	85	95		Missing: Incorporates into ribosomes in vivo. {ECO:0000269|PubMed:13130133}.	
P61175	91	91		G->A,D,S: Abolishes translation elongation arrest of SecM. {ECO:0000269|PubMed:11893334}.	
P61175	93	93		A->S,T,V: Abolishes translation elongation arrest of SecM. {ECO:0000269|PubMed:11893334}.	
P60422	230	230		H->Q: Loss of peptidyltransferase activity in reconstituted ribosomes. No change in rRNA binding or assembly into ribosomes. {ECO:0000269|PubMed:8722025}.	
P0ADZ0	16	18		VSE->AAA: Strongly reduces trigger factor binding. {ECO:0000269|PubMed:12226666}.	
P0ADZ0	18	18		E->A: Binds normally to ribosomes; strongly reduces trigger factor binding. {ECO:0000269|PubMed:12226666}.	
P0ADZ0	18	18		E->Q: Strongly reduces trigger factor binding. {ECO:0000269|PubMed:12226666}.	
P0ADZ0	51	53	1	FEV->AAA: No effect on trigger factor binding. {ECO:0000269|PubMed:12226666}.	
P0ADZ0	52	52	1	E->K: No effect on trigger factor binding. {ECO:0000269|PubMed:12226666}.	
P60723	40	88		Missing: Regulates the S10 operon normally. Assembles into ribosomes in vivo. {ECO:0000269|PubMed:8846294}.	
P60723	67	103		Missing: Regulates the S10 operon normally. Does not assemble into ribosomes in vivo. {ECO:0000269|PubMed:8846294}.	
P60723	93	101		Missing: Regulates the S10 operon normally. Not stably associated with the ribosome in vivo. {ECO:0000269|PubMed:8846294}.	
P60723	131	131		T->I: Does not regulate the S10 operon; assembles into ribosomes in vivo. {ECO:0000269|PubMed:8846294}.	
P60723	134	134		L->P: Does not regulate the S10 operon in vivo. {ECO:0000269|PubMed:8846294}.	
P60723	160	160		A->V: Does not regulate the S10 operon; assembles into ribosomes in vivo. {ECO:0000269|PubMed:8846294}.	
P60723	167	167		V->D: Does not regulate the S10 operon in vivo. {ECO:0000269|PubMed:8846294}.	
P60723	171	201		DATGIDPVSLIAFDKVVMTADAVKQVEEMLA->RRSK: Loss of S10 operon regulation. Assembles into ribosomes in vivo. {ECO:0000269|PubMed:8846294}.	
P0ABD3	18	18		E->A: Highly decreased Fe(2+) oxidation activity. Is also severely restricted in its ability to lay down an iron core. {ECO:0000269|PubMed:14636073}.	
P0ABD3	31	31	1	M->H,L: No loss of heme binding. {ECO:0000269|PubMed:7559480}.	
P0ABD3	46	46		H->A: Fe(2+)-binding and single turnover oxidation at the ferroxidase center occur normally but iron mineralization within the cavity is significantly impaired. {ECO:0000269|PubMed:19391621}.	
P0ABD3	50	50		D->A: Fe(2+)-binding and single turnover oxidation at the ferroxidase center occur normally but iron mineralization within the cavity is significantly impaired. {ECO:0000269|PubMed:19391621}.	
P0ABD3	52	52		M->H,L: Loss of heme binding. Is still capable of accumulating iron. {ECO:0000269|PubMed:7559480}.	
P0ABD3	86	86	1	M->L: No loss of heme binding. {ECO:0000269|PubMed:7559480}.	
P0ABD3	127	127		E->Q: Decreased Fe(2+) oxidation activity. Is also affected in its ability to lay down an iron core. {ECO:0000269|PubMed:14636073}.	
P0ABD3	130	130		H->E: Decreased Fe(2+) oxidation activity. Is also severely restricted in its ability to lay down an iron core. {ECO:0000269|PubMed:14636073}.	
P0CE47	20	20		H->A: No change in binding GDP and 3-fold reduction in binding EF-Ts. {ECO:0000269|PubMed:9468511}.	
P0CE47	21	21		V->G: Lowers GTPase activity 5 to 10- fold. {ECO:0000269|PubMed:2684669}.	
P0CE47	83	83		P->T: Loss of GTPase activity and creation of an autophosphorylation site. {ECO:0000269|PubMed:2157708}.	
P0CE47	115	115		Q->A: Weaker binding for GDP and for EF- Ts. {ECO:0000269|PubMed:9468511}.	
P0CE47	125	125		Q->K: Kirromycin resistant. {ECO:0000269|PubMed:2508560}.	
P0CE47	137	137		K->R,Q,E,I: Reduces affinity for GDP. {ECO:0000269|PubMed:2498311}.	
P0CE47	139	139		D->N: Reduces affinity for GDP; increases affinity for XDP. {ECO:0000269|PubMed:3308869}.	
P0CE47	223	223		G->D: Inhibits codon-induced conformational changes leading to GTPase activation on the ribosome. {ECO:0000269|PubMed:2508560}.	
P0CE47	231	231		R->C: Pulvomycin resistant. {ECO:0000269|PubMed:2508560}.	
P0CE47	317	317		G->D: Kirromycin resistant. {ECO:0000269|PubMed:2508560}.	
P0CE47	334	334		R->C: Pulvomycin resistant. {ECO:0000269|PubMed:2508560}.	
P0CE47	335	335		T->A: Pulvomycin resistant. {ECO:0000269|PubMed:2508560}.	
P0CE47	349	349	1	E->A: No change in binding GDP but higher binding constant for EF-Ts. {ECO:0000269|PubMed:9468511}.	
P0CE47	376	376		A->T,V: Kirromycin resistant. {ECO:0000269|PubMed:2508560}.	
P0CE47	383	383	1	T->V: No longer phosphorylated by phage protein doc, has no effect on translation. {ECO:0000269|PubMed:24141193}.	
P02359	2	18		Missing: Defective in ribosome assembly; accumulates to abnormally high levels on polysomes; significantly decreases affinity for its own mRNA.	
P02359	36	36		K->A,E: Defective in ribosome assembly.	
P02359	116	116		M->G: Significantly decreases affinity for its own mRNA.	
P0A7S3	57	57		L->H: Protein is not incorporated into ribosomes. {ECO:0000269|PubMed:10209746}.	
P0A7S3	88	88		K->Q: Confers low-level resistance to streptomycin and a 15% decrease in the translational elongation rate. {ECO:0000269|PubMed:10209746}.	
P45531	76	76	1	C->S: No effect. {ECO:0000269|PubMed:16472754}.	
P45531	79	79	1	C->S: No effect. {ECO:0000269|PubMed:16472754}.	
P45532	78	78		C->S: Loss of activity. {ECO:0000269|PubMed:16387657, ECO:0000269|PubMed:16472754}.	
P45532	122	122		C->S: Reduced activity. {ECO:0000269|PubMed:16472754}.	
P0A9K9	42	42		I->S: Decrease in PPIase activity, but has little impact on chaperone activity and interaction with HypB. Almost complete loss of PPIase activity; when associated with Y-132. {ECO:0000269|PubMed:17720786}.	
P0A9K9	132	132		F->Y: Almost complete loss of PPIase activity, but has little impact on chaperone activity and interaction with HypB; when associated with S-42. {ECO:0000269|PubMed:17720786}.	
P0A9K9	167	168		CC->AA: Reduces nickel-binding capacity. {ECO:0000269|PubMed:19947632}.	
P0A9K9	184	185		CC->AA: Reduces nickel-binding capacity. {ECO:0000269|PubMed:19947632}.	
P0ACJ8	20	20		H->A,L,Y: Decreased transcription activation at class II promoters, decreased interaction with RNAP, binds DNA. {ECO:0000269|PubMed:8978616}.	
P0ACJ8	22	22		H->A,L: Decreased transcription activation at class II promoters, decreased interaction with RNAP, binds DNA. {ECO:0000269|PubMed:8978616}.	
P0ACJ8	53	53		K->N: Increased activation at class II promoters, increased interaction with RNAP. {ECO:0000269|PubMed:8978616}.	
P0ACJ8	54	56		DEE->AAA: 80% reduction in activation of class II promoters; 95% loss when associated with A-59. {ECO:0000269|PubMed:10860739}.	
P0ACJ8	59	59		E->A: 45% reduction in activation of class II promoters; 95% loss when associated with AAA-54-56. {ECO:0000269|PubMed:10860739, ECO:0000269|PubMed:10860740}.	
P0ACJ8	59	59		E->G,K: Reduction in activation of class II promoters. {ECO:0000269|PubMed:10860739, ECO:0000269|PubMed:10860740}.	
P0ACJ8	63	63		S->A: Enhanced cAMP-binding, enhanced transcription. {ECO:0000269|PubMed:2845936}.	
P0ACJ8	83	83		R->L: Loss of cAMP-binding. {ECO:0000269|PubMed:2845936}.	
P0ACJ8	84	84	1	S->A,K: No modification of cAMP-binding. {ECO:0000269|PubMed:2845936}.	
P0ACJ8	97	97		E->A: Increased transcription activation at class II promoters, binds DNA. {ECO:0000269|PubMed:8978616}.	
P0ACJ8	102	102		K->E: Disrupts AR2. No activation of class II promoters, decreased interaction with RNAP, binds DNA. {ECO:0000269|PubMed:15520470, ECO:0000269|PubMed:8978616}.	
P0ACJ8	128	129		TS->LI: Constitutively active at class I and II promoters in the absence of cAMP, binds DNA almost as well in the absence as in the presence of cAMP. Binds cAMP normally. {ECO:0000269|PubMed:16260780, ECO:0000269|PubMed:23644478}.	
P0ACJ8	128	128	1	T->A: No modification of cAMP-binding. {ECO:0000269|PubMed:2845936}.	
P0ACJ8	129	129		S->A: Reduced DNA-binding; no modification of cAMP-binding. {ECO:0000269|PubMed:2845936, ECO:0000269|PubMed:3333845}.	
P0ACJ8	139	139		D->L: Some stabilization of an inactive (apo-) form. Decreased affinity for DNA, normal subunit association. {ECO:0000269|PubMed:15096034, ECO:0000269|PubMed:19805344, ECO:0000269|PubMed:8380500}.	
P0ACJ8	157	157		A->D,P: Decreased transcription activation (6-29%), binds DNA. {ECO:0000269|PubMed:7966284, ECO:0000269|PubMed:8392187}.	
P0ACJ8	159	159		T->A,I,N,S,V: Decreased transcription activation (15-87%) at class I and II promoters, binds DNA. {ECO:0000269|PubMed:7966284, ECO:0000269|PubMed:8392187, ECO:0000269|PubMed:8978616}.	
P0ACJ8	160	160		H->A,K,L,N,P,Q,R,Y: Disrupts AR1. Decreased transcription activation (3- 45%) at class I and II promoters, binds DNA. {ECO:0000269|PubMed:15520470, ECO:0000269|PubMed:7966284, ECO:0000269|PubMed:8392187, ECO:0000269|PubMed:8978616}.	
P0ACJ8	163	163		G->A,C,D,R,S,V: Decreased transcription activation (2-62%) at class I and II promoters, binds DNA. {ECO:0000269|PubMed:7966284, ECO:0000269|PubMed:8392187, ECO:0000269|PubMed:8978616}.	
P0ACJ8	181	181		R->K: Suppresses DNA-binding. {ECO:0000269|PubMed:3333845}.	
P0ACJ8	181	181		R->L: Suppresses DNA-binding. {ECO:0000269|PubMed:3333845}.	
P0ACJ8	186	186	1	R->K: No modification of DNA-binding. {ECO:0000269|PubMed:3333845}.	
P0ACJ8	186	186		R->L: Marginally reduced DNA-binding. {ECO:0000269|PubMed:3333845}.	
P00903	79	79		C->S: 10000-fold decrease in catalytic efficiency. {ECO:0000269|PubMed:8096767}.	
P00903	168	168		H->Q: Loss of activity. {ECO:0000269|PubMed:8096767}.	
P00903	170	170		E->A: 150-fold decrease in catalytic efficiency. {ECO:0000269|PubMed:8096767}.	
P00903	170	170		E->D: 4-fold decrease in catalytic efficiency. {ECO:0000269|PubMed:8096767}.	
P00903	170	170		E->K,Q: Loss of activity. {ECO:0000269|PubMed:8096767}.	
P20605	55	55		G->R: Inhibitory effect on cell division induced by cAMP with temperature sensitivity. {ECO:0000269|PubMed:2546924}.	
P0AFL3	136	136		F->W: Enhances susceptibility to CSA inhibition. {ECO:0000269|PubMed:2001362}.	
P0AEA8	21	21		G->D: It has methyltransferase and ferrochelatase activities but a greatly reduced dehydrogenase activity. It is able to bind AdoMet. {ECO:0000269|PubMed:9461500}.	
P0AEA8	224	224		G->A: It abolishes methyltransferase activity, but has dehydrogenase and ferrochelatase activities. It is unable to bind AdoMet. {ECO:0000269|PubMed:9461500}.	
P0AEA8	227	227	1	D->A: It has all activities of CysG. {ECO:0000269|PubMed:9461500}.	
P0AEA8	248	248		D->A: It abolishes methyltransferase activity, but has dehydrogenase and ferrochelatase activities. It is able to bind AdoMet.	
P0AEA8	270	270		K->I: It has all activities of CysG. It is able to bind AdoMet. {ECO:0000269|PubMed:9461500}.	
P0AEA8	298	298		R->L: It abolishes methyltransferase activity, but has dehydrogenase and ferrochelatase activities. It is unable to bind AdoMet. {ECO:0000269|PubMed:9461500}.	
P0AEA8	303	303		D->A: It has all activities of CysG. It is able to bind AdoMet. {ECO:0000269|PubMed:9461500}.	
P0AEA8	309	309		R->L: It abolishes methyltransferase activity, but has dehydrogenase and ferrochelatase activities. It is able to bind AdoMet. {ECO:0000269|PubMed:9461500}.	
P11557	351	351		Q->K: Eliminates septal localization. {ECO:0000269|PubMed:23290046}.	
P11557	354	354		S->K: Impairs septal localization. {ECO:0000269|PubMed:23290046}.	
P11557	416	416		W->L: Impairs septal localization. {ECO:0000269|PubMed:23290046}.	
P22259	65	65		R->Q: Slightly lower catalytic efficiency compared to wild-type and the affinity binding for OAA is 330-fold higher than for wild-type. {ECO:0000269|PubMed:17475535}.	
P22259	268	268		D->N: In PCK51; altered-activity mutant that catalyzes the conversion from oxaloacetate to pyruvate (OAA decarboxylase activity). {ECO:0000269|PubMed:7883719}.	
P22259	284	284		G->S: In PCK53; shows reduced-activity. {ECO:0000269|PubMed:7883719}.	
P0AEJ4	193	193		A->L: Promotes the formation of alpha- helical secondary structure of the HAMP domain. {ECO:0000269|PubMed:17635923}.	
P0AEJ4	193	193	1	A->V: No effect. {ECO:0000269|PubMed:17635923}.	
P0AEJ4	347	347		N->D: Loss of ATP binding; loss of autophosphorylation. {ECO:0000269|PubMed:9817206}.	
P33650	94	94	1	D->N: No effect. {ECO:0000269|PubMed:12446835}.	
P33650	123	123		D->N: Loss of guanine nucleotide specificity and Fe(2+) uptake. {ECO:0000269|PubMed:12446835}.	
P13001	82	82		S->A: No effect on CoA-binding. Loss of Carboxylesterase activity. {ECO:0000269|PubMed:11904168, ECO:0000269|PubMed:20693992}.	
P63020	39	39		C->S: No effect on activity in vivo. Still able to bind a Fe/S cluster in vitro. {ECO:0000269|PubMed:18339628}.	
P63020	44	44	1	C->S: No effect on activity in vivo. {ECO:0000269|PubMed:18339628}.	
P63020	149	149		C->S: Loss of activity in vivo. Still able to bind a Fe/S cluster in vitro. {ECO:0000269|PubMed:18339628}.	
P63020	152	152		C->S: Loss of activity in vivo. Still able to bind a Fe/S cluster in vitro. {ECO:0000269|PubMed:18339628}.	
P46849	103	103	1	Q->A: No effect on RNA cyclase activity and RtcA adenylation. {ECO:0000269|PubMed:20399182}.	
P46849	128	128	1	S->A: No effect on RNA cyclase activity and RtcA adenylation. {ECO:0000269|PubMed:20399182}.	
P46849	130	130		P->G: 33% of wild-type RNA cyclase activity and 13% of wild-type RtcA adenylation. {ECO:0000269|PubMed:20399182}.	
P46849	134	134		F->A: 3% of wild-type RNA cyclase activity and 2% of wild-type RtcA adenylation. {ECO:0000269|PubMed:20399182}.	
P46849	250	250		F->A: 28% of wild-type RNA cyclase activity and 38% of wild-type RtcA adenylation. {ECO:0000269|PubMed:20399182}.	
P46849	269	269		E->A: Nearly no effect on RNA cyclase activity and 2-fold decrease in RtcA adenylation. {ECO:0000269|PubMed:20399182}.	
P46849	283	283		Y->A: 12% of wild-type RNA cyclase activity and 2% of wild-type RtcA adenylation. {ECO:0000269|PubMed:20399182}.	
P46849	286	286		D->A: Loss of RNA cyclase activity and RtcA adenylation. {ECO:0000269|PubMed:20399182}.	
P46849	287	287		Q->A: Loss of RNA cyclase activity and RtcA adenylation. {ECO:0000269|PubMed:20399182}.	
P46849	308	308		H->A,G: Loss of RNA cyclase activity and RtcA adenylation. {ECO:0000269|PubMed:20399182}.	
P46850	337	337		H->A,N,Q: Loss of function. Abolishes formation of guanylylated RtcB intermediate. {ECO:0000269|PubMed:22474365}.	
P09391	154	154		N->A: Reduced catalytic activity. {ECO:0000269|PubMed:16216077, ECO:0000269|PubMed:16621838}.	
P09391	199	199		G->C: Loss of catalytic activity. {ECO:0000269|PubMed:17493126}.	
P09391	201	201		S->A,C: Loss of catalytic activity. {ECO:0000269|PubMed:16216077, ECO:0000269|PubMed:16621838, ECO:0000269|PubMed:17099694, ECO:0000269|PubMed:17493126}.	
P09391	254	254		H->A,C: Loss of catalytic activity. {ECO:0000269|PubMed:16216077, ECO:0000269|PubMed:16621838, ECO:0000269|PubMed:17493126}.	
P0A6V1	195	195	1	K->E,I,H,Q,R: No loss in enzyme activity. {ECO:0000269|PubMed:1648099}.	
P0A9Q9	135	135		C->A: Complete loss of activity. {ECO:0000269|PubMed:1350921}.	
P0A9Q9	135	135		C->S: 99.7% loss of activity. {ECO:0000269|PubMed:1350921}.	
P18956	391	391		T->A: Abolishes autocatalytic cleavage. {ECO:0000269|PubMed:17135273}.	
P18956	513	513		R->A: Not processed into its subunits. {ECO:0000269|PubMed:1360205}.	
P18956	571	571		R->G: Not processed into its subunits. {ECO:0000269|PubMed:1360205}.	
P37613	45	45		N->A: Retains affinity for PanD, but is unable to enhance cleavage of the PanD proenzyme. {ECO:0000269|PubMed:23170229}.	
P0AGB3	80	80		Q->N,R: Decrease in activity. Exhibits reduced affinity for core RNAP. {ECO:0000269|PubMed:9144163}.	
P0A9R7	41	41		K->R: Does not bind ATP. {ECO:0000269|PubMed:10048040}.	
P0A9R7	49	49		C->A: Prevents dimer formation. Does not alter ATP-binding. {ECO:0000269|PubMed:10048040}.	
P10121	14	14		G->A: Blocks proteolytic cleavage and impairs activity in cotranslational targeting. {ECO:0000269|PubMed:18281057}.	
P0A890	19	19		C->S: Loss of activity. {ECO:0000269|PubMed:16387657}.	
P0A890	21	21		E->K: In sirA1; affects the stability of sigma-S during the logarithmic growth phase. {ECO:0000269|PubMed:9555915}.	
P0A890	56	56	1	C->S: No effect. {ECO:0000269|PubMed:16387657}.	
P0A6Z6	3	3		R->A: Loss of DNA-binding. {ECO:0000269|PubMed:10595554}.	
P37634	4	4		Y->A: Loss of catalytic activity. {ECO:0000269|PubMed:23945937}.	
P37634	4	4		Y->F: 40-fold reduction in catalytic activity. {ECO:0000269|PubMed:23945937}.	
P37634	6	6		H->D: Loss of catalytic activity. {ECO:0000269|PubMed:23945937}.	
P37634	18	18		K->A: Loss of catalytic activity. {ECO:0000269|PubMed:23945937}.	
P37634	18	18		K->R: 10-fold reduction in catalytic activity. {ECO:0000269|PubMed:23945937}.	
P37634	164	164		D->A: Loss of catalytic activity. {ECO:0000269|PubMed:23945937}.	
P0AET2	55	56		WW->AA: Folded, but does not form homodimers at pH 7. {ECO:0000269|PubMed:22138344}.	
P37646	48	48		E->A: Loss of c-di-GMP phosphodiesterase activity. {ECO:0000269|PubMed:18765794}.	
P37665	116	116		F->A: Does not suppress BamB ts-mutants. {ECO:0000269|PubMed:21228468}.	
P37665	150	150		G->A: Partially suppresses BamB ts- mutants. {ECO:0000269|PubMed:21228468}.	
P37665	153	153		D->A: Does not suppress BamB ts-mutants. {ECO:0000269|PubMed:21228468}.	
P37665	156	156		G->A: Does not suppress BamB ts-mutants. {ECO:0000269|PubMed:21228468}.	
P37665	164	164		L->A: Partially suppresses BamB ts- mutants. {ECO:0000269|PubMed:21228468}.	
P37665	168	168		R->A: Does not suppress BamB ts-mutants. {ECO:0000269|PubMed:21228468}.	
P37685	197	197		R->E: Less than 10% of wild-type acetaldehyde dehydrogenase activity. {ECO:0000269|PubMed:15659684}.	
P0A821	224	224	1	K->N: Still binds PLP. {ECO:0000269|PubMed:9688279}.	
P0A821	295	295		K->N: Loss of activity and PLP binding. {ECO:0000269|PubMed:9688279}.	
P0A821	328	328		K->N: Loss of PLP binding. {ECO:0000269|PubMed:9688279}.	
P37690	321	321	1	K->A: Retains AmiA and AmiB activation. {ECO:0000269|PubMed:23796240}.	
P37690	321	321		K->E: Loss of AmiA and AmiB activation; does not complement double envC-nlpD disruption, protein localizes normally. {ECO:0000269|PubMed:23796240}.	
P37690	324	324	1	V->A: Retains AmiA and AmiB activation. {ECO:0000269|PubMed:23796240}.	
P37690	324	324		V->E: Loss of AmiA and AmiB activation; does not complement double envC-nlpD disruption, protein localizes normally. {ECO:0000269|PubMed:23796240}.	
P37690	350	350		Y->A: Loss of AmiA and AmiB activation; does not complement double envC-nlpD disruption, protein localizes normally. {ECO:0000269|PubMed:23796240}.	
P37690	353	353		V->A: Loss of AmiA and AmiB activation; does not complement double envC-nlpD disruption, protein localizes normally. {ECO:0000269|PubMed:23796240}.	
P37690	366	366		Y->H: Partially unstable, loss of AmiA and AmiB activation. {ECO:0000269|PubMed:23796240}.	
P37690	401	401		Y->E: Partially unstable, loss of AmiA and AmiB activation; does not complement double envC-nlpD disruption, protein localizes normally. {ECO:0000269|PubMed:23796240}.	
P37690	405	405		R->H: Loss of activation of amidases; does not complement double envC-nlpD disruption, protein localizes normally. {ECO:0000269|PubMed:23796240}.	
P67910	140	140		Y->F: Severely compromises epimerase activitie. {ECO:0000269|PubMed:17316025}.	
P67910	178	178		K->M: Severely compromises epimerase activitie. {ECO:0000269|PubMed:17316025}.	
P67910	208	208	1	K->M: Activity similar to that of the wild-type. {ECO:0000269|PubMed:17316025}.	
P67910	210	210	1	D->N: Activity similar to that of the wild-type. {ECO:0000269|PubMed:17316025}.	
P05523	3	3		E->Q: Strong decrease of glycosylase activity; slight decrease of AP lyase activity. {ECO:0000269|PubMed:11106507}.	
P05523	6	6		E->Q: Decrease of glycosylase activity; no effect on AP lyase activity. {ECO:0000269|PubMed:11106507}.	
P05523	90	90		H->A: Increase of substrate affinity and decrease of activity. {ECO:0000269|PubMed:14607836}.	
P05523	107	107	1	D->N: No effect on glycosylase and AP lyase activity. {ECO:0000269|PubMed:11106507}.	
P05523	109	109		R->A: Over 100-fold decrease of activity. {ECO:0000269|PubMed:14607836}.	
P05523	110	110		R->A: Over 100-fold increase of substrate affinity and decrease of activity. {ECO:0000269|PubMed:14607836}.	
P05523	132	132		E->Q: Decrease of glycosylase activity; slight decrease of AP lyase activity. {ECO:0000269|PubMed:11106507}.	
P05523	160	160	1	D->N: No effect on glycosylase and AP lyase activity. {ECO:0000269|PubMed:11106507}.	
P05523	174	174		E->Q: Strong decrease of glycosylase activity; slight decrease of AP lyase activity. {ECO:0000269|PubMed:11106507}.	
P05523	218	218		K->T: Slight increase of substrate affinity and decrease of activity. {ECO:0000269|PubMed:14607836}.	
P0ABQ0	11	11		G->D: In Dfp-707; temperature-sensitive, impairs folding. {ECO:0000269|PubMed:11358972}.	
P0ABQ0	14	14		G->S: No FMN binding. {ECO:0000269|PubMed:11358972}.	
P0ABQ0	15	15		G->A: Less than 5% of wild-type activity. {ECO:0000269|PubMed:11358972}.	
P0ABQ0	16	16		I->L: Severely reduced activity. {ECO:0000269|PubMed:11358972}.	
P0ABQ0	16	16		I->V: Slightly reduced activity. {ECO:0000269|PubMed:11358972}.	
P0ABQ0	17	17		A->D: Less than 5% of wild-type activity. {ECO:0000269|PubMed:11358972}.	
P0ABQ0	17	17	1	A->G,S: Almost wild-type activity. {ECO:0000269|PubMed:11358972}.	
P0ABQ0	19	19	1	Y->F: Almost wild-type activity. {ECO:0000269|PubMed:11358972}.	
P0ABQ0	19	19		Y->L: Reduced activity. {ECO:0000269|PubMed:11358972}.	
P0ABQ0	20	20		K->N,Q: Reduced activity. {ECO:0000269|PubMed:11358972}.	
P0ABQ0	20	20	1	K->R: Almost wild-type activity. {ECO:0000269|PubMed:11358972}.	
P0ABQ0	46	46		F->L: Reduced activity. {ECO:0000269|PubMed:10922366}.	
P0ABQ0	75	75		H->N: Loss of activity. {ECO:0000269|PubMed:10922366}.	
P0ABQ0	89	89		P->A: Binds FMN, but more loosely than wild-type. {ECO:0000269|PubMed:10922366}.	
P0ABQ0	89	89		P->D: No FMN binding. {ECO:0000269|PubMed:10922366}.	
P0ABQ0	91	91	1	T->V: Binds FMN. {ECO:0000269|PubMed:10922366}.	
P0ABQ0	124	124	1	M->L: No effect. {ECO:0000269|PubMed:10922366}.	
P0ABQ0	125	125		N->D,Q: Loss of activity. {ECO:0000269|PubMed:10922366, ECO:0000269|PubMed:11358972}.	
P0ABQ0	128	128		M->L: Severely reduced activity. {ECO:0000269|PubMed:10922366}.	
P0ABQ0	158	158		C->A,S: Loss of activity.	
P0ABQ0	194	194		T->V: Loss of dimerization. {ECO:0000269|PubMed:12140293}.	
P0ABQ0	198	198		T->V: Loss of dimerization. {ECO:0000269|PubMed:12140293}.	
P0ABQ0	203	203		D->N: Loss of dimerization. {ECO:0000269|PubMed:12140293}.	
P0ABQ0	210	210		N->D: Loss of activity, reaction intermediate detectable. {ECO:0000269|PubMed:12140293, ECO:0000269|PubMed:14686929}.	
P0ABQ0	210	210		N->H,K: Loss of activity, reaction intermediate not detectable. {ECO:0000269|PubMed:12140293, ECO:0000269|PubMed:14686929}.	
P0ABQ0	212	212	1	S->A: Small effect on activity. {ECO:0000269|PubMed:12140293}.	
P0ABQ0	215	215	1	K->Q: No effect. {ECO:0000269|PubMed:12140293}.	
P0ABQ0	275	275		A->V: Loss of dimerization. {ECO:0000269|PubMed:12140293, ECO:0000269|PubMed:14686929}.	
P0ABQ0	289	289		K->Q: Loss of activity. {ECO:0000269|PubMed:12140293}.	
P0ABQ0	291	291		K->Q: Reduced activity. {ECO:0000269|PubMed:12140293}.	
P0ABQ0	292	292	1	K->Q: Small effect on activity. {ECO:0000269|PubMed:12140293}.	
P06968	89	89		D->N: Reduces catalytic activity 40000- fold. {ECO:0000269|PubMed:15208312}.	
P0C093	33	33		T->A: Does not associate with DNA, but can inhibit division when overproduced. {ECO:0000269|PubMed:21321206}.	
P0C093	73	73		R->D: Loss of activity. Binds DNA, but does not associate with FtsZ polymers. {ECO:0000269|PubMed:21321206}.	
P25772	124	124		K->A: Loss of activity. {ECO:0000269|PubMed:11812821}.	
P0AG24	73	73		D->N: Obviates hydrolysis of ppGpp, moderately decreases biofilm formation, loss of biofilm induction in response to translation inhibitors. {ECO:0000269|PubMed:19460094}.	
P0AG24	259	259	1	D->N: Obviates synthesis of ppGpp, strongly increases biofilm formation. {ECO:0000269|PubMed:19460094}.	
P0AG24	293	293		D->A: Unable to restore (p)ppGpp synthesis nor complement a relA/spoT double disruption. {ECO:0000269|PubMed:12596879}.	
P0AG24	294	294	1	Y->I: Synthesizes (p)ppGpp, complements a relA/spoT double disruption.	
P24230	411	693		Missing: In radC102; causes mild UV and X-ray sensitivity. {ECO:0000269|PubMed:11053371}.	
P31434	307	308		CF->ID: Converts the enzyme to have alpha-glucosidase activity. {ECO:0000269|PubMed:16631751}.	
Q6BF17	185	185		H->N,Q: Loss of activity. {ECO:0000269|Ref.7}.	
Q6BF17	285	285		H->N: Loss of activity. {ECO:0000269|Ref.7}.	
Q6BF17	310	310		E->Q: Loss of activity. {ECO:0000269|Ref.7}.	
Q6BF16	37	37		E->N: 50-fold decrease in catalytic efficiency and 6-fold decrease of binding affinity. {ECO:0000269|PubMed:17981470}.	
Q6BF16	154	154		V->T: Little stereoselectivity, accepting KDPG and KDPGal as substrate with roughly equal efficacy. Reduced the preference for KDPGal. It diminishes the activity against KDPGal and increases activity against KDPG. {ECO:0000269|PubMed:17981470}.	
P0A8Y5	9	9		D->A: Loss of the phosphatase activity. {ECO:0000269|PubMed:16990279}.	
P0AES6	424	424		E->A,Q: Strongly reduced activity regarding both DNA supercoiling and relaxation. Reduces ATP hydrolysis in response to DNA binding, but has only minor effect on the basal rate of ATP hydrolysis. {ECO:0000269|PubMed:12051843}.	
P0AES6	498	498		D->A,N: Strongly reduced activity regarding both DNA supercoiling and relaxation. Reduces ATP hydrolysis in response to DNA binding, but has only minor effect on the basal rate of ATP hydrolysis. {ECO:0000269|PubMed:12051843}.	
P0AES6	500	500		D->A: Strongly reduced activity regarding both DNA supercoiling and relaxation. Reduces ATP hydrolysis in response to DNA binding, but has only minor effect on the basal rate of ATP hydrolysis. {ECO:0000269|PubMed:12051843}.	
P0AES6	502	502		D->A: Strongly reduced activity regarding both DNA supercoiling and relaxation. Reduces ATP hydrolysis in response to DNA binding, but has only minor effect on the basal rate of ATP hydrolysis. {ECO:0000269|PubMed:12051843}.	
P0A7H0	36	36		K->R: Weakly active. {ECO:0000269|PubMed:1542576}.	
P0A988	66	66		G->E: In dnaN159; a temperature- and UV- sensitive mutation, displays altered DNA polymerase usage, chronically induced SOS response; when associated with A-174. {ECO:0000269|PubMed:15466025}.	
P0A988	174	174		G->A: In dnaN159; a temperature- and UV- sensitive mutation, displays altered DNA polymerase usage, chronically induced SOS response; when associated with A-66. {ECO:0000269|PubMed:15466025}.	
P25714	24	27		EQDK->IEGR: Cold-sensitive at 30 degrees Celsius; when associated with 334-W--G- 338. Protein accumulates stably.	
P25714	334	338		WFISQ->LEVLFQG: Cold-sensitive at 30 degrees Celsius; when associated with 24- I--R-27. Protein accumulates stably. {ECO:0000269|PubMed:12707259}.	
P25714	361	361		I->S: Loss of function. {ECO:0000269|PubMed:14506280}.	
P25714	436	436		L->S: Loss of function. {ECO:0000269|PubMed:14506280}.	
P25714	483	487		PTTVT->LVPRGS: Temperature-sensitive at 42 degrees Celsius; when associated with 512-ENLYFQG. Protein is not stable. {ECO:0000269|PubMed:12707259}.	
P25714	512	512		G->ENLYFQG: Temperature-sensitive at 42 degrees Celsius; when associated with 483-L--S-487. Protein is not stable. {ECO:0000269|PubMed:12707259}.	
P25522	224	224		R->A: 1.5-fold decrease in GTPase activity and almost no change in affinity. {ECO:0000269|PubMed:15983041}.	
P25522	226	226		N->A: 100-fold decrease in GTPase activity. 5-fold decrease of affinity for GTP. {ECO:0000269|PubMed:16763562}.	
P25522	226	226		N->K: 70-fold decrease in GTPase activity. 2-fold decrease of affinity for GTP. {ECO:0000269|PubMed:16763562}.	
P25522	228	228		G->A: Loss of GTP binding and hydrolase activity. Completely impairs tRNA modifying function. {ECO:0000269|PubMed:12730230}.	
P25522	249	249		G->A: 22-fold decrease in GTPase activity and 7-fold increase of affinity. {ECO:0000269|PubMed:15983041}.	
P25522	250	250		T->A: 4-fold decrease in GTPase activity and 1.5-fold increase of affinity. {ECO:0000269|PubMed:15983041}.	
P25522	250	250		T->S: 1.8-fold decrease in GTPase activity and 1.5-fold increase of affinity. {ECO:0000269|PubMed:15983041}.	
P25522	251	251		T->A: 92-fold decrease in GTPase activity and 59-fold increase of affinity. {ECO:0000269|PubMed:15983041}.	
P25522	251	251		T->S: 4-fold decrease in GTPase activity and 1.2-fold decrease of affinity. {ECO:0000269|PubMed:15983041}.	
P25522	252	252		R->A: 7-fold decrease in GTPase activity and 6-fold increase of affinity. {ECO:0000269|PubMed:15983041}.	
P25522	252	252		R->K: 2-fold decrease in GTPase activity and no change in affinity. {ECO:0000269|PubMed:15983041}.	
P25522	253	253		D->A: 9-fold decrease in GTPase activity and 13-fold increase of affinity. {ECO:0000269|PubMed:15983041}.	
P25522	255	255		L->D: 1.5-fold decrease in affinity for GTP. {ECO:0000269|PubMed:16763562}.	
P25522	256	256		R->A: 2-fold decrease in GTPase activity and almost no change in affinity. {ECO:0000269|PubMed:15983041}.	
P25522	270	270		D->A: Does not affect GTP binding, but impairs hydrolase activity. Completely impairs tRNA modifying function. {ECO:0000269|PubMed:12730230}.	
P25522	275	275		R->A: 6-fold decrease in GTPase activity and 1.9-fold increase of affinity. {ECO:0000269|PubMed:15983041}.	
P25522	282	282		E->A: 1900-fold decrease in GTPase activity. {ECO:0000269|PubMed:16763562}.	
P25522	282	282		E->Q: 370-fold decrease in GTPase activity. {ECO:0000269|PubMed:16763562}.	
P25522	288	288		R->A: 1.7-fold decrease in GTPase activity and 1.5-fold increase of affinity. {ECO:0000269|PubMed:15983041}.	
P25522	338	338		D->N: Strong decrease in GTP binding. Does not affect hydrolase activity, but has 10-fold higher affinity for XTP than for GTP. Partially impairs tRNA modifying function. {ECO:0000269|PubMed:12730230}.	
P25522	451	451		C->S: No change in GTP binding and hydrolase activity. Does not affect association to the cell inner membrane. Completely impairs tRNA modifying function. {ECO:0000269|PubMed:12730230}.	
P0A853	294	294	1	C->S: Identical to wild-type. {ECO:0000269|PubMed:2659590}.	
P0A853	298	298		C->S: Alters activity. {ECO:0000269|PubMed:2659590}.	
P0AGE6	85	85	1	Y->N: Improves chromate reductase activity compared to the wild-type enzyme. {ECO:0000269|PubMed:22558308}.	
P0AGE6	125	125	1	R->M: Improves chromate reductase activity compared to the wild-type enzyme. {ECO:0000269|PubMed:22558308}.	
P0AGE6	128	128	1	Y->N: Improves chromate reductase activity compared to the wild-type enzyme. Increase of the affinity binding and catalytic efficiency for both chromate and uranate. {ECO:0000269|PubMed:17088379}.	
P0AGE6	146	146	1	E->T: Improves chromate reductase activity compared to the wild-type enzyme. {ECO:0000269|PubMed:22558308}.	
P31466	38	38	1	T->A: Almost no change in activity. {ECO:0000269|PubMed:24214977}.	
P31466	38	38		T->H: Lack of activity. {ECO:0000269|PubMed:24214977}.	
P31466	91	91	1	A->G,S: Almost no change in activity. {ECO:0000269|PubMed:24214977}.	
P31466	267	267		D->A,N: Lack of activity. {ECO:0000269|PubMed:24214977}.	
P31466	267	267		D->E: Strong decrease in activity. {ECO:0000269|PubMed:24214977}.	
P31466	271	271	1	T->A,S: Almost no change in activity. {ECO:0000269|PubMed:24214977}.	
P31466	271	271		T->D: Lack of activity. {ECO:0000269|PubMed:24214977}.	
P31466	271	271		T->N: Strong decrease in activity. {ECO:0000269|PubMed:24214977}.	
P31466	298	298	1	D->E: Almost no change in activity. {ECO:0000269|PubMed:24214977}.	
P31466	298	298		D->N: Lack of activity. {ECO:0000269|PubMed:24214977}.	
P31466	317	317	1	I->A: Almost no change in activity. {ECO:0000269|PubMed:24214977}.	
P31466	317	317		I->E: Strong decrease in activity. {ECO:0000269|PubMed:24214977}.	
P31466	318	318		E->D: Strong decrease in activity. {ECO:0000269|PubMed:24214977}.	
P31466	318	318		E->Q: Lack of activity. {ECO:0000269|PubMed:24214977}.	
P31466	319	319	1	S->A,N: Almost no change in activity. {ECO:0000269|PubMed:24214977}.	
P0AAH0	48	48		G->I: Loss of phosphate transport. {ECO:0000269|PubMed:8682808}.	
P0AAH0	49	49		K->Q: Loss of phosphate transport. {ECO:0000269|PubMed:8682808}.	
P0ACC7	14	14		G->A: 8-fold decrease in uridyltransferase activity. Creates steric conflict and decreases affinity for UTP. {ECO:0000269|PubMed:10428949}.	
P0ACC7	18	18		R->A: Dramatically impairs the uridyltransferase activity. {ECO:0000269|PubMed:10428949}.	
P0ACC7	25	25		K->A: 8-fold decrease in uridyltransferase activity. {ECO:0000269|PubMed:10428949}.	
P0ACC7	296	296	1	C->A: No effect. {ECO:0000269|PubMed:9733680}.	
P0ACC7	307	307		C->A: 1350-fold decrease in acetyltransferase activity. {ECO:0000269|PubMed:9733680}.	
P0ACC7	324	324		C->A: 8-fold decrease in acetyltransferase activity. {ECO:0000269|PubMed:9733680}.	
P0ACC7	385	385	1	C->A: No effect. {ECO:0000269|PubMed:9733680}.	
P0ABB4	157	157		T->A,C: Impairs ATPase activity. {ECO:0000269|PubMed:1832155}.	
P0ABB0	175	175		K->E: Reduced activity and reduced ATP- binding. {ECO:0000269|PubMed:2903146}.	
P0ABB0	175	175		K->I: Reduced activity and loss of ATP- binding. {ECO:0000269|PubMed:2903146}.	
P68699	23	23		G->D: In uncE429; unable to assemble in the membrane. {ECO:0000269|PubMed:6309138}.	
P68699	28	28		I->V: In DC1; has a functional F0 as well as F1 part. However, the ATPase activity is inhibited. {ECO:0000269|PubMed:6446460}.	
P68699	31	31		L->F: In uncE408 and uncE463; unable to assemble in the membrane. {ECO:0000269|PubMed:6309138}.	
P68699	61	61		D->G: In DG 7/1; contains an enzymatically active F1 component, but no functional F0 component. {ECO:0000269|PubMed:6446460}.	
P0AB98	206	206		S->L: Reduced activity.	
P0AB98	207	207	1	L->Y,F: No change in activity.	
P0AB98	210	210		R->K,I,V,E: Completely defective.	
P0AB98	214	214		N->H: Completely defective.	
P0AB98	214	214		N->V: Reduced activity.	
P0AB98	217	217		A->H: Reduced activity.	
P0AB98	217	217		A->R: Completely defective.	
P0AB98	245	245		H->Y: Reduced activity.	
P0A6U5	39	39		N->A: Lack of activity. Low-level streptomycin resistance. Slight decrease in AdoMet affinity. {ECO:0000269|Ref.8}.	
P0A6U5	53	53		H->A: Decrease in activity. Very low- level streptomycin resistance. Slight decrease in AdoMet affinity. {ECO:0000269|PubMed:22337945}.	
P0A6U5	56	56		D->A: Strong decrease in activity. Low- level streptomycin resistance. Slight decrease in AdoMet affinity. {ECO:0000269|PubMed:22337945}.	
P0A6U5	71	71		D->A: Lack of activity. Low-level streptomycin resistance. 10-fold increase in AdoMet affinity. {ECO:0000269|PubMed:22337945}.	
P0A6U5	73	73		G->A: Slight decrease in activity. Streptomycin-sensitive. Slight decrease in AdoMet affinity. {ECO:0000269|PubMed:22337945}.	
P0A6U5	75	75		G->A: Lack of activity. Low-level streptomycin resistance. 24-fold decrease in AdoMet affinity. {ECO:0000269|PubMed:22337945}.	
P0A6U5	77	77		G->A: Lack of activity. Low-level streptomycin resistance. 10-fold decrease in AdoMet affinity. {ECO:0000269|PubMed:22337945}.	
P0A6U5	79	79		P->A: Lack of activity. Low-level streptomycin resistance. 11-fold decrease in AdoMet affinity. {ECO:0000269|PubMed:22337945}.	
P0A6U5	96	96		D->A: Lack of activity. Low-level streptomycin resistance. {ECO:0000269|PubMed:22337945}.	
P0A6U5	100	101		KR->AA: Lack of activity. Low-level streptomycin resistance. {ECO:0000269|PubMed:22337945}.	
P0A6U5	123	123		R->A: Slight decrease in activity. Streptomycin-sensitive. {ECO:0000269|PubMed:22337945}.	
P0A6U5	139	139		R->A: Lack of activity. Low-level streptomycin resistance. No change in AdoMet affinity. {ECO:0000269|PubMed:22337945}.	
P0A6U5	139	139		R->K: Decrease in activity. Very low- level streptomycin resistance. {ECO:0000269|PubMed:22337945}.	
P0A6U5	165	165		K->A: Slight decrease in activity. Streptomycin-sensitive. {ECO:0000269|PubMed:22337945}.	
P0A6U5	197	197		R->A: Strong decrease in activity. Low- level streptomycin resistance. {ECO:0000269|PubMed:22337945}.	
P0A6U3	13	13		G->A: Decrease in FAD binding and partial loss of activity. Loss of activity; when associated with A-15. {ECO:0000269|PubMed:17062623}.	
P0A6U3	15	15		G->A: Decrease in FAD binding and partial loss of activity. Loss of activity; when associated with A-13. {ECO:0000269|PubMed:17062623}.	
P04982	20	20		H->A: Loss of pyranase activity. {ECO:0000269|PubMed:15060078}.	
P04982	106	106		H->A: Retains one-third of the original activity. {ECO:0000269|PubMed:15060078}.	
P04983	43	43		K->R: Loss of transport. {ECO:0000269|PubMed:8762140}.	
P0AG30	62	62		F->L,A: Defective for RNA-binding. {ECO:0000269|PubMed:2461932}.	
P0AG30	64	64		F->L,A: Defective for RNA-binding. {ECO:0000269|PubMed:2461932}.	
P0AG30	181	181		K->Q: Partial loss of ATPase, helicase and termination activity. {ECO:0000269|PubMed:2461932}.	
P0AG30	184	184		K->Q: Improves ATPase and helicase activity but reduced termination activity. {ECO:0000269|PubMed:2461932}.	
P0AG30	202	202	1	C->G,S: Does not affect the kinetics of ATP hydrolysis and inhibition by bicyclomycin. {ECO:0000269|PubMed:7487110}.	
P0AG30	265	265		D->N: Loss of ATPase activity, helicase and termination activity. {ECO:0000269|PubMed:2461932}.	
P0AC78	35	35		D->G: Decrease in activity; both in vivo and in vitro. {ECO:0000269|PubMed:11832520}.	
P0AC78	90	91		DD->EE,GG: Loss of activity in vivo. Decrease in activity in vitro. No change in binding to tunicamycin. {ECO:0000269|PubMed:11832520}.	
P0AC78	90	90		D->E,N: Reduces slightly the velocity and shows a small increase of the affinity for the transferase. {ECO:0000269|PubMed:17237164}.	
P0AC78	91	91		D->N: Reduces slightly the velocity and shows a small increase of the affinity for the transferase. {ECO:0000269|PubMed:17237164}.	
P0AC78	94	94	1	D->G: No loss in activity; both in vivo and in vitro. {ECO:0000269|PubMed:11832520}.	
P0AC78	156	156		D->E,N: Loss of activity. {ECO:0000269|PubMed:11832520, ECO:0000269|PubMed:17237164}.	
P0AC78	156	156		D->E: Loss of activity; both in vivo and in vitro; when associated with E-159. {ECO:0000269|PubMed:11832520, ECO:0000269|PubMed:17237164}.	
P0AC78	156	156		D->G: Loss of activity; both in vivo and in vitro. No binding to tunicamycin; when associated with G-159. {ECO:0000269|PubMed:11832520, ECO:0000269|PubMed:17237164}.	
P0AC78	159	159		D->E,N: The activity is detectable but drastically reduced. {ECO:0000269|PubMed:11832520, ECO:0000269|PubMed:17237164}.	
P0AC78	159	159		D->E: Loss of activity; both in vivo and in vitro; when associated with E-156. {ECO:0000269|PubMed:11832520, ECO:0000269|PubMed:17237164}.	
P0AC78	159	159		D->G: Loss of activity; both in vivo and in vitro. No binding to tunicamycin; when associated with G-156. {ECO:0000269|PubMed:11832520, ECO:0000269|PubMed:17237164}.	
P0AC78	265	265		R->K: Decrease in activity. Reduces binding to tunicamycin. {ECO:0000269|PubMed:11700352}.	
P0AC78	276	276	1	D->G: No loss of activity; both in vivo and in vitro. {ECO:0000269|PubMed:11832520}.	
P0AC78	279	282		HIHH->GGGG: Loss of activity. No binding to tunicamycin. {ECO:0000269|PubMed:11700352}.	
P0AC78	279	279		H->S: Loss of activity. No binding to tunicamycin. {ECO:0000269|PubMed:11700352}.	
P27828	15	15		K->A: More than 100-fold increase in KM for UDP-GlcNAc. {ECO:0000269|PubMed:15210128}.	
P27828	95	95		D->N: Strong decrease in activity. {ECO:0000269|PubMed:15210128}.	
P27828	117	117		E->Q: Strong decrease in activity. {ECO:0000269|PubMed:15210128}.	
P27828	131	131		E->Q: Strong decrease in activity. {ECO:0000269|PubMed:15210128}.	
P27828	213	213		H->N: 30-fold increase in KM for UDP- GlcNAc and 50-fold decrease in kcat. {ECO:0000269|PubMed:15210128}.	
P06983	7	7	1	R->L: No loss of activity.	
P06983	11	11		R->L: Loss of activity.	
P06983	55	55	1	K->Q: No loss of activity. {ECO:0000269|PubMed:2122889}.	
P06983	59	59		K->Q: 25-fold decrease in activity. {ECO:0000269|PubMed:2122889}.	
P06983	101	101	1	R->L: No loss of activity.	
P06983	131	131		R->L: Complete loss of activity.	
P06983	132	132		R->L: Complete loss of activity.	
P06983	155	155		R->L: Loss of activity.	
P06983	176	176		R->L: Loss of activity.	
P0A8P6	243	243		R->Q: Abolishes DNA cleavage activity. {ECO:0000269|PubMed:7744017}.	
P0A8P6	252	254		ESS->NHG: Abolishes chromosomal recombination but not plasmid resolution. {ECO:0000269|PubMed:10635320}.	
P0A8P6	275	275		Y->F: Abolishes DNA cleavage activity. {ECO:0000269|PubMed:7744017, ECO:0000269|PubMed:8402918, ECO:0000269|PubMed:9268326}.	
P0A921	172	172		S->F: Inactive protein. {ECO:0000269|PubMed:8300539}.	
P25665	641	641		H->N: Impaired activity, lower affinity for zinc binding. {ECO:0000269|PubMed:10625458}.	
P25665	641	641		H->Q: Impaired activity, lower affinity for zinc binding. Binds homocysteine 2-4x more weakly than wild-type. {ECO:0000269|PubMed:10625458}.	
P25665	643	643		C->S: Impaired activity, lower affinity for zinc binding. Binds homocysteine 7x tighter than wild-type. {ECO:0000269|PubMed:10625458}.	
P25665	726	726		C->S: Impaired activity, lower affinity for zinc binding. Binds homocysteine 2-4x more weakly than wild-type. {ECO:0000269|PubMed:10625458, ECO:0000269|PubMed:8823155}.	
P12758	5	5	1	D->A,E,N: No change in activity. {ECO:0000269|PubMed:9661793}.	
P0A887	142	142		G->D: In ubiE401; defective. {ECO:0000269|PubMed:9045837}.	
P69428	39	39		F->A: Homooligomerizes more efficiently than wt, blocks translocation. {ECO:0000269|PubMed:20169075}.	
P69423	17	17		R->A: No anaerobic growth and no TorA export. {ECO:0000269|PubMed:11781311}.	
P69423	20	22		Missing: No anaerobic growth and 75% decrease in TorA export. {ECO:0000269|PubMed:11781311}.	
P69423	20	20		L->A: 25% decrease in anaerobic growth and 75% decrease in TorA export. {ECO:0000269|PubMed:11781311}.	
P69423	94	94		F->A,L: Loss of function. {ECO:0000269|PubMed:11952898}.	
P69423	94	94		F->A: Export of TorA restored; when associated with A-211. {ECO:0000269|PubMed:11952898}.	
P69423	103	103		E->A,D,R: Loss of function. {ECO:0000269|PubMed:11952898}.	
P69423	103	103		E->A: Export of TorA restored; when associated with A-211. {ECO:0000269|PubMed:11952898}.	
P69423	103	103		E->Q: Severely retard but does not abolish activity. {ECO:0000269|PubMed:11952898}.	
P69423	211	211		D->A: Export activity of TorA blocked. Export of TorA restored; when associated with A-94 or A-103. {ECO:0000269|PubMed:11952898}.	
P69423	211	211		D->E,N: Decrease in TorA export activity. {ECO:0000269|PubMed:11952898}.	
P21177	116	116		G->F: Absence of both enoyl-CoA hydratase and 3-hydroxyacyl-CoA epimerase activities. Delta(3)-cis-Delta(2)-trans- enoyl-CoA isomerase is only slightly affected. {ECO:0000269|PubMed:8454629}.	
P21177	322	322		G->A: 10-fold increase in KM for NADH. {ECO:0000269|PubMed:8755745}.	
P21177	450	450		H->A,Q: Almost complete loss of 3- hydroxyacyl-CoA dehydrogenase activity. {ECO:0000269|PubMed:8755745}.	
P32173	12	14		LAG->TAA: 7.5-fold decrease in affinity for GTP and nearly no effect on catalytic activity. Displays a 3-fold decrease in activity with GTP and gains a low activity with CTP as substrate; when associated with 79-LLTS-82. {ECO:0000269|PubMed:21081498}.	
P32173	15	15		G->L: Complete loss of catalytic activity. Still capable of binding MPT and MGD and interacting with both MoeA and MobB. {ECO:0000269|PubMed:12719427}.	
P32173	19	19		R->A: Slight reduction in catalytic activity. {ECO:0000269|PubMed:12719427}.	
P32173	22	22	1	G->L: Nearly no effect on catalytic activity. {ECO:0000269|PubMed:12719427}.	
P32173	25	25		K->A: Marked reduction in catalytic activity. Still capable of interacting with both MoeA and MobB. {ECO:0000269|PubMed:12719427}.	
P32173	78	78	1	G->L: Nearly no effect on catalytic activity. {ECO:0000269|PubMed:12719427}.	
P32173	79	82		PLAG->LLTS: 11-fold decrease in affinity for GTP and nearly no effect on catalytic activity. Displays a 3-fold decrease in activity with GTP and gains a low activity with CTP as substrate; when associated with 12-TAA-14. {ECO:0000269|PubMed:21081498}.	
P32173	82	82		G->L: Slight reduction in catalytic activity. {ECO:0000269|PubMed:12719427}.	
P32173	101	101		D->A: Complete loss of catalytic activity. {ECO:0000269|PubMed:12719427}.	
P32173	101	101		D->N: Marked reduction in catalytic activity. Still capable of interacting with both MoeA and MobB. {ECO:0000269|PubMed:12719427}.	
P32173	156	156	1	R->A: Nearly no effect on catalytic activity. {ECO:0000269|PubMed:12719427}.	
P32173	180	180	1	N->D: Nearly no effect on catalytic activity. {ECO:0000269|PubMed:12719427}.	
P32173	182	182	1	N->D: Nearly no effect on catalytic activity. {ECO:0000269|PubMed:12719427}.	
P0C0K3	36	36		S->A: Partial loss of kinase activity, only partially protects bacteria against hyperlethal stress. {ECO:0000269|PubMed:23416055}.	
P0C0K3	217	217		D->A: Loss of kinase activity; does not protect bacteria against hyperlethal stress. {ECO:0000269|PubMed:17302814, ECO:0000269|PubMed:23416055}.	
P0A8H6	65	65	1	R->A: No change in ability to stimulate Der GTPase. {ECO:0000269|PubMed:20434458}.	
P0A8H6	135	135	1	R->A: No change in ability to stimulate Der GTPase. {ECO:0000269|PubMed:20434458}.	
P0A8H6	164	164	1	R->A: No change in ability to stimulate Der GTPase. {ECO:0000269|PubMed:20434458}.	
P0A8H6	167	167	1	R->A: No change in ability to stimulate Der GTPase. {ECO:0000269|PubMed:20434458}.	
P32131	56	56		Y->A,L: Loss of activity. {ECO:0000269|PubMed:12114526, ECO:0000269|PubMed:15967800}.	
P32131	56	56		Y->F: Decreases activity by 50%. {ECO:0000269|PubMed:12114526, ECO:0000269|PubMed:15967800}.	
P32131	58	58		H->L: Results in loss of iron-sulfur cluster and activity. {ECO:0000269|PubMed:12114526}.	
P32131	62	62		C->S: Results in loss of iron-sulfur cluster and activity. {ECO:0000269|PubMed:12114526}.	
P32131	66	66		C->S: Results in loss of iron-sulfur cluster and activity. {ECO:0000269|PubMed:12114526}.	
P32131	68	68	1	F->L: No effect. {ECO:0000269|PubMed:12114526}.	
P32131	69	69		C->S: Results in loss of iron-sulfur cluster and activity. {ECO:0000269|PubMed:12114526}.	
P32131	71	71	1	C->S: No effect on iron-sulfur cluster, but results in activity loss. {ECO:0000269|PubMed:12114526}.	
P32131	111	111		G->V: Loss of activity and much less iron-sulfur cluster formed; when associated with V-113. {ECO:0000269|PubMed:12114526}.	
P32131	113	113		G->V: Loss of activity and much less iron-sulfur cluster formed; when associated with V-111. {ECO:0000269|PubMed:12114526}.	
P32131	145	145		E->A,I: Loss of activity. Iron content reduced by about 80%. {ECO:0000269|PubMed:15967800}.	
P32131	310	310		F->A,L: Loss of activity. Iron content reduced by about 50%. Can cleave up to one molecule of S-adenosyl-L-methionine (in vitro). {ECO:0000269|PubMed:15967800}.	
P32131	311	311		Q->A: Loss of activity. No change in iron content. Can cleave up to one molecule of S-adenosyl-L-methionine (in vitro). {ECO:0000269|PubMed:15967800}.	
P32131	329	329		I->A: Loss of activity. No change in iron content. Can cleave up to one molecule of S-adenosyl-L-methionine (in vitro). {ECO:0000269|PubMed:15967800}.	
P32140	55	55		R->A: Loss of activity. {ECO:0000269|PubMed:18328504}.	
P32140	176	176		H->A: Loss of activity. {ECO:0000269|PubMed:18328504}.	
P32140	248	248		H->A: Loss of activity. {ECO:0000269|PubMed:18328504}.	
P32140	251	251		E->A: Strong decrease in activity. {ECO:0000269|PubMed:18328504}.	
P32140	320	320		E->A: Loss of activity. {ECO:0000269|PubMed:18328504}.	
P32140	383	383		H->A: Loss of activity. {ECO:0000269|PubMed:18328504}.	
P32156	18	18		Y->F: Loss of mutarotase activity. {ECO:0000269|PubMed:15876375}.	
P32171	69	69	1	E->A: Same kinase activity as the wild- type; when associated with A-70 and A-73. {ECO:0000269|PubMed:16674975}.	
P32171	70	70	1	E->A: Same kinase activity as the wild- type; when associated with A-69 and A-73. {ECO:0000269|PubMed:16674975}.	
P32171	73	73	1	R->A: Same kinase activity as the wild- type; when associated with A-69 and A-70. {ECO:0000269|PubMed:16674975}.	
P09377	201	201		L->A: 48% of wild-type activity. {ECO:0000269|PubMed:10464186}.	
P09377	202	202		R->A: 4% of wild-type activity. {ECO:0000269|PubMed:10464186}.	
P09377	205	205		H->A: 28% of wild-type activity. {ECO:0000269|PubMed:10464186}.	
P09377	206	206		R->A: 0.1% of wild-type activity. {ECO:0000269|PubMed:10464186}.	
P09377	246	246		C->A: 66% of wild-type activity. {ECO:0000269|PubMed:10464186}.	
P09377	247	247		G->A: 6.2% of wild-type activity. {ECO:0000269|PubMed:10464186}.	
P09377	247	247		G->R: 0.9% of wild-type activity. {ECO:0000269|PubMed:10464186}.	
P09377	248	248		F->A: 0.9% of wild-type activity. {ECO:0000269|PubMed:10464186}.	
P09377	248	248		F->V: 3.3% of wild-type activity. {ECO:0000269|PubMed:10464186}.	
P09377	249	249		S->G: 93% of wild-type activity. {ECO:0000269|PubMed:10464186}.	
P09377	250	250		D->A: 8.3% of wild-type activity. {ECO:0000269|PubMed:10464186}.	
P09377	251	251		S->G: 87% of wild-type activity. {ECO:0000269|PubMed:10464186}.	
P09377	252	252		N->A: 31% of wild-type activity. {ECO:0000269|PubMed:10464186}.	
P09377	252	252		N->H: 0.4% of wild-type activity. {ECO:0000269|PubMed:10464186}.	
P09377	252	252		N->I: 0.3% of wild-type activity. {ECO:0000269|PubMed:10464186}.	
P09377	252	252		N->S: 37% of wild-type activity. {ECO:0000269|PubMed:10464186}.	
P09377	253	253		H->A: 48% of wild-type activity. {ECO:0000269|PubMed:10464186}.	
P09377	253	253		H->Q: 32% of wild-type activity. {ECO:0000269|PubMed:10464186}.	
P09377	254	254		F->A: 1.2% of wild-type activity. {ECO:0000269|PubMed:10464186}.	
P09377	255	255		S->A: 80% of wild-type activity. {ECO:0000269|PubMed:10464186}.	
P09377	256	256		T->A: 61% of wild-type activity. {ECO:0000269|PubMed:10464186}.	
P0A796	128	128		D->S: 18000-fold reduction of catalytic rate. {ECO:0000269|PubMed:2953977}.	
P0A796	172	172		R->S: 3.4-fold reduction in turnover numbers. {ECO:0000269|PubMed:2953977}.	
P0A9C9	29	29		K->A: 2.4-fold increase in FBPase activity, and no effect on substrate affinity. {ECO:0000269|PubMed:19073594}.	
P0A9C9	57	57		E->A: Strong decrease in FBPase activity. {ECO:0000269|PubMed:19073594}.	
P0A9C9	59	59		E->A: 5.5-fold decrease in FBPase activity, and 1.4-fold decrease in substrate affinity. {ECO:0000269|PubMed:19073594}.	
P0A9C9	61	61		D->A: Great decrease in FBPase activity. {ECO:0000269|PubMed:19073594}.	
P0A9C9	85	85		D->A: Great decrease in FBPase activity. {ECO:0000269|PubMed:19073594}.	
P0A9C9	88	88		E->A: Strong decrease in FBPase activity. {ECO:0000269|PubMed:19073594}.	
P0A9C9	90	90		T->A: Strong decrease in FBPase activity. {ECO:0000269|PubMed:19073594}.	
P0A9C9	119	119		Y->A: Strong decrease in FBPase activity. {ECO:0000269|PubMed:19073594}.	
P0A9C9	164	164		K->A: Strong decrease in FBPase activity. {ECO:0000269|PubMed:19073594}.	
P0A9C9	166	166		R->A: Strong decrease in FBPase activity. {ECO:0000269|PubMed:19073594}.	
P0A9C9	186	186		D->A: 5-fold decrease in FBPase activity, and 3-fold decrease in substrate affinity. {ECO:0000269|PubMed:19073594}.	
P0A9C9	188	188		D->A: Great decrease in FBPase activity. {ECO:0000269|PubMed:19073594}.	
P0A9C9	213	213		E->A: Great decrease in FBPase activity. {ECO:0000269|PubMed:19073594}.	
P0A9C9	235	235		R->A: Nearly no effect on FBPase activity, and 3-fold decrease in substrate affinity. {ECO:0000269|PubMed:19073594}.	
P0A9C9	239	239		K->A: 1.3-fold increase in FBPase activity, and 1.4-fold decrease in substrate affinity. {ECO:0000269|PubMed:19073594}.	
P0A6F3	59	59		S->W: Abolishes inhibition of GK by FBP via disruption of the dimer-tetramer assembly reaction. Inhibition by EIIA-Glc is unchanged compared to wild type. The activity of this mutant is significantly higher than wild-type, and the Michaelis constants are increased slightly compared to wild-type. {ECO:0000269|PubMed:10090737}.	
P0A6F3	66	66		A->T: Although it completely abolishes FBP regulation and disruptes dimer- tetramer equilibrium, the crystal structure is essentially identical to the symmetric tetramer found in the FBP-bound form of the enzyme. {ECO:0000269|PubMed:9817843}.	
P0A6F3	231	231		G->D: Displays an increased enzymatic activity and a decreased allosteric regulation by FBP compared to wild-type. It displays a dimer form and is resistant to tetramer formation in the presence of FBP, whereas wild-type dimers are converted into inactive tetramers in the presence of FBP. {ECO:0000269|PubMed:17441732}.	
P0A6F3	237	237		R->A: Drastically reduces inhibition of GK by FBP and lowers, but did not eliminate, the ability of FBP to promote tetramer association. {ECO:0000269|PubMed:9843423}.	
P0A6F3	305	305		G->S: In glpK22; abolishes glucose control of glycerol utilization.	
P0A6F3	475	475		I->D: It decreases Vmax to about 10% of the wild-type value and the affinity for substrate is increased about two- to fourfold. This mutation decreases the catalytic activity in a manner that is analogous to that obtained upon EIIA-Glc binding. It increases the affinity for FBP about fivefold. {ECO:0000269|PubMed:9817843}.	
P0A6F3	480	480		R->D: It decreases Vmax to about 10% of the wild-type value and the affinity for substrate is increased about two- to fourfold. This mutation decreases the catalytic activity in a manner that is analogous to that obtained upon EIIA-Glc binding. Regulation by FBP is not affected by this substitution. No inhibition by EIIA-Glc is observed, which is consistent with a decrease in affinity for EIIA-Glc of about 250-fold. {ECO:0000269|PubMed:9817843}.	
P0AER0	236	237	1	PL->FW: No detectable water or glycerol permeability.	
P0A6H5	63	63		K->T: Can neither bind nor hydrolyze ATP. Do not form multimers, but stays as monomer. {ECO:0000269|PubMed:8977096}.	
P0A6H5	80	80		K->T: Some effect on protease activity. {ECO:0000269|PubMed:11114186}.	
P0A6H5	88	88		E->Q: Severly reduced protease activity. {ECO:0000269|PubMed:11114186}.	
P0A6H5	91	91		Y->G: Partial loss of protease activity. {ECO:0000269|PubMed:11114186}.	
P0A6H5	92	92		V->G: Partial loss of protease activity. {ECO:0000269|PubMed:11114186}.	
P0A6H5	93	93		G->A: Almost no protease or ATP hydrolysis activity. {ECO:0000269|PubMed:11114186}.	
P0A6H5	95	95		E->W: Partial loss of protease activity. {ECO:0000269|PubMed:11114186}.	
P0A6H5	262	262	1	C->V: No effect on ATP hydrolysis. Can support HslV-mediated proteolysis at wild-type levels. {ECO:0000269|PubMed:9722513}.	
P0A6H5	266	266	1	E->Q: No effect. {ECO:0000269|PubMed:11114186}.	
P0A6H5	286	286		E->Q: Reduced protease activity. {ECO:0000269|PubMed:11114186}.	
P0A6H5	288	288		C->V: No ATP hydrolysis activity. Binds ATP with lower affinity than wild-type. Can support HslV-mediated proteolysis to some extent. {ECO:0000269|PubMed:9722513}.	
P0A6H5	312	312	1	I->W: No effect. {ECO:0000269|PubMed:11114186}.	
P0A6H5	321	321		E->Q: Complete loss of activity. {ECO:0000269|PubMed:11114186}.	
P0A6H5	325	325		R->E: Complete loss of activity. Forms wild-type complexes with HslV and is able to bind ATP. {ECO:0000269|PubMed:11114186}.	
P0A6H5	385	385	1	E->K: No effect. {ECO:0000269|PubMed:11114186}.	
P0A6H5	393	393		R->A: Complete loss of activity. {ECO:0000269|PubMed:11114186}.	
P0A6H5	436	436		E->K: Partial loss of protease activity; when associated with K-437.	
P0A6H5	437	437		D->K: Partial loss of protease activity; when associated with K-436.	
P0A7B8	2	2		T->S: 80% reduced protease activity in the absence of HslU. Almost no effect in the presence of HslU. {ECO:0000269|PubMed:9257689}.	
P0A7B8	2	2		T->V: No protease activity. {ECO:0000269|PubMed:9257689}.	
P0A7B8	3	3		T->S,V: 80% reduced protease activity. {ECO:0000269|PubMed:9257689}.	
P0A7B8	6	6	1	S->A: No effect. {ECO:0000269|PubMed:9257689}.	
P0A7B8	104	104		S->A: 50% reduced protease activity. {ECO:0000269|PubMed:9257689}.	
P0A7B8	125	125		S->A: Almost no protease activity. {ECO:0000269|PubMed:9257689}.	
P0A7B8	144	144	1	S->A: No effect. {ECO:0000269|PubMed:9257689}.	
P0A7B8	160	160		C->A,S: No protease activity. Cannot form complexes with HslU. {ECO:0000269|PubMed:9722513}.	
P0A7B8	173	173		S->A: Almost no protease activity. {ECO:0000269|PubMed:9257689}.	
P17888	226	226		T->V: Strong decrease in ATPase and helicase activities. Does not affect DNA binding. {ECO:0000269|PubMed:12622722}.	
P17888	230	230		K->D: Lack of ATPase activity and strong decrease in helicase activity. Does not affect DNA binding. {ECO:0000269|PubMed:10356325, ECO:0000269|PubMed:12622722}.	
P17888	230	230		K->R: Lack of helicase activity. Decreases Mu DNA replication. {ECO:0000269|PubMed:10356325, ECO:0000269|PubMed:12622722}.	
P17888	320	320		D->A: Strong decrease in ATPase and helicase activities. Decreases DNA binding. {ECO:0000269|PubMed:12622722}.	
P17888	584	584		R->A: Does not affect DNA binding, but impairs ATPase activity. {ECO:0000269|PubMed:12622722}.	
P0A7M9	16	16		C->S: No Zn(2+) binding. {ECO:0000269|PubMed:22196016}.	
P0A7M9	18	18	1	C->S: Binds Zn(2+) normally. {ECO:0000269|PubMed:22196016}.	
P0A7M9	37	40		CSKC->SSKS: Binds Zn(2+) normally. {ECO:0000269|PubMed:22196016}.	
P0AEZ1	28	28		E->Q: Abolishes enzyme activity. {ECO:0000269|PubMed:11371182, ECO:0000269|PubMed:16114881}.	
P0AEZ1	120	120		D->N: Strongly reduces enzyme activity. Strongly reduces affinity for 5- methyltetrahydrofolate. {ECO:0000269|PubMed:11371182}.	
P0AEZ1	177	177		A->V: Increases the propensity to lose its essential flavin cofactor. {ECO:0000269|PubMed:10201405}.	
P0AEZ1	223	223		F->A: Strongly decreases substrate and NADH binding. {ECO:0000269|PubMed:19610625}.	
P0AEZ1	223	223		F->L: Slightly reduced enzyme activity. {ECO:0000269|PubMed:19610625}.	
P00864	138	138		H->N: Loss of activity. {ECO:0000269|PubMed:1765093}.	
P00864	579	579		H->N: 29% of wild-type activity. {ECO:0000269|PubMed:2016273}.	
P00864	579	579		H->P: 5.4% of wild-type activity. {ECO:0000269|PubMed:2016273}.	
P00864	587	587		R->S: Loss of activity. {ECO:0000269|PubMed:7490260}.	
P0A6C8	8	8		K->R: Reduces activity 50-fold. Increases KM for N-acetyl-L-glutamate and ATP about 10-fold. {ECO:0000269|PubMed:14623187}.	
P0A6C8	66	66		R->K: Increases KM for N-acetyl-L- glutamate over 1000-fold. Increases KM for ATP nearly 20-fold. {ECO:0000269|PubMed:14623187}.	
P0A6C8	158	158		N->Q: Increases KM for N-acetyl-L- glutamate over 1000-fold. Increases KM for ATP over 20-fold. {ECO:0000269|PubMed:14623187}.	
P0A6C8	162	162		D->E: Reduces activity over 99%. No effect on KM for N-acetyl-L-glutamate and ATP. {ECO:0000269|PubMed:14623187}.	
P0ACQ4	199	199		C->S,A: No activation following redox signaling. {ECO:0000269|PubMed:9497290}.	
P0ACQ4	208	208		C->S,A: No activation following redox signaling. {ECO:0000269|PubMed:9497290}.	
P23003	358	358		E->Q: Loss of catalytic activity. {ECO:0000269|PubMed:18451029}.	
P06129	28	28		L->P: Inactivates uptake. {ECO:0000269|PubMed:11705387}.	
P06129	30	30		V->G,P: Inactivates uptake. {ECO:0000269|PubMed:11705387}.	
P06709	52	52	1	T->I: Does not affect repressor activity. {ECO:0000269|PubMed:24189073}.	
P06709	52	52		T->S: 5-fold increase of repressor activity. Increases binding to DNA. {ECO:0000269|PubMed:24189073}.	
P06709	57	57		G->S: Lack of repressor activity. Does not bind DNA. {ECO:0000269|PubMed:24189073}.	
P06709	58	58		Y->F: Lack of repressor activity. {ECO:0000269|PubMed:24189073}.	
P06709	58	58	1	Y->T: Does not affect repressor activity. {ECO:0000269|PubMed:24189073}.	
P0CE48	20	20		H->A: No change in binding GDP and 3-fold reduction in binding EF-Ts. {ECO:0000269|PubMed:9468511}.	
P0CE48	115	115		Q->A: Weaker binding for GDP and for EF- Ts. {ECO:0000269|PubMed:9468511}.	
P0CE48	137	137		K->R,Q,E,I: Reduces affinity for GDP. {ECO:0000269|PubMed:2498311}.	
P0CE48	139	139		D->N: Reduces affinity for GDP; increases affinity for XDP. {ECO:0000269|PubMed:3308869}.	
P0CE48	223	223		G->D: Inhibits codon-induced conformational changes leading to GTPase activation on the ribosome. {ECO:0000269|PubMed:2508560}.	
P0CE48	349	349		E->A: No change in binding GDP but higher binding constant for EF-Ts. {ECO:0000269|PubMed:9468511}.	
P0CE48	383	383		T->V: No longer phosphorylated by phage protein doc. {ECO:0000269|PubMed:24141193}.	
P0AG96	120	120		S->C: Massive ion flux when cross-linked to SecY C-67 mutation. {ECO:0000269|PubMed:17531809}.	
P0A7J3	156	165		Missing: Generation time doubles, only 1 L12 dimer binds to the ribosome. Decreased association of IF-2 with L7/L12 and decreased stimulation of GTPase activity of EF-G by L7/L12. {ECO:0000269|PubMed:22102582}.	
P0A7K2	66	66		K->A: EF-Tu-binding and EF-Tu-promoted GTP hydrolysis reduced. {ECO:0000269|PubMed:15989950}.	
P0A7K2	67	67		V->D: EF-Tu-binding and EF-Tu-promoted GTP hydrolysis reduced. {ECO:0000269|PubMed:15989950}.	
P0A7K2	70	70		I->A: EF-Tu-binding and EF-Tu-promoted GTP hydrolysis reduced. {ECO:0000269|PubMed:15989950}.	
P0A7K2	71	71		K->A: EF-Tu-binding and EF-Tu-promoted GTP hydrolysis reduced. {ECO:0000269|PubMed:15989950}.	
P0A7K2	74	74		R->M: EF-Tu-binding and EF-Tu-promoted GTP hydrolysis reduced. {ECO:0000269|PubMed:15989950}.	
P0A7K2	85	85		K->A: EF-Tu-binding and EF-Tu-promoted GTP hydrolysis reduced. {ECO:0000269|PubMed:15989950}.	
P0A8V2	813	813		E->K: Disrupts the enzyme's active center. {ECO:0000269|PubMed:2068078}.	
P30138	174	174		W->A: No adenylation of ThiS. {ECO:0000269|PubMed:15896804}.	
P30138	184	184		C->S: No cross-link formed with ThiS. No effect on ThiS thiocarboxylate formation in vitro. Does not support growth. {ECO:0000269|PubMed:11438688}.	
P68739	35	35		D->A: Lack of activity on RNA. {ECO:0000269|PubMed:23912683}.	
P0A9G6	195	195		C->A: Large decrease in activity. {ECO:0000269|PubMed:7826335}.	
P0A9G6	195	195		C->S: Large decrease in activity. {ECO:0000269|PubMed:7826335}.	
P0A9G6	219	219		A->C: Isocitrate lyase activity is reduced compared to the wild-type. {ECO:0000269|PubMed:11526312}.	
P11071	336	336		K->M: Inhibits enzyme. {ECO:0000269|PubMed:2557093}.	
P11071	371	371		D->A,E,Q: Loss of activity. {ECO:0000269|PubMed:11258918}.	
P11071	377	377	1	N->A: No loss of activity. {ECO:0000269|PubMed:11258918}.	
P11071	403	403	1	D->A: No loss of activity. {ECO:0000269|PubMed:11258918}.	
P11071	439	439	1	E->A: No loss of activity. {ECO:0000269|PubMed:11258918}.	
P16528	143	143		L->D: Strongly reduced promoter binding and tetramerization. {ECO:0000269|PubMed:17426033}.	
P16528	146	146		M->D: Strongly reduced promoter binding and tetramerization. {ECO:0000269|PubMed:17426033}.	
P16528	154	154		L->D: Strongly reduced promoter binding and tetramerization. {ECO:0000269|PubMed:17426033}.	
P16528	220	220		L->D: Loss of promoter binding and tetramerization. {ECO:0000269|PubMed:17426033}.	
P13009	310	310		C->A,S: Loss of zinc binding. Loss of catalytic activity. {ECO:0000269|PubMed:9201956}.	
P13009	311	311		C->A,S: Loss of zinc binding. Loss of catalytic activity. {ECO:0000269|PubMed:9201956}.	
P13009	757	757		D->E: Decreases activity by about 70%. {ECO:0000269|PubMed:8652590}.	
P13009	757	757		D->N: Decreases activity by about 45%. {ECO:0000269|PubMed:8652590}.	
P13009	759	759		H->G: Loss of catalytic activity. {ECO:0000269|PubMed:8652590}.	
P13009	810	810		S->A: Decreases activity by about 40%. {ECO:0000269|PubMed:8652590}.	
P32684	107	107		D->N,T: Loss of activity. {ECO:0000269|PubMed:11720289}.	
P08660	8	8		K->R: Reduces activity about 98%. Increases KM for aspartate about 40-fold, enzyme is less sensitive to lysine inhibition. {ECO:0000269|PubMed:14623187}.	
P08660	119	119		E->D: Increases KM for aspartate about 3000-fold. {ECO:0000269|PubMed:14623187}.	
P08660	198	198		R->K: Increases KM for aspartate about 200-fold. {ECO:0000269|PubMed:14623187}.	
P08660	202	202		D->E: Reduces activity about 98%. Increases KM for aspartate about 40-fold, enzyme is less sensitive to lysine inhibition. {ECO:0000269|PubMed:14623187}.	
P0AGF4	24	24		F->A: Decreases xylose transport. {ECO:0000269|PubMed:23075985}.	
P0AGF4	83	83		G->A: Abolishes xylose transport. {ECO:0000269|PubMed:23075985}.	
P0AGF4	133	133		R->C,H,L: Abolishes xylose transport. {ECO:0000269|PubMed:23075985}.	
P0AGF4	153	153		E->A: Abolishes xylose transport. {ECO:0000269|PubMed:23075985}.	
P0AGF4	160	160		R->A: Abolishes xylose transport. {ECO:0000269|PubMed:23075985}.	
P0AGF4	168	168		Q->A: Abolishes xylose transport. {ECO:0000269|PubMed:23075985}.	
P0AGF4	288	288		Q->A: Abolishes xylose transport. {ECO:0000269|PubMed:23075985}.	
P0AGF4	289	289		Q->A: Strongly decreases xylose transport. {ECO:0000269|PubMed:23075985}.	
P0AGF4	294	294		N->A: Abolishes xylose transport. {ECO:0000269|PubMed:23075985}.	
P0AGF4	298	298		Y->A: Abolishes xylose transport. {ECO:0000269|PubMed:23075985}.	
P0AGF4	325	325	1	N->A: No effect on xylose transport. {ECO:0000269|PubMed:23075985}.	
P0AGF4	340	340		G->A: Abolishes xylose transport. {ECO:0000269|PubMed:23075985}.	
P0AGF4	341	341		R->A,W: Abolishes xylose transport. {ECO:0000269|PubMed:23075985}.	
P0AGF4	392	392		W->A: Abolishes xylose transport. {ECO:0000269|PubMed:23075985}.	
P0AGF4	397	397		E->A: Abolishes xylose transport. {ECO:0000269|PubMed:23075985}.	
P0AGF4	404	404		R->A: Strongly decreases xylose transport. {ECO:0000269|PubMed:23075985}.	
P0AGF4	415	415		Q->A: Strongly decreases xylose transport.	
P0AGF4	416	416		W->A: Strongly decreases xylose transport. {ECO:0000269|PubMed:23075985}.	
P68183	190	190		E->A,C,K,L: Reduction of transport rate. {ECO:0000269|PubMed:10809785, ECO:0000269|PubMed:9214624}.	
P68183	192	192		A->D,S,L: Loss of transport and MalK dissociation from the membrane. {ECO:0000269|PubMed:10809785, ECO:0000269|PubMed:9214624}.	
P68183	196	196	1	G->A: No effect. {ECO:0000269|PubMed:10809785, ECO:0000269|PubMed:9214624}.	
P68183	196	196		G->P: Loss of transport and MalK dissociation from the membrane. {ECO:0000269|PubMed:10809785, ECO:0000269|PubMed:9214624}.	
P68183	209	209	1	P->A: No effect. {ECO:0000269|PubMed:9214624}.	
P02916	334	334		L->W: Ability to transport lactose in a saturable manner. {ECO:0000269|PubMed:9401026}.	
P02916	372	372		L->W: Growth on maltose but not on media containing either maltoheptaose or maltoheptaose plus maltose. {ECO:0000269|PubMed:8636026}.	
P02916	376	376		N->K,H: No growth on maltose. {ECO:0000269|PubMed:8636026}.	
P02916	380	380		G->C,S: No growth on maltose. {ECO:0000269|PubMed:8636026}.	
P02916	401	401		E->A,C,K,L: Reduction of transport rate. {ECO:0000269|PubMed:10809785, ECO:0000269|PubMed:9214624}.	
P02916	403	403		S->C,D,K,L: Reduction of transport rate. {ECO:0000269|PubMed:10809785, ECO:0000269|PubMed:9214624}.	
P02916	407	407	1	G->A,P: No effect. {ECO:0000269|PubMed:9214624}.	
P02916	420	420	1	P->A: No effect. {ECO:0000269|PubMed:9214624}.	
P68187	85	85	1	A->M: Suppressor of EAA loop mutations in MalFG. {ECO:0000269|PubMed:9214624}.	
P68187	106	106	1	K->C: Suppressor of EAA loop mutations in MalFG. {ECO:0000269|PubMed:10809785}.	
P68187	114	114	1	V->C: Suppressor of EAA loop mutations in MalFG. {ECO:0000269|PubMed:10809785}.	
P68187	117	117	1	V->M: Suppressor of EAA loop mutations in MalFG. {ECO:0000269|PubMed:9214624}.	
P68187	119	119		E->K: Resistant to inhibitory effects of alpha-methylglucoside but retains transport capacity. {ECO:0000269|PubMed:2007546}.	
P68187	124	124		A->T: Resistant to inhibitory effects of alpha-methylglucoside but retains transport capacity. {ECO:0000269|PubMed:2250006}.	
P68187	137	137		G->A: Loss of maltose transport. Has greater ability to decrease mal gene expression than wild-type MalK. {ECO:0000269|PubMed:2007546}.	
P68187	158	158		D->N: Loss of maltose transport but retains ability to repress mal genes. {ECO:0000269|PubMed:2007546}.	
P68187	228	228		R->C: Resistant to inhibitory effects of alpha-methylglucoside but retains transport capacity. {ECO:0000269|PubMed:2007546}.	
P68187	241	241		F->I: Resistant to inhibitory effects of alpha-methylglucoside but retains transport capacity. {ECO:0000269|PubMed:2250006}.	
P68187	267	267	1	W->G: Normal maltose transport but constitutive mal gene expression. {ECO:0000269|PubMed:2007546}.	
P68187	278	278		G->P: Resistant to inhibitory effects of alpha-methylglucoside but retains transport capacity. {ECO:0000269|PubMed:2250006}.	
P68187	282	282		S->L: Resistant to inhibitory effects of alpha-methylglucoside but retains transport capacity. {ECO:0000269|PubMed:2007546}.	
P68187	284	284		G->S: Resistant to inhibitory effects of alpha-methylglucoside but retains transport capacity. {ECO:0000269|PubMed:2250006}.	
P68187	302	302		G->D: Resistant to inhibitory effects of alpha-methylglucoside but retains transport capacity. {ECO:0000269|PubMed:2007546}.	
P68187	308	308		E->Q: Maltose transport is affected but retains ability to interact with MalT. {ECO:0000269|PubMed:11709552}.	
P68187	322	322		S->F: Resistant to inhibitory effects of alpha-methylglucoside but retains transport capacity. {ECO:0000269|PubMed:2007546}.	
P68187	340	340		G->A: Maltose transport is affected but retains ability to interact with MalT. {ECO:0000269|PubMed:11709552}.	
P68187	346	346	1	G->S: Normal maltose transport but constitutive mal gene expression. {ECO:0000269|PubMed:2007546}.	
P68187	355	355		F->Y: Maltose transport is affected but retains ability to interact with MalT. {ECO:0000269|PubMed:11709552}.	
P02943	33	33		R->H: Reduces ligand affinity and pore size, no longer selective for maltodextrins. {ECO:0000269|PubMed:3301537}.	
P02943	99	99		W->R: Decreases starch affinity, slightly increases maltose affinity. {ECO:0000269|PubMed:3301537}.	
P02943	107	107		R->S: Decreases maltodextrin affinity, increases sucrose binding and transport. {ECO:0000269|PubMed:3301537}.	
P02943	134	134		R->A: Considerable increase in pore size and sucrose transport, slight decrease in maltose transport; when associated with A-143. {ECO:0000269|PubMed:11742115}.	
P02943	134	134		R->D,N: Slight increase in pore size; increase in sucrose transport and slight decrease in maltose transport; when associated with D-143 and F-146. {ECO:0000269|PubMed:11742115}.	
P02943	143	143		Y->F: Increases affinity for starch and maltose, pore size and transport of maltohexaose. {ECO:0000269|PubMed:11742115, ECO:0000269|PubMed:3301537}.	
P02943	146	146	1	D->G: Increases affinity for large dextrins. {ECO:0000269|PubMed:11742115, ECO:0000269|PubMed:3301537}.	
P26602	91	91		G->A: Increases the inhibition by product by about 40%. No effect on substrate affinity. {ECO:0000269|PubMed:16343413}.	
P26602	156	156		E->K: Loss of activity. {ECO:0000269|PubMed:8012607}.	
P0A7A7	306	306		H->A: Abolishes acyltransferase activity. {ECO:0000269|PubMed:10231527, ECO:0000269|PubMed:9515909}.	
P0A7A7	306	306		H->G: Reduced acyltransferase activity. {ECO:0000269|PubMed:10231527, ECO:0000269|PubMed:9515909}.	
P0A7A7	308	308	1	S->A: No effect. {ECO:0000269|PubMed:10231527}.	
P0A7A7	311	311		D->A: Prevents assembly into the membrane, suggesting that it paticipates to folding. {ECO:0000269|PubMed:10231527, ECO:0000269|PubMed:9515909}.	
P0A7A7	311	311		D->G: Strongly reduced acyltransferase activity. {ECO:0000269|PubMed:10231527, ECO:0000269|PubMed:9515909}.	
P0A7A7	349	349		A->T: In plsB26; results in high KM for glycerol-3-phosphate and reduced specific activity. {ECO:0000269|PubMed:10074094}.	
P0A7A7	351	351		F->A: Strongly reduced acyltransferase activity. {ECO:0000269|PubMed:10231527}.	
P0A7A7	352	352		I->A: Reduced acyltransferase activity. {ECO:0000269|PubMed:10231527}.	
P0A7A7	354	354		R->C: Reduced acyltransferase activity. {ECO:0000269|PubMed:10231527}.	
P0A7A7	354	354	1	R->K: No effect. {ECO:0000269|PubMed:10231527}.	
P0A7A7	385	385		E->R: Strongly reduced acyltransferase activity. {ECO:0000269|PubMed:10231527}.	
P0A7A7	386	386	1	G->A: No effect. {ECO:0000269|PubMed:10231527}.	
P0A7A7	386	386		G->L: Reduced acyltransferase activity. {ECO:0000269|PubMed:10231527}.	
P0A7A7	389	389	1	S->A: No effect. {ECO:0000269|PubMed:10231527}.	
P0A7A7	421	421		P->S: Reduced acyltransferase activity. {ECO:0000269|PubMed:10231527}.	
P0A6B4	164	164		D->A: Slightly reduces affinity for D-Ala and L-Ala. {ECO:0000269|PubMed:18434499}.	
P0A6B4	164	164		D->K: Reduces catalytic activity. Slightly reduces affinity for D-Ala and L-Ala. {ECO:0000269|PubMed:18434499}.	
P0A6B4	165	165		E->A: Slightly reduces affinity for D-Ala and L-Ala. {ECO:0000269|PubMed:18434499}.	
P0A6B4	165	165		E->K: Reduces catalytic activity. Slightly reduces affinity for D-Ala and L-Ala. {ECO:0000269|PubMed:18434499}.	
P0A6B4	219	219	1	P->A: No effect on catalytic activity. No effect on affinity for D-Ala and L-Ala. {ECO:0000269|PubMed:18434499}.	
P0A6B4	221	221	1	E->A,K,P: Slightly increases catalytic activity. Slightly increases affinity for D-Ala and L-Ala. {ECO:0000269|PubMed:18434499}.	
P0A698	253	253		C->A,H,S: Reduced activity. {ECO:0000269|PubMed:2550431}.	
P0AGE0	5	5		G->D: Increased frequency of precise excision of transposon Tn10 derivatives (mutant SSB-200). {ECO:0000269|PubMed:3301414}.	
P0AGE0	11	11		L->F: Increased frequency of precise excision of transposon Tn10 derivatives (mutant SSB-202). {ECO:0000269|PubMed:3301414}.	
P0AGE0	25	25		P->S: Increased frequency of precise excision of transposon Tn10 derivatives (mutant SSB-202). {ECO:0000269|PubMed:3301414}.	
P0AGE0	56	56		H->L: Reduces DNA-binding affinity. {ECO:0000269|PubMed:3301414}.	
P0AGE0	56	56		H->Y: Destabilizes the tetramer (mutant SSB-1). {ECO:0000269|PubMed:3301414}.	
P0AGE0	61	61		F->A: Reduces DNA-binding affinity. {ECO:0000269|PubMed:3301414}.	
P0AGE0	103	103		V->M: Increased frequency of precise excision of transposon Tn10 derivatives (mutant SSB-201). {ECO:0000269|PubMed:3301414}.	
P0AGE0	177	177		P->S: Strongly reduced exonuclease I (sbcB) stimulation. {ECO:0000269|PubMed:18591666}.	
P0AF52	35	35	1	T->A: Almost no change in activity. {ECO:0000269|PubMed:24214977}.	
P0AF52	35	35		T->H: Lack of activity. {ECO:0000269|PubMed:24214977}.	
P0AF52	88	88	1	A->G,S: Almost no change in activity. {ECO:0000269|PubMed:24214977}.	
P0AF52	271	271		D->A,N: Strong decrease in activity. {ECO:0000269|PubMed:24214977}.	
P0AF52	271	271		D->E: Lack of activity. {ECO:0000269|PubMed:24214977}.	
P0AF52	275	275		T->A,D,N: Lack of activity. {ECO:0000269|PubMed:24214977}.	
P0AF52	275	275		T->S: Strong decrease in activity. {ECO:0000269|PubMed:24214977}.	
P0AF52	302	302		D->E: Lack of activity. {ECO:0000269|PubMed:24214977}.	
P0AF52	302	302	1	D->N: Almost no change in activity. {ECO:0000269|PubMed:24214977}.	
P0AF52	321	321		I->A: Lack of activity. {ECO:0000269|PubMed:24214977}.	
P0AF52	321	321	1	I->E: Almost no change in activity. {ECO:0000269|PubMed:24214977}.	
P0AF52	322	322		E->D: Strong decrease in activity. {ECO:0000269|PubMed:24214977}.	
P0AF52	322	322		E->Q: Lack of activity. {ECO:0000269|PubMed:24214977}.	
P0AF52	323	323		S->A,N: Lack of activity. {ECO:0000269|PubMed:24214977}.	
P0ABK9	126	126		K->H,I,L: Almost complete loss of nitrite reductase activity. {ECO:0000269|PubMed:9593308}.	
P0ABK9	263	263	1	Q->E: Increases affinity for nitrite without changing Vmax. {ECO:0000269|PubMed:18311941}.	
P32718	73	73	1	A->G: 60-fold increase in catalytic efficiency for glucose phosphorylation. 45-fold increase in D-glucose affinity. No change in catalytic efficiency for D- allose phosphorylation. {ECO:0000269|PubMed:17979299}.	
P32718	145	145	1	F->L: 10-fold increase in catalytic efficiency for glucose phosphorylation. Slight increase in catalytic efficiency for D-allose phosphorylation. {ECO:0000269|PubMed:17979299}.	
P32719	196	196		Missing: Shortens the substrate-binding pocket. Slightly lower activity towards allulose 6-phosphate and increased activity towards ribulose 5-phosphate. {ECO:0000269|PubMed:18700786}.	
P32719	197	197		Missing: Shortens the substrate-binding pocket. Slightly lower activity towards allulose 6-phosphate and increased activity towards ribulose 5-phosphate. {ECO:0000269|PubMed:18700786}.	
P32719	198	198		Missing: Shortens the substrate-binding pocket. Slightly lower activity towards allulose 6-phosphate and increased activity towards ribulose 5-phosphate. {ECO:0000269|PubMed:18700786}.	
P37351	99	99		H->N: Strongly reduced enzyme activity. {ECO:0000269|PubMed:18640127}.	
P16692	54	54		D->A: Has a 1000-fold lower activity. {ECO:0000269|PubMed:21830807}.	
P16692	75	75		T->A: Has 40-fold lower activity. {ECO:0000269|PubMed:21830807}.	
P16692	78	78		H->A: Has 250-fold lower activity. {ECO:0000269|PubMed:21830807}.	
P16692	80	80		D->A: Has 1000-fold lower activity, and has 100-fold lower affinity for manganese. {ECO:0000269|PubMed:19366688}.	
P16692	164	164		D->A: Has a 1000-fold lower activity. {ECO:0000269|PubMed:21830807}.	
P16692	187	187	1	D->A: No effect. {ECO:0000269|PubMed:21830807}.	
P16692	200	200		H->A: Has 10-fold lower activity. {ECO:0000269|PubMed:21830807}.	
P16692	222	222		H->A: Has 9-fold lower activity. {ECO:0000269|PubMed:21830807}.	
P0ACH8	222	222	1	N->A: No effect. {ECO:0000269|PubMed:1445207}.	
P0ACH8	269	269	1	R->G: No effect. {ECO:0000269|PubMed:1445207}.	
P0ACH8	271	271		S->A: 50% reduced activity. {ECO:0000269|PubMed:1445207}.	
P0ACH8	272	272		S->N: 75% reduced activity. {ECO:0000269|PubMed:1445207}.	
P02921	59	59		D->C: Loses ability to catalyze Na(+) or H(+)-coupled melibiose transport against a concentration gradient. {ECO:0000269|PubMed:1872836}.	
P0AEC8	107	107		R->A: Abolishes the stimulation by fumarate to the same extent as complete deletion of the dcuS gene. {ECO:0000269|PubMed:12907689}.	
P0AEC8	110	110		H->A: Abolishes the stimulation by fumarate to the same extent as complete deletion of the dcuS gene. {ECO:0000269|PubMed:12907689}.	
P0AEC8	147	147		R->A: Abolishes the stimulation by fumarate to the same extent as complete deletion of the dcuS gene. {ECO:0000269|PubMed:12907689}.	
P0AEC8	248	248		N->A,D,G: Causes constitutive active state of the kinase, leading to constitutive expression of a target gene, without addition of C4-dicarboxylates. {ECO:0000269|PubMed:18820688}.	
P0AEC8	304	304		N->D: Causes constitutive active state of the kinase, leading to constitutive expression of a target gene, without addition of C4-dicarboxylates. {ECO:0000269|PubMed:18820688}.	
P0AF61	14	14	1	F->A: Still digests ghoT RNA. {ECO:0000269|PubMed:22941047}.	
P0AF61	15	15	1	D->A: Still digests ghoT RNA. {ECO:0000269|PubMed:22941047}.	
P0AF61	25	25		L->I: Protein becomes toxic upon overexpression. Becomes classic type II TA toxin protein, increased cell persistence to ampicillin; when associated with L-31. {ECO:0000269|PubMed:24797297}.	
P0AF61	26	26		R->A: Slightly impaired digestion of ghoT RNA. {ECO:0000269|PubMed:22941047}.	
P0AF61	28	28		R->A: Reduced digestion of ghoT RNA, less efficient neutralization of GhoT in vivo. {ECO:0000269|PubMed:22941047}.	
P0AF61	31	31		M->L: Protein becomes toxic upon overexpression. Becomes classic type II TA toxin protein, increased cell persistence to ampicillin; when associated with I-25. {ECO:0000269|PubMed:24797297}.	
P0AF61	55	55		F->A: Reduced digestion of ghoT RNA. {ECO:0000269|PubMed:22941047}.	
P64646	1	1		M->T: Not toxic in a disrupted ghoS strain as no protein produced. {ECO:0000269|PubMed:24373067}.	
P64646	21	21		I->R: Protein remains toxic. {ECO:0000269|PubMed:24373067}.	
P64646	38	38	1	F->R: Not toxic, protein still targeted to cell pole. No change in intracellular ATP levels, no dissipation of the membrane potential. {ECO:0000269|PubMed:24373067}.	
P39276	20	20		E->A: Lack of activity. {ECO:0000269|PubMed:21933132}.	
P39276	20	20		E->D: Decrease in activity. {ECO:0000269|PubMed:21933132}.	
P39276	20	20		E->Q: Decrease in activity. Abolishes the pH dependency. {ECO:0000269|PubMed:21933132}.	
P39276	388	388		E->A: Lack of activity. {ECO:0000269|PubMed:21933132}.	
P39276	388	388		E->D: Decrease in activity. {ECO:0000269|PubMed:21933132}.	
P39276	388	388		E->Q: Decrease in activity. Does not bind Ala-Lys dipeptide. {ECO:0000269|PubMed:21933132, ECO:0000269|PubMed:22940668}.	
P23890	120	124		PPPIP->AAAIS: Significantly reduced dependence on EF-P for translation, increased levels of protein in an efp- strain. {ECO:0000269|PubMed:23239623}.	
P23890	121	121		P->A: Reduced dependence on EF-P for translation, increased levels of protein in an efp- strain. {ECO:0000269|PubMed:23239623}.	
P36655	13	13	1	C->A: No loss of activity. {ECO:0000269|PubMed:10545108}.	
P36655	122	122		C->A: Loss of activity. {ECO:0000269|PubMed:10545108, ECO:0000269|PubMed:10712691, ECO:0000269|PubMed:10760137}.	
P36655	128	128		C->A: Loss of activity. {ECO:0000269|PubMed:10545108, ECO:0000269|PubMed:10712691, ECO:0000269|PubMed:10760137}.	
P36655	182	182		C->A: Loss of activity. {ECO:0000269|PubMed:10545108, ECO:0000269|PubMed:10712691, ECO:0000269|PubMed:10760137}.	
P36655	301	301	1	C->A: No loss of activity. {ECO:0000269|PubMed:10545108, ECO:0000269|PubMed:10712691, ECO:0000269|PubMed:10760137}.	
P36655	304	304		C->A: Loss of activity. {ECO:0000269|PubMed:10545108, ECO:0000269|PubMed:10712691, ECO:0000269|PubMed:10760137}.	
P36655	480	480		C->A: Loss of activity; when associated with A-483. {ECO:0000269|PubMed:10545108, ECO:0000269|PubMed:10712691, ECO:0000269|PubMed:10760137}.	
P36655	483	483		C->A: Loss of activity; when associated with A-480. {ECO:0000269|PubMed:10545108, ECO:0000269|PubMed:10712691, ECO:0000269|PubMed:10760137}.	
P0AC38	10	10		D->A: Loss of activity. {ECO:0000269|PubMed:9230046}.	
P0AC38	10	10		D->N: Reduces Kcal by 80%. Increases KM for aspartic acid 3-fold. {ECO:0000269|PubMed:9230046}.	
P0AC38	15	15		R->A: No effect on Kcat. Increases KM for aspartic acid 2.5-fold. {ECO:0000269|PubMed:9230046}.	
P0AC38	26	26		H->N: No effect on Kcat. Increases KM for aspartic acid 3-fold. {ECO:0000269|PubMed:9230046}.	
P0AC38	29	29		R->A: No effect on Kcat. Increases KM for aspartic acid 40-fold. {ECO:0000269|PubMed:9230046}.	
P0AC38	55	55		K->R: Loss of activity. {ECO:0000269|PubMed:8119980}.	
P0AC38	124	124		H->L: Reduces activity by 30%. {ECO:0000269|PubMed:8119980}.	
P0AC38	143	143		S->G: Reduces Kcat by 90%. Increases KM for aspartic acid 4-fold. {ECO:0000269|PubMed:9230046}.	
P0AC38	143	143		S->T: Reduces Kcat by 98.5%. Increases KM for aspartic acid 2-fold. {ECO:0000269|PubMed:9230046}.	
P0AC38	327	327		K->R: Reduces activity by 99.7%. Increases KM for aspartic acid 5-fold. {ECO:0000269|PubMed:8119980}.	
P0A6N4	31	31		K->A: No lysylation. {ECO:0000269|PubMed:20729861}.	
P0A6N4	33	33		G->K: No lysylation. Loss of in vivo EF-P function for cell growth. {ECO:0000269|PubMed:20729861}.	
P0A6N4	34	34		K->A: No lysylation and loss of EF-P activity. No facilitation of translation of poly-Pro stretches. {ECO:0000269|PubMed:20729861, ECO:0000269|PubMed:22128152, ECO:0000269|PubMed:23239623}.	
P00811	80	80		S->D,E,G: Loss of activity. {ECO:0000269|PubMed:12144785}.	
P00811	83	83		K->Q,T: Lowers activity more than 1000- fold and increases protein stability. {ECO:0000269|PubMed:12144785}.	
P00811	166	166		Y->E: Lowers activity more than 1000- fold. {ECO:0000269|PubMed:12144785}.	
P00811	168	168		N->D,H: Lowers activity more than 1000- fold. {ECO:0000269|PubMed:12144785}.	
P00811	331	331		K->A: Lowers activity more than 1000- fold. {ECO:0000269|PubMed:12144785}.	
P0AC47	58	58		C->S: Affects center 1 (2Fe-2S). {ECO:0000269|PubMed:2174169}.	
P0AC47	63	63		C->S: Affects center 1 (2Fe-2S). {ECO:0000269|PubMed:2174169}.	
P0AC47	66	66		C->S: Affects center 1 (2Fe-2S). {ECO:0000269|PubMed:2174169}.	
P0AC47	78	78		C->S: Affects center 1 (2Fe-2S). {ECO:0000269|PubMed:2174169}.	
P00363	45	45		H->R: Inactivates enzyme. {ECO:0000269|PubMed:2668268}.	
P00363	45	45		H->S,C,Y: Decreased ability (greater than 70%) to reduce fumarate. {ECO:0000269|PubMed:2668268}.	
P00363	233	233		H->S: Severely affect succinate oxidation and decrease fumarate oxidation by 75%. {ECO:0000269|PubMed:1856194}.	
P00363	248	248	1	C->S,A: Does not inactivate enzyme. {ECO:0000269|PubMed:1856194}.	
P00363	249	249		R->H,L: Inactivates enzyme. {ECO:0000269|PubMed:1856194}.	
P0A8N7	50	50	1	D->A: No effect on lysylation activity. {ECO:0000269|PubMed:20729861}.	
P0A8N7	76	76		S->A: Loss of catalytic activity. {ECO:0000269|PubMed:21841797}.	
P0A8N7	100	100		R->A: Loss of lysylation activity. {ECO:0000269|PubMed:20729861}.	
P0A8N7	102	102	1	E->A: No effect on lysylation activity. {ECO:0000269|PubMed:20729861}.	
P0A8N7	103	103		E->A: Loss of lysylation activity. {ECO:0000269|PubMed:20729861}.	
P0A8N7	108	108		H->A: Severe reduction in lysylation activity. {ECO:0000269|PubMed:20729861}.	
P0A8N7	185	185		E->A: Slight reduction in lysylation activity. {ECO:0000269|PubMed:20729861}.	
P0A8N7	193	193		Q->A: Slight reduction in lysylation activity. {ECO:0000269|PubMed:20729861}.	
P0A8N7	244	244		E->A: Loss of lysylation activity. {ECO:0000269|PubMed:20729861}.	
P0A8N7	247	247		N->A: Loss of lysylation activity. {ECO:0000269|PubMed:20729861}.	
P0A8N7	298	298		A->G: 96% increase in the affinity for L- alpha-lysine. 4-fold decrease in the catalytic efficiency of the (R)-beta- lysine activation reaction. {ECO:0000269|PubMed:21841797}.	
P0A8N7	303	303		R->A: Loss of lysylation activity. {ECO:0000269|PubMed:20729861}.	
P0A8K1	254	254		S->A: No processing of the proenzyme, complete loss of activity. {ECO:0000269|PubMed:2406271}.	
P0A8K1	254	254		S->C: Reduced processing, 16% wild-type activity. {ECO:0000269|PubMed:2406271}.	
P0A8K1	254	254		S->T: Reduced processing, 2% wild-type activity. {ECO:0000269|PubMed:2406271}.	
P39286	220	220		K->A: Reduction in GTPase activity. Strong reduction; when associated with A- 221. {ECO:0000269|PubMed:12220175}.	
P39286	221	221		S->A: Reduction in GTPase activity. Strong reduction; when associated with A- 220. {ECO:0000269|PubMed:12220175}.	
P0ABC7	145	145		A->V: In hflK13; stabilizes overproduced SecY but not overproduced cII protein. {ECO:0000269|PubMed:8947034}.	
P0ABC3	145	145		G->A: In hflC9; stabilizes overproduced SecY but not overproduced cII protein. {ECO:0000269|PubMed:8947034}.	
P0ABC3	165	200	1	Missing: No effect on phage lambda lysogenization frequency. {ECO:0000269|PubMed:9159109}.	
P0A7D4	13	13		G->V: Significant reduction in activity. {ECO:0000269|PubMed:1733940}.	
P0A7D4	16	16		G->V: Significant reduction in activity. {ECO:0000269|PubMed:1733940}.	
P0A7D4	17	17		K->Q: Reduces catalytic efficiency by 50%. {ECO:0000269|PubMed:1733940}.	
P0A7D4	18	18		G->V: Significant reduction in activity. {ECO:0000269|PubMed:1733940}.	
P0A7D4	19	19		K->R: Significant reduction in activity. {ECO:0000269|PubMed:1733940}.	
P0A7D4	20	20		I->T: Significant reduction in activity. {ECO:0000269|PubMed:1733940}.	
P0A7D4	141	141		K->I: Total loss of activity. {ECO:0000269|PubMed:1733940}.	
P0A7D4	144	144	1	R->L: Does not reduce catalytic efficiency. {ECO:0000269|PubMed:1733940}.	
P0A7D4	148	148		R->L: Reduced activity. {ECO:0000269|PubMed:2061308}.	
P0A7D4	304	304		R->L: Reduces catalytic efficiency by 87%. {ECO:0000269|PubMed:1733940}.	
P21499	272	272		D->N: Loss of RNase activity, but exhibits helicase activity. {ECO:0000269|PubMed:20023028}.	
P21499	280	280		D->N: Loss of RNase activity, but exhibits helicase activity. {ECO:0000269|PubMed:20023028}.	
P21499	544	544		K->A: Lack of acetylation. Maintains protein's instability in exponential phase. Becomes unstable in stationary phase. {ECO:0000269|PubMed:21981926}.	
P21499	544	544		K->R: Lack of acetylation. Stabilizes exponential phase RNase R. {ECO:0000269|PubMed:21981926}.	
P21499	764	764		E->A: Becomes unstable in stationary phase; when associated with A-766. {ECO:0000269|PubMed:21981926}.	
P21499	766	766		D->A: Becomes unstable in stationary phase; when associated with A-764. {ECO:0000269|PubMed:21981926}.	
P33224	437	437	1	R->Q: Does not affect DNA binding affinity. {ECO:0000269|PubMed:18829440}.	
P33224	518	518		R->Q: Reduces DNA binding affinity. {ECO:0000269|PubMed:18829440}.	
P39304	33	33		E->K: Loss of activity. {ECO:0000269|PubMed:15157077}.	
P39304	64	64		K->A: 16% of wild-type activity. {ECO:0000269|PubMed:15157077}.	
P39304	67	67		D->A: 5% of wild-type activity. {ECO:0000269|PubMed:15157077}.	
P39304	112	112		E->A: 0.5% of wild-type activity. {ECO:0000269|PubMed:15157077}.	
P39304	136	136		H->A: 5% of wild-type activity. {ECO:0000269|PubMed:15157077}.	
P39304	139	139		R->V: 17% of wild-type activity. {ECO:0000269|PubMed:15157077}.	
P39315	139	139		W->A,I: 3-fold increase in the Km for methyl-1,4-benzoquinone. {ECO:0000269|PubMed:18455185}.	
P39315	139	139	1	W->F: Almost no change in the Km for methyl-1,4-benzoquinone. {ECO:0000269|PubMed:18455185}.	
P39315	140	140		Y->A,I: Almost complete loss of catalytic activity. {ECO:0000269|PubMed:18455185}.	
P39315	140	140	1	Y->F: No change. {ECO:0000269|PubMed:18455185}.	
P39315	143	143		N->A,L: 6-fold increase in the Km for methyl-1,4-benzoquinone. No change in affinity for NADPH. {ECO:0000269|PubMed:18455185}.	
P0A744	52	52		C->S: Loss of activity. {ECO:0000269|PubMed:10964927}.	
P0A744	87	87	1	C->S: No effect. {ECO:0000269|PubMed:10964927}.	
P0A744	199	199		C->S: Decrease in activity. {ECO:0000269|PubMed:10964927}.	
P0A744	207	207		C->S: Decrease in activity. {ECO:0000269|PubMed:10964927}.	
P0A7A9	21	21		E->D: 16% activity.	
P0A7A9	30	30		K->R: 2% activity.	
P0A7A9	32	32		E->D: 6% activity.	
P0A7A9	44	44		R->K: 10% activity.	
P0A7A9	52	52		Y->F: 64% activity.	
P0A7A9	56	56		Y->F: 7% activity.	
P0A7A9	66	66		D->E: 6% activity.	
P0A7A9	68	68		D->E: 1% activity.	
P0A7A9	71	71		D->E: No activity.	
P0A7A9	98	98		D->E: 22% activity.	
P0A7A9	98	98		D->V: No activity.	
P0A7A9	99	99		E->V: 33% activity.	
P0A7A9	103	103		D->E: 3% activity.	
P0A7A9	103	103		D->V: No activity.	
P0A7A9	105	105		K->I: No activity.	
P0A7A9	105	105		K->R: 3% activity.	
P0A7A9	142	142		Y->F: 22% activity.	
P39333	50	50		E->Q,V: Shows higher affinity for cyclic- di-GMP, increases swimming motility and biofilm dispersal. Biofilm formation is almost completely removed. {ECO:0000269|PubMed:21059164}.	
P04391	56	56		S->H: Much less active than the wild- type. {ECO:0000269|PubMed:8845761}.	
P04391	58	58		R->G: The mutant is drastically inefficient in catalysis, but affects only moderately the binding of carbamoyl phosphate. {ECO:0000269|PubMed:2674127, ECO:0000269|PubMed:3072022}.	
P04391	87	87		K->Q: Much less active than the wild- type. {ECO:0000269|PubMed:8845761}.	
P04391	274	274		C->A: Zinc ion is no longer a tight- binding inhibitor and does not promote isomerization. {ECO:0000269|PubMed:2405164}.	
P04391	320	320		R->A: Much less active than the wild- type. {ECO:0000269|PubMed:8845761}.	
P04391	326	326		A->G: Activity greater than the wild-type and Km for ornithwinas increases about twofold. {ECO:0000269|PubMed:8845761}.	
P07118	222	222		T->P: Produces mischarged Thr-tRNA(Val) and Cys-tRNA(Val). {ECO:0000269|PubMed:11313495}.	
P07118	277	277		K->A: Reduces posttransfer Thr-tRNA(Val) editing rate significantly and alters amino acid discrimination in the editing site, resulting in hydrolysis of the correctly charged cognate product. {ECO:0000269|PubMed:12475234}.	
P68767	354	354		E->A: Loss of activity. {ECO:0000269|PubMed:8057849}.	
P39371	30	30	1	K->A: No effect on catalytic activity. {ECO:0000269|PubMed:18063573}.	
P39371	228	228		E->A: Great decrease in catalytic activity. {ECO:0000269|PubMed:18063573}.	
P39371	234	234		R->A: Decrease in catalytic activity. {ECO:0000269|PubMed:18063573}.	
P39371	297	297	1	H->A: No effect on catalytic activity. {ECO:0000269|PubMed:18063573}.	
P39371	302	302	1	K->A: No effect on catalytic activity. {ECO:0000269|PubMed:18063573}.	
P39371	328	328	1	Y->A: No effect on catalytic activity. {ECO:0000269|PubMed:18063573}.	
P39371	344	344	1	E->A: No effect on catalytic activity. {ECO:0000269|PubMed:18063573}.	
P39377	77	77		E->D,Q: Reduces activity 100000-fold. {ECO:0000269|PubMed:15882050, ECO:0000269|PubMed:16289685}.	
P39377	137	137		Y->A,F: Reduces activity 1000-fold. {ECO:0000269|PubMed:15882050, ECO:0000269|PubMed:16289685}.	
P39377	169	169		R->K: Reduces activity 1000-fold. {ECO:0000269|PubMed:15882050}.	
P39377	169	169		R->M: Loss of activity. {ECO:0000269|PubMed:15882050}.	
P39377	233	233		R->K: Reduces activity 1000-fold. {ECO:0000269|PubMed:15882050}.	
P39377	233	233		R->M: Loss of activity. {ECO:0000269|PubMed:15882050}.	
P39377	285	285		D->A: Reduces activity 100000-fold. {ECO:0000269|PubMed:15882050}.	
P39406	86	86		K->S: Reduces activity by 84%; when associated with S-88. {ECO:0000269|PubMed:17576679}.	
P39406	88	88		K->S: Reduces activity by 84%; when associated with S-86. {ECO:0000269|PubMed:17576679}.	
P39406	202	202		D->A: Abolishes affinity for S-adenosyl- L-methionine. Loss of activity. {ECO:0000269|PubMed:17576679}.	
P39406	227	227		D->A: Strongly reduces affinity for S- adenosyl-L-methionine. Reduces activity by 87%. {ECO:0000269|PubMed:17576679}.	
P39406	268	268		N->A: Reduces affinity for S-adenosyl-L- methionine. Reduces activity by 80%. {ECO:0000269|PubMed:17576679}.	
P32099	73	73		S->A: 20-fold decrease in affinity for ATP. {ECO:0000269|PubMed:16043486}.	
P32099	141	141		R->A: More than 10-fold reduction in Vmax. {ECO:0000269|PubMed:16043486}.	
P0A9W3	188	188		E->Q: Arrests growth, inhibits tripeptide but not dipeptide formation, stably binds 70S ribosomes, probably locked in an ATP- bound form as it should not have ATPase activity; when associated with Q-470. {ECO:0000269|PubMed:24389465, ECO:0000269|PubMed:24389466}.	
P0A9W3	470	470		E->Q: Arrests growth, inhibits tripeptide but not dipeptide formation, stably binds 70S ribosomes, probably locked in an ATP- bound form as it should not have ATPase activity; when associated with Q-188. {ECO:0000269|PubMed:24389465, ECO:0000269|PubMed:24389466}.	
P0AGC3	505	505		E->Q: Inactivates the enzyme.	
